U.S. patent application number 11/683241 was filed with the patent office on 2012-05-17 for compositions for use in identification of bacteria.
Invention is credited to Lawrence Blyn, David J. Ecker, Thomas A. Hall, Rangarajan Sampath.
Application Number | 20120122096 11/683241 |
Document ID | / |
Family ID | 38533927 |
Filed Date | 2012-05-17 |
United States Patent
Application |
20120122096 |
Kind Code |
A1 |
Sampath; Rangarajan ; et
al. |
May 17, 2012 |
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA
Abstract
The present invention provides compositions, kits and methods
for rapid identification and quantification of bacteria by
molecular mass and base composition analysis.
Inventors: |
Sampath; Rangarajan; (San
Diego, CA) ; Hall; Thomas A.; (Oceanside, CA)
; Ecker; David J.; (Encinitas, CA) ; Blyn;
Lawrence; (Mission Viego, CA) |
Family ID: |
38533927 |
Appl. No.: |
11/683241 |
Filed: |
March 7, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11409535 |
Apr 21, 2006 |
|
|
|
11683241 |
|
|
|
|
11060135 |
Feb 17, 2005 |
|
|
|
11409535 |
|
|
|
|
10728486 |
Dec 5, 2003 |
7718354 |
|
|
11409535 |
|
|
|
|
60545425 |
Feb 18, 2004 |
|
|
|
60559754 |
Apr 5, 2004 |
|
|
|
60632862 |
Dec 3, 2004 |
|
|
|
60639068 |
Dec 22, 2004 |
|
|
|
60648188 |
Jan 28, 2005 |
|
|
|
60501926 |
Sep 11, 2003 |
|
|
|
60674118 |
Apr 21, 2005 |
|
|
|
60705631 |
Aug 3, 2005 |
|
|
|
60732539 |
Nov 1, 2005 |
|
|
|
60773124 |
Feb 13, 2006 |
|
|
|
Current U.S.
Class: |
435/6.12 ;
536/24.33 |
Current CPC
Class: |
C12Q 1/689 20130101;
C12Q 1/6816 20130101; C12Q 1/6858 20130101; C12Q 1/6858 20130101;
C12Q 1/6816 20130101; C12Q 2565/627 20130101; C12Q 2600/156
20130101; C12Q 2565/627 20130101; C12Q 2537/143 20130101 |
Class at
Publication: |
435/6.12 ;
536/24.33 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; C07H 21/04 20060101 C07H021/04 |
Goverment Interests
STATEMENT OF GOVERNMENT SUPPORT
[0003] This invention was made with United States Government
support under CDC contract RO1 CI000099-01. The United States
Government has certain rights in the invention.
Claims
1. An oligonucleotide primer pair comprising a forward and a
reverse primer, wherein said forward primer comprises the sequence
of SEQ ID NO: 437, and said reverse primer comprises a sequence 90%
identical to SEQ ID NO: 1232.
2.-8. (canceled)
9. The oligonucleotide primer pair of claim 1 wherein said forward
primer is SEQ ID NO: 437.
10. (canceled)
11. The oligonucleotide primer pair of claim wherein said reverse
primer is SEQ ID NO: 1232.
12. The oligonucleotide primer pair of claim 1 wherein at least one
of said forward primer and said reverse primer comprises at least
one modified nucleobase.
13. The oligonucleotide primer pair of claim 12 wherein at least
one of said at least one modified nucleobase is a mass modified
nucleobase.
14. The oligonucleotide primer pair of claim 13 wherein said mass
modified nucleobase is 5-Iodo-C.
15. The composition of claim 13 wherein said mass modified
nucleobase comprises a molecular mass modifying tag.
16. The oligonucleotide primer pair of claim 12 wherein at least
one of said at least one modified nucleobase is a universal
nucleobase.
17. The oligonucleotide primer pair of claim 16 wherein said
universal nucleobase is inosine.
18. The oligonucleotide primer pair of claim 1 wherein at least one
of said forward primer and said reverse primer comprises a
non-templated T residue at its 5' end.
19. A kit for identifying, determining one or more characteristics
of, or detecting a Staphylococcus aureus bioagent comprising the
oligonucleotide primer pair of claim 1 and at least one additional
primer pair designed to hybridize to a Staphylococcus aureus gene
encoding aroE, gmk, pta, tpi, yqi, or a combination thereof.
20. The kit of claim 19 further comprising at least one other
additional primer pair designed to hybridize to a Staphylococcus
aureus gene encoding mecA, mecR1, pvluk, or a combination
thereof.
21. The kit of claim 19 wherein said at least one additional primer
pair comprises SEQ ID NO: 590:891, SEQ ID NO: 474:869, SEQ ID NO:
268:1284, SEQ ID NO: 418:1301, SEQ ID NO: 318:1300, SEQ ID NO:
440:1076, SEQ ID NO: 219:1013, or a combination thereof.
22. The kit of claim 19 wherein said oligonucleotide primer pair of
claim 1 and said at least one additional primer pair consists of
eight oligonucleotide primer pairs having at least 70% sequence
identity with the primer pairs represented by: SEQ ID NOs:, SEQ ID
NOs: 590:891, SEQ ID NOs: 474:869, SEQ ID NOs: 268:1284, SEQ ID
NOs: 418:1301, SEQ ID NOs: 318:1300, SEQ ID NOs: 440:1076, and SEQ
ID NOs: 219:1013.
23. A method for identifying, determining one or more
characteristics of, or detecting a Staphylococcus aureus bioagent
in a sample comprising: a) amplifying a nucleic acid from said
sample using an oligonucleotide primer pair targeted to a
Staphylococcus aureus arcC gene comprising a forward and a reverse
primer, each being between 13 and 35 linked nucleotides in length,
wherein said forward primer comprises at least 70% complementarity
to a first region within nucleotides 37-353 of a reference
sequence, said reference sequence being a sequence extraction of
coordinates 2725050-2724595 of Genbank gi number 21281729, and
wherein said reverse primer comprises at least 70% complementarity
to a second region within nucleotides 37-353 of said reference
sequence, wherein said amplifying generates at least one
amplification product that comprises between about 45 and about 200
linked nucleotides; and b) determining the molecular mass of said
at least one amplification product by mass spectrometry.
24. The method of claim 23 further comprising comparing said
determined molecular mass to a plurality of molecular masses of
bioagent identifying amplicons, each indexed to said
oligonucleotide primer pair and a Staphylococcus aureus bioagent,
wherein a match between said determined molecular mass and one of
said plurality of molecular masses identifies, determines one or
more characteristic of, or detects said Staphylococcus aureus
bioagent in said sample.
25. The method of claim 23 further comprising calculating a base
composition of said at least one amplification product using said
molecular mass.
26. The method of claim 25 further comprising comparing said
calculated base composition to a database comprising a plurality of
base compositions of bioagent identifying amplicons, each indexed
to said oligonucleotide primer pair and to a Staphylococcus aureus
bioagent, wherein a match between said calculated base composition
and a base composition in said database identifies, determines one
or more characteristics of, or detects said Staphylococcus aureus
bioagent in said sample.
27. The method of claim 23 wherein said forward primer comprises at
least 70% sequence identity with SEQ ID NO: 437.
28. The method of claim 23 wherein said reverse primer comprises at
least 70% sequence identity with SEQ ID NO: 1232.
29. The method of claim 23 further comprising repeating said
amplifying and determining steps using at least one additional
oligonucleotide primer pair designed to hybridize a Staphylococcus
aureus gene encoding aroE, gmk, pta, tpi, or Yqi, arcC, or a
combination thereof.
30. The method of claim 23 further comprising repeating said
amplifying and determining steps using at least three additional
primer pairs, each designed to hybridize to a Staphylococcus aureus
gene encoding aroE or gmk.
31. A method for identifying, determining one or more
characteristics of, or detecting a Staphylococcus aureus bioagent
in a sample comprising: c) amplifying a nucleic acid from said
sample using at least four oligonucleotide primer pairs, each
designed to hybridize to a Staphylococcus aureus gene and
comprising a forward and a reverse primer, each being between 13
and 35 nucleobases in length, four of said at least four primer
pairs comprising at least 70% sequence identity with the four
primer pairs represented by SEQ ID NOs: 437:1232, SEQ ID NOs:
590:891, SEQ ID NOs: 474:869, and SEQ ID NOs: 268:1284, wherein
said amplifying generates at least one amplification product that
comprises between about 45 and about 200 linked nucleotides; and d)
determining the molecular mass of said at least one amplification
product by mass spectrometry.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 11/409,535, filed Apr. 21, 2006, which is a
continuation-in-part of U.S. application Ser. No. 11/060,135, filed
Feb. 17, 2005 which claims the benefit of priority to U.S.
Provisional Application Ser. No. 60/545,425 filed Feb. 18, 2004;
U.S. Provisional Application Ser. No. 60/559,754, filed Apr. 5,
2004; U.S. Provisional Application Ser. No. 60/632,862, filed Dec.
3, 2004; U.S. Provisional Application Ser. No. 60/639,068, filed
Dec. 22, 2004; and U.S. Provisional Application Ser. No.
60/648,188, filed Jan. 28, 2005. U.S. application Ser. No.
11/409,535 is a also continuation-in-part of U.S. application Ser.
No. 10/728,486, filed Dec. 5, 2003 which claims the benefit of
priority to U.S. Provisional Application Ser. No. 60/501,926, filed
Sep. 11, 2003. U.S. application Ser. No. 11/409,535 also claims the
benefit of priority to: U.S. Provisional Application Ser. No.
60/674,118, filed Apr. 21, 2005; U.S. Provisional Application Ser.
No. 60/705,631, filed Aug. 3, 2005; U.S. Provisional Application
Ser. No. 60/732,539, filed Nov. 1, 2005; and U.S. Provisional
Application Ser. No. 60/773,124, filed Feb. 13, 2006. Each of the
above-referenced U.S. Applications is incorporated herein by
reference in its entirety. Methods disclosed in U.S. application
Ser. Nos. 09/891,793, 10/156,608, 10/405,756, 10/418,514,
10/660,122, 10,660,996, 10/660,997, 10/660,998, 10/728,486,
11/060,135, and 11/073,362, are commonly owned and incorporated
herein by reference in their entirety for any purpose.
SEQUENCE LISTING
[0002] The present application is being filed along with a Sequence
Listing in electronic format. The Sequence Listing is provided as a
file entitled DIBIS0083USC1SEQ.txt, created on Mar. 6, 2007 which
is 252 Kb in size. The information in the electronic format of the
sequence listing is incorporated herein by reference in its
entirety.
FIELD OF THE INVENTION
[0004] The present invention provides compositions, kits and
methods for rapid identification and quantification of bacteria by
molecular mass and base composition analysis.
BACKGROUND OF THE INVENTION
[0005] A problem in determining the cause of a natural infectious
outbreak or a bioterrorist attack is the sheer variety of organisms
that can cause human disease. There are over 1400 organisms
infectious to humans; many of these have the potential to emerge
suddenly in a natural epidemic or to be used in a malicious attack
by bioterrorists (Taylor et al. Philos. Trans. R. Soc. London B.
Biol. Sci., 2001, 356, 983-989). This number does not include
numerous strain variants, bioengineered versions, or pathogens that
infect plants or animals.
[0006] Much of the new technology being developed for detection of
biological weapons incorporates a polymerase chain reaction (PCR)
step based upon the use of highly specific primers and probes
designed to selectively detect certain pathogenic organisms.
Although this approach is appropriate for the most obvious
bioterrorist organisms, like smallpox and anthrax, experience has
shown that it is very difficult to predict which of hundreds of
possible pathogenic organisms might be employed in a terrorist
attack. Likewise, naturally emerging human disease that has caused
devastating consequence in public health has come from unexpected
families of bacteria, viruses, fungi, or protozoa. Plants and
animals also have their natural burden of infectious disease agents
and there are equally important biosafety and security concerns for
agriculture.
[0007] A major conundrum in public health protection, biodefense,
and agricultural safety and security is that these disciplines need
to be able to rapidly identify and characterize infectious agents,
while there is no existing technology with the breadth of function
to meet this need. Currently used methods for identification of
bacteria rely upon culturing the bacterium to effect isolation from
other organisms and to obtain sufficient quantities of nucleic acid
followed by sequencing of the nucleic acid, both processes which
are time and labor intensive.
[0008] Mass spectrometry provides detailed information about the
molecules being analyzed, including high mass accuracy. It is also
a process that can be easily automated. DNA chips with specific
probes can only determine the presence or absence of specifically
anticipated organisms. Because there are hundreds of thousands of
species of benign bacteria, some very similar in sequence to threat
organisms, even arrays with 10,000 probes lack the breadth needed
to identify a particular organism.
[0009] The present invention provides oligonucleotide primers and
compositions and kits containing the oligonucleotide primers, which
define bacterial bioagent identifying amplicons and, upon
amplification, produce corresponding amplification products whose
molecular masses provide the means to identify bacteria, for
example, at and below the species taxonomic level.
SUMMARY OF THE INVENTION
[0010] The present invention provides compositions, kits and
methods for rapid identification and quantification of bacteria by
molecular mass and base composition analysis.
[0011] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 456.
[0012] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1261.
[0013] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 456 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1261.
[0014] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 288.
[0015] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1269.
[0016] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 288 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1269.
[0017] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 698.
[0018] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1420.
[0019] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 698 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1420.
[0020] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 217.
[0021] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1167
[0022] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 217 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1167.
[0023] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 399.
[0024] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1041.
[0025] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 399 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1041.
[0026] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 430.
[0027] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1321.
[0028] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 430 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1321.
[0029] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 174.
[0030] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 853.
[0031] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 174 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 853.
[0032] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 172.
[0033] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1360.
[0034] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 172 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1360.
[0035] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 456 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1261.
[0036] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 456 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1261 and further comprising one or more primer pairs wherein each
member of said one or more primer pairs is of a length of 14 to 35
nucleobases and has 70% to 100% sequence identity with the
corresponding member from the group of primer pairs represented by
SEQ ID NOs: 288:1269, 698:1420, 217:1167, 399:1041, 430:1321,
174:853, and 172:1360.
[0037] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 681.
[0038] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1022.
[0039] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 681 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1022.
[0040] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 315.
[0041] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1379.
[0042] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 315 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1379.
[0043] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 346.
[0044] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 955.
[0045] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 346 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 955.
[0046] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 504.
[0047] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1409.
[0048] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 504 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1409.
[0049] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 323.
[0050] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1068.
[0051] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 323 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 1068.
[0052] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 479.
[0053] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 938.
[0054] Another embodiment is an oligonucleotide primer pair
including an oligonucleotide primer 14 to 35 nucleobases in length
having at least 70% sequence identity with SEQ ID NO: 479 and an
oligonucleotide primer 14 to 35 nucleobases in length having at
least 70% sequence identity with SEQ ID NO: 938.
[0055] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 681 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1022.
[0056] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 681 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1022 and further comprising one or more primer pairs wherein each
member of said one or more primer pairs is of a length of 14 to 35
nucleobases and has 70% to 100% sequence identity with the
corresponding member from the group of primer pairs represented by
SEQ ID NOs: 315:1379, 346:955, 504:1409, 323:1068, 479:938.
[0057] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 583.
[0058] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 923.
[0059] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 583 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
923.
[0060] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 454.
[0061] Another embodiment is an primer-14 to 35 nucleobases in
length having at least 70% sequence identity with SEQ ID NO:
1418.
[0062] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 454 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1418.
[0063] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 250.
[0064] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 902.
[0065] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 250 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
902.
[0066] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 384.
[0067] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 878.
[0068] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 384 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
878.
[0069] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 694.
[0070] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1215.
[0071] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 694 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1215.
[0072] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 194.
[0073] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1173.
[0074] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 194 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1173.
[0075] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 375.
[0076] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 890.
[0077] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 375 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
890.
[0078] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 656.
[0079] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1224.
[0080] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 656 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1224.
[0081] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 618.
[0082] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1157.
[0083] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 618 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1157.
[0084] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 302.
[0085] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 852.
[0086] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 302 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
852.
[0087] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 199.
[0088] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 889.
[0089] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 199 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
889.
[0090] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 596.
[0091] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1169.
[0092] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 596 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1169.
[0093] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 150.
[0094] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1242.
[0095] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 150 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1242.
[0096] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 166.
[0097] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1069.
[0098] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 166 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1069.
[0099] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 166.
[0100] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1168.
[0101] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 166 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1168.
[0102] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 583 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO: 923
and further comprising one or more primer pairs wherein each member
of said one or more primer pairs is of a length of 14 to 35
nucleobases and has 70% to 100% sequence identity with the
corresponding member from the group of primer pairs represented by
SEQ ID NOs: 454:1418, 250:902, 384:878, 694:1215, 194:1173,
375:890, 656:1224, 618:1157, 302:852, 199:889, 596:1169, 150:1242,
166:1069 and 166:1168.
[0103] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 437.
[0104] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1137.
[0105] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 437 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1137.
[0106] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 530.
[0107] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 891.
[0108] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 530 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
891.
[0109] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 474.
[0110] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 869.
[0111] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 474 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
869.
[0112] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 268.
[0113] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1284.
[0114] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 268 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1284.
[0115] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 418.
[0116] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1301.
[0117] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 418 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1301.
[0118] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 318.
[0119] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1300.
[0120] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 318 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1300.
[0121] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 440.
[0122] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1076.
[0123] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 440 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1076.
[0124] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 219.
[0125] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1013.
[0126] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 219 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1013.
[0127] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 437 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1137 and further comprising one or more primer pairs wherein each
member of said one or more primer pairs is of a length of 14 to 35
nucleobases and has 70% to 100% sequence identity with the
corresponding member from the group of primer pairs represented by
SEQ ID NOs: 530:891, 474:869, 268:1284, 418:1301, 318:1300,
440:1076 and 219:1013.
[0128] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 325.
[0129] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1163.
[0130] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 325 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1163.
[0131] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 278.
[0132] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1039.
[0133] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 278 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1039.
[0134] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 465.
[0135] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1037.
[0136] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 465 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1037.
[0137] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 148.
[0138] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1172.
[0139] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 148 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1172.
[0140] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 190.
[0141] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1254.
[0142] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 190 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1254.
[0143] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 266.
[0144] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1094.
[0145] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 266 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1094.
[0146] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 508.
[0147] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1297.
[0148] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 508 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1297.
[0149] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 259.
[0150] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1060.
[0151] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 259 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1060.
[0152] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 325 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1163 and further comprising one or more primer pairs wherein each
member of said one or more primer pairs is of a length of 14 to 35
nucleobases and has 70% to 100% sequence identity with the
corresponding member from the group of primer pairs represented by
SEQ ID NOs: 278:1039: 465:1037, 148:1172, 190:1254, 266:1094,
508:1297 and 259:1060.
[0153] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 376.
[0154] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1265.
[0155] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 376 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1265.
[0156] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 267.
[0157] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1341.
[0158] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 267 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1341.
[0159] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 705.
[0160] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1056.
[0161] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 705 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1056.
[0162] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 710.
[0163] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1259.
[0164] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 710 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1259.
[0165] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 374.
[0166] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1111.
[0167] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 374 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1111.
[0168] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 545.
[0169] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 978.
[0170] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 545 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
978.
[0171] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 249.
[0172] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1095.
[0173] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 249 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1095.
[0174] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 195.
[0175] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1376.
[0176] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 195 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1376.
[0177] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 311.
[0178] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1014.
[0179] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 311 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1014.
[0180] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 365.
[0181] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1052.
[0182] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 365 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1052.
[0183] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 527.
[0184] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1071.
[0185] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 527 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1071.
[0186] One embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 490.
[0187] Another embodiment is an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 1182.
[0188] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 490 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1182.
[0189] Another embodiment is a kit comprising an oligonucleotide
primer pair including an oligonucleotide primer 14 to 35
nucleobases in length having at least 70% sequence identity with
SEQ ID NO: 376 and an oligonucleotide primer 14 to 35 nucleobases
in length having at least 70% sequence identity with SEQ ID NO:
1265 and further comprising one or more primer pairs wherein each
member of said one or more primer pairs is of a length of 14 to 35
nucleobases and has 70% to 100% sequence identity with the
corresponding member from the group of primer pairs represented by
SEQ ID NOs: 267:1341, 705:1056, 710:1259, 374:1111, 545:978,
249:1095, 195:1376, 311:1014, 365:1052, 527:1071 and 490:1182.
[0190] In some embodiments, either or both of the primers of a
primer pair composition contain at least one modified nucleobase
such as 5-propynyluracil or 5-propynylcytosine for example.
[0191] In some embodiments, either or both of the primers of the
primer pair comprises at least one universal nucleobase such as
inosine for example.
[0192] In some embodiments, either or both of the primers of the
primer pair comprises at least one non-templated T residue on the
5'-end.
[0193] In some embodiments, either or both of the primers of the
primer pair comprises at least one non-template tag.
[0194] In some embodiments, either or both of the primers of the
primer pair comprises at least one molecular mass modifying
tag.
[0195] In some embodiments, the present invention provides primers
and compositions comprising pairs of primers, and kits containing
the same, and methods for use in identification of bacteria. The
primers are designed to produce amplification products of DNA
encoding genes that have conserved and variable regions across
different subgroups and genotypes of bacteria.
[0196] Some embodiments are kits that contain one or more of the
primer pair compositions. In some embodiments, each member of the
one or more primer pairs of the kit is of a length of 14 to 35
nucleobases and has 70% to 100% sequence identity with the
corresponding member from any of the primer pairs listed in Table
2.
[0197] Some embodiments of the kits contain at least one
calibration polynucleotide for use in quantitiation of bacteria in
a given sample, and also for use as a positive control for
amplification.
[0198] Some embodiments of the kits contain at least one anion
exchange functional group linked to a magnetic bead.
[0199] In some embodiments, the present invention also provides
methods for identification of bacteria. Nucleic acid from the
bacterium is amplified using the primers described above to obtain
an amplification product. The molecular mass of the amplification
product is measured. Optionally, the base composition of the
amplification product is determined from the molecular mass. The
molecular mass or base composition is compared with a plurality of
molecular masses or base compositions of known analogous bacterial
identifying amplicons, wherein a match between the molecular mass
or base composition and a member of the plurality of molecular
masses or base compositions identifies the bacterium. In some
embodiments, the molecular mass is measured by mass spectrometry in
a modality such as electrospray ionization (ESI) time of flight
(TOF) mass spectrometry or ESI Fourier transform ion cyclotron
resonance (FTICR) mass spectrometry, for example. Other mass
spectrometry techniques can also be used to measure the molecular
mass of bacterial bioagent identifying amplicons.
[0200] In some embodiments, the present invention is also directed
to a method for determining the presence or absence of a bacterium
in a sample. Nucleic acid from the sample is amplified using the
composition described above to obtain an amplification product. The
molecular mass of the amplification product is determined.
Optionally, the base composition of the amplification product is
determined from the molecular mass. The molecular mass or base
composition of the amplification product is compared with the known
molecular masses or base compositions of one or more known
analogous bacterial bioagent identifying amplicons, wherein a match
between the molecular mass or base composition of the amplification
product and the molecular mass or base composition of one or more
known bacterial bioagent identifying amplicons indicates the
presence of the bacterium in the sample. In some embodiments, the
molecular mass is measured by mass spectrometry.
[0201] In some embodiments, the present invention also provides
methods for determination of the quantity of an unknown bacterium
in a sample. The sample is contacted with the composition described
above and a known quantity of a calibration polynucleotide
comprising a calibration sequence. Nucleic acid from the unknown
bacterium in the sample is concurrently amplified with the
composition described above and nucleic acid from the calibration
polynucleotide in the sample is concurrently amplified with the
composition described above to obtain a first amplification product
comprising a bacterial bioagent identifying amplicon and a second
amplification product comprising a calibration amplicon. The
molecular masses and abundances for the bacterial bioagent
identifying amplicon and the calibration amplicon are determined.
The bacterial bioagent identifying amplicon is distinguished from
the calibration amplicon based on molecular mass and comparison of
bacterial bioagent identifying amplicon abundance and calibration
amplicon abundance indicates the quantity of bacterium in the
sample. In some embodiments, the base composition of the bacterial
bioagent identifying amplicon is determined.
[0202] In some embodiments, the present invention provides methods
for detecting or quantifying bacteria by combining a nucleic acid
amplification process with a mass determination process. In some
embodiments, such methods identify or otherwise analyze the
bacterium by comparing mass information from an amplification
product with a calibration or control product. Such methods can be
carried out in a highly multiplexed and/or parallel manner allowing
for the analysis of as many as 300 samples per 24 hours on a single
mass measurement platform. The accuracy of the mass determination
methods in some embodiments of the present invention permits allows
for the ability to discriminate between different bacteria such as,
for example, various genotypes and drug resistant strains of
Staphylococcus aureus.
BRIEF DESCRIPTION OF THE DRAWINGS
[0203] The foregoing summary of the invention, as well as the
following detailed description of the invention, is better
understood when read in conjunction with the accompanying drawings
which are included by way of example and not by way of
limitation.
[0204] FIG. 1: process diagram illustrating a representative primer
pair selection process.
[0205] FIG. 2: process diagram illustrating an embodiment of the
calibration method.
[0206] FIG. 3: common pathogenic bacteria and primer pair coverage.
The primer pair number in the upper right hand corner of each
polygon indicates that the primer pair can produce a bioagent
identifying amplicon for all species within that polygon.
[0207] FIG. 4: a representative 3D diagram of base composition
(axes A, G and C) of bioagent identifying amplicons obtained with
primer pair number 14 (a precursor of primer pair number 348 which
targets 16S rRNA). The diagram indicates that the experimentally
determined base compositions of the clinical samples (labeled NHRC
samples) closely match the base compositions expected for
Streptococcus pyogenes and are distinct from the expected base
compositions of other organisms.
[0208] FIG. 5: a representative mass spectrum of amplification
products indicating the presence of bioagent identifying amplicons
of Streptococcus pyogenes, Neisseria meningitidis, and Haemophilus
influenzae obtained from amplification of nucleic acid from a
clinical sample with primer pair number 349 which targets 23S rRNA.
Experimentally determined molecular masses and base compositions
for the sense strand of each amplification product are shown.
[0209] FIG. 6: a representative mass spectrum of amplification
products representing a bioagent identifying amplicon of
Streptococcus pyogenes, and a calibration amplicon obtained from
amplification of nucleic acid from a clinical sample with primer
pair number 356 which targets rp1B. The experimentally determined
molecular mass and base composition for the sense strand of the
Streptococcus pyogenes amplification product is shown.
[0210] FIG. 7: a representative mass spectrum of an amplified
nucleic acid mixture which contained the Ames strain of Bacillus
anthracis, a known quantity of combination calibration
polynucleotide (SEQ ID NO: 1464), and primer pair number 350 which
targets the capC gene on the virulence plasmid pX02 of Bacillus
anthracis. Calibration amplicons produced in the amplification
reaction are visible in the mass spectrum as indicated and
abundance data (peak height) are used to calculate the quantity of
the Ames strain of Bacillus anthracis.
DEFINITIONS
[0211] As used herein, the term "abundance" refers to an amount.
The amount may be described in terms of concentration which are
common in molecular biology such as "copy number," "pfu or
plate-forming unit" which are well known to those with ordinary
skill. Concentration may be relative to a known standard or may be
absolute.
[0212] As used herein, the term "amplifiable nucleic acid" is used
in reference to nucleic acids that may be amplified by any
amplification method. It is contemplated that "amplifiable nucleic
acid" also comprises "sample template."
[0213] As used herein the term "amplification" refers to a special
case of nucleic acid replication involving template specificity. It
is to be contrasted with non-specific template replication (i.e.,
replication that is template-dependent but not dependent on a
specific template). Template specificity is here distinguished from
fidelity of replication (i.e., synthesis of the proper
polynucleotide sequence) and nucleotide (ribo- or deoxyribo-)
specificity. Template specificity is frequently described in terms
of "target" specificity. Target sequences are "targets" in the
sense that they are sought to be sorted out from other nucleic
acid. Amplification techniques have been designed primarily for
this sorting out. Template specificity is achieved in most
amplification techniques by the choice of enzyme. Amplification
enzymes are enzymes that, under conditions they are used, will
process only specific sequences of nucleic acid in a heterogeneous
mixture of nucleic acid. For example, in the case of Q.beta.
replicase, MDV-1 RNA is the specific template for the replicase (D.
L. Kacian et al., Proc. Natl. Acad. Sci. USA 69:3038 [1972]). Other
nucleic acid will not be replicated by this amplification enzyme.
Similarly, in the case of T7 RNA polymerase, this amplification
enzyme has a stringent specificity for its own promoters
(Chamberlin et al., Nature 228:227 [1970]). In the case of T4 DNA
ligase, the enzyme will not ligate the two oligonucleotides or
polynucleotides, where there is a mismatch between the
oligonucleotide or polynucleotide substrate and the template at the
ligation junction (D. Y. Wu and R. B. Wallace, Genomics 4:560
[1989]). Finally, Taq and Pfu polymerases, by virtue of their
ability to function at high temperature, are found to display high
specificity for the sequences bounded and thus defined by the
primers; the high temperature results in thermodynamic conditions
that favor primer hybridization with the target sequences and not
hybridization with non-target sequences (H. A. Erlich (ed.), PCR
Technology, Stockton Press [1989]).
[0214] As used herein, the term "amplification reagents" refers to
those reagents (deoxyribonucleotide triphosphates, buffer, etc.),
needed for amplification, excluding primers, nucleic acid template,
and the amplification enzyme. Typically, amplification reagents
along with other reaction components are placed and contained in a
reaction vessel (test tube, microwell, etc.).
[0215] As used herein, the term "analogous" when used in context of
comparison of bioagent identifying amplicons indicates that the
bioagent identifying amplicons being compared are produced with the
same pair of primers. For example, bioagent identifying amplicon
"A" and bioagent identifying amplicon "B", produced with the same
pair of primers are analogous with respect to each other. Bioagent
identifying amplicon "C", produced with a different pair of primers
is not analogous to either bioagent identifying amplicon "A" or
bioagent identifying amplicon "B".
[0216] As used herein, the term "anion exchange functional group"
refers to a positively charged functional group capable of binding
an anion through an electrostatic interaction. The most well known
anion exchange functional groups are the amines, including primary,
secondary, tertiary and quaternary amines.
[0217] The term "bacteria" or "bacterium" refers to any member of
the groups of eubacteria and archaebacteria.
[0218] As used herein, a "base composition" is the exact number of
each nucleobase (for example, A, T, C and G) in a segment of
nucleic acid. For example, amplification of nucleic acid of
Staphylococcus aureus strain carrying the lukS-PV gene with primer
pair number 2095 (SEQ ID NOs: 456:1261) produces an amplification
product 117 nucleobases in length from nucleic acid of the lukS-PV
gene that has a base composition of A35 G17 C19 T46 (by
convention--with reference to the sense strand of the amplification
product). Because the molecular masses of each of the four natural
nucleotides and chemical modifications thereof are known (if
applicable), a measured molecular mass can be deconvoluted to a
list of possible base compositions. Identification of a base
composition of a sense strand which is complementary to the
corresponding antisense strand in terms of base composition
provides a confirmation of the true base composition of an unknown
amplification product. For example, the base composition of the
antisense strand of the 139 nucleobase amplification product
described above is A46 G19 C17 T35.
[0219] As used herein, a "base composition probability cloud" is a
representation of the diversity in base composition resulting from
a variation in sequence that occurs among different isolates of a
given species. The "base composition probability cloud" represents
the base composition constraints for each species and is typically
visualized using a pseudo four-dimensional plot.
[0220] In the context of this invention, a "bioagent" is any
organism, cell, or virus, living or dead, or a nucleic acid derived
from such an organism, cell or virus. Examples of bioagents
include, but are not limited, to cells, (including but not limited
to human clinical samples, bacterial cells and other pathogens),
viruses, fungi, protists, parasites, and pathogenicity markers
(including but not limited to: pathogenicity islands, antibiotic
resistance genes, virulence factors, toxin genes and other
bioregulating compounds). Samples may be alive or dead or in a
vegetative state (for example, vegetative bacteria or spores) and
may be encapsulated or bioengineered. In the context of this
invention, a "pathogen" is a bioagent which causes a disease or
disorder.
[0221] As used herein, a "bioagent division" is defined as group of
bioagents above the species level and includes but is not limited
to, orders, families, classes, clades, genera or other such
groupings of bioagents above the species level.
[0222] As used herein, the term "bioagent identifying amplicon"
refers to a polynucleotide that is amplified from a bioagent in an
amplification reaction and which 1) provides sufficient variability
to distinguish among bioagents from whose nucleic acid the bioagent
identifying amplicon is produced and 2) whose molecular mass is
amenable to a rapid and convenient molecular mass determination
modality such as mass spectrometry, for example.
[0223] As used herein, the term "biological product" refers to any
product originating from an organism. Biological products are often
products of processes of biotechnology. Examples of biological
products include, but are not limited to: cultured cell lines,
cellular components, antibodies, proteins and other cell-derived
biomolecules, growth media, growth harvest fluids, natural products
and bio-pharmaceutical products.
[0224] The terms "biowarfare agent" and "bioweapon" are synonymous
and refer to a bacterium, virus, fungus or protozoan that could be
deployed as a weapon to cause bodily harm to individuals. Military
or terrorist groups may be implicated in deployment of biowarfare
agents.
[0225] In context of this invention, the term "broad range survey
primer pair" refers to a primer pair designed to produce bioagent
identifying amplicons across different broad groupings of
bioagents. For example, the ribosomal RNA-targeted primer pairs are
broad range survey primer pairs which have the capability of
producing bacterial bioagent identifying amplicons for essentially
all known bacteria. With respect to broad range primer pairs
employed for identification of bacteria, a broad range survey
primer pair for bacteria such as 16S rRNA primer pair number 346
(SEQ ID NOs: 202:1110) for example, will produce an bacterial
bioagent identifying amplicon for essentially all known
bacteria.
[0226] The term "calibration amplicon" refers to a nucleic acid
segment representing an amplification product obtained by
amplification of a calibration sequence with a pair of primers
designed to produce a bioagent identifying amplicon.
[0227] The term "calibration sequence" refers to a polynucleotide
sequence to which a given pair of primers hybridizes for the
purpose of producing an internal (i.e: included in the reaction)
calibration standard amplification product for use in determining
the quantity of a bioagent in a sample. The calibration sequence
may be expressly added to an amplification reaction, or may already
be present in the sample prior to analysis.
[0228] The term "clade primer pair" refers to a primer pair
designed to produce bioagent identifying amplicons for species
belonging to a clade group. A clade primer pair may also be
considered as a "speciating" primer pair which is useful for
distinguishing among closely related species.
[0229] The term "codon" refers to a set of three adjoined
nucleotides (triplet) that codes for an amino acid or a termination
signal.
[0230] In context of this invention, the term "codon base
composition analysis," refers to determination of the base
composition of an individual codon by obtaining a bioagent
identifying amplicon that includes the codon. The bioagent
identifying amplicon will at least include regions of the target
nucleic acid sequence to which the primers hybridize for generation
of the bioagent identifying amplicon as well as the codon being
analyzed, located between the two primer hybridization regions.
[0231] As used herein, the terms "complementary" or
"complementarity" are used in reference to polynucleotides (i.e., a
sequence of nucleotides such as an oligonucleotide or a target
nucleic acid) related by the base-pairing rules. For example, for
the sequence "5'-A-G-T-3'," is complementary to the sequence
"3'-T-C-A-5'." Complementarity may be "partial," in which only some
of the nucleic acids' bases are matched according to the base
pairing rules. Or, there may be "complete" or "total"
complementarity between the nucleic acids. The degree of
complementarity between nucleic acid strands has significant
effects on the efficiency and strength of hybridization between
nucleic acid strands. This is of particular importance in
amplification reactions, as well as detection methods that depend
upon binding between nucleic acids. Either term may also be used in
reference to individual nucleotides, especially within the context
of polynucleotides. For example, a particular nucleotide within an
oligonucleotide may be noted for its complementarity, or lack
thereof, to a nucleotide within another nucleic acid strand, in
contrast or comparison to the complementarity between the rest of
the oligonucleotide and the nucleic acid strand.
[0232] The term "complement of a nucleic acid sequence" as used
herein refers to an oligonucleotide which, when aligned with the
nucleic acid sequence such that the 5' end of one sequence is
paired with the 3' end of the other, is in "antiparallel
association." Certain bases not commonly found in natural nucleic
acids may be included in the nucleic acids of the present invention
and include, for example, inosine and 7-deazaguanine.
Complementarity need not be perfect; stable duplexes may contain
mismatched base pairs or unmatched bases. Those skilled in the art
of nucleic acid technology can determine duplex stability
empirically considering a number of variables including, for
example, the length of the oligonucleotide, base composition and
sequence of the oligonucleotide, ionic strength and incidence of
mismatched base pairs. Where a first oligonucleotide is
complementary to a region of a target nucleic acid and a second
oligonucleotide has complementary to the same region (or a portion
of this region) a "region of overlap" exists along the target
nucleic acid. The degree of overlap will vary depending upon the
extent of the complementarity.
[0233] In context of this invention, the term "division-wide primer
pair" refers to a primer pair designed to produce bioagent
identifying amplicons within sections of a broader spectrum of
bioagents For example, primer pair number 352 (SEQ ID NOs:
687:1411), a division-wide primer pair, is designed to produce
bacterial bioagent identifying amplicons for members of the
Bacillus group of bacteria which comprises, for example, members of
the genera Streptococci, Enterococci, and Staphylococci. Other
division-wide primer pairs may be used to produce bacterial
bioagent identifying amplicons for other groups of bacterial
bioagents.
[0234] As used herein, the term "concurrently amplifying" used with
respect to more than one amplification reaction refers to the act
of simultaneously amplifying more than one nucleic acid in a single
reaction mixture.
[0235] As used herein, the term "drill-down primer pair" refers to
a primer pair designed to produce bioagent identifying amplicons
for identification of sub-species characteristics or confirmation
of a species assignment. For example, primer pair number 2146 (SEQ
ID NOs: 437:1137), a drill-down Staphylococcus aureus genotyping
primer pair, is designed to produce Staphylococcus aureus
genotyping amplicons. Other drill-down primer pairs may be used to
produce bioagent identifying amplicons for Staphylococcus aureus
and other bacterial species.
[0236] The term "duplex" refers to the state of nucleic acids in
which the base portions of the nucleotides on one strand are bound
through hydrogen bonding the their complementary bases arrayed on a
second strand. The condition of being in a duplex form reflects on
the state of the bases of a nucleic acid. By virtue of base
pairing, the strands of nucleic acid also generally assume the
tertiary structure of a double helix, having a major and a minor
groove. The assumption of the helical form is implicit in the act
of becoming duplexed.
[0237] As used herein, the term "etiology" refers to the causes or
origins, of diseases or abnormal physiological conditions.
[0238] The term "gene" refers to a DNA sequence that comprises
control and coding sequences necessary for the production of an RNA
having a non-coding function (e.g., a ribosomal or transfer RNA), a
polypeptide or a precursor. The RNA or polypeptide can be encoded
by a full length coding sequence or by any portion of the coding
sequence so long as the desired activity or function is
retained.
[0239] The terms "homology," "homologous" and "sequence identity"
refer to a degree of identity. There may be partial homology or
complete homology. A partially homologous sequence is one that is
less than 100% identical to another sequence. Determination of
sequence identity is described in the following example: a primer
20 nucleobases in length which is otherwise identical to another 20
nucleobase primer but having two non-identical residues has 18 of
20 identical residues (18/20=0.9 or 90% sequence identity). In
another example, a primer 15 nucleobases in length having all
residues identical to a 15 nucleobase segment of a primer 20
nucleobases in length would have 15/20=0.75 or 75% sequence
identity with the 20 nucleobase primer. In context of the present
invention, sequence identity is meant to be properly determined
when the query sequence and the subject sequence are both described
and aligned in the 5' to 3' direction. Sequence alignment
algorithms such as BLAST, will return results in two different
alignment orientations. In the Plus/Plus orientation, both the
query sequence and the subject sequence are aligned in the 5' to 3'
direction. On the other hand, in the Plus/Minus orientation, the
query sequence is in the 5' to 3' direction while the subject
sequence is in the 3' to 5' direction. It should be understood that
with respect to the primers of the present invention, sequence
identity is properly determined when the alignment is designated as
Plus/Plus. Sequence identity may also encompass alternate or
modified nucleobases that perform in a functionally similar manner
to the regular nucleobases adenine, thymine, guanine and cytosine
with respect to hybridization and primer extension in amplification
reactions. In a non-limiting example, if the 5-propynyl pyrimidines
propyne C and/or propyne T replace one or more C or T residues in
one primer which is otherwise identical to another primer in
sequence and length, the two primers will have 100% sequence
identity with each other. In another non-limiting example, Inosine
(I) may be used as a replacement for G or T and effectively
hybridize to C, A or U (uracil). Thus, if inosine replaces one or
more C, A or U residues in one primer which is otherwise identical
to another primer in sequence and length, the two primers will have
100% sequence identity with each other. Other such modified or
universal bases may exist which would perform in a functionally
similar manner for hybridization and amplification reactions and
will be understood to fall within this definition of sequence
identity.
[0240] As used herein, "housekeeping gene" refers to a gene
encoding a protein or RNA involved in basic functions required for
survival and reproduction of a bioagent. Housekeeping genes
include, but are not limited to genes encoding RNA or proteins
involved in translation, replication, recombination and repair,
transcription, nucleotide metabolism, amino acid metabolism, lipid
metabolism, energy generation, uptake, secretion and the like.
[0241] As used herein, the term "hybridization" is used in
reference to the pairing of complementary nucleic acids.
Hybridization and the strength of hybridization (i.e., the strength
of the association between the nucleic acids) is influenced by such
factors as the degree of complementary between the nucleic acids,
stringency of the conditions involved, and the T.sub.m of the
formed hybrid. "Hybridization" methods involve the annealing of one
nucleic acid to another, complementary nucleic acid, i.e., a
nucleic acid having a complementary nucleotide sequence. The
ability of two polymers of nucleic acid containing complementary
sequences to find each other and anneal through base pairing
interaction is a well-recognized phenomenon. The initial
observations of the "hybridization" process by Marmur and Lane,
Proc. Natl. Acad. Sci. USA 46:453 (1960) and Doty et al., Proc.
Natl. Acad. Sci. USA 46:461 (1960) have been followed by the
refinement of this process into an essential tool of modern
biology.
[0242] The term "in silico" refers to processes taking place via
computer calculations. For example, electronic PCR (ePCR) is a
process analogous to ordinary PCR except that it is carried out
using nucleic acid sequences and primer pair sequences stored on a
computer formatted medium.
[0243] As used herein, "intelligent primers" are primers that are
designed to bind to highly conserved sequence regions of a bioagent
identifying amplicon that flank an intervening variable region and,
upon amplification, yield amplification products which ideally
provide enough variability to distinguish individual bioagents, and
which are amenable to molecular mass analysis. By the term "highly
conserved," it is meant that the sequence regions exhibit between
about 80-100%, or between about 90-100%, or between about 95-100%
identity among all, or at least 70%, at least 80%, at least 90%, at
least 95%, or at least 99% of species or strains.
[0244] The "ligase chain reaction" (LCR; sometimes referred to as
"Ligase Amplification Reaction" (LAR) described by Barany, Proc.
Natl. Acad. Sci., 88:189 (1991); Barany, PCR Methods and Applic.,
1:5 (1991); and Wu and Wallace, Genomics 4:560 (1989) has developed
into a well-recognized alternative method for amplifying nucleic
acids. In LCR, four oligonucleotides, two adjacent oligonucleotides
which uniquely hybridize to one strand of target DNA, and a
complementary set of adjacent oligonucleotides, that hybridize to
the opposite strand are mixed and DNA ligase is added to the
mixture. Provided that there is complete complementarity at the
junction, ligase will covalently link each set of hybridized
molecules. Importantly, in LCR, two probes are ligated together
only when they base-pair with sequences in the target sample,
without gaps or mismatches. Repeated cycles of denaturation,
hybridization and ligation amplify a short segment of DNA. LCR has
also been used in combination with PCR to achieve enhanced
detection of single-base changes. However, because the four
oligonucleotides used in this assay can pair to form two short
ligatable fragments, there is the potential for the generation of
target-independent background signal. The use of LCR for mutant
screening is limited to the examination of specific nucleic acid
positions.
[0245] The term "locked nucleic acid" or "LNA" refers to a nucleic
acid analogue containing one or more 2'-O,
4'-.beta.-methylene-(3-D-ribofuranosyl nucleotide monomers in an
RNA mimicking sugar conformation. LNA oligonucleotides display
unprecedented hybridization affinity toward complementary
single-stranded RNA and complementary single- or double-stranded
DNA. LNA oligonucleotides induce A-type (RNA-like) duplex
conformations. The primers of the present invention may contain LNA
modifications.
[0246] As used herein, the term "mass-modifying tag" refers to any
modification to a given nucleotide which results in an increase in
mass relative to the analogous non-mass modified nucleotide.
Mass-modifying tags can include heavy isotopes of one or more
elements included in the nucleotide such as carbon-13 for example.
Other possible modifications include addition of substituents such
as iodine or bromine at the 5 position of the nucleobase for
example.
[0247] The term "mass spectrometry" refers to measurement of the
mass of atoms or molecules. The molecules are first converted to
ions, which are separated using electric or magnetic fields
according to the ratio of their mass to electric charge. The
measured masses are used to identity the molecules.
[0248] The term "microorganism" as used herein means an organism
too small to be observed with the unaided eye and includes, but is
not limited to bacteria, virus, protozoans, fungi; and
ciliates.
[0249] The term "multi-drug resistant" or multiple-drug resistant"
refers to a microorganism which is resistant to more than one of
the antibiotics or antimicrobial agents used in the treatment of
said microorganism.
[0250] The term "multiplex PCR" refers to a PCR reaction where more
than one primer set is included in the reaction pool allowing 2 or
more different DNA targets to be amplified by PCR in a single
reaction tube.
[0251] The term "non-template tag" refers to a stretch of at least
three guanine or cytosine nucleobases of a primer used to produce a
bioagent identifying amplicon which are not complementary to the
template. A non-template tag is incorporated into a primer for the
purpose of increasing the primer-duplex stability of later cycles
of amplification by incorporation of extra G-C pairs which each
have one additional hydrogen bond relative to an A-T pair.
[0252] The term "nucleic acid sequence" as used herein refers to
the linear composition of the nucleic acid residues A, T, C or G or
any modifications thereof, within an oligonucleotide, nucleotide or
polynucleotide, and fragments or portions thereof, and to DNA or
RNA of genomic or synthetic origin which may be single or double
stranded, and represent the sense or antisense strand
[0253] As used herein, the term "nucleobase" is synonymous with
other terms in use in the art including "nucleotide,"
"deoxynucleotide," "nucleotide residue," "deoxynucleotide residue,"
"nucleotide triphosphate (NTP)," or deoxynucleotide triphosphate
(dNTP).
[0254] The term "nucleotide analog" as used herein refers to
modified or non-naturally occurring nucleotides such as 5-propynyl
pyrimidines (i.e., 5-propynyl-dTTP and 5-propynyl-dTCP), 7-deaza
purines (i.e., 7-deaza-dATP and 7-deaza-dGTP). Nucleotide analogs
include base analogs and comprise modified forms of
deoxyribonucleotides as well as ribonucleotides.
[0255] The term "oligonucleotide" as used herein is defined as a
molecule comprising two or more deoxyribonucleotides or
ribonucleotides, preferably at least 5 nucleotides, more preferably
at least about 13 to 35 nucleotides. The exact size will depend on
many factors, which in turn depend on the ultimate function or use
of the oligonucleotide. The oligonucleotide may be generated in any
manner, including chemical synthesis, DNA replication, reverse
transcription, PCR, or a combination thereof. Because
mononucleotides are reacted to make oligonucleotides in a manner
such that the 5' phosphate of one mononucleotide pentose ring is
attached to the 3' oxygen of its neighbor in one direction via a
phosphodiester linkage, an end of an oligonucleotide is referred to
as the "5'-end" if its 5' phosphate is not linked to the 3' oxygen
of a mononucleotide pentose ring and as the "3'-end" if its 3'
oxygen is not linked to a 5' phosphate of a subsequent
mononucleotide pentose ring. As used herein, a nucleic acid
sequence, even if internal to a larger oligonucleotide, also may be
said to have 5' and 3' ends. A first region along a nucleic acid
strand is said to be upstream of another region if the 3' end of
the first region is before the 5' end of the second region when
moving along a strand of nucleic acid in a 5' to 3' direction. All
oligonucleotide primers disclosed herein are understood to be
presented in the 5' to 3' direction when reading left to right.
When two different, non-overlapping oligonucleotides anneal to
different regions of the same linear complementary nucleic acid
sequence, and the 3' end of one oligonucleotide points towards the
5' end of the other, the former may be called the "upstream"
oligonucleotide and the latter the "downstream" oligonucleotide.
Similarly, when two overlapping oligonucleotides are hybridized to
the same linear complementary nucleic acid sequence, with the first
oligonucleotide positioned such that its 5' end is upstream of the
5' end of the second oligonucleotide, and the 3' end of the first
oligonucleotide is upstream of the 3' end of the second
oligonucleotide, the first oligonucleotide may be called the
"upstream" oligonucleotide and the second oligonucleotide may be
called the "downstream" oligonucleotide.
[0256] In the context of this invention, a "pathogen" is a bioagent
which causes a disease or disorder.
[0257] As used herein, the terms "PCR product," "PCR fragment," and
"amplification product" refer to the resultant mixture of compounds
after two or more cycles of the PCR steps of denaturation,
annealing and extension are complete. These terms encompass the
case where there has been amplification of one or more segments of
one or more target sequences.
[0258] The term "peptide nucleic acid" ("PNA") as used herein
refers to a molecule comprising bases or base analogs such as would
be found in natural nucleic acid, but attached to a peptide
backbone rather than the sugar-phosphate backbone typical of
nucleic acids. The attachment of the bases to the peptide is such
as to allow the bases to base pair with complementary bases of
nucleic acid in a manner similar to that of an oligonucleotide.
These small molecules, also designated anti gene agents, stop
transcript elongation by binding to their complementary strand of
nucleic acid (Nielsen, et al. Anticancer Drug Des. 8:53 63). The
primers of the present invention may comprise PNAs.
[0259] The term "polymerase" refers to an enzyme having the ability
to synthesize a complementary strand of nucleic acid from a
starting template nucleic acid strand and free dNTPs.
[0260] As used herein, the term "polymerase chain reaction" ("PCR")
refers to the method of K. B. Mullis U.S. Pat. Nos. 4,683,195,
4,683,202, and 4,965,188, hereby incorporated by reference, that
describe a method for increasing the concentration of a segment of
a target sequence in a mixture of genomic DNA without cloning or
purification. This process for amplifying the target sequence
consists of introducing a large excess of two oligonucleotide
primers to the DNA mixture containing the desired target sequence,
followed by a precise sequence of thermal cycling in the presence
of a DNA polymerase. The two primers are complementary to their
respective strands of the double stranded target sequence. To
effect amplification, the mixture is denatured and the primers then
annealed to their complementary sequences within the target
molecule. Following annealing, the primers are extended with a
polymerase so as to form a new pair of complementary strands. The
steps of denaturation, primer annealing, and polymerase extension
can be repeated many times (i.e., denaturation, annealing and
extension constitute one "cycle"; there can be numerous "cycles")
to obtain a high concentration of an amplified segment of the
desired target sequence. The length of the amplified segment of the
desired target sequence is determined by the relative positions of
the primers with respect to each other, and therefore, this length
is a controllable parameter. By virtue of the repeating aspect of
the process, the method is referred to as the "polymerase chain
reaction" (hereinafter "PCR"). Because the desired amplified
segments of the target sequence become the predominant sequences
(in terms of concentration) in the mixture, they are said to be
"PCR amplified." With PCR, it is possible to amplify a single copy
of a specific target sequence in genomic DNA to a level detectable
by several different methodologies (e.g., hybridization with a
labeled probe; incorporation of biotinylated primers followed by
avidin-enzyme conjugate detection; incorporation of 32P-labeled
deoxynucleotide triphosphates, such as dCTP or dATP, into the
amplified segment). In addition to genomic DNA, any oligonucleotide
or polynucleotide sequence can be amplified with the appropriate
set of primer molecules. In particular, the amplified segments
created by the PCR process itself are, themselves, efficient
templates for subsequent PCR amplifications.
[0261] The term "polymerization means" or "polymerization agent"
refers to any agent capable of facilitating the addition of
nucleoside triphosphates to an oligonucleotide. Preferred
polymerization means comprise DNA and RNA polymerases.
[0262] As used herein, the terms "pair of primers," or "primer
pair" are synonymous. A primer pair is used for amplification of a
nucleic acid sequence. A pair of primers comprises a forward primer
and a reverse primer. The forward primer hybridizes to a sense
strand of a target gene sequence to be amplified and primes
synthesis of an antisense strand (complementary to the sense
strand) using the target sequence as a template. A reverse primer
hybridizes to the antisense strand of a target gene sequence to be
amplified and primes synthesis of a sense strand (complementary to
the antisense strand) using the target sequence as a template.
[0263] The primers are designed to bind to highly conserved
sequence regions of a bioagent identifying amplicon that flank an
intervening variable region and yield amplification products which
ideally provide enough variability to distinguish each individual
bioagent, and which are amenable to molecular mass analysis. In
some embodiments, the highly conserved sequence regions exhibit
between about 80-100%, or between about 90-100%, or between about
95-100% identity, or between about 99-100% identity. The molecular
mass of a given amplification product provides a means of
identifying the bioagent from which it was obtained, due to the
variability of the variable region. Thus design of the primers
requires selection of a variable region with appropriate
variability to resolve the identity of a given bioagent. Bioagent
identifying amplicons are ideally specific to the identity of the
bioagent.
[0264] Properties of the primers may include any number of
properties related to structure including, but not limited to:
nucleobase length which may be contiguous (linked together) or
non-contiguous (for example, two or more contiguous segments which
are joined by a linker or loop moiety), modified or universal
nucleobases (used for specific purposes such as for example,
increasing hybridization affinity, preventing non-templated
adenylation and modifying molecular mass) percent complementarity
to a given target sequences.
[0265] Properties of the primers also include functional features
including, but not limited to, orientation of hybridization
(forward or reverse) relative to a nucleic acid template. The
coding or sense strand is the strand to which the forward priming
primer hybridizes (forward priming orientation) while the reverse
priming primer hybridizes to the non-coding or antisense strand
(reverse priming orientation). The functional properties of a given
primer pair also include the generic template nucleic acid to which
the primer pair hybridizes. For example, identification of
bioagents can be accomplished at different levels using primers
suited to resolution of each individual level of identification.
Broad range survey primers are designed with the objective of
identifying a bioagent as a member of a particular division (e.g.,
an order, family, genus or other such grouping of bioagents above
the species level of bioagents). In some embodiments, broad range
survey intelligent primers are capable of identification of
bioagents at the species or sub-species level. Other primers may
have the functionality of producing bioagent identifying amplicons
for members of a given taxonomic genus, clade, species, sub-species
or genotype (including genetic variants which may include presence
of virulence genes or antibiotic resistance genes or mutations).
Additional functional properties of primer pairs include the
functionality of performing amplification either singly (single
primer pair per amplification reaction vessel) or in a multiplex
fashion (multiple primer pairs and multiple amplification reactions
within a single reaction vessel).
[0266] As used herein, the terms "purified" or "substantially
purified" refer to molecules, either nucleic or amino acid
sequences, that are removed from their natural environment,
isolated or separated, and are at least 60% free, preferably 75%
free, and most preferably 90% free from other components with which
they are naturally associated. An "isolated polynucleotide" or
"isolated oligonucleotide" is therefore a substantially purified
polynucleotide.
[0267] The term "reverse transcriptase" refers to an enzyme having
the ability to transcribe DNA from an RNA template. This enzymatic
activity is known as reverse transcriptase activity. Reverse
transcriptase activity is desirable in order to obtain DNA from RNA
viruses which can then be amplified and analyzed by the methods of
the present invention.
[0268] The term "ribosomal RNA" or "rRNA" refers to the primary
ribonucleic acid constituent of ribosomes. Ribosomes are the
protein-manufacturing organelles of cells and exist in the
cytoplasm. Ribosomal RNAs are transcribed from the DNA genes
encoding them.
[0269] The term "sample" in the present specification and claims is
used in its broadest sense. On the one hand it is meant to include
a specimen or culture (e.g., microbiological cultures). On the
other hand, it is meant to include both biological and
environmental samples. A sample may include a specimen of synthetic
origin. Biological samples may be animal, including human, fluid,
solid (e.g., stool) or tissue, as well as liquid and solid food and
feed products and ingredients such as dairy items, vegetables, meat
and meat by-products, and waste. Biological samples may be obtained
from all of the various families of domestic animals, as well as
feral or wild animals, including, but not limited to, such animals
as ungulates, bear, fish, lagamorphs, rodents, etc. Environmental
samples include environmental material such as surface matter,
soil, water, air and industrial samples, as well as samples
obtained from food and dairy processing instruments, apparatus,
equipment, utensils, disposable and non-disposable items. These
examples are not to be construed as limiting the sample types
applicable to the present invention. The term "source of target
nucleic acid" refers to any sample that contains nucleic acids (RNA
or DNA). Particularly preferred sources of target nucleic acids are
biological samples including, but not limited to blood, saliva,
cerebral spinal fluid, pleural fluid, milk, lymph, sputum and
semen.
[0270] As used herein, the term "sample template" refers to nucleic
acid originating from a sample that is analyzed for the presence of
"target" (defined below). In contrast, "background template" is
used in reference to nucleic acid other than sample template that
may or may not be present in a sample. Background template is often
a contaminant. It may be the result of carryover, or it may be due
to the presence of nucleic acid contaminants sought to be purified
away from the sample. For example, nucleic acids from organisms
other than those to be detected may be present as background in a
test sample.
[0271] A "segment" is defined herein as a region of nucleic acid
within a target sequence.
[0272] The "self-sustained sequence replication reaction" (3SR)
(Guatelli et al., Proc. Natl. Acad. Sci., 87:1874-1878 [1990], with
an erratum at Proc. Natl. Acad. Sci., 87:7797 [1990]) is a
transcription-based in vitro amplification system (Kwok et al.,
Proc. Natl. Acad. Sci., 86:1173-1177 [1989]) that can exponentially
amplify RNA sequences at a uniform temperature. The amplified RNA
can then be utilized for mutation detection (Fahy et al., PCR Meth.
Appl., 1:25-33 [1991]). In this method, an oligonucleotide primer
is used to add a phage RNA polymerase promoter to the 5' end of the
sequence of interest. In a cocktail of enzymes and substrates that
includes a second primer, reverse transcriptase, RNase H, RNA
polymerase and ribo- and deoxyribonucleoside triphosphates, the
target sequence undergoes repeated rounds of transcription, cDNA
synthesis and second-strand synthesis to amplify the area of
interest. The use of 3SR to detect mutations is kinetically limited
to screening small segments of DNA (e.g., 200-300 base pairs).
[0273] As used herein, the term ""sequence alignment"" refers to a
listing of multiple DNA or amino acid sequences and aligns them to
highlight their similarities. The listings can be made using
bioinformatics computer programs.
[0274] In context of this invention, the term "speciating primer
pair" refers to a primer pair designed to produce a bioagent
identifying amplicon with the diagnostic capability of identifying
species members of a group of genera or a particular genus of
bioagents. Primer pair number 2249 (SEQ ID NOs: 430:1321), for
example, is a speciating primer pair used to distinguish
Staphylococcus aureus from other species of the genus
Staphylococcus.
[0275] As used herein, a "sub-species characteristic" is a genetic
characteristic that provides the means to distinguish two members
of the same bioagent species. For example, one viral strain could
be distinguished from another viral strain of the same species by
possessing a genetic change (e.g., for example, a nucleotide
deletion, addition or substitution) in one of the viral genes, such
as the RNA-dependent RNA polymerase. Sub-species characteristics
such as virulence genes and drug-are responsible for the phenotypic
differences among the different strains of bacteria.
[0276] As used herein, the term "target" is used in a broad sense
to indicate the gene or genomic region being amplified by the
primers. Because the present invention provides a plurality of
amplification products from any given primer pair (depending on the
bioagent being analyzed), multiple amplification products from
different specific nucleic acid sequences may be obtained. Thus,
the term "target" is not used to refer to a single specific nucleic
acid sequence. The "target" is sought to be sorted out from other
nucleic acid sequences and contains a sequence that has at least
partial complementarity with an oligonucleotide primer. The target
nucleic acid may comprise single- or double-stranded DNA or RNA. A
"segment" is defined as a region of nucleic acid within the target
sequence.
[0277] The term "template" refers to a strand of nucleic acid on
which a complementary copy is built from nucleoside triphosphates
through the activity of a template-dependent nucleic acid
polymerase. Within a duplex the template strand is, by convention,
depicted and described as the "bottom" strand. Similarly, the
non-template strand is often depicted and described as the "top"
strand.
[0278] As used herein, the term "T." is used in reference to the
"melting temperature." The melting temperature is the temperature
at which a population of double-stranded nucleic acid molecules
becomes half dissociated into single strands. Several equations for
calculating the T.sub.m of nucleic acids are well known in the art.
As indicated by standard references, a simple estimate of the
T.sub.m value may be calculated by the equation:
T.sub.m=81.5+0.41(% G+C), when a nucleic acid is in aqueous
solution at 1 M NaCl (see e.g., Anderson and Young, Quantitative
Filter Hybridization, in Nucleic Acid Hybridization (1985). Other
references (e.g., Allawi, H. T. & SantaLucia, J., Jr.
Thermodynamics and NMR of internal G.T mismatches in DNA.
Biochemistry 36, 10581-94 (1997) include more sophisticated
computations which take structural and environmental, as well as
sequence characteristics into account for the calculation of
T.sub.m.
[0279] The term "triangulation genotyping analysis" refers to a
method of genotyping a bioagent by measurement of molecular masses
or base compositions of amplification products, corresponding to
bioagent identifying amplicons, obtained by amplification of
regions of more than one gene. In this sense, the term
"triangulation" refers to a method of establishing the accuracy of
information by comparing three or more types of independent points
of view bearing on the same findings. Triangulation genotyping
analysis carried out with a plurality of triangulation genotyping
analysis primers yields a plurality of base compositions that then
provide a pattern or "barcode" from which a species type can be
assigned. The species type may represent a previously known
sub-species or strain, or may be a previously unknown strain having
a specific and previously unobserved base composition barcode
indicating the existence of a previously unknown genotype.
[0280] As used herein, the term "triangulation genotyping analysis
primer pair" is a primer pair designed to produce bioagent
identifying amplicons for determining species types in a
triangulation genotyping analysis.
[0281] The employment of more than one bioagent identifying
amplicon for identification of a bioagent is herein referred to as
"triangulation identification." Triangulation identification is
pursued by analyzing a plurality of bioagent identifying amplicons
produced with different primer pairs. This process is used to
reduce false negative and false positive signals, and enable
reconstruction of the origin of hybrid or otherwise engineered
bioagents. For example, identification of the three part toxin
genes typical of B. anthracis (Bowen et al., J. Appl. Microbiol.,
1999, 87, 270-278) in the absence of the expected signatures from
the B. anthracis genome would suggest a genetic engineering
event.
[0282] In the context of this invention, the term "unknown
bioagent" may mean either: (i) a bioagent whose existence is known
(such as the well known bacterial species Staphylococcus aureus for
example) but which is not known to be in a sample to be analyzed,
or (ii) a bioagent whose existence is not known (for example, the
SARS coronavirus was unknown prior to April 2003). For example, if
the method for identification of coronaviruses disclosed in
commonly owned U.S. patent Ser. No. 10/829,826 (incorporated herein
by reference in its entirety) was to be employed prior to April
2003 to identify the SARS coronavirus in a clinical sample, both
meanings of "unknown" bioagent are applicable since the SARS
coronavirus was unknown to science prior to April, 2003 and since
it was not known what bioagent (in this case a coronavirus) was
present in the sample. On the other hand, if the method of U.S.
patent Ser. No. 10/829,826 was to be employed subsequent to April
2003 to identify the SARS coronavirus in a clinical sample, only
the first meaning (i) of "unknown" bioagent would apply since the
SARS coronavirus became known to science subsequent to April 2003
and since it was not known what bioagent was present in the
sample.
[0283] The term "variable sequence" as used herein refers to
differences in nucleic acid sequence between two nucleic acids. For
example, the genes of two different bacterial species may vary in
sequence by the presence of single base substitutions and/or
deletions or insertions of one or more nucleotides. These two forms
of the structural gene are said to vary in sequence from one
another. In the context of the present invention, "viral nucleic
acid" includes, but is not limited to, DNA, RNA, or DNA that has
been obtained from viral RNA, such as, for example, by performing a
reverse transcription reaction. Viral RNA can either be
single-stranded (of positive or negative polarity) or
double-stranded.
[0284] The term "virus" refers to obligate, ultramicroscopic,
parasites that are incapable of autonomous replication (i.e.,
replication requires the use of the host cell's machinery). Viruses
can survive outside of a host cell but cannot replicate.
[0285] The term "wild-type" refers to a gene or a gene product that
has the characteristics of that gene or gene product when isolated
from a naturally occurring source. A wild-type gene is that which
is most frequently observed in a population and is thus arbitrarily
designated the "normal" or "wild-type" form of the gene. In
contrast, the term "modified", "mutant" or "polymorphic" refers to
a gene or gene product that displays modifications in sequence and
or functional properties (i.e., altered characteristics) when
compared to the wild-type gene or gene product. It is noted that
naturally-occurring mutants can be isolated; these are identified
by the fact that they have altered characteristics when compared to
the wild-type gene or gene product.
[0286] As used herein, a "wobble base" is a variation in a codon
found at the third nucleotide position of a DNA triplet. Variations
in conserved regions of sequence are often found at the third
nucleotide position due to redundancy in the amino acid code.
DETAILED DESCRIPTION OF EMBODIMENTS
A. Bioagent Identifying Amplicons
[0287] The present invention provides methods for detection and
identification of unknown bioagents using bioagent identifying
amplicons. Primers are selected to hybridize to conserved sequence
regions of nucleic acids derived from a bioagent, and which bracket
variable sequence regions to yield a bioagent identifying amplicon,
which can be amplified and which is amenable to molecular mass
determination. The molecular mass then provides a means to uniquely
identify the bioagent without a requirement for prior knowledge of
the possible identity of the bioagent. The molecular mass or
corresponding base composition signature of the amplification
product is then matched against a database of molecular masses or
base composition signatures. A match is obtained when an
experimentally-determined molecular mass or base composition of an
analyzed amplification product is compared with known molecular
masses or base compositions of known bioagent identifying amplicons
and the experimentally determined molecular mass or base
composition is the same as the molecular mass or base composition
of one of the known bioagent identifying amplicons. Alternatively,
the experimentally-determined molecular mass or base composition
may be within experimental error of the molecular mass or base
composition of a known bioagent identifying amplicon and still be
classified as a match. In some cases, the match may also be
classified using a probability of match model such as the models
described in U.S. Ser. No. 11/073,362, which is commonly owned and
incorporated herein by reference in entirety. Furthermore, the
method can be applied to rapid parallel multiplex analyses, the
results of which can be employed in a triangulation identification
strategy. The present method provides rapid throughput and does not
require nucleic acid sequencing of the amplified target sequence
for bioagent detection and identification.
[0288] Despite enormous biological diversity, all forms of life on
earth share sets of essential, common features in their genomes.
Since genetic data provide the underlying basis for identification
of bioagents by the methods of the present invention, it is
necessary to select segments of nucleic acids which ideally provide
enough variability to distinguish each individual bioagent and
whose molecular mass is amenable to molecular mass
determination.
[0289] Unlike bacterial genomes, which exhibit conservation of
numerous genes (i.e. housekeeping genes) across all organisms,
viruses do not share a gene that is essential and conserved among
all virus families. Therefore, viral identification is achieved
within smaller groups of related viruses, such as members of a
particular virus family or genus. For example, RNA-dependent RNA
polymerase is present in all single-stranded RNA viruses and can be
used for broad priming as well as resolution within the virus
family.
[0290] In some embodiments of the present invention, at least one
bacterial nucleic acid segment is amplified in the process of
identifying the bacterial bioagent. Thus, the nucleic acid segments
that can be amplified by the primers disclosed herein and that
provide enough variability to distinguish each individual bioagent
and whose molecular masses are amenable to molecular mass
determination are herein described as bioagent identifying
amplicons.
[0291] In some embodiments of the present invention, bioagent
identifying amplicons comprise from about 45 to about 150
nucleobases (i.e. from about 45 to about 200 linked nucleosides),
although both longer and short regions may be used. One of ordinary
skill in the art will appreciate that the invention embodies
compounds of 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106,
107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119,
120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132,
133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145,
146, 147, 148, 149, and 150 nucleobases in length, or any range
therewithin.
[0292] It is the combination of the portions of the bioagent
nucleic acid segment to which the primers hybridize (hybridization
sites) and the variable region between the primer hybridization
sites that comprises the bioagent identifying amplicon. Thus, it
can be said that a given bioagent identifying amplicon is "defined
by" a given pair of primers.
[0293] In some embodiments, bioagent identifying amplicons amenable
to molecular mass determination which are produced by the primers
described herein are either of a length, size or mass compatible
with the particular mode of molecular mass determination or
compatible with a means of providing a predictable fragmentation
pattern in order to obtain predictable fragments of a length
compatible with the particular mode of molecular mass
determination. Such means of providing a predictable fragmentation
pattern of an amplification product include, but are not limited
to, cleavage with chemical reagents, restriction enzymes or
cleavage primers, for example. Thus, in some embodiments, bioagent
identifying amplicons are larger than 150 nucleobases and are
amenable to molecular mass determination following restriction
digestion. Methods of using restriction enzymes and cleavage
primers are well known to those with ordinary skill in the art.
[0294] In some embodiments, amplification products corresponding to
bioagent identifying amplicons are obtained using the polymerase
chain reaction (PCR) that is a routine method to those with
ordinary skill in the molecular biology arts. Other amplification
methods may be used such as ligase chain reaction (LCR),
low-stringency single primer PCR, and multiple strand displacement
amplification (MDA). These methods are also known to those with
ordinary skill.
B. Primers and Primer Pairs
[0295] In some embodiments, the primers are designed to bind to
conserved sequence regions of a bioagent identifying amplicon that
flank an intervening variable region and yield amplification
products which provide variability sufficient to distinguish each
individual bioagent, and which are amenable to molecular mass
analysis. In some embodiments, the highly conserved sequence
regions exhibit between about 80-100%, or between about 90-100%, or
between about 95-100% identity, or between about 99-100% identity.
The molecular mass of a given amplification product provides a
means of identifying the bioagent from which it was obtained, due
to the variability of the variable region. Thus, design of the
primers involves selection of a variable region with sufficient
variability to resolve the identity of a given bioagent. In some
embodiments, bioagent identifying amplicons are specific to the
identity of the bioagent.
[0296] In some embodiments, identification of bioagents is
accomplished at different levels using primers suited to resolution
of each individual level of identification. Broad range survey
primers are designed with the objective of identifying a bioagent
as a member of a particular division (e.g., an order, family, genus
or other such grouping of bioagents above the species level of
bioagents). In some embodiments, broad range survey intelligent
primers are capable of identification of bioagents at the species
or sub-species level. Examples of broad range survey primers
include, but are not limited to: primer pair numbers: 346 (SEQ ID
NOs: 202:1110), 347 (SEQ ID NOs: 560:1278), 348 SEQ ID NOs:
706:895), and 361 (SEQ ID NOs: 697:1398) which target DNA encoding
16S rRNA, and primer pair numbers 349 (SEQ ID NOs: 401:1156) and
360 (SEQ ID NOs: 409:1434) which target DNA encoding 23S rRNA.
[0297] In some embodiments, drill-down primers are designed with
the objective of identifying a bioagent at the sub-species level
(including strains, subtypes, variants and isolates) based on
sub-species characteristics which may, for example, include single
nucleotide polymorphisms (SNPs), variable number tandem repeats
(VNTRs), deletions, drug resistance mutations or any other
modification of a nucleic acid sequence of a bioagent relative to
other members of a species having different sub-species
characteristics. Drill-down intelligent primers are not always
required for identification at the sub species level because broad
range survey intelligent primers may, in some cases provide
sufficient identification resolution to accomplishing this
identification objective. Examples of drill-down primers include,
but are not limited to: confirmation primer pairs such as primer
pair numbers 351 (SEQ ID NOs: 355:1423) and 353 (SEQ ID NOs:
220:1394), which target the pX01 virulence plasmid of Bacillus
anthracis. Other examples of drill-down primer pairs are found in
sets of triangulation genotyping primer pairs such as, for example,
the primer pair number 2146 (SEQ ID NOs: 437:1137) which targets
the arcC gene (encoding carmabate kinase) and is included in an 8
primer pair panel or kit for use in genotyping Staphylococcus
aureus, or in other panels or kits of primer pairs used for
determining drug-resistant bacterial strains, such as, for example,
primer pair number 2095 (SEQ ID NOs: 456:1261) which targets the
pv-luk gene (encoding Panton-Valentine leukocidin) and is included
in an 8 primer pair panel or kit for use in identification of drug
resistant strains of Staphylococcus aureus.
[0298] A representative process flow diagram used for primer
selection and validation process is outlined in FIG. 1. For each
group of organisms, candidate target sequences are identified (200)
from which nucleotide alignments are created (210) and analyzed
(220). Primers are then designed by selecting appropriate priming
regions (230) to facilitate the selection of candidate primer pairs
(240). The primer pairs are then subjected to in silico analysis by
electronic PCR (ePCR) (300) wherein bioagent identifying amplicons
are obtained from sequence databases such as GenBank or other
sequence collections (310) and checked for specificity in silico
(320). Bioagent identifying amplicons obtained from GenBank
sequences (310) can also be analyzed by a probability model which
predicts the capability of a given amplicon to identify unknown
bioagents such that the base compositions of amplicons with
favorable probability scores are then stored in a base composition
database (325). Alternatively, base compositions of the bioagent
identifying amplicons obtained from the primers and GenBank
sequences can be directly entered into the base composition
database (330). Candidate primer pairs (240) are validated by
testing their ability to hybridize to target nucleic acid by an in
vitro amplification by a method such as PCR analysis (400) of
nucleic acid from a collection of organisms (410). Amplification
products thus obtained are analyzed by gel electrophoresis or by
mass spectrometry to confirm the sensitivity, specificity and
reproducibility of the primers used to obtain the amplification
products (420).
[0299] Many of the important pathogens, including the organisms of
greatest concern as biowarfare agents, have been completely
sequenced. This effort has greatly facilitated the design of
primers for the detection of unknown bioagents. The combination of
broad-range priming with division-wide and drill-down priming has
been used very successfully in several applications of the
technology, including environmental surveillance for biowarfare
threat agents and clinical sample analysis for medically important
pathogens.
Synthesis of primers is well known and routine in the art. The
primers may be conveniently and routinely made through the
well-known technique of solid phase synthesis. Equipment for such
synthesis is sold by several vendors including, for example,
Applied Biosystems (Foster City, Calif.). Any other means for such
synthesis known in the art may additionally or alternatively be
employed.
[0300] In some embodiments primers are employed as compositions for
use in methods for identification of bacterial bioagents as
follows: a primer pair composition is contacted with nucleic acid
(such as, for example, bacterial DNA or DNA reverse transcribed
from the rRNA) of an unknown bacterial bioagent. The nucleic acid
is then amplified by a nucleic acid amplification technique, such
as PCR for example, to obtain an amplification product that
represents a bioagent identifying amplicon. The molecular mass of
each strand of the double-stranded amplification product is
determined by a molecular mass measurement technique such as mass
spectrometry for example, wherein the two strands of the
double-stranded amplification product are separated during the
ionization process. In some embodiments, the mass spectrometry is
electrospray Fourier transform ion cyclotron resonance mass
spectrometry (ESI-FTICR-MS) or electrospray time of flight mass
spectrometry (ESI-TOF-MS). A list of possible base compositions can
be generated for the molecular mass value obtained for each strand
and the choice of the correct base composition from the list is
facilitated by matching the base composition of one strand with a
complementary base composition of the other strand. The molecular
mass or base composition thus determined is then compared with a
database of molecular masses or base compositions of analogous
bioagent identifying amplicons for known viral bioagents. A match
between the molecular mass or base composition of the amplification
product and the molecular mass or base composition of an analogous
bioagent identifying amplicon for a known viral bioagent indicates
the identity of the unknown bioagent. In some embodiments, the
primer pair used is one of the primer pairs of Table 2. In some
embodiments, the method is repeated using one or more different
primer pairs to resolve possible ambiguities in the identification
process or to improve the confidence level for the identification
assignment.
[0301] In some embodiments, a bioagent identifying amplicon may be
produced using only a single primer (either the forward or reverse
primer of any given primer pair), provided an appropriate
amplification method is chosen, such as, for example, low
stringency single primer PCR (LSSP-PCR). Adaptation of this
amplification method in order to produce bioagent identifying
amplicons can be accomplished by one with ordinary skill in the art
without undue experimentation.
[0302] In some embodiments, the oligonucleotide primers are broad
range survey primers which hybridize to conserved regions of
nucleic acid encoding the hexon gene of all (or between 80% and
100%, between 85% and 100%, between 90% and 100% or between 95% and
100%) known bacteria and produce bacterial bioagent identifying
amplicons.
[0303] In some cases, the molecular mass or base composition of a
bacterial bioagent identifying amplicon defined by a broad range
survey primer pair does not provide enough resolution to
unambiguously identify a bacterial bioagent at or below the species
level. These cases benefit from further analysis of one or more
bacterial bioagent identifying amplicons generated from at least
one additional broad range survey primer pair or from at least one
additional division-wide primer pair. The employment of more than
one bioagent identifying amplicon for identification of a bioagent
is herein referred to as triangulation identification.
[0304] In other embodiments, the oligonucleotide primers are
division-wide primers which hybridize to nucleic acid encoding
genes of species within a genus of bacteria. In other embodiments,
the oligonucleotide primers are drill-down primers which enable the
identification of sub-species characteristics. Drill down primers
provide the functionality of producing bioagent identifying
amplicons for drill-down analyses such as strain typing when
contacted with nucleic acid under amplification conditions.
Identification of such sub-species characteristics is often
critical for determining proper clinical treatment of viral
infections. In some embodiments, sub-species characteristics are
identified using only broad range survey primers and division-wide
and drill-down primers are not used.
[0305] In some embodiments, the primers used for amplification
hybridize to and amplify genomic DNA, and DNA of bacterial
plasmids.
[0306] In some embodiments, various computer software programs may
be used to aid in design of primers for amplification reactions
such as Primer Premier 5 (Premier Biosoft, Palo Alto, Calif.) or
OLIGO Primer Analysis Software (Molecular Biology Insights,
Cascade, Colo.). These programs allow the user to input desired
hybridization conditions such as melting temperature of a
primer-template duplex for example. In some embodiments, an in
silico PCR search algorithm, such as (ePCR) is used to analyze
primer specificity across a plurality of template sequences which
can be readily obtained from public sequence databases such as
GenBank for example. An existing RNA structure search algorithm
(Macke et al., Nucl. Acids Res., 2001, 29, 4724-4735, which is
incorporated herein by reference in its entirety) has been modified
to include PCR parameters such as hybridization conditions,
mismatches, and thermodynamic calculations (SantaLucia, Proc. Natl.
Acad. Sci. U.S.A., 1998, 95, 1460-1465, which is incorporated
herein by reference in its entirety). This also provides
information on primer specificity of the selected primer pairs. In
some embodiments, the hybridization conditions applied to the
algorithm can limit the results of primer specificity obtained from
the algorithm. In some embodiments, the melting temperature
threshold for the primer template duplex is specified to be
35.degree. C. or a higher temperature. In some embodiments the
number of acceptable mismatches is specified to be seven mismatches
or less. In some embodiments, the buffer components and
concentrations and primer concentrations may be specified and
incorporated into the algorithm, for example, an appropriate primer
concentration is about 250 nM and appropriate buffer components are
50 mM sodium or potassium and 1.5 mM Mg.sup.2+.
[0307] One with ordinary skill in the art of design of
amplification primers will recognize that a given primer need not
hybridize with 100% complementarity in order to effectively prime
the synthesis of a complementary nucleic acid strand in an
amplification reaction. Moreover, a primer may hybridize over one
or more segments such that intervening or adjacent segments are not
involved in the hybridization event. (e.g., for example, a loop
structure or a hairpin structure). The primers of the present
invention may comprise at least 70%, at least 75%, at least 80%, at
least 85%, at least 90%, at least 95% or at least 99% sequence
identity with any of the primers listed in Table 2. Thus, in some
embodiments of the present invention, an extent of variation of 70%
to 100%, or any range therewithin, of the sequence identity is
possible relative to the specific primer sequences disclosed
herein. Determination of sequence identity is described in the
following example: a primer 20 nucleobases in length which is
identical to another 20 nucleobase primer having two non-identical
residues has 18 of 20 identical residues (18/20=0.9 or 90% sequence
identity). In another example, a primer 15 nucleobases in length
having all residues identical to a 15 nucleobase segment of primer
20 nucleobases in length would have 15/20=0.75 or 75% sequence
identity with the 20 nucleobase primer.
[0308] Percent homology, sequence identity or complementarity, can
be determined by, for example, the Gap program (Wisconsin Sequence
Analysis Package, Version 8 for UNIX, Genetics Computer Group,
University Research Park, Madison Wis.), using default settings,
which uses the algorithm of Smith and Waterman (Adv. Appl. Math.,
1981, 2, 482-489). In some embodiments, complementarity of primers
with respect to the conserved priming regions of viral nucleic acid
is between about 70% and about 75% 80%. In other embodiments,
homology, sequence identity or complementarity, is between about
75% and about 80%. In yet other embodiments, homology, sequence
identity or complementarity, is at least 85%, at least 90%, at
least 92%, at least 94%, at least 95%, at least 96%, at least 97%,
at least 98%, at least 99% or is 100%.
[0309] In some embodiments, the primers described herein comprise
at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 92%, at least 94%, at least 95%, at least 96%, at
least 98%, or at least 99%, or 100% (or any range therewithin)
sequence identity with the primer sequences specifically disclosed
herein.
[0310] One with ordinary skill is able to calculate percent
sequence identity or percent sequence homology and able to
determine, without undue experimentation, the effects of variation
of primer sequence identity on the function of the primer in its
role in priming synthesis of a complementary strand of nucleic acid
for production of an amplification product of a corresponding
bioagent identifying amplicon.
[0311] In one embodiment, the primers are at least 13 nucleobases
in length. In another embodiment, the primers are less than 36
nucleobases in length.
[0312] In some embodiments of the present invention, the
oligonucleotide primers are 13 to 35 nucleobases in length (13 to
35 linked nucleotide residues). These embodiments comprise
oligonucleotide primers 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleobases in
length, or any range therewithin. The present invention
contemplates using both longer and shorter primers. Furthermore,
the primers may also be linked to one or more other desired
moieties, including, but not limited to, affinity groups, ligands,
regions of nucleic acid that are not complementary to the nucleic
acid to be amplified, labels, etc. Primers may also form hairpin
structures. For example, hairpin primers may be used to amplify
short target nucleic acid molecules. The presence of the hairpin
may stabilize the amplification complex (see e.g., TAQMAN MicroRNA
Assays, Applied Biosystems, Foster City, Calif.).
[0313] In some embodiments, any oligonucleotide primer pair may
have one or both primers with less then 70% sequence homology with
a corresponding member of any of the primer pairs of Table 2 if the
primer pair has the capability of producing an amplification
product corresponding to a bioagent identifying amplicon. In other
embodiments, any oligonucleotide primer pair may have one or both
primers with a length greater than 35 nucleobases if the primer
pair has the capability of producing an amplification product
corresponding to a bioagent identifying amplicon.
[0314] In some embodiments, the function of a given primer may be
substituted by a combination of two or more primers segments that
hybridize adjacent to each other or that are linked by a nucleic
acid loop structure or linker which allows a polymerase to extend
the two or more primers in an amplification reaction.
[0315] In some embodiments, the primer pairs used for obtaining
bioagent identifying amplicons are the primer pairs of Table 2. In
other embodiments, other combinations of primer pairs are possible
by combining certain members of the forward primers with certain
members of the reverse primers. An example can be seen in Table 2
for two primer pair combinations of forward primer
16S_EC.sub.--789.sub.--810_F (SEQ ID NO: 206), with the reverse
primers 16S_EC.sub.--880.sub.--894_R (SEQ ID NO: 796), or
16S_EC.sub.--882.sub.--899_R or (SEQ ID NO: 818). Arriving at a
favorable alternate combination of primers in a primer pair depends
upon the properties of the primer pair, most notably the size of
the bioagent identifying amplicon that would be produced by the
primer pair, which preferably is between about 45 to about 150
nucleobases in length. Alternatively, a bioagent identifying
amplicon longer than 150 nucleobases in length could be cleaved
into smaller segments by cleavage reagents such as chemical
reagents, or restriction enzymes, for example.
[0316] In some embodiments, the primers are configured to amplify
nucleic acid of a bioagent to produce amplification products that
can be measured by mass spectrometry and from whose molecular
masses candidate base compositions can be readily calculated.
[0317] In some embodiments, any given primer comprises a
modification comprising the addition of a non-templated T residue
to the 5' end of the primer (i.e., the added T residue does not
necessarily hybridize to the nucleic acid being amplified). The
addition of a non-templated T residue has an effect of minimizing
the addition of non-templated adenosine residues as a result of the
non-specific enzyme activity of Taq polymerase (Magnuson et al.,
Biotechniques, 1996, 21, 700-709), an occurrence which may lead to
ambiguous results arising from molecular mass analysis.
[0318] In some embodiments of the present invention, primers may
contain one or more universal bases. Because any variation (due to
codon wobble in the 3.sup.rd position) in the conserved regions
among species is likely to occur in the third position of a DNA (or
RNA) triplet, oligonucleotide primers can be designed such that the
nucleotide corresponding to this position is a base which can bind
to more than one nucleotide, referred to herein as a "universal
nucleobase." For example, under this "wobble" pairing, inosine (I)
binds to U, C or A; guanine (G) binds to U or C, and uridine (U)
binds to U or C. Other examples of universal nucleobases include
nitroindoles such as 5-nitroindole or 3-nitropyrrole (Loakes et
al., Nucleosides and Nucleotides, 1995, 14, 1001-1003), the
degenerate nucleotides dP or dK (Hill et al.), an acyclic
nucleoside analog containing 5-nitroindazole (Van Aerschot et al.,
Nucleosides and Nucleotides, 1995, 14, 1053-1056) or the purine
analog 1-(2-deoxy-.beta.-D-ribofuranosyl)-imidazole-4-carboxamide
(Sala et al., Nucl. Acids Res., 1996, 24, 3302-3306).
[0319] In some embodiments, to compensate for the somewhat weaker
binding by the wobble base, the oligonucleotide primers are
designed such that the first and second positions of each triplet
are occupied by nucleotide analogs that bind with greater affinity
than the unmodified nucleotide. Examples of these analogs include,
but are not limited to, 2,6-diaminopurine which binds to thymine,
5-propynyluracil (also known as propynylated thymine) which binds
to adenine and 5-propynylcytosine and phenoxazines, including
G-clamp, which binds to G. Propynylated pyrimidines are described
in U.S. Pat. Nos. 5,645,985, 5,830,653 and 5,484,908, each of which
is commonly owned and incorporated herein by reference in its
entirety. Propynylated primers are described in U.S Pre-Grant
Publication No. 2003-0170682, which is also commonly owned and
incorporated herein by reference in its entirety. Phenoxazines are
described in U.S. Pat. Nos. 5,502,177, 5,763,588, and 6,005,096,
each of which is incorporated herein by reference in its entirety.
G-clamps are described in U.S. Pat. Nos. 6,007,992 and 6,028,183,
each of which is incorporated herein by reference in its
entirety.
[0320] In some embodiments, primer hybridization is enhanced using
primers containing 5-propynyl deoxy-cytidine and deoxy-thymidine
nucleotides. These modified primers offer increased affinity and
base pairing selectivity.
[0321] In some embodiments, non-template primer tags are used to
increase the melting temperature (T.sub.m) of a primer-template
duplex in order to improve amplification efficiency. A non-template
tag is at least three consecutive A or T nucleotide residues on a
primer which are not complementary to the template. In any given
non-template tag, A can be replaced by C or G and T can also be
replaced by C or G. Although Watson-Crick hybridization is not
expected to occur for a non-template tag relative to the template,
the extra hydrogen bond in a G-C pair relative to an A-T pair
confers increased stability of the primer-template duplex and
improves amplification efficiency for subsequent cycles of
amplification when the primers hybridize to strands synthesized in
previous cycles.
[0322] In other embodiments, propynylated tags may be used in a
manner similar to that of the non-template tag, wherein two or more
5-propynylcytidine or 5-propynyluridine residues replace template
matching residues on a primer. In other embodiments, a primer
contains a modified internucleoside linkage such as a
phosphorothioate linkage, for example.
[0323] In some embodiments, the primers contain mass-modifying
tags. Reducing the total number of possible base compositions of a
nucleic acid of specific molecular weight provides a means of
avoiding a persistent source of ambiguity in determination of base
composition of amplification products. Addition of mass-modifying
tags to certain nucleobases of a given primer will result in
simplification of de novo determination of base composition of a
given bioagent identifying amplicon from its molecular mass.
[0324] In some embodiments of the present invention, the mass
modified nucleobase comprises one or more of the following: for
example, 7-deaza-2'-deoxyadenosine-5-triphosphate,
5-iodo-2'-deoxyuridine-5'-triphosphate,
5-bromo-2'-deoxyuridine-5'-triphosphate,
5-bromo-2'-deoxycytidine-5'-triphosphate,
5-iodo-2'-deoxycytidine-5'-triphosphate,
5-hydroxy-2'-deoxyuridine-5'-triphosphate,
4-thiothymidine-5'-triphosphate,
5-aza-2'-deoxyuridine-5'-triphosphate,
5-fluoro-2'-deoxyuridine-5'-triphosphate,
O6-methyl-2'-deoxyguanosine-5'-triphosphate,
N2-methyl-2'-deoxyguanosine-5'-triphosphate,
8-oxo-2'-deoxyguanosine-5'-triphosphate or
thiothymidine-5'-triphosphate. In some embodiments, the
mass-modified nucleobase comprises .sup.15N or .sup.13C or both
.sup.15N and .sup.13C.
[0325] In some embodiments, multiplex amplification is performed
where multiple bioagent identifying amplicons are amplified with a
plurality of primer pairs. The advantages of multiplexing are that
fewer reaction containers (for example, wells of a 96- or 384-well
plate) are needed for each molecular mass measurement, providing
time, resource and cost savings because additional bioagent
identification data can be obtained within a single analysis.
Multiplex amplification methods are well known to those with
ordinary skill and can be developed without undue experimentation.
However, in some embodiments, one useful and non-obvious step in
selecting a plurality candidate bioagent identifying amplicons for
multiplex amplification is to ensure that each strand of each
amplification product will be sufficiently different in molecular
mass that mass spectral signals will not overlap and lead to
ambiguous analysis results. In some embodiments, a 10 Da difference
in mass of two strands of one or more amplification products is
sufficient to avoid overlap of mass spectral peaks.
[0326] In some embodiments, as an alternative to multiplex
amplification, single amplification reactions can be pooled before
analysis by mass spectrometry. In these embodiments, as for
multiplex amplification embodiments, it is useful to select a
plurality of candidate bioagent identifying amplicons to ensure
that each strand of each amplification product will be sufficiently
different in molecular mass that mass spectral signals will not
overlap and lead to ambiguous analysis results.
C Determination of Molecular Mass of Bioagent Identifying
Amplicons
[0327] In some embodiments, the molecular mass of a given bioagent
identifying amplicon is determined by mass spectrometry. Mass
spectrometry has several advantages, not the least of which is high
bandwidth characterized by the ability to separate (and isolate)
many molecular peaks across a broad range of mass to charge ratio
(m/z). Thus mass spectrometry is intrinsically a parallel detection
scheme without the need for radioactive or fluorescent labels,
since every amplification product is identified by its molecular
mass. The current state of the art in mass spectrometry is such
that less than femtomole quantities of material can be readily
analyzed to afford information about the molecular contents of the
sample. An accurate assessment of the molecular mass of the
material can be quickly obtained, irrespective of whether the
molecular weight of the sample is several hundred, or in excess of
one hundred thousand atomic mass units (amu) or Daltons.
[0328] In some embodiments, intact molecular ions are generated
from amplification products using one of a variety of ionization
techniques to convert the sample to gas phase. These ionization
methods include, but are not limited to, electrospray ionization
(ES), matrix-assisted laser desorption ionization (MALDI) and fast
atom bombardment (FAB). Upon ionization, several peaks are observed
from one sample due to the formation of ions with different
charges. Averaging the multiple readings of molecular mass obtained
from a single mass spectrum affords an estimate of molecular mass
of the bioagent identifying amplicon. Electrospray ionization mass
spectrometry (ESI-MS) is particularly useful for very high
molecular weight polymers such as proteins and nucleic acids having
molecular weights greater than 10 kDa, since it yields a
distribution of multiply-charged molecules of the sample without
causing a significant amount of fragmentation.
[0329] The mass detectors used in the methods of the present
invention include, but are not limited to, Fourier transform ion
cyclotron resonance mass spectrometry (FT-ICR-MS), time of flight
(TOF), ion trap, quadrupole, magnetic sector, Q-TOF, and triple
quadrupole.
D. Base Compositions of Bioagent Identifying Amplicons
[0330] Although the molecular mass of amplification products
obtained using intelligent primers provides a means for
identification of bioagents, conversion of molecular mass data to a
base composition signature is useful for certain analyses. As used
herein, "base composition" is the exact number of each nucleobase
(A, T, C and G) determined from the molecular mass of a bioagent
identifying amplicon. In some embodiments, a base composition
provides an index of a specific organism. Base compositions can be
calculated from known sequences of known bioagent identifying
amplicons and can be experimentally determined by measuring the
molecular mass of a given bioagent identifying amplicon, followed
by determination of all possible base compositions which are
consistent with the measured molecular mass within acceptable
experimental error. The following example illustrates determination
of base composition from an experimentally obtained molecular mass
of a 46-mer amplification product originating at position 1337 of
the 16S rRNA of Bacillus anthracis. The forward and reverse strands
of the amplification product have measured molecular masses of
14208 and 14079 Da, respectively. The possible base compositions
derived from the molecular masses of the forward and reverse
strands for the B. anthracis products are listed in Table 1.
TABLE-US-00001 TABLE 1 Possible Base Compositions for B. anthracis
46mer Amplification Product Calc. Mass Mass Error Base Calc. Mass
Mass Error Base Forward Forward Composition of Reverse Reverse
Composition of Strand Strand Forward Strand Strand Strand Reverse
Strand 14208.2935 0.079520 A1 G17 C10 T18 14079.2624 0.080600 A0
G14 C13 T19 14208.3160 0.056980 A1 G20 C15 T10 14079.2849 0.058060
A0 G17 C18 T11 14208.3386 0.034440 A1 G23 C20 T2 14079.3075
0.035520 A0 G20 C23 T3 14208.3074 0.065560 A6 G11 C3 T26 14079.2538
0.089180 A5 G5 C1 T35 14208.3300 0.043020 A6 G14 C8 T18 14079.2764
0.066640 A5 G8 C6 T27 14208.3525 0.020480 A6 G17 C13 T10 14079.2989
0.044100 A5 G11 C11 T19 14208.3751 0.002060 A6 G20 C18 T2
14079.3214 0.021560 A5 G14 C16 T11 14208.3439 0.029060 A11 G8 C1
T26 14079.3440 0.000980 A5 G17 C21 T3 14208.3665 0.006520 A11 G11
C6 T18 14079.3129 0.030140 A10 G5 C4 T27 14208.3890 0.016020 A11
G14 C11 T10 14079.3354 0.007600 A10 G8 C9 T19 14208.4116 0.038560
A11 G17 C16 T2 14079.3579 0.014940 A10 G11 C14 T11 14208.4030
0.029980 A16 G8 C4 T18 14079.3805 0.037480 A10 G14 C19 T3
14208.4255 0.052520 A16 G11 C9 T10 14079.3494 0.006360 A15 G2 C2
T27 14208.4481 0.075060 A16 G14 C14 T2 14079.3719 0.028900 A15 G5
C7 T19 14208.4395 0.066480 A21 G5 C2 T18 14079.3944 0.051440 A15 G8
C12 T11 14208.4620 0.089020 A21 G8 C7 T10 14079.4170 0.073980 A15
G11 C17 T3 -- -- -- 14079.4084 0.065400 A20 G2 C5 T19 -- -- --
14079.4309 0.087940 A20 G5 C10 T13
[0331] Among the 16 possible base compositions for the forward
strand and the 18 possible base compositions for the reverse strand
that were calculated, only one pair (shown in bold) are
complementary base compositions, which indicates the true base
composition of the amplification product. It should be recognized
that this logic is applicable for determination of base
compositions of any bioagent identifying amplicon, regardless of
the class of bioagent from which the corresponding amplification
product was obtained.
[0332] In some embodiments, assignment of previously unobserved
base compositions (also known as "true unknown base compositions")
to a given phylogeny can be accomplished via the use of pattern
classifier model algorithms. Base compositions, like sequences,
vary slightly from strain to strain within species, for example. In
some embodiments, the pattern classifier model is the mutational
probability model. On other embodiments, the pattern classifier is
the polytope model. The mutational probability model and polytope
model are both commonly owned and described in U.S. patent
application Ser. No. 11/073,362 which is incorporated herein by
reference in entirety.
[0333] In one embodiment, it is possible to manage this diversity
by building "base composition probability clouds" around the
composition constraints for each species. This permits
identification of organisms in a fashion similar to sequence
analysis. A "pseudo four-dimensional plot" can be used to visualize
the concept of base composition probability clouds. Optimal primer
design requires optimal choice of bioagent identifying amplicons
and maximizes the separation between the base composition
signatures of individual bioagents. Areas where clouds overlap
indicate regions that may result in a misclassification, a problem
which is overcome by a triangulation identification process using
bioagent identifying amplicons not affected by overlap of base
composition probability clouds.
[0334] In some embodiments, base composition probability clouds
provide the means for screening potential primer pairs in order to
avoid potential misclassifications of base compositions. In other
embodiments, base composition probability clouds provide the means
for predicting the identity of a bioagent whose assigned base
composition was not previously observed and/or indexed in a
bioagent identifying amplicon base composition database due to
evolutionary transitions in its nucleic acid sequence. Thus, in
contrast to probe-based techniques, mass spectrometry determination
of base composition does not require prior knowledge of the
composition or sequence in order to make the measurement.
[0335] The present invention provides bioagent classifying
information similar to DNA sequencing and phylogenetic analysis at
a level sufficient to identify a given bioagent. Furthermore, the
process of determination of a previously unknown base composition
for a given bioagent (for example, in a case where sequence
information is unavailable) has downstream utility by providing
additional bioagent indexing information with which to populate
base composition databases. The process of future bioagent
identification is thus greatly improved as more BCS indexes become
available in base composition databases.
E. Triangulation Identification
[0336] In some cases, a molecular mass of a single bioagent
identifying amplicon alone does not provide enough resolution to
unambiguously identify a given bioagent. The employment of more
than one bioagent identifying amplicon for identification of a
bioagent is herein referred to as "triangulation identification."
Triangulation identification is pursued by determining the
molecular masses of a plurality of bioagent identifying amplicons
selected within a plurality of housekeeping genes. This process is
used to reduce false negative and false positive signals, and
enable reconstruction of the origin of hybrid or otherwise
engineered bioagents. For example, identification of the three part
toxin genes typical of B. anthracis (Bowen et al., J. Appl.
Microbiol., 1999, 87, 270-278) in the absence of the expected
signatures from the B. anthracis genome would suggest a genetic
engineering event.
[0337] In some embodiments, the triangulation identification
process can be pursued by characterization of bioagent identifying
amplicons in a massively parallel fashion using the polymerase
chain reaction (PCR), such as multiplex PCR where multiple primers
are employed in the same amplification reaction mixture, or PCR in
multi-well plate format wherein a different and unique pair of
primers is used in multiple wells containing otherwise identical
reaction mixtures. Such multiplex and multi-well PCR methods are
well known to those with ordinary skill in the arts of rapid
throughput amplification of nucleic acids. In other related
embodiments, one PCR reaction per well or container may be carried
out, followed by an amplicon pooling step wherein the amplification
products of different wells are combined in a single well or
container which is then subjected to molecular mass analysis. The
combination of pooled amplicons can be chosen such that the
expected ranges of molecular masses of individual amplicons are not
overlapping and thus will not complicate identification of
signals.
F. Codon Base Composition Analysis
[0338] In some embodiments of the present invention, one or more
nucleotide substitutions within a codon of a gene of an infectious
organism confer drug resistance upon an organism which can be
determined by codon base composition analysis. The organism can be
a bacterium, virus, fungus or protozoan.
[0339] In some embodiments, the amplification product containing
the codon being analyzed is of a length of about 35 to about 200
nucleobases. The primers employed in obtaining the amplification
product can hybridize to upstream and downstream sequences directly
adjacent to the codon, or can hybridize to upstream and downstream
sequences one or more sequence positions away from the codon. The
primers may have between about 70% to 100% sequence complementarity
with the sequence of the gene containing the codon being
analyzed.
[0340] In some embodiments, the codon base composition analysis is
undertaken
[0341] In some embodiments, the codon analysis is undertaken for
the purpose of investigating genetic disease in an individual. In
other embodiments, the codon analysis is undertaken for the purpose
of investigating a drug resistance mutation or any other
deleterious mutation in an infectious organism such as a bacterium,
virus, fungus or protozoan. In some embodiments, the bioagent is a
bacterium identified in a biological product.
[0342] In some embodiments, the molecular mass of an amplification
product containing the codon being analyzed is measured by mass
spectrometry. The mass spectrometry can be either electrospray
(ESI) mass spectrometry or matrix-assisted laser desorption
ionization (MALDI) mass spectrometry. Time-of-flight (TOF) is an
example of one mode of mass spectrometry compatible with the
analyses of the present invention.
[0343] The methods of the present invention can also be employed to
determine the relative abundance of drug resistant strains of the
organism being analyzed. Relative abundances can be calculated from
amplitudes of mass spectral signals with relation to internal
calibrants. In some embodiments, known quantities of internal
amplification calibrants can be included in the amplification
reactions and abundances of analyte amplification product estimated
in relation to the known quantities of the calibrants.
[0344] In some embodiments, upon identification of one or more
drug-resistant strains of an infectious organism infecting an
individual, one or more alternative treatments can be devised to
treat the individual.
G. Determination of the Quantity of a Bioagent
[0345] In some embodiments, the identity and quantity of an unknown
bioagent can be determined using the process illustrated in FIG. 2.
Primers (500) and a known quantity of a calibration polynucleotide
(505) are added to a sample containing nucleic acid of an unknown
bioagent. The total nucleic acid in the sample is then subjected to
an amplification reaction (510) to obtain amplification products.
The molecular masses of amplification products are determined (515)
from which are obtained molecular mass and abundance data. The
molecular mass of the bioagent identifying amplicon (520) provides
the means for its identification (525) and the molecular mass of
the calibration amplicon obtained from the calibration
polynucleotide (530) provides the means for its identification
(535). The abundance data of the bioagent identifying amplicon is
recorded (540) and the abundance data for the calibration data is
recorded (545), both of which are used in a calculation (550) which
determines the quantity of unknown bioagent in the sample.
[0346] A sample comprising an unknown bioagent is contacted with a
pair of primers that provide the means for amplification of nucleic
acid from the bioagent, and a known quantity of a polynucleotide
that comprises a calibration sequence. The nucleic acids of the
bioagent and of the calibration sequence are amplified and the rate
of amplification is reasonably assumed to be similar for the
nucleic acid of the bioagent and of the calibration sequence. The
amplification reaction then produces two amplification products: a
bioagent identifying amplicon and a calibration amplicon. The
bioagent identifying amplicon and the calibration amplicon should
be distinguishable by molecular mass while being amplified at
essentially the same rate. Effecting differential molecular masses
can be accomplished by choosing as a calibration sequence, a
representative bioagent identifying amplicon (from a specific
species of bioagent) and performing, for example, a 2-8 nucleobase
deletion or insertion within the variable region between the two
priming sites. The amplified sample containing the bioagent
identifying amplicon and the calibration amplicon is then subjected
to molecular mass analysis by mass spectrometry, for example. The
resulting molecular mass analysis of the nucleic acid of the
bioagent and of the calibration sequence provides molecular mass
data and abundance data for the nucleic acid of the bioagent and of
the calibration sequence. The molecular mass data obtained for the
nucleic acid of the bioagent enables identification of the unknown
bioagent and the abundance data enables calculation of the quantity
of the bioagent, based on the knowledge of the quantity of
calibration polynucleotide contacted with the sample.
[0347] In some embodiments, construction of a standard curve where
the amount of calibration polynucleotide spiked into the sample is
varied provides additional resolution and improved confidence for
the determination of the quantity of bioagent in the sample. The
use of standard curves for analytical determination of molecular
quantities is well known to one with ordinary skill and can be
performed without undue experimentation.
[0348] In some embodiments, multiplex amplification is performed
where multiple bioagent identifying amplicons are amplified with
multiple primer pairs which also amplify the corresponding standard
calibration sequences. In this or other embodiments, the standard
calibration sequences are optionally included within a single
vector which functions as the calibration polynucleotide. Multiplex
amplification methods are well known to those with ordinary skill
and can be performed without undue experimentation.
[0349] In some embodiments, the calibrant polynucleotide is used as
an internal positive control to confirm that amplification
conditions and subsequent analysis steps are successful in
producing a measurable amplicon. Even in the absence of copies of
the genome of a bioagent, the calibration polynucleotide should
give rise to a calibration amplicon. Failure to produce a
measurable calibration amplicon indicates a failure of
amplification or subsequent analysis step such as amplicon
purification or molecular mass determination. Reaching a conclusion
that such failures have occurred is in itself, a useful event.
[0350] In some embodiments, the calibration sequence is comprised
of DNA. In some embodiments, the calibration sequence is comprised
of RNA.
[0351] In some embodiments, the calibration sequence is inserted
into a vector that itself functions as the calibration
polynucleotide. In some embodiments, more than one calibration
sequence is inserted into the vector that functions as the
calibration polynucleotide. Such a calibration polynucleotide is
herein termed a "combination calibration polynucleotide." The
process of inserting polynucleotides into vectors is routine to
those skilled in the art and can be accomplished without undue
experimentation. Thus, it should be recognized that the calibration
method should not be limited to the embodiments described herein.
The calibration method can be applied for determination of the
quantity of any bioagent identifying amplicon when an appropriate
standard calibrant polynucleotide sequence is designed and used.
The process of choosing an appropriate vector for insertion of a
calibrant is also a routine operation that can be accomplished by
one with ordinary skill without undue experimentation.
H. Identification of Bacteria
[0352] In other embodiments of the present invention, the primer
pairs produce bioagent identifying amplicons within stable and
highly conserved regions of bacteria. The advantage to
characterization of an amplicon defined by priming regions that
fall within a highly conserved region is that there is a low
probability that the region will evolve past the point of primer
recognition, in which case, the primer hybridization of the
amplification step would fail. Such a primer set is thus useful as
a broad range survey-type primer. In another embodiment of the
present invention, the intelligent primers produce bioagent
identifying amplicons including a region which evolves more quickly
than the stable region described above. The advantage of
characterization bioagent identifying amplicon corresponding to an
evolving genomic region is that it is useful for distinguishing
emerging strain variants or the presence of virulence genes, drug
resistance genes, or codon mutations that induce drug
resistance.
[0353] The present invention also has significant advantages as a
platform for identification of diseases caused by emerging
bacterial strains such as, for example, drug-resistant strains of
Staphylococcus aureus. The present invention eliminates the need
for prior knowledge of bioagent sequence to generate hybridization
probes. This is possible because the methods are not confounded by
naturally occurring evolutionary variations occurring in the
sequence acting as the template for production of the bioagent
identifying amplicon. Measurement of molecular mass and
determination of base composition is accomplished in an unbiased
manner without sequence prejudice.
[0354] Another embodiment of the present invention also provides a
means of tracking the spread of a bacterium, such as a particular
drug-resistant strain when a plurality of samples obtained from
different locations are analyzed by the methods described above in
an epidemiological setting. In one embodiment, a plurality of
samples from a plurality of different locations is analyzed with
primer pairs which produce bioagent identifying amplicons, a subset
of which contains a specific drug-resistant bacterial strain. The
corresponding locations of the members of the drug-resistant strain
subset indicate the spread of the specific drug-resistant strain to
the corresponding locations.
I. Kits
[0355] The present invention also provides kits for carrying out
the methods described herein. In some embodiments, the kit may
comprise a sufficient quantity of one or more primer pairs to
perform an amplification reaction on a target polynucleotide from a
bioagent to form a bioagent identifying amplicon. In some
embodiments, the kit may comprise from one to fifty primer pairs,
from one to twenty primer pairs, from one to ten primer pairs, or
from two to five primer pairs. In some embodiments, the kit may
comprise one or more primer pairs recited in Table 2.
[0356] In some embodiments, the kit comprises one or more broad
range survey primer(s), division wide primer(s), or drill-down
primer(s), or any combination thereof. If a given problem involves
identification of a specific bioagent, the solution to the problem
may require the selection of a particular combination of primers to
provide the solution to the problem. A kit may be designed so as to
comprise particular primer pairs for identification of a particular
bioagent. A drill-down kit may be used, for example, to distinguish
different genotypes or strains, drug-resistant, or otherwise. In
some embodiments, the primer pair components of any of these kits
may be additionally combined to comprise additional combinations of
broad range survey primers and division-wide primers so as to be
able to identify a bacterium.
[0357] In some embodiments, the kit contains standardized
calibration polynucleotides for use as internal amplification
calibrants. Internal calibrants are described in commonly owned
U.S. Patent Application Ser. No. 60/545,425 which is incorporated
herein by reference in its entirety.
[0358] In some embodiments, the kit comprises a sufficient quantity
of reverse transcriptase (if RNA is to be analyzed for example), a
DNA polymerase, suitable nucleoside triphosphates (including
alternative dNTPs such as inosine or modified dNTPs such as the
5-propynyl pyrimidines or any dNTP containing molecular
mass-modifying tags such as those described above), a DNA ligase,
and/or reaction buffer, or any combination thereof, for the
amplification processes described above. A kit may further include
instructions pertinent for the particular embodiment of the kit,
such instructions describing the primer pairs and amplification
conditions for operation of the method. A kit may also comprise
amplification reaction containers such as microcentrifuge tubes and
the like. A kit may also comprise reagents or other materials for
isolating bioagent nucleic acid or bioagent identifying amplicons
from amplification, including, for example, detergents, solvents,
or ion exchange resins which may be linked to magnetic beads. A kit
may also comprise a table of measured or calculated molecular
masses and/or base compositions of bioagents using the primer pairs
of the kit.
[0359] Some embodiments are kits that contain one or more survey
bacterial primer pairs represented by primer pair compositions
wherein each member of each pair of primers has 70% to 100%
sequence identity with the corresponding member from the group of
primer pairs represented by any of the primer pairs of Table 5. The
survey primer pairs may include broad range primer pairs which
hybridize to ribosomal RNA, and may also include division-wide
primer pairs which hybridize to housekeeping genes such as rplB,
tufB, rpoB, rpoC, valS, and infB, for example.
[0360] In some embodiments, a kit may contain one or more survey
bacterial primer pairs and one or more triangulation genotyping
analysis primer pairs such as the primer pairs of Tables 8, 12, 14,
19, 21, 23, or 24. In some embodiments, the kit may represent a
less expansive genotyping analysis but include triangulation
genotyping analysis primer pairs for more than one genus or species
of bacteria. For example, a kit for surveying nosocomial infections
at a health care facility may include, for example, one or more
broad range survey primer pairs, one or more division wide primer
pairs, one or more Acinetobacter baumannii triangulation genotyping
analysis primer pairs and one or more Staphylococcus aureus
triangulation genotyping analysis primer pairs. One with ordinary
skill will be capable of analyzing in silico amplification data to
determine which primer pairs will be able to provide optimal
identification resolution for the bacterial bioagents of
interest.
[0361] In some embodiments, a kit may be assembled for
identification of strains of bacteria involved in contamination of
food. An example of such a kit embodiment is a kit comprising one
or more bacterial survey primer pairs of Table 5 with one or more
triangulation genotyping analysis primer pairs of Table 12 which
provide strain resolving capabilities for identification of
specific strains of Campylobacter jejuni.
[0362] Some embodiments of the kits are 96-well or 384-well plates
with a plurality of wells containing any or all of the following
components: dNTPs, buffer salts, Mg.sup.2+, betaine, and primer
pairs. In some embodiments, a polymerase is also included in the
plurality of wells of the 96-well or 384-well plates.
[0363] Some embodiments of the kit contain instructions for PCR and
mass spectrometry analysis of amplification products obtained using
the primer pairs of the kits.
[0364] Some embodiments of the kit include a barcode which uniquely
identifies the kit and the components contained therein according
to production lots and may also include any other information
relative to the components such as concentrations, storage
temperatures, etc. The barcode may also include analysis
information to be read by optical barcode readers and sent to a
computer controlling amplification, purification and mass
spectrometric measurements. In some embodiments, the barcode
provides access to a subset of base compositions in a base
composition database which is in digital communication with base
composition analysis software such that a base composition measured
with primer pairs from a given kit can be compared with known base
compositions of bioagent identifying amplicons defined by the
primer pairs of that kit.
[0365] In some embodiments, the kit contains a database of base
compositions of bioagent identifying amplicons defined by the
primer pairs of the kit. The database is stored on a convenient
computer readable medium such as a compact disk or USB drive, for
example.
[0366] In some embodiments, the kit includes a computer program
stored on a computer formatted medium (such as a compact disk or
portable USB disk drive, for example) comprising instructions which
direct a processor to analyze data obtained from the use of the
primer pairs of the present invention. The instructions of the
software transform data related to amplification products into a
molecular mass or base composition which is a useful concrete and
tangible result used in identification and/or classification of
bioagents. In some embodiments, the kits of the present invention
contain all of the reagents sufficient to carry out one or more of
the methods described herein.
[0367] While the present invention has been described with
specificity in accordance with certain of its embodiments, the
following examples serve only to illustrate the invention and are
not intended to limit the same. In order that the invention
disclosed herein may be more efficiently understood, examples are
provided below. It should be understood that these examples are for
illustrative purposes only and are not to be construed as limiting
the invention in any manner.
EXAMPLES
Example 1
Design and Validation of Primers that Define Bioagent Identifying
Amplicons for Identification of Bacteria
[0368] For design of primers that define bacterial bioagent
identifying amplicons, a series of bacterial genome segment
sequences were obtained, aligned and scanned for regions where
pairs of PCR primers would amplify products of about 45 to about
150 nucleotides in length and distinguish subgroups and/or
individual strains from each other by their molecular masses or
base compositions. A typical process shown in FIG. 1 is employed
for this type of analysis.
[0369] A database of expected base compositions for each primer
region was generated using an in silico PCR search algorithm, such
as (ePCR). An existing RNA structure search algorithm (Macke et
al., Nucl. Acids Res., 2001, 29, 4724-4735, which is incorporated
herein by reference in its entirety) has been modified to include
PCR parameters such as hybridization conditions, mismatches, and
thermodynamic calculations (SantaLucia, Proc. Natl. Acad. Sci.
U.S.A., 1998, 95, 1460-1465, which is incorporated herein by
reference in its entirety). This also provides information on
primer specificity of the selected primer pairs.
[0370] Table 2 represents a collection of primers (sorted by primer
pair number) designed to identify bacteria using the methods
described herein. The primer pair number is an in-house database
index number. Primer sites were identified on segments of genes,
such as, for example, the 16S rRNA gene. The forward or reverse
primer name shown in Table 2 indicates the gene region of the
bacterial genome to which the primer hybridizes relative to a
reference sequence. In Table 2, for example, the forward primer
name 16S_EC.sub.--1077.sub.--1106_F indicates that the forward
primer (_F) hybridizes to residues 1077-1106 of the reference
sequence represented by a sequence extraction of coordinates
4033120 . . . 4034661 from GenBank gi number 16127994 (as indicated
in Table 3). As an additional example: the forward primer name
BONTA_X52066.sub.--450.sub.--473 indicates that the primer
hybridizes to residues 450-437 of the gene encoding Clostridium
botulinum neurotoxin type A (BoNT/A) represented by GenBank
Accession No. X52066 (primer pair name codes appearing in Table 2
are defined in Table 3. One with ordinary skill knows how to obtain
individual gene sequences or portions thereof from genomic
sequences present in GenBank. In Table 2, Tp=5-propynyluracil;
Cp=5-propynylcytosine; *=phosphorothioate linkage; I=inosine. T.
GenBank Accession Numbers for reference sequences of bacteria are
shown in Table 3 (below). In some cases, the reference sequences
are extractions from bacterial genomic sequences or complements
thereof.
TABLE-US-00002 TABLE 2 Primer Pairs for Identification of Bacteria
Primer Pair Forward SEQ Number Forward Primer Name Forward Sequence
ID NO: 1 16S_EC_1077_1106_F GTGAGATGTTGGGTTAAGTCCCGTAA 134 CGAG 2
16S_EC_1082_1106_F ATGTTGGGTTAAGTCCCGCAACGAG 38 3
16S_EC_1090_1111_F TTAAGTCCCGCAACGATCGCAA 651 4 16S_EC_1222_1241_F
GCTACACACGTGCTACAATG 114 5 16S_EC_1332_1353_F
AAGTCGGAATCGCTAGTAATCG 10 6 16S_EC_30_54_F
TGAACGCTGGTGGCATGCTTAACAC 429 7 16S_EC_38_64_F
GTGGCATGCCTAATACATGCAAGTCG 136 8 16S_EC_49_68_F
TAACACATGCAAGTCGAACG 152 9 16S_EC_683_700_F GTGTAGCGGTGAAATGCG 137
10 16S_EC_713_732_F AGAACACCGATGGCGAAGGC 21 11 16S_EC_785_806_F
GGATTAGAGACCCTGGTAGTCC 118 12 16S_EC_785_810_F
GGATTAGATACCCTGGTAGTCCACGC 119 13 16S_EC_789_810_F
TAGATACCCTGGTAGTCCACGC 206 14 16S_EC_960_981_F
TTCGATGCAACGCGAAGAACCT 672 15 16S_EC_969_985_F ACGCGAAGAACCTTACC 19
16 23S_EC_1826_1843_F CTGACACCTGCCCGGTGC 80 17 23S_EC_2645_2669_F
TCTGTCCCTAGTACGAGAGGACCGG 408 18 23S_EC_2645_2669_2_F
CTGTCCCTAGTACGAGAGGACCGG 83 19 23S_EC_493_518_F
GGGGAGTGAAAGAGATCCTGAAACCG 125 20 23S_EC_493_518_2_F
GGGGAGTGAAAGAGATCCTGAAACCG 125 21 23S_EC_971_992_F
CGAGAGGGAAACAACCCAGACC 66 22 CAPC_BA_104_131_F
GTTATTTAGCACTCGTTTTTAATCAG 139 CC 23 CAPC_BA_114_133_F
ACTCGTTTTTAATCAGCCCG 20 24 CAPC_BA_274_303_F
GATTATTGTTATCCTGTTATGCCATT 109 TGAG 25 CAPC_BA_276_296_F
TTATTGTTATCCTGTTATGCC 663 26 CAPC_BA_281_301_F
GTTATCCTGTTATGCCATTTG 138 27 CAPC_BA_315_334_F CCGTGGTATTGGAGTTATTG
59 28 CYA_BA_1055_1072_F GAAAGAGTTCGGATTGGG 92 29
CYA_BA_1349_1370_F ACAACGAAGTACAATACAAGAC 12 30 CYA_BA_1353_1379_F
CGAAGTACAATACAAGACAAAAGAAGG 64 31 CYA_BA_1359_1379_F
ACAATACAAGACAAAAGAAGG 13 32 CYA_BA_914_937_F
CAGGTTTAGTACCAGAACATGCAG 53 33 CYA_BA_916_935_F
GGTTTAGTACCAGAACATGC 131 34 INFB_EC_1365_1393_F
TGCTCGTGGTGCACAAGTAACGGATA 524 TTA 35 LEF_BA_1033_1052_F
TCAAGAAGAAAAAGAGC 254 36 LEF_BA_1036_1066_F
CAAGAAGAAAAAGAGCTTCTAAAAAG 44 AATAC 37 LEF_BA_756_781_F
AGCTTTTGCATATTATATCGAGCCAC 26 38 LEF_BA_758_778_F
CTTTTGCATATTATATCGAGC 90 39 LEF_BA_795_813_F TTTACAGCTTTATGCACCG
700 40 LEF_BA_883_899_F CAACGGATGCTGGCAAG 43 41 PAG_BA_122_142_F
CAGAATCAAGTTCCCAGGGG 49 42 PAG_BA_123_145_F AGAATCAAGTTCCCAGGGGTTAC
22 43 PAG_BA_269_287_F AATCTGCTATTTGGTCAGG 11 44 PAG_BA_655_675_F
GAAGGATATACGGTTGATGTC 93 45 PAG_BA_753_772_F TCCTGAAAAATGGAGCACGG
341 46 PAG_BA_763_781_F TGGAGCACGGCTTCTGATC 552 47
RPOC_EC_1018_1045_F CAAAACTTATTAGGTAAGCGTGTTGA 39 CT 48
RPOC_EC_1018_1045_2_F CAAAACTTATTAGGTAAGCGTGTTGA 39 CT 49
RPOC_EC_114_140_F TAAGAAGCCGGAAACCATCAACTACCG 158 50
RPOC_EC_2178_2196_F TGATTCTGGTGCCCGTGGT 478 51
RPOC_EC_2178_2196_2_F TGATTCCGGTGCCCGTGGT 477 52
RPOC_EC_2218_2241_F CTGGCAGGTATGCGTGGTCTGATG 81 53
RPOC_EC_2218_2241_2_F CTTGCTGGTATGCGTGGTCTGATG 86 54
RPOC_EC_808_833_F CGTCGGGTGATTAACCGTAACAACCG 75 55
RPOC_EC_808_833_2_F CGTCGTGTAATTAACCGTAACAACCG 76 56
RPOC_EC_993_1019_F CAAAGGTAAGCAAGGTCGTTTCCGTCA 41 57
RPOC_EC_993_1019_2_F CAAAGGTAAGCAAGGACGTTTCCGTCA 40 58
SSPE_BA_115_137_F CAAGCAAACGCACAATCAGAAGC 45 59 TUFB_EC_239_259_F
TAGACTGCCCAGGACACGCTG 204 60 TUFB_EC_239_259_2_F
TTGACTGCCCAGGTCACGCTG 678 61 TUFB_EC_976_1000_F
AACTACCGTCCGCAGTTCTACTTCC 4 62 TUFB_EC_976_1000_2_F
AACTACCGTCCTCAGTTCTACTTCC 5 63 TUFB_EC_985_1012_F
CCACAGTTCTACTTCCGTACTACTGA 56 CG 66 RPLB_EC_650_679_F
GACCTACAGTAAGAGGTTCTGTAATG 98 AACC 67 RPLB_EC_688_710_F
CATCCACACGGTGGTGGTGAAGG 54 68 RPOC_EC_1036_1060_F
CGTGTTGACTATTCGGGGCGTTCAG 78 69 RPOB_EC_3762_3790_F
TCAACAACCTCTTGGAGGTAAAGCTC 248 AGT 70 RPLB_EC_688_710_F
CATCCACACGGTGGTGGTGAAGG 54 71 VALS_EC_1105_1124_F
CGTGGCGGCGTGGTTATCGA 77 72 RPOB_EC_1845_1866_F
TATCGCTCAGGCGAACTCCAAC 233 73 RPLB_EC_669_698_F
TGTAATGAACCCTAATGACCATCCAC 623 ACGG 74 RPLB_EC_671_700_F
TAATGAACCCTAATGACCATCCACAC 169 GGTG 75 SP101_SPET11_1_29_F
AACCTTAATTGGAAAGAAACCCAAGA 2 AGT 76 SP101_SPET11_118_147_F
GCTGGTGAAAATAACCCAGATGTCGT 115 CTTC 77 SP101_SPET11_216_243_F
AGCAGGTGGTGAAATCGGCCACATGA 24 TT 78 SP101_SPET11_266_295_F
CTTGTACTTGTGGCTCACACGGCTGT 89 TTGG 79 SP101_SPET11_322_344_F
GTCAAAGTGGCACGTTTACTGGC 132 80 SP101_SPET11_358_387_F
GGGGATTCAGCCATCAAAGCAGCTAT 126 TGAC 81 SP101_SPET11_600_629_F
CCTTACTTCGAACTATGAATCTTTTG 62 GAAG 82 SP101_SPET11_658_684_F
GGGGATTGATATCACCGATAAGAAGAA 127 83 SP101_SPET11_776_801_F
TCGCCAATCAAAACTAAGGGAATGGC 364 84 SP101_SPET11_893_921_F
GGGCAACAGCAGCGGATTGCGATTGC 123 GCG 85 SP101_SPET11_1154_1179_F
CAATACCGCAACAGCGGTGGCTTGGG 47 86 SP101_SPET11_1314_1336_F
CGCAAAAAAATCCAGCTATTAGC 68 87 SP101_SPET11_1408_1437_F
CGAGTATAGCTAAAAAAATAGTTTAT 67 GACA 88 SP101_SPET11_1688_1716_F
CCTATATTAATCGTTTACAGAAACTG 60 GCT 89 SP101_SPET11_1711_1733_F
CTGGCTAAAACTTTGGCAACGGT 82 90 SP101_SPET11_1807_1835_F
ATGATTACAATTCAAGAAGGTCGTCA 33 CGC 91 SP101_SPET11_1967_1991_F
TAACGGTTATCATGGCCCAGATGGG 155 92 SP101_SPET11_2260_2283_F
CAGAGACCGTTTTATCCTATCAGC 50 93 SP101_SPET11_2375_2399_F
TCTAAAACACCAGGTCACCCAGAAG 390 94 SP101_SPET11_2468_2487_F
ATGGCCATGGCAGAAGCTCA 35 95 SP101_SPET11_2961_2984_F
ACCATGACAGAAGGCATTTTGACA 15 96 SP101_SPET11_3075_3103_F
GATGACTTTTTAGCTAATGGTCAGGC 108 AGC 97 SP101_SPET11_3386_3403_F
AGCGTAAAGGTGAACCTT 25 98 SP101_SPET11_3511_3535_F
GCTTCAGGAATCAATGATGGAGCAG 116 111 RPOB_EC_3775_3803_F
CTTGGAGGTAAGTCTCATTTTGGTGG 87 GCA 112 VALS_EC_1833_1850_F
CGACGCGCTGCGCTTCAC 65 113 RPOB_EC_1336_1353_F GACCACCTCGGCAACCGT 97
114 TUFB_EC_225_251_F GCACTATGCACACGTAGATTGTCCTGG 111 115
DNAK_EC_428_449_F CGGCGTACTTCAACGACAGCCA 72 116 VALS_EC_1920_1943_F
CTTCTGCAACAAGCTGTGGAACGC 85 117 TUFB_EC_757_774_F
AAGACGACCTGCACGGGC 6 118 23S_EC_2646_2667_F CTGTTCTTAGTACGAGAGGACC
84 119 16S_EC_969_985_1P_F ACGCGAAGAACCTTACpC 19 120
16S_EC_972_985_2P_F CGAAGAACpCpTTACC 63 121 16S_EC_972_985_F
CGAAGAACCTTACC 63 122 TRNA_ILE- CCTGATAAGGGTGAGGTCG 61
RRNH_EC_32_50.2_F
123 23S_EC_-7_15_F GTTGTGAGGTTAAGCGACTAAG 140 124 23S_EC_-7_15_F
GTTGTGAGGTTAAGCGACTAAG 141 125 23S_EC_430_450_F
ATACTCCTGACTGACCGATAG 30 126 23S_EC_891_910_F GACTTACCAACCCGATGCAA
100 127 23S_EC_1424_1442_F GGACGGAGAAGGCTATGTT 117 128
23S_EC_1908_1931_F CGTAACTATAACGGTCCTAAGGTA 73 129
23S_EC_2475_2494_F ATATCGACGGCGGTGTTTGG 31 131 16S_EC_-60_-39_F
AGTCTCAAGAGTGAACACGTAA 28 132 16S_EC_326_345_F GACACGGTCCAGACTCCTAC
95 133 16S_EC_705_724_F GATCTGGAGGAATACCGGTG 107 134
16S_EC_1268_1287_F GAGAGCAAGCGGACCTCATA 101 135 16S_EC_969_985_F
ACGCGAAGAACCTTACC 19 137 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 138
16S_EC_969_985_F ACGCGAAGAACCTTACC 19 139 16S_EC_969_985_F
ACGCGAAGAACCTTACC 19 140 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 141
16S_EC_969_985_F ACGCGAAGAACCTTACC 19 142 16S_EC_969_985_F
ACGCGAAGAACCTTACC 19 143 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 147
23S_EC_2652_2669_F CTAGTACGAGAGGACCGG 79 158 16S_EC_683_700_F
GTGTAGCGGTGAAATGCG 137 159 16S_EC_1100_1116_F CAACGAGCGCAACCCTT 42
215 SSPE_BA_121_137_F AACGCACAATCAGAAGC 3 220 GROL_EC_941_959_F
TGGAAGATCTGGGTCAGGC 544 221 INFB_EC_1103_1124_F
GTCGTGAAAACGAGCTGGAAGA 133 222 HFLB_EC_1082_1102_F
TGGCGAACCTGGTGAACGAAGC 569 223 INFB_EC_1969_1994_F
CGTCAGGGTAAATTCCGTGAAGTTAA 74 224 GROL_EC_219_242_F
GGTGAAAGAAGTTGCCTCTAAAGC 128 225 VALS_EC_1105_1124_F
CGTGGCGGCGTGGTTATCGA 77 226 16S_EC_556_575_F CGGAATTACTGGGCGTAAAG
70 227 RPOC_EC_1256_1277_F ACCCAGTGCTGCTGAACCGTGC 16 228
16S_EC_774_795_F GGGAGCAAACAGGATTAGATAC 122 229 RPOC_EC_1584_1604_F
TGGCCCGAAAGAAGCTGAGCG 567 230 16S_EC_1082_1100_F
ATGTTGGGTTAAGTCCCGC 37 231 16S_EC_1389_1407_F CTTGTACACACCGCCCGTC
88 232 16S_EC_1303_1323_F CGGATTGGAGTCTGCAACTCG 71 233
23S_EC_23_37_F GGTGGATGCCTTGGC 129 234 23S_EC_187_207_F
GGGAACTGAAACATCTAAGTA 121 235 23S_EC_1602_1620_F
TACCCCAAACCGACACAGG 184 236 23S_EC_1685_1703_F CCGTAACTTCGGGAGAAGG
58 237 23S_EC_1827_1843_F GACGCCTGCCCGGTGC 99 238
23S_EC_2434_2456_F AAGGTACTCCGGGGATAACAGGC 9 239 23S_EC_2599_2616_F
GACAGTTCGGTCCCTATC 96 240 23S_EC_2653_2669_F TAGTACGAGAGGACCGG 227
241 23S_BS_-68_-44_F AAACTAGATAACAGTAGACATCAC 1 242 16S_EC_8_27_F
AGAGTTTGATCATGGCTCAG 23 243 16S_EC_314_332_F CACTGGAACTGAGACACGG 48
244 16S_EC_518_536_F CCAGCAGCCGCGGTAATAC 57 245 16S_EC_683_700_F
GTGTAGCGGTGAAATGCG 137 246 16S_EC_937_954_F AAGCGGTGGAGCATGTGG 7
247 16S_EC_1195_1213_F CAAGTCATCATGGCCCTTA 46 248 16S_EC_8_27_F
AGAGTTTGATCATGGCTCAG 23 249 23S_EC_1831_1849_F ACCTGCCCAGTGCTGGAAG
18 250 16S_EC_1387_1407_F GCCTTGTACACACCTCCCGTC 112 251
16S_EC_1390_1411_F TTGTACACACCGCCCGTCATAC 693 252
16S_EC_1367_1387_F TACGGTGAATACGTTCCCGGG 191 253 16S_EC_804_822_F
ACCACGCCGTAAACGATGA 14 254 16S_EC_791_812_F GATACCCTGGTAGTCCACACCG
106 255 16S_EC_789_810_F TAGATACCCTGGTAGTCCACGC 206 256
16S_EC_1092_1109_F TAGTCCCGCAACGAGCGC 228 257 23S_EC_2586_2607_F
TAGAACGTCGCGAGACAGTTCG 203 258 RNASEP_SA_31_49_F
GAGGAAAGTCCATGCTCAC 103 258 RNASEP_SA_31_49_F GAGGAAAGTCCATGCTCAC
103 258 RNASEP_SA_31_49_F GAGGAAAGTCCATGCTCAC 103 258
RNASEP_BS_43_61_F GAGGAAAGTCCATGCTCGC 104 258 RNASEP_BS_43_61_F
GAGGAAAGTCCATGCTCGC 104 258 RNASEP_BS_43_61_F GAGGAAAGTCCATGCTCGC
104 258 RNASEP_EC_61_77_F GAGGAAAGTCCGGGCTC 105 258
RNASEP_EC_61_77_F GAGGAAAGTCCGGGCTC 105 258 RNASEP_EC_61_77_F
GAGGAAAGTCCGGGCTC 105 259 RNASEP_BS_43_61_F GAGGAAAGTCCATGCTCGC 104
260 RNASEP_EC_61_77_F GAGGAAAGTCCGGGCTC 105 262 RNASEP_SA_31_49_F
GAGGAAAGTCCATGCTCAC 103 263 16S_EC_1082_1100_F ATGTTGGGTTAAGTCCCGC
37 264 16S_EC_556_575_F CGGAATTACTGGGCGTAAAG 70 265
16S_EC_1082_1100_F ATGTTGGGTTAAGTCCCGC 37 266 16S_EC_1082_1100_F
ATGTTGGGTTAAGTCCCGC 37 268 YAED_EC_513_532_F_MOD
GGTGTTAAATAGCCTGGCAG 130 269 16S_EC_1082_1100_F_MOD
ATGTTGGGTTAAGTCCCGC 37 270 23S_EC_2586_2607_F_MOD
TAGAACGTCGCGAGACAGTTCG 203 272 16S_EC_969_985_F ACGCGAAGAACCTTACC
19 273 16S_EC_683_700_F GTGTAGCGGTGAAATGCG 137 274 16S_EC_49_68_F
TAACACATGCAAGTCGAACG 152 275 16S_EC_49_68_F TAACACATGCAAGTCGAACG
152 277 CYA_BA_1349_1370_F ACAACGAAGTACAATACAAGAC 12 278
16S_EC_1090_1111_2_F TTAAGTCCCGCAACGAGCGCAA 650 279
16S_EC_405_432_F TGAGTGATGAAGGCCTTAGGGTTGTA 464 AA 280
GROL_EC_496_518_F ATGGACAAGGTTGGCAAGGAAGG 34 281 GROL_EC_511_536_F
AAGGAAGGCGTGATCACCGTTGAAGA 8 288 RPOB_EC_3802_3821_F
CAGCGTTTCGGCGAAATGGA 51 289 RPOB_EC_3799_3821_F
GGGCAGCGTTTCGGCGAAATGGA 124 290 RPOC_EC_2146_2174_F
CAGGAGTCGTTCAACTCGATCTACAT 52 GAT 291 ASPS_EC_405_422_F
GCACAACCTGCGGCTGCG 110 292 RPOC_EC_1374_1393_F CGCCGACTTCGACGGTGACC
69 293 TUFB_EC_957_979_F CCACACGCCGTTCTTCAACAACT 55 294
16S_EC_7_33_F GAGAGTTTGATCCTGGCTCAGAACGAA 102 295 VALS_EC_610_649_F
ACCGAGCAAGGAGACCAGC 17 344 16S_EC_971_990_F GCGAAGAACCTTACCAGGTC
113 346 16S_EC_713_732_TMOD_F TAGAACACCGATGGCGAAGGC 202 347
16S_EC_785_806_TMOD_F TGGATTAGAGACCCTGGTAGTCC 560 348
16S_EC_960_981_TMOD_F TTTCGATGCAACGCGAAGAACCT 706 349
23S_EC_1826_1843_TMOD_F TCTGACACCTGCCCGGTGC 401 350
CAPC_BA_274_303_TMOD_F TGATTATTGTTATCCTGTTATGCCAT 476 TTGAG 351
CYA_BA_1353_1379_TMOD_F TCGAAGTACAATACAAGACAAAAGAA 355 GG 352
INFB_EC_1365_1393_TMOD_F TTGCTCGTGGTGCACAAGTAACGGAT 687 ATTA 353
LEF_BA_756_781_TMOD_F TAGCTTTTGCATATTATATCGAGCCAC 220 354
RPOC_EC_2218_2241_TMOD_F TCTGGCAGGTATGCGTGGTCTGATG 405 355
SSPE_BA_115_137_TMOD_F TCAAGCAAACGCACAATCAGAAGC 255 356
RPLB_EC_650_679_TMOD_F TGACCTACAGTAAGAGGTTCTGTAAT 449 GAACC 357
RPLB_EC_688_710_TMOD_F TCATCCACACGGTGGTGGTGAAGG 296 358
VALS_EC_1105_1124_TMOD_F TCGTGGCGGCGTGGTTATCGA 385 359
RPOB_EC_1845_1866_TMOD_F TTATCGCTCAGGCGAACTCCAAC 659 360
23S_EC_2646_2667_TMOD_F TCTGTTCTTAGTACGAGAGGACC 409 361
16S_EC_1090_1111_2_TMOD_F TTTAAGTCCCGCAACGAGCGCAA 697 362
RPOB_EC_3799_3821_TMOD_F TGGGCAGCGTTTCGGCGAAATGGA 581 363
RPOC_EC_2146_2174_TMOD_F TCAGGAGTCGTTCAACTCGATCTACA 284 TGAT 364
RPOC_EC_1374_1393_TMOD_F TCGCCGACTTCGACGGTGACC 367 367
TUFB_EC_957_979_TMOD_F TCCACACGCCGTTCTTCAACAACT 308 423
SP101_SPET11_893_921_TMOD_F TGGGCAACAGCAGCGGATTGCGATTG 580 CGCG 424
SP101_SPET11_1154_1179_TMOD_F TCAATACCGCAACAGCGGTGGCTTGGG 258 425
SP101_SPET11_118_147_TMOD_F TGCTGGTGAAAATAACCCAGATGTCG 528
TCTTC
426 SP101_SPET11_1314_1336_TMOD_F TCGCAAAAAAATCCAGCTATTAGC 363 427
SP101_SPET11_1408_1437_TMOD_F TCGAGTATAGCTAAAAAAATAGTTTA 359 TGACA
428 SP101_SPET11_1688_1716_TMOD_F TCCTATATTAATCGTTTACAGAAACT 334
GGCT 429 SP101_SPET11_1711_1733_TMOD_F TCTGGCTAAAACTTTGGCAACGGT 406
430 SP101_SPET11_1807_1835_TMOD_F TATGATTACAATTCAAGAAGGTCGTC 235
ACGC 431 SP101_SPET11_1967_1991_TMOD_F TTAACGGTTATCATGGCCCAGATGGG
649 432 SP101_SPET11_216_243_TMOD_F TAGCAGGTGGTGAAATCGGCCACATG 210
ATT 433 SP101_SPET11_2260_2283_TMOD_F TCAGAGACCGTTTTATCCTATCAGC 272
434 SP101_SPET11_2375_2399_TMOD_F TTCTAAAACACCAGGTCACCCAGAAG 675
435 SP101_SPET11_2468_2487_TMOD_F TATGGCCATGGCAGAAGCTCA 238 436
SP101_SPET11_266_295_TMOD_F TCTTGTACTTGTGGCTCACACGGCTG 417 TTTGG
437 SP101_SPET11_2961_2984_TMOD_F TACCATGACAGAAGGCATTTTGACA 183 438
SP101_SPET11_3075_3103_TMOD_F TGATGACTTTTTAGCTAATGGTCAGG 473 CAGC
439 SP101_SPET11_322_344_TMOD_F TGTCAAAGTGGCACGTTTACTGGC 631 440
SP101_SPET11_3386_3403_TMOD_F TAGCGTAAAGGTGAACCTT 215 441
SP101_SPET11_3511_3535_TMOD_F TGCTTCAGGAATCAATGATGGAGCAG 531 442
SP101_SPET11_358_387_TMOD_F TGGGGATTCAGCCATCAAAGCAGCTA 588 TTGAC
443 SP101_SPET11_600_629_TMOD_F TCCTTACTTCGAACTATGAATCTTTT 348
GGAAG 444 SP101_SPET11_658_684_TMOD_F TGGGGATTGATATCACCGATAAGAAG
589 AA 445 SP101_SPET11_776_801_TMOD_F TTCGCCAATCAAAACTAAGGGAATGGC
673 446 SP101_SPET11_1_29_TMOD_F TAACCTTAATTGGAAAGAAACCCAAG 154
AAGT 447 SP101_SPET11_364_385_F TCAGCCATCAAAGCAGCTATTG 276 448
SP101_SPET11_3085_3104_F TAGCTAATGGTCAGGCAGCC 216 449
RPLB_EC_690_710_F TCCACACGGTGGTGGTGAAGG 309 481
BONTA_X52066_538_552_F TATGGCTCTACTCAA 239 482
BONTA_X52066_538_552P_F TA*TpGGC*Tp*Cp*TpA*Cp*Tp*CpAA 143 483
BONTA_X52066_701_720_F GAATAGCAATTAATCCAAAT 94 484
BONTA_X52066_701_720P_F GAA*TpAG*CpAA*Tp*TpAA*Tp*Cp 91 *CpAAAT 485
BONTA_X52066_450_473_F TCTAGTAATAATAGGACCCTCAGC 393 486
BONTA_X52066_450_473P_F T*Cp*TpAGTAATAATAGGA*Cp*Cp 142 *Cp*Tp*CpAGC
487 BONTA_X52066_591_620_F TGAGTCACTTGAAGTTGATACAAATC 463 CTCT 608
SSPE_BA_156_168P_F TGGTpGCpTpAGCpATT 616 609 SSPE_BA_75_89P_F
TACpAGAGTpTpTpGCpGAC 192 610 SSPE_BA_150_168P_F
TGCTTCTGGTpGCpTpAGCpATT 533 611 SSPE_BA_72_89P_F
TGGTACpAGAGTpTpTpGCpGAC 602 612 SSPE_BA_114_137P_F
TCAAGCAAACGCACAATpCpAGAAGC 255 699 SSPE_BA_123_153_F
TGCACAATCAGAAGCTAAGAAAGCGC 488 AAGCT 700 SSPE_BA_156_168_F
TGGTGCTAGCATT 612 701 SSPE_BA_75_89_F TACAGAGTTTGCGAC 179 702
SSPE_BA_150_168_F TGCTTCTGGTGCTAGCATT 533 703 SSPE_BA_72_89_F
TGGTACAGAGTTTGCGAC 600 704 SSPE_BA_146_168_F
TGCAAGCTTCTGGTGCTAGCATT 484 705 SSPE_BA_63_89_F
TGCTAGTTATGGTACAGAGTTTGCGAC 518 706 SSPE_BA_114_137_F
TCAAGCAAACGCACAATCAGAAGC 255 770 PLA_AF053945_7377_7402_F
TGACATCCGGCTCACGTTATTATGGT 442 771 PLA_AF053945_7382_7404_F
TCCGGCTCACGTTATTATGGTAC 327 772 PLA_AF053945_7481_7503_F
TGCAAAGGAGGTACTCAGACCAT 481 773 PLA_AF053945_7186_7211_F
TTATACCGGAAACTTCCCGAAAGGAG 657 774 CAF1_AF053947_33407_33430_F
TCAGTTCCGTTATCGCCATTGCAT 292 775 CAF1_AF053947_33515_33541_F
TCACTCTTACATATAAGGAAGGCGCTC 270 776 CAF1_AF053947_33435_33457_F
TGGAACTATTGCAACTGCTAATG 542 777 CAF1_AF053947_33687_33716_F
TCAGGATGGAAATAACCACCAATTCA 286 CTAC 778 INV_U22457_515_539_F
TGGCTCCTTGGTATGACTCTGCTTC 573 779 INV_U22457_699_724_F
TGCTGAGGCCTGGACCGATTATTTAC 525 780 INV_U22457_834_858_F
TTATTTACCTGCACTCCCACAACTG 664 781 INV_U22457_1558_1581_F
TGGTAACAGAGCCTTATAGGCGCA 597 782 LL_NC003143_2366996_2367019_F
TGTAGCCGCTAAGCACTACCATCC 627 783 LL_NC003143_2367172_2367194_F
TGGACGGCATCACGATTCTCTAC 550 874 RPLB_EC_649_679_F
TGICCIACIGTIIGIGGTTCTGTAAT 620 GAACC 875 RPLB_EC_642_679P_F
TpCpCpTpTpGITpGICCIACIGTII 646 GIGGTTCTGTAATGAACC 876
MECIA_Y14051_3315_3341_F TTACACATATCGTGAGCAATGAACTGA 653 877
MECA_Y14051_3774_3802_F TAAAACAAACTACGGTAACATTGATC 144 GCA 878
MECA_Y14051_3645_3670_F TGAAGTAGAAATGACTGAACGTCCGA 434 879
MECA_Y14051_4507_4530_F TCAGGTACTGCTATCCACCCTCAA 288 880
MECA_Y14051_4510_4530_F TGTACTGCTATCCACCCTCAA 626 881
MECA_Y14051_4669_4698_F TCACCAGGTTCAACTCAAAAAATATT 262 AACA 882
MECA_Y14051_4520_4530P_F TCpCpACpCpCpTpCpAA 389 883
MECA_Y14051_4520_4530P_F TCpCpACpCpCpTpCpAA 389 902
TRPE_AY094355_1467_1491_F ATGTCGATTGCAATCCGTACTTGTG 36 903
TRPE_AY094355_1445_1471_F TGGATGGCATGGTGAAATGGATATGTC 557 904
TRPE_AY094355_1278_1303_F TCAAATGTACAAGGTGAAGTGCGTGA 247 905
TRPE_AY094355_1064_1086_F TCGACCTTTGGCAGGAACTAGAC 357 906
TRPE_AY094355_666_688_F GTGCATGCGGATACAGAGCAGAG 135 907
TRPE_AY094355_757_776_F TGCAAGCGCGACCACATACG 483 908
RECA_AF251469_43_68_F TGGTACATGTGCCTTCATTGATGCTG 601 909
RECA_AF251469_169_190_F TGACATGCTTGTCCGTTCAGGC 446 910
PARC_X95819_87_110_F TGGTGACTCGGCATGTTATGAAGC 609 911
PARC_X95819_87_110_F TGGTGACTCGGCATGTTATGAAGC 609 912
PARC_X95819_123_147_F GGCTCAGCCATTTAGTTACCGCTAT 120 913
PARC_X95819_43_63_F TCAGCGCGTACAGTGGGTGAT 277 914
OMPA_AY485227_272_301_F TTACTCCATTATTGCTTGGTTACACT 655 TTCC 915
OMPA_AY485227_379_401_F TGCGCAGCTCTTGGTATCGAGTT 509 916
OMPA_AY485227_311_335_F TACACAACAATGGCGGTAAAGATGG 178 917
OMPA_AY485227_415_441_F TGCCTCGAAGCTGAATATAACCAAGTT 506 918
OMPA_AY485227_494_520_F TCAACGGTAACTTCTATGTTACTTCTG 252 919
OMPA_AY485227_551_577_F TCAAGCCGTACGTATTATTAGGTGCTG 257 920
OMPA_AY485227_555_581_F TCCGTACGTATTATTAGGTGCTGGTCA 328 921
OMPA_AY485227_556_583_F TCGTACGTATTATTAGGTGCTGGTCA 379 CT 922
OMPA_AY485227_657_679_F TGTTGGTGCTTTCTGGCGCTTAA 645 923
OMPA_AY485227_660_683_F TGGTGCTTTCTGGCGCTTAAACGA 613 924
GYRA_AF100557_4_23_F TCTGCCCGTGTCGTTGGTGA 402 925
GYRA_AF100557_70_94_F TCCATTGTTCGTATGGCTCAAGACT 316 926
GYRB_AB008700_19_40_F TCAGGTGGCTTACACGGCGTAG 289 927
GYRB_AB008700_265_292_F TCTTTCTTGAATGCTGGTGTACGTAT 420 CG 928
GYRB_AB008700_368_394_F TCAACGAAGGTAAAAACCATCTCAACG 251 929
GYRB_AB008700_477_504_F TGTTCGCTGTTTCACAAACAACATTC 641 CA 930
GYRB_AB008700_760_787_F TACTTACTTGAGAATCCACAAGCTGC 198 AA 931
WAAA_Z96925_2_29_F TCTTGCTCTTTCGTGAGTTCAGTAAA 416 TG 932
WAAA_Z96925_286_311_F TCGATCTGGTTTCATGCTGTTTCAGT 360 939
RPOB_EC_3798_3821_F TGGGCAGCGTTTCGGCGAAATGGA 581 940
RPOB_EC_3798_3821_F TGGGCAGCGTTTCGGCGAAATGGA 581 941
TUFB_EC_275_299_F TGATCACTGGTGCTGCTCAGATGGA 468 942
TUFB_EC_251_278_F TGCACGCCGACTATGTTAAGAACATG 493 AT 949
GYRB_AB008700_760_787_F TACTTACTTGAGAATCCACAAGCTGC 198 AA 958
RPOC_EC_2223_2243_F TGGTATGCGTGGTCTGATGGC 605 959 RPOC_EC_918_938_F
TCTGGATAACGGTCGTCGCGG 404 960 RPOC_EC_2334_2357_F
TGCTCGTAAGGGTCTGGCGGATAC 523 961 RPOC_EC_917_938_F
TATTGGACAACGGTCGTCGCGG 242 962 RPOB_EC_2005_2027_F
TCGTTCCTGGAACACGATGACGC 387 963 RPOB_EC_1527_1549_F
TCAGCTGTCGCAGTTCATGGACC 282 964 INFB_EC_1347_1367_F
TGCGTTTACCGCAATGCGTGC 515 965 VALS_EC_1128_1151_F
TATGCTGACCGACCAGTGGTACGT 237
978 RPOC_EC_2145_2175_F TCAGGAGTCGTTCAACTCGATCTACA 285 TGATG 1045
CJST_CJ_1668_1700_F TGCTCGAGTGATTGACTTTGCTAAAT 522 TTAGAGA 1046
CJST_CJ_2171_2197_F TCGTTTGGTGGTGGTAGATGAAAAAGG 388 1047
CJST_CJ_584_616_F TCCAGGACAAATGTATGAAAAATGTC 315 CAAGAAG 1048
CJST_CJ_360_394_F TCCTGTTATCCCTGAAGTAGTTAATC 346 AAGTTTGTT 1049
CJST_CJ_2636_2668_F TGCCTAGAAGATCTTAAAAATTTCCG 504 CCAACTT 1050
CJST_CJ_1290_1320_F TGGCTTATCCAAATTTAGATCGTGGT 575 TTTAC 1051
CJST_CJ_3267_3293_F TTTGATTTTACGCCGTCCTCCAGGTCG 707 1052
CJST_CJ_5_39_F TAGGCGAAGATATACAAAGAGTATTA 222 GAAGCTAGA 1053
CJST_CJ_1080_1110_F TTGAGGGTATGCACCGTCTTTTTGAT 681 TCTTT 1054
CJST_CJ_2060_2090_F TCCCGGACTTAATATCAATGAAAATT 323 GTGGA 1055
CJST_CJ_2869_2895_F TGAAGCTTGTTCTTTAGCAGGACTTCA 432 1056
CJST_CJ_1880_1910_F TCCCAATTAATTCTGCCATTTTTCCA 317 GGTAT 1057
CJST_CJ_2185_2212_F TAGATGAAAAGGGCGAAGTGGCTAAT 208 GG 1058
CJST_CJ_1643_1670_F TTATCGTTTGTGGAGCTAGTGCTTAT 660 GC 1059
CJST_CJ_2165_2194_F TGCGGATCGTTTGGTGGTTGTAGATG 511 AAAA 1060
CJST_CJ_599_632_F TGAAAAATGTCCAAGAAGCATAGCAA 424 AAAAAGCA 1061
CJST_CJ_360_393_F TCCTGTTATCCCTGAAGTAGTTAATC 345 AAGTTTGT 1062
CJST_CJ_2678_2703_F TCCCCAGGACACCCTGAAATTTCAAC 321 1063
CJST_CJ_1268_1299_F AGTTATAAACACGGCTTTCCTATGGC 29 TTATCC 1064
CJST_CJ_1680_1713_F TGATTTTGCTAAATTTAGAGAAATTG 479 CGGATGAA 1065
CJST_CJ_2857_2887_F TGGCATTTCTTATGAAGCTTGTTCTT 565 TAGCA 1070
RNASEP_BKM_580_599_F TGCGGGTAGGGAGCTTGAGC 512 1071
RNASEP_BKM_616_637_F TCCTAGAGGAATGGCTGCCACG 333 1072
RNASEP_BDP_574_592_F TGGCACGGCCATCTCCGTG 561 1073
23S_BRM_1110_1129_F TGCGCGGAAGATGTAACGGG 510 1074 23S_BRM_515_536_F
TGCATACAAACAGTCGGAGCCT 496 1075 RNASEP_CLB_459_487_F
TAAGGATAGTGCAACAGAGATATACC 162 GCC 1076 RNASEP_CLB_459_487_F
TAAGGATAGTGCAACAGAGATATACC 162 GCC 1077 ICD_CXB_93_120_F
TCCTGACCGACCCATTATTCCCTTTA 343 TC 1078 ICD_CXB_92_120_F
TTCCTGACCGACCCATTATTCCCTTT 671 ATC 1079 ICD_CXB_176_198_F
TCGCCGTGGAAAAATCCTACGCT 369 1080 IS1111A_NC002971_6866_6891_F
TCAGTATGTATCCACCGTAGCCAGTC 290 1081 IS1111A_NC002971_7456_7483_F
TGGGTGACATTCATCAATTTCATCGT 594 TC 1082 RNASEP_RKP_419_448_F
TGGTAAGAGCGCACCGGTAAGTTGGT 599 AACA 1083 RNASEP_RKP_422_443_F
TAAGAGCGCACCGGTAAGTTGG 159 1084 RNASEP_RKP_466_491_F
TCCACCAAGAGCAAGATCAAATAGGC 310 1085 RNASEP_RKP_264_287_F
TCTAAATGGTCGTGCAGTTGCGTG 391 1086 RNASEP_RKP_426_448_F
TGCATACCGGTAAGTTGGCAACA 497 1087 OMPB_RKP_860_890_F
TTACAGGAAGTTTAGGTGGTAATCTA 654 AAAGG 1088 OMPB_RKP_1192_1221_F
TCTACTGATTTTGGTAATCTTGCAGC 392 ACAG 1089 OMPB_RKP_3417_3440_F
TGCAAGTGGTACTTCAACATGGGG 485 1090 GLTA_RKP_1043_1072_F
TGGGACTTGAAGCTATCGCTCTTAAA 576 GATG 1091 GLTA_RKP_400_428_F
TCTTCTCATCCTATGGCTATTATGCT 413 TGC 1092 GLTA_RKP_1023_1055_F
TCCGTTCTTACAAATAGCAATAGAAC 330 TTGAAGC 1093 GLTA_RKP_1043_1072_2_F
TGGAGCTTGAAGCTATCGCTCTTAAA 553 GATG 1094 GLTA_RKP_1043_1072_3_F
TGGAACTTGAAGCTCTCGCTCTTAAA 543 GATG 1095 GLTA_RKP_400_428_F
TCTTCTCATCCTATGGCTATTATGCT 413 TGC 1096 CTXA_VBC_117_142_F
TCTTATGCCAAGAGGACAGAGTGAGT 410 1097 CTXA_VBC_351_377_F
TGTATTAGGGGCATACAGTCCTCATCC 630 1098 RNASEP_VBC_331_349_F
TCCGCGGAGTTGACTGGGT 325 1099 TOXR_VBC_135_158_F
TCGATTAGGCAGCAACGAAAGCCG 362 1100 ASD_FRT_1_29_F
TTGCTTAAAGTTGGTTTTATTGGTTG 690 GCG 1101 ASD_FRT_43_76_F
TCAGTTTTAATGTCTCGTATGATCGA 295 ATCAAAAG 1102 GALE_FRT_168_199_F
TTATCAGCTAGACCTTTTAGGTAAAG 658 CTAAGC 1103 GALE_FRT_834_865_F
TCAAAAAGCCCTAGGTAAAGAGATTC 245 CATATC 1104 GALE_FRT_308_339_F
TCCAAGGTACACTAAACTTACTTGAG 306 CTAATG 1105 IPAH_SGF_258_277_F
TGAGGACCGTGTCGCGCTCA 458 1106 IPAH_SGF_113_134_F
TCCTTGACCGCCTTTCCGATAC 350 1107 IPAH_SGF_462_486_F
TCAGACCATGCTCGCAGAGAAACTT 271 1111 RNASEP_BRM_461_488_F
TAAACCCCATCGGGAGCAAGACCGAA 147 TA 1112 RNASEP_BRM_325_347_F
TACCCCAGGGAAAGTGCCACAGA 185 1128 HUPB_CJ_113_134_F
TAGTTGCTCAAACAGCTGGGCT 230 1129 HUPB_CJ_76_102_F
TCCCGGAGCTTTTATGACTAAAGCAG 324 AT 1130 HUPB_CJ_76_102_F
TCCCGGAGCTTTTATGACTAAAGCAG 324 AT 1151 AB_MLST-11-
TGAGATTGCTGAACATTTAATGCTGA 454 OIF007_62_91_F TTGA 1152 AB_MLST-11-
TATTGTTTCAAATGTACAAGGTGAAG 243 OIF007_185_214_F TGCG 1153
AB_MLST-11- TGGAACGTTATCAGGTGCCCCAAAAA 541 OIF007_260_289_F TTCG
1154 AB_MLST-11- TGAAGTGCGTGATGATATCGATGCAC 436 OIF007_206_239_F
TTGATGTA 1155 AB_MLST-11- TCGGTTTAGTAAAAGAACGTATTGCT 378
OIF007_522_552_F CAACC 1156 AB_MLST-11- TCAACCTGACTGCGTGAATGGTTGT
250 OIF007_547_571_F 1157 AB_MLST-11- TCAAGCAGAAGCTTTGGAAGAAGAAGG
256 OIF007_601_627_F 1158 AB_MLST-11- TCGTGCCCGCAATTTGCATAAAGC 384
OIF007_1202_1225_F 1159 AB_MLST-11- TCGTGCCCGCAATTTGCATAAAGC 384
OIF007_1202_1225_F 1160 AB_MLST-11- TTGTAGCACAGCAAGGCAAATTTCCT 694
OIF007_1234_1264_F GAAAC 1161 AB_MLST-11-
TAGGTTTACGTCAGTATGGCGTGATT 225 OIF007_1327_1356_F ATGG 1162
AB_MLST-11- TCGTGATTATGGATGGCAACGTGAA 383 OIF007_1345_1369_F 1163
AB_MLST-11- TTATGGATGGCAACGTGAAACGCGT 662 OIF007_1351_1375_F 1164
AB_MLST-11- TCTTTGCCATTGAAGATGACTTAAGC 422 OIF007_1387_1412_F 1165
AB_MLST-11- TACTAGCGGTAAGCTTAAACAAGATT 194 OIF007_1542_1569_F GC
1166 AB_MLST-11- TTGCCAATGATATTCGTTGGTTAGCA 684 OIF007_1566_1593_F
AG 1167 AB_MLST-11- TCGGCGAAATCCGTATTCCTGAAAAT 375
OIF007_1611_1638_F GA 1168 AB_MLST-11- TACCACTATTAATGTCGCTGGTGCTTC
182 OIF007_1726_1752_F 1169 AB_MLST-11- TTATAACTTACTGCAATCTATTCAGT
656 OIF007_1792_1826_F TGCTTGGTG 1170 AB_MLST-11-
TTATAACTTACTGCAATCTATTCAGT 656 OIF007_1792_1826_F TGCTTGGTG 1171
AB_MLST-11- TGGTTATGTACCAAATACTTTGTCTG 618 OIF007_1970_2002_F
AAGATGG 1172 RNASEP_BRM_461_488_F TAAACCCCATCGGGAGCAAGACCGAA 147 TA
2000 CTXB_NC002505_46_70_F TCAGCGTATGCACATGGAACTCCTC 278 2001
FUR_NC002505_87_113_F TGAGTGCCAACATATCAGTGCTGAAGA 465 2002
FUR_NC002505_87_113_F TGAGTGCCAACATATCAGTGCTGAAGA 465 2003
GAPA_NC002505_533_560_F TCGACAACACCATTATCTATGGTGTG 356 AA 2004
GAPA_NC002505_694_721_F TCAATGAACGACCAACAAGTGATTGA 259 TG 2005
GAPA_NC002505_753_782_F TGCTAGTCAATCTATCATTCCGGTTG 517 ATAC
2006 GYRB_NC002505_2_32_F TGCCGGACAATTACGATTCATCGAGT 501 ATTAA 2007
GYRB_NC002505_123_152_F TGAGGTGGTGGATAACTCAATTGATG 460 AAGC 2008
GYRB_NC002505_768_794_F TATGCAGTGGAACGATGGTTTCCAAGA 236 2009
GYRB_NC002505_837_860_F TGGTACTCACTTAGCGGGTTTCCG 603 2010
GYRB_NC002505_934_956_F TCGGGTGATGATGCGCGTGAAGG 377 2011
GYRB_NC002505_1161_1190_F TAAAGCCCGTGAAATGACTCGTCGTA 148 AAGG 2012
OMPU_NC002505_85_110_F TACGCTGACGGAATCAACCAAAGCGG 190 2013
OMPU_NC002505_258_283_F TGACGGCCTATACGGTGTTGGTTTCT 451 2014
OMPU_NC002505_431_455_F TCACCGATATCATGGCTTACCACGG 266 2015
OMPU_NC002505_533_557_F TAGGCGTGAAAGCAAGCTACCGTTT 223 2016
OMPU_NC002505_689_713_F TAGGTGCTGGTTACGCAGATCAAGA 224 2017
OMPU_NC002505_727_747_F TACATGCTAGCCGCGTCTTAC 181 2018
OMPU_NC002505_931_953_F TACTACTTCAAGCCGAACTTCCG 193 2019
OMPU_NC002505_927_953_F TACTTACTACTTCAAGCCGAACTTCCG 197 2020
TCPA_NC002505_48_73_F TCACGATAAGAAAACCGGTCAAGAGG 269 2021
TDH_NC004605_265_289_F TGGCTGACATCCTACATGACTGTGA 574 2022
VVHA_NC004460_772_802_F TCTTATTCCAACTTCAAACCGAACTA 412 TGACG 2023
23S_EC_2643_2667_F TGCCTGTTCTTAGTACGAGAGGACC 508 2024
16S_EC_713_732_TMOD_F TAGAACACCGATGGCGAAGGC 202 2025
16S_EC_784_806_F TGGATTAGAGACCCTGGTAGTCC 560 2026 16S_EC_959_981_F
TGTCGATGCAACGCGAAGAACCT 634 2027 TUFB_EC_956_979_F
TGCACACGCCGTTCTTCAACAACT 489 2028 RPOC_EC_2146_2174_TMOD_F
TCAGGAGTCGTTCAACTCGATCTACA 284 TGAT 2029 RPOB_EC_1841_1866_F
TGGTTATCGCTCAGGCGAACTCCAAC 617 2030 RPLB_EC_650_679_TMOD_F
TGACCTACAGTAAGAGGTTCTGTAAT 449 GAACC 2031 RPLB_EC_690_710_F
TCCACACGGTGGTGGTGAAGG 309 2032 INFB_EC_1366_1393_F
TCTCGTGGTGCACAAGTAACGGATAT 397 TA 2033 VALS_EC_1105_1124_TMOD_F
TCGTGGCGGCGTGGTTATCGA 385 2034 SSPE_BA_113_137_F
TGCAAGCAAACGCACAATCAGAAGC 482 2035 RPOC_EC_2218_2241_TMOD_F
TCTGGCAGGTATGCGTGGTCTGATG 405 2056 MECI-R_NC003923-
TTTACACATATCGTGAGCAATGAACT 698 41798-41609_33_60_F GA 2057
AGR-III_NC003923- TCACCAGTTTGCCACGTATCTTCAA 263 2108074-
2109507_1_23_F 2058 AGR-III_NC003923- TGAGCTTTTAGTTGACTTTTTCAACA
457 2108074- GC 2109507_569_596_F 2059 AGR-III_NC003923-
TTTCACACAGCGTGTTTATAGTTCTA 701 2108074- CCA 2109507_1024_1052_F
2060 AGR- TGGTGACTTCATAATGGATGAAGTTG 610 I_AJ617706_622_651_F AAGT
2061 AGR- TGGGATTTTAAAAAACATTGGTAACA 579 I_AJ617706_580_611_F
TCGCAG 2062 AGR-II_NC002745- TCTTGCAGCAGTTTATTTGATGAACC 415
2079448- TAAAGT 2080879_620_651_F 2063 AGR-II_NC002745-
TGTACCCGCTGAATTAACGAATTTAT 624 2079448- ACGAC 2080879_649_679_F
2064 AGR- TGGTATTCTATTTTGCTGATAATGAC 606 IV_AJ617711_931_961_F
CTCGC 2065 AGR- TGGCACTCTTGCCTTTAATATTAGTA 562
IV_AJ617711_250_283_F AACTATCA 2066 BLAZ_NC002952(1913827 . . .
1914672)_68_68_F TCCACTTATCGCAAATGGAAAATTAA 312 GCAA 2067
BLAZ_NC002952(1913827 . . . 1914672)_68_68_2_F
TGCACTTATCGCAAATGGAAAATTAA 494 GCAA 2068 BLAZ_NC002952(1913827 . .
. 1914672)_68_68_3_F TGATACTTCAACGCCTGCTGCTTTC 467 2069
BLAZ_NC002952(1913827 . . . 1914672)_68_68_4_F
TATACTTCAACGCCTGCTGCTTTC 232 2070 BLAZ_NC002952(1913827 . . .
1914672)_1_33_F TGCAATTGCTTTAGTTTTAAGTGCAT 487 GTAATTC 2071
BLAZ_NC002952(1913827 . . . 1914672)_3_34_F
TCCTTGCTTTAGTTTTAAGTGCATGT 351 AATTCAA 2072 BSA-A_NC003923-
TAGCGAATGTGGCTTTACTTCACAATT 214 1304065- 1303589_99_125_F 2073
BSA-A_NC003923- ATCAATTTGGTGGCCAAGAACCTGG 32 1304065-
1303589_194_218_F 2074 BSA-A_NC003923- TTGACTGCGGCACAACACGGAT 679
1304065- 1303589_328_349_F 2075 BSA-A_NC003923-
TGCTATGGTGTTACCTTCCCTATGCA 519 1304065- 1303589_253_278_F 2076
BSA-B_NC003923- TAGCAACAAATATATCTGAAGCAGCG 209 1917149- TACT
1914156_953_982_F 2077 BSA-B_NC003923- TGAAAAGTATGGATTTGAACAACTCG
426 1917149- TGAATA 1914156_1050_1081_F 2078 BSA-B_NC003923-
TCATTATCATGCGCCAATGAGTGCAGA 300 1917149- 1914156_1260_1286_F 2079
BSA-B_NC003923- TTTCATCTTATCGAGGACCCGAAATC 703 1917149- GA
1914156_2126_2153_F 2080 ERMA_NC002952- TCGCTATCTTATCGTTGAGAAGGGATT
372 55890- 56621_366_392_F 2081 ERMA_NC002952-
TAGCTATCTTATCGTTGAGAAGGGAT 217 55890- TTGC 56621_366_395_F 2082
ERMA_NC002952- TGATCGTTGAGAAGGGATTTGCGAAA 470 55890- AGA
56621_374_402_F 2083 ERMA_NC002952- TGCAAAATCTGCAACGAGCTTTGG 480
55890- 56621_404_427_F 2084 ERMA_NC002952-
TCATCCTAAGCCAAGTGTAGACTCTG 297 55890- TA 56621_489_516_F 2085
ERMA_NC002952- TATAAGTGGGTAAACCGTGAATATCG 231 55890- TGT
56621_586_614_F 2086 ERMC_NC005908-2004- TCTGAACATGATAATATCTTTGAAAT
399 2738_85_116_F CGGCTC 2087 ERMC_NC005908-2004-
TCATGATAATATCTTTGAAATCGGCT 298 2738_90_120_F CAGGA 2088
ERMC_NC005908-2004- TCAGGAAAAGGGCATTTTACCCTTG 283 2738_115_139_F
2089 ERMC_NC005908-2004- TAATCGTGGAATACGGGTTTGCTA 168
2738_374_397_F 2090 ERMC_NC005908-2004- TCTTTGAAATCGGCTCAGGAAAAGG
421 2738_101_125_F 2091 ERMB_Y13600-625- TGTTGGGAGTATTCCTTACCATTTAA
644 1362_291_321_F GCACA 2092 ERMB_Y13600-625-
TGGAAAGCCATGCGTCTGACATCT 536 1362_344_367_F 2093 ERMB_Y13600-625-
TGGATATTCACCGAACACTAGGGTTG 556 1362_404_429_F 2094 ERMB_Y13600-625-
TAAGCTGCCAGCGGAATGCTTTC 161 1362_465_487_F 2095 PVLUK_NC003923-
TGAGCTGCATCAACTGTATTGGATAG 456 1529595- 1531285_688_713_F 2096
PVLUK_NC003923- TGGAACAAAATAGTCTCTCGGATTTT 539 1529595- GACT
1531285_1039_1068_F 2097 PVLUK_NC003923- TGAGTAACATCCATATTTCTGCCATA
461 1529595- CGT 1531285_908_936_F 2098 PVLUK_NC003923-
TCGGAATCTGATGTTGCAGTTGTT 373 1529595- 1531285_610_633_F 2099
SA442_NC003923- TGTCGGTACACGATATTCTTCACGA 635 2538576-
2538831_11_35_F 2100 SA442_NC003923- TGAAATCTCATTACGTTGCATCGGAAA
427 2538576- 2538831_98_124_F 2101 SA442_NC003923-
TCTCATTACGTTGCATCGGAAACA 395 2538576- 2538831_103_126_F 2102
SA442_NC003923- TAGTACCGAAGCTGGTCATACGA 226 2538576-
2538831_166_188_F 2103 SEA_NC003923- TGCAGGGAACAGCTTTAGGCA 495
2052219- 2051456_115_135_F 2104 SEA_NC003923-
TAACTCTGATGTTTTTGATGGGAAGGT 156 2052219- 2051456_572_598_F 2105
SEA_NC003923- TGTATGGTGGTGTAACGTTACATGAT 629 2052219- AATAATC
2051456_382_414_F
2106 SEA_NC003923- TTGTATGTATGGTGGTGTAACGTTAC 695 2052219- ATGA
2051456_377_406_F 2107 SEB_NC002758- TTTCACATGTAATTTTGATATTCGCA 702
2135540- CTGA 2135140_208_237_F 2108 SEB_NC002758-
TATTTCACATGTAATTTTGATATTCG 244 2135540- CACT 2135140_206_235_F 2109
SEB_NC002758- TAACAACTCGCCTTATGAAACGGGAT 151 2135540- ATA
2135140_402_402_F 2110 SEB_NC002758- TTGTATGTATGGTGGTGTAACTGAGCA
696 2135540- 2135140_402_402_2_F 2111 SEC_NC003923-
TTAACATGAAGGAAACCACTTTGATA 648 851678- ATGG 852768_546_575_F 2112
SEC_NC003923- TGGAATAACAAAACATGAAGGAAACC 546 851678- ACTT
852768_537_566_F 2113 SEC_NC003923- TGAGTTTAACAGTTCACCATATGAAA 466
851678- CAGG 852768_720_749_F 2114 SEC_NC003923-
TGGTATGATATGATGCCTGCACCA 604 851678- 852768_787_810_F 2115
SED_M28521_657_682_F TGGTGGTGAAATAGATAGGACTGCTT 615 2116
SED_M28521_690_711_F TGGAGGTGTCACTCCACACGAA 554 2117
SED_M28521_833_854_F TTGCACAAGCAAGGCGCTATTT 683 2118
SED_M28521_962_987_F TGGATGTTAAGGGTGATTTTCCCGAA 559 2119
SEA-SEE_NC002952- TTTACACTACTTTTATTCATTGCCCT 699 2131289- AACG
2130703_16_45_F 2120 SEA-SEE_NC002952- TGATCATCCGTGGTATAACGATTTAT
469 2131289- TAGT 2130703_249_278_F 2121 SEE_NC002952-
TGACATGATAATAACCGATTGACCGA 445 2131289- AGA 2130703_409_437_F 2122
SEE_NC002952- TGTTCAAGAGCTAGATCTTCAGGCAA 640 2131289-
2130703_525_550_F 2123 SEE_NC002952- TGTTCAAGAGCTAGATCTTCAGGCA 639
2131289- 2130703_525_549_F 2124 SEE_NC002952-
TCTGGAGGCACACCAAATAAAACA 403 2131289- 2130703_361_384_F 2125
SEG_NC002758- TGCTCAACCCGATCCTAAATTAGACGA 520 1955100-
1954171_225_251_F 2126 SEG_NC002758- TGGACAATAGACAATCACTTGGATTT 548
1955100- ACA 1954171_623_651_F 2127 SEG_NC002758-
TGGAGGTTGTTGTATGTATGGTGGT 555 1955100- 1954171_540_564_F 2128
SEG_NC002758- TACAAAGCAAGACACTGGCTCACTA 173 1955100-
1954171_694_718_F 2129 SEH_NC002953-60024- TTGCAACTGCTGATTTAGCTCAGA
682 60977_449_472_F 2130 SEH_NC002953-60024-
TAGAAATCAAGGTGATAGTGGCAATGA 201 60977_408_434_F 2131
SEH_NC002953-60024- TCTGAATGTCTATATGGAGGTACAAC 400 60977_547_576_F
ACTA 2132 SEH_NC002953-60024- TTCTGAATGTCTATATGGAGGTACAA 677
60977_546_575_F CACT 2133 SEI_NC002758- TCAACTCGAATTTTCAACAGGTACCA
253 1957830- 1956949_324_349_F 2134 SEI_NC002758-
TTCAACAGGTACCAATGATTTGATCT 666 1957830- CA 1956949_336_363_F 2135
SEI_NC002758- TGATCTCAGAATCTAATAATTGGGAC 471 1957830- GAA
1956949_356_384_F 2136 SEI_NC002758- TCTCAAGGTGATATTGGTGTAGGTAA 394
1957830- CTTAA 1956949_223_253_F 2137 SEJ_AF053140_1307_1332_F
TGTGGAGTAACACTGCATGAAAACAA 637 2138 SEJ_AF053140_1378_1403_F
TAGCATCAGAACTGTTGTTCCGCTAG 211 2139 SEJ_AF053140_1431_1459_F
TAACCATTCAAGAACTAGATCTTCAG 153 GCA 2140 SEJ_AF053140_1434_1461_F
TCATTCAAGAACTAGATCTTCAGGCA 301 AG 2141 TSST_NC002758-
TGGTTTAGATAATTCCTTAGGATCTA 619 2137564- TGCGT 2138293_206_236_F
2142 TSST_NC002758- TGCGTATAAAAAACACAGATGGCAGCA 514 2137564-
2138293_232_258_F 2143 TSST_NC002758- TCCAAATAAGTGGCGTTACAAATACT
304 2137564- GAA 2138293_382_410_F 2144 TSST_NC002758-
TCTTTTACAAAAGGGGAAAAAGTTGA 423 2137564- CTT 2138293_297_325_F 2145
ARCC_NC003923- TCGCCGGCAATGCCATTGGATA 368 2725050- 2724595_37_58_F
2146 ARCC_NC003923- TGAATAGTGATAGAACTGTAGGCACA 437 2725050- ATCGT
2724595_131_161_F 2147 ARCC_NC003923- TTGGTCCTTTTTATACGAAAGAAGAA
691 2725050- GTTGAA 2724595_218_249_F 2148 AROE_NC003923-
TTGCGAATAGAACGATGGCTCGT 686 1674726- 1674277_371_393_F 2149
AROE_NC003923- TGGGGCTTTAAATATTCCAATTGAAG 590 1674726- ATTTTCA
1674277_30_62_F 2150 AROE_NC003923- TGATGGCAAGTGGATAGGGTATAATA 474
1674726- CAG 1674277_204_232_F 2151 GLPF_NC003923-
TGCACCGGCTATTAAGAATTACTTTG 491 1296927- CCAACT 1297391_270_301_F
2152 GLPF_NC003923- TGGATGGGGATTAGCGGTTACAATG 558 1296927-
1297391_27_51_F 2153 GLPF_NC003923- TAGCTGGCGCGAAATTAGGTGT 218
1296927- 1297391_239_260_F 2154 GMK_NC003923-
TACTTTTTTAAAACTAGGGATGCGTT 200 1190906- TGAAGC 1191334_91_122_F
2155 GMK_NC003923- TGAAGTAGAAGGTGCAAAGCAAGTTA 435 1190906- GA
1191334_240_267_F 2156 GMK_NC003923- TCACCTCCAAGTTTAGATCACTTGAG 268
1190906- AGA 1191334_301_329_F 2157 PTA_NC003923-
TCTTGTTTATGCTGGTAAAGCAGATGG 418 628885- 629355_237_263_F 2158
PTA_NC003923- TGAATTAGTTCAATCATTTGTTGAAC 439 628885- GACGT
629355_141_171_F 2159 PTA_NC003923- TCCAAACCAGGTGTATCAAGAACATC 303
628885- AGG 629355_328_356_F 2160 TPI_NC003923-
TGCAAGTTAAGAAAGCTGTTGCAGGT 486 830671- TTAT 831072_131_160_F 2161
TPI_NC003923- TCCCACGAAACAGATGAAGAAATTAA 318 830671- CAAAAAAG
831072_1_34_F 2162 TPI_NC003923- TCAAACTGGGCAATCGGAACTGGTAA 246
830671- ATC 831072_199_227_F 2163 YQI_NC003923-
TGAATTGCTGCTATGAAAGGTGGCTT 440 378916- 379431_142_167_F 2164
YQI_NC003923- TACAACATATTATTAAAGAGACGGGT 175 378916- TTGAATCC
379431_44_77_F 2165 YQI_NC003923- TCCAGCACGAATTGCTGCTATGAAAG 314
378916- 379431_135_160_F 2166 YQI_NC003923-
TAGCTGGCGGTATGGAGAATATGTCT 219 378916- 379431_275_300_F 2167
BLAZ_(1913827 . . . 1914672)_546_575_F TCCACTTATCGCAAATGGAAAATTAA
312 GCAA 2168 BLAZ_(1913827 . . . 1914672)_546_575_2_F
TGCACTTATCGCAAATGGAAAATTAA 494 GCAA 2169 BLAZ_(1913827 . . .
1914672)_507_531_F TGATACTTCAACGCCTGCTGCTTTC 467 2170 BLAZ_(1913827
. . . 1914672)_508_531_F TATACTTCAACGCCTGCTGCTTTC 232 2171
BLAZ_(1913827 . . . 1914672)_24_56_F TGCAATTGCTTTAGTTTTAAGTGCAT 487
GTAATTC 2172 BLAZ_(1913827 . . . 1914672)_26_58_F
TCCTTGCTTTAGTTTTAAGTGCATGT 351 AATTCAA 2173 BLAZ_NC002952-
TCCACTTATCGCAAATGGAAAATTAA 312 1913827- GCAA 1914672_546_575_F 2174
BLAZ_NC002952- TGCACTTATCGCAAATGGAAAATTAA 494 1913827- GCAA
1914672_546_575_2_F
2175 BLAZ_NC002952- TGATACTTCAACGCCTGCTGCTTTC 467 1913827-
1914672_507_531_F 2176 BLAZ_NC002952- TATACTTCAACGCCTGCTGCTTTC 232
1913827- 1914672_508_531_F 2177 BLAZ_NC002952-
TGCAATTGCTTTAGTTTTAAGTGCAT 487 1913827- GTAATTC 1914672_24_56_F
2178 BLAZ_NC002952- TCCTTGCTTTAGTTTTAAGTGCATGT 351 1913827- AATTCAA
1914672_26_58_F 2247 TUFB_NC002758- TGTTGAACGTGGTCAAATCAAAGTTG 643
615038- GTG 616222_693_721_F 2248 TUFB_NC002758-
TCGTGTTGAACGTGGTCAAATCAAAGT 386 615038- 616222_690_716_F 2249
TUFB_NC002758- TGAACGTGGTCAAATCAAAGTTGGTG 430 615038- AAGA
616222_696_725_F 2250 TUFB_NC002758- TCCCAGGTGACGATGTACCTGTAATC 320
615038- 616222_488_513_F 2251 TUFB_NC002758-
TGAAGGTGGACGTCACACTCCATTCT 433 615038- TC 616222_945_972_F 2252
TUFB_NC002758- TCCAATGCCACAAACTCGTGAACA 307 615038-
616222_333_356_F 2253 NUC_NC002758- TCCTGAAGCAAGTGCATTTACGA 342
894288- 894974_402_424_F 2254 NUC_NC002758-
TCCTTATAGGGATGGCTATCAGTAAT 349 894288- GTT 894974_53_81_F 2255
NUC_NC002758- TCAGCAAATGCATCACAAACAGATAA 273 894288-
894974_169_194_F 2256 NUC_NC002758- TACAAAGGTCAACCAATGACATTCAG 174
894288- ACTA 894974_316_345_F 2270 RPOB_EC_3798_3821_1_F
TGGCCAGCGCTTCGGTGAAATGGA 566 2271 RPOB_EC_3789_3812_F
TCAGTTCGGCGGTCAGCGCTTCGG 294 2272 RPOB_EC_3789_3812_F
TCAGTTCGGCGGTCAGCGCTTCGG 294 2273 RPOB_EC_3789_3812_F
TCAGTTCGGCGGTCAGCGCTTCGG 294 2274 RPOB_EC_3789_3812_F
TCAGTTCGGCGGTCAGCGCTTCGG 294 2275 RPOB_EC_3793_3812_F
TTCGGCGGTCAGCGCTTCGG 674 2276 RPOB_EC_3793_3812_F
TTCGGCGGTCAGCGCTTCGG 674 2309 MUPR_X75439_1658_1689_F
TCCTTTGATATATTATGCGATGGAAG 352 GTTGGT 2310 MUPR_X75439_1330_1353_F
TTCCTCCTTTTGAAAGCGACGGTT 669 2312 MUPR_X75439_1314_1338_F
TTTCCTCCTTTTGAAAGCGACGGTT 704 2313 MUPR_X75439_2486_2516_F
TAATTGGGCTCTTTCTCGCTTAAACA 172 CCTTA 2314 MUPR_X75439_2547_2572_F
TACGATTTCACTTCCGCAGCCAGATT 188 2315 MUPR_X75439_2666_2696_F
TGCGTACAATACGCTTTATGAAATTT 513 TAACA 2316 MUPR_X75439_2813_2843_F
TAATCAAGCATTGGAAGATGAAATGC 165 ATACC 2317 MUPR_X75439_884_914_F
TGACATGGACTCCCCCTATATAACTC 447 TTGAG 2318 CTXA_NC002505-
TGGTCTTATGCCAAGAGGACAGAGTG 608 1568114- AGT 1567341_114_142_F 2319
CTXA_NC002505- TCTTATGCCAAGAGGACAGAGTGAGT 411 1568114- ACT
1567341_117_145_F 2320 CTXA_NC002505- TGGTCTTATGCCAAGAGGACAGAGTG
608 1568114- AGT 1567341_114_142_F 2321 CTXA_NC002505-
TCTTATGCCAAGAGGACAGAGTGAGT 411 1568114- ACT 1567341_117_145_F 2322
CTXA_NC002505- AGGACAGAGTGAGTACTTTGACCGAG 27 1568114- GT
1567341_129_156_F 2323 CTXA_NC002505- TGCCAAGAGGACAGAGTGAGTACTTT
500 1568114- GA 1567341_122_149_F 2324 INV_U22457-74-
TGCTTATTTACCTGCACTCCCACAAC 530 3772_831_858_F TG 2325
INV_U22457-74- TGAATGCTTATTTACCTGCACTCCCA 438 3772_827_857_F CAACT
2326 INV_U22457-74- TGCTGGTAACAGAGCCTTATAGGCGCA 526
3772_1555_1581_F 2327 INV_U22457-74- TGGTAACAGAGCCTTATAGGCGCATA 598
3772_1558_1585_F TG 2328 ASD_NC006570- TGAGGGTTTTATGCTTAAAGTTGGTT
459 439714- TTATTGGTT 438608_3_37_F 2329 ASD_NC006570-
TAAAGTTGGTTTTATTGGTTGGCGCG 149 439714- GA 438608_18_45_F 2330
ASD_NC006570- TTAAAGTTGGTTTTATTGGTTGGCGC 647 439714- GGA
438608_17_45_F 2331 ASD_NC006570- TTTTATGCTTAAAGTTGGTTTTATTG 709
439714- GTTGGC 438608_9_40_F 2332 GALE_AF513299_171_200_F
TCAGCTAGACCTTTTAGGTAAAGCTA 280 AGCT 2333 GALE_AF513299_168_199_F
TTATCAGCTAGACCTTTTAGGTAAAG 658 CTAAGC 2334 GALE_AF513299_168_199_F
TTATCAGCTAGACCTTTTAGGTAAAG 658 CTAAGC 2335 GALE_AF513299_169_198_F
TCCCAGCTAGACCTTTTAGGTAAAGC 319 TAAG 2336 PLA_AF053945_7371_7403_F
TTGAGAAGACATCCGGCTCACGTTAT 680 TATGGTA 2337
PLA_AF053945_7377_7403_F TGACATCCGGCTCACGTTATTATGGTA 443 2338
PLA_AF053945_7377_7404_F TGACATCCGGCTCACGTTATTATGGT 444 AC 2339
CAF_AF053947_33412_33441_F TCCGTTATCGCCATTGCATTATTTGG 329 AACT 2340
CAF_AF053947_33426_33458_F TGCATTATTTGGAACTATTGCAACTG 499 CTAATGC
2341 CAF_AF053947_33407_33429_F TCAGTTCCGTTATCGCCATTGCA 291 2342
CAF_AF053947_33407_33431_F TCAGTTCCGTTATCGCCATTGCATT 293 2344
GAPA_NC_002505_1_28_F_1 TCAATGAACGATCAACAAGTGATTGA 260 TG 2472
OMPA_NC000117_68_89_F TGCCTGTAGGGAATCCTGCTGA 507 2473
OMPA_NC000117_798_821_F TGATTACCATGAGTGGCAAGCAAG 475 2474
OMPA_NC000117_645_671_F TGCTCAATCTAAACCTAAAGTCGAAGA 521 2475
OMPA_NC000117_947_973_F TAACTGCATGGAACCCTTCTTTACTAG 157 2476
OMPA_NC000117_774_795_F TACTGGAACAAAGTCTGCGACC 196 2477
OMPA_NC000117_457_483_F TTCTATCTCGTTGGTTTATTCGGAGTT 676 2478
OMPA_NC000117_687_710_F TAGCCCAGCACAATTTGTGATTCA 212 2479
OMPA_NC000117_540_566_F TGGCGTAGTAGAGCTATTTACAGACAC 571 2480
OMPA_NC000117_338_360_F TGCACGATGCGGAATGGTTCACA 492 2481
OMP2_NC000117_18_40_F TATGACCAAACTCATCAGACGAG 234 2482
OMP2_NC000117_354_382_F TGCTACGGTAGGATCTCCTTATCCTA 516 TTG 2483
OMP2_NC000117_1297_1319_F TGGAAAGGTGTTGCAGCTACTCA 537 2484
OMP2_NC000117_1465_1493_F TCTGGTCCAACAAAAGGAACGATTAC 407 AGG 2485
OMP2_NC000117_44_66_F TGACGATCTTCGCGGTGACTAGT 450 2486
OMP2_NC000117_166_190_F TGACAGCGAAGAAGGTTAGACTTGTCC 441 2487
GYRA_NC000117_514_536_F TCAGGCATTGCGGTTGGGATGGC 287 2488
GYRA_NC000117_801_827_F TGTGAATAAATCACGATTGATTGAGCA 636 2489
GYRA_NC002952_219_242_F TGTCATGGGTAAATATCACCCTCA 632 2490
GYRA_NC002952_964_983_F TACAAGCACTCCCAGCTGCA 176 2491
GYRA_NC002952_1505_1520_F TCGCCCGCGAGGACGT 366 2492
GYRA_NC002952_59_81_F TCAGCTACATCGACTATGCGATG 279 2493
GYRA_NC002952_216_239_F TGACGTCATCGGTAAGTACCACCC 452 2494
GYRA_NC002952_219_242_2_F TGTACTCGGTAAGTATCACCCGCA 625 2495
GYRA_NC002952_115_141_F TGAGATGGATTTAAACCTGTTCACCGC 453 2496
GYRA_NC002952_517_539_F TCAGGCATTGCGGTTGGGATGGC 287 2497
GYRA_NC002952_273_293_F TCGTATGGCTCAATGGTGGAG 380 2498
GYRA_NC000912_257_278_F TGAGTAAGTTCCACCCGCACGG 462 2504
ARCC_NC003923- TAGTpGATpAGAACpTpGTAGGCpAC 229 2725050- pAATpCpGT
2724595_135_161P_F 2505 PTA_NC003923- TCTTGTpTpTpATGCpTpGGTAAAGC
417 628885- AGATGG 629355_237_263P_F 2517 CJMLST_ST1_1852_1883_F
TTTGCGGATGAAGTAGGTGCCTATCT 708 TTTTGC 2518 CJMLST_ST1_2963_2992_F
TGAAATTGCTACAGGCCCTTTAGGAC 428 AAGG 2519 CJMLST_ST1_2350_2378_F
TGCTTTTGATGGTGATGCAGATCGTT 535 TGG 2520 CJMLST_ST1_654_684_F
TATGTCCAAGAAGCATAGCAAAAAAA 240
GCAAT 2521 CJMLST_ST1_360_395_F TCCTGTTATTCCTGAAGTAGTTAATC 347
AAGTTTGTTA 2522 CJMLST_ST1_1231_1258_F TGGCAGTTTTACAAGGTGCTGTTTCA
564 TC 2523 CJMLST_ST1_3543_3574_F TGCTGTAGCTTATCGCGAAATGTCTT 529
TGATTT 2524 CJMLST_ST1_1_17_F TAAAACTTTTGCCGTAATGATGGGTG 145
AAGATAT 2525 CJMLST_ST1_1312_1342_F TGGAAATGGCAGCTAGAATAGTAGCT 538
AAAAT 2526 CJMLST_ST1_2254_2286_F TGGGCCTAATGGGCTTAATATCAATG 582
AAAATTG 2527 CJMLST_ST1_1380_1411_F TGCTTTCCTATGGCTTATCCAAATTT 534
AGATCG 2528 CJMLST_ST1_3413_3437_F TTGTAAATGCCGGTGCTTCAGATCC 692
2529 CJMLST_ST1_1130_1156_F TACGCGTCTTGAAGCGTTTCGTTATGA 189 2530
CJMLST_ST1_2840_2872_F TGGGGCTTTGCTTTATAGTTTTTTAC 591 ATTTAAG 2531
CJMLST_ST1_2058_2084_F TATTCAAGGTGGTCCTTTGATGCATGT 241 2532
CJMLST_ST1_553_585_F TCCTGATGCTCAAAGTGCTTTTTTAG 344 ATCCTTT 2564
GLTA_NC002163- TCATGTTGAGCTTAAACCTATAGAAG 299 1604930- TAAAAGC
1604529_306_338_F 2565 UNCA_NC002163- TCCCCCACGCTTTAATTGTTTATGAT
322 112166- GATTTGAG 112647_80_113_F 2566 UNCA_NC002163-
TAATGATGAATTAGGTGCGGGTTCTTT 170 112166- 112647_233_259_F 2567
PGM_NC002163- TCTTGATACTTGTAATGTGGGCGATA 414 327773- AATATGT
328270_273_305_F 2568 TKT_NC002163- TTATGAAGCGTGTTCTTTAGCAGGAC 661
1569415- TTCA 1569873_255_284_F 2570 GLTA_NC002163-
TCGTCTTTTTGATTCTTTCCCTGATA 381 1604930- ATGC 1604529_39_68_F 2571
TKT_NC002163- TGATCTTAAAAATTTCCGCCAACTTC 472 1569415- ATTC
1569903_33_62_F 2572 TKT_NC002163- TAAGGTTTATTGTCTTTGTGGAGATG 164
1569415- GGGATTT 1569903_207_239_F 2573 TKT_NC002163-
TAGCCTTTAACGAAAATGTAAAAATG 213 1569415- CGTTTTGA 1569903_350_383_F
2574 TKT_NC002163- TTCAAAAACTCCAGGCCATCCTGAAA 665 1569415- TTTCAAC
1569903_60_92_F 2575 GLTA_NC002163- TCGTCTTTTTGATTCTTTCCCTGATA 382
1604930- ATGCTC 1604529_39_70_F 2576 GLYA_NC002163-
TCAGCTATTTTTCCAGGTATCCAAGG 281 367572- TGG 368079_386_414_F 2577
GLYA_NC002163- TGGTGCGAGTGCTTATGCTCGTATTAT 611 367572-
368079_148_174_F 2578 GLYA_NC002163- TGTAAGCTCTACAACCCACAAAACCT 622
367572- TACG 368079_298_327_F 2579 GLYA_NC002163-
TGGTGGACATTTAACACATGGTGCAAA 614 367572- 368079_1_27_F 2580
PGM_NC002163- TGAGCAATGGGGCTTTGAAAGAATTT 455 327746- TTAAAT
328270_254_285_F 2581 PGM_NC002163- TGAAAAGGGTGAAGTAGCAAATGGAG 425
327746- ATAG 328270_153_182_F 2582 PGM_NC002163-
TGGCCTAATGGGCTTAATATCAATGA 568 327746- AAATTG 328270_19_50_F 2583
UNCA_NC002163- TAAGCATGCTGTGGCTTATCGTGAAA 160 112166- TG
112647_114_141_F 2584 UNCA_NC002163- TGCTTCGGATCCAGCAGCACTTCAATA
532 112166- 112647_3_29_F 2585 ASPA_NC002163-
TTAATTTGCCAAAAATGCAACCAGGT 652 96692- AG 97166_308_335_F 2586
ASPA_NC002163- TCGCGTTGCAACAAAACTTTCTAAAG 370 96692- TATGT
97166_228_258_F 2587 GLNA_NC002163- TGGAATGATGATAAAGATTTCGCAGA 547
658085- TAGCTA 657609_244_275_F 2588 TKT_NC002163-
TCGCTACAGGCCCTTTAGGACAAG 371 1569415- 1569903_107_130_F 2589
TKT_NC002163- TGTTCTTTAGCAGGACTTCACAAACT 642 1569415- TGATAA
1569903_265_296_F 2590 GLYA_NC002163- TGCCTATCTTTTTGCTGATATAGCAC
505 367572- ATATTGC 368095_214_246_F 2591 GLYA_NC002163-
TCCTTTGATGCATGTAATTGCTGCAA 353 367572- AAGC 368095_415_444_F 2592
PGM_NC002163_21_54_F TCCTAATGGACTTAATATCAATGAAA 332 ATTGTGGA 2593
PGM_NC002163_149_176_F TAGATGAAAAAGGCGAAGTGGCTAAT 207 GG 2594
GLNA_NC002163- TGTCCAAGAAGCATAGCAAAAAAAGC 633 658085- AA
657609_79_106_F 2595 ASPA_NC002163- TCCTGTTATTCCTGAAGTAGTTAATC 347
96685- AAGTTTGTTA 97196_367_402_F 2596 ASPA_NC002163-
TGCCGTAATGATAGGTGAAGATATAC 502 96685-97196_1_33_F AAAGAGT 2597
ASPA_NC002163- TGGAACAGGAATTAATTCTCATCCTG 540 96685- ATTATCC
97196_85_117_F 2598 PGM_NC002163- TGGCAGCTAGAATAGTAGCTAAAATC 563
327746- CCTAC 328270_165_195_F 2599 PGM_NC002163-
TGGGTCGTGGTTTTACAGAAAATTTC 593 327746- TTATATATG 328270_252_286_F
2600 PGM_NC002163- TGGGATGAAAAAGCGTTCTTTTATCC 577 327746- ATGA
328270_1_30_F 2601 PGM_NC002163- TAAACACGGCTTTCCTATGGCTTATC 146
327746- CAAAT 328270_220_250_F 2602 UNCA_NC002163-
TGTAGCTTATCGCGAAATGTCTTTGA 628 112166- TTTT 112647_123_152_F 2603
UNCA_NC002163- TCCAGATGGACAAATTTTCTTAGAAA 313 112166- CTGATTT
112647_333_365_F 2734 GYRA_AY291534_237_264_F
TCACCCTCATGGTGATTCAGCTGTTT 265 AT 2735 GYRA_AY291534_224_252_F
TAATCGGTAAGTATCACCCTCATGGT 167 GAT 2736 GYRA_AY291534_170_198_F
TAGGAATTACGGCTGATAAAGCGTAT 221 AAA 2737 GYRA_AY291534_224_252_F
TAATCGGTAAGTATCACCCTCATGGT 167 GAT 2738 GYRA_NC002953-7005-
TAAGGTATGACACCGGATAAATCATA 163 9668_166_195_F TAAA 2739
GYRA_NC002953-7005- TAATGGGTAAATATCACCCTCATGGT 171 9668_221_249_F
GAC 2740 GYRA_NC002953-7005- TAATGGGTAAATATCACCCTCATGGT 171
9668_221_249_F GAC 2741 GYRA_NC002953-7005-
TCACCCTCATGGTGACTCATCTATTT 264 9668_234_261_F AT 2842
CAPC_AF188935- TGGGATTATTGTTATCCTGTTATGCC 578 56074- ATTTGAGA
55628_271_304_F 2843 CAPC_AF188935- TGATTATTGTTATCCTGTTATGCpCp 476
56074- ATpTpTpGAG 55628_273_303P_F 2844 CAPC_AF188935-
TCCGTTGATTATTGTTATCCTGTTAT 331 56074- GCCATTTGAG 55628_268_303_F
2845 CAPC_AF188935- TCCGTTGATTATTGTTATCCTGTTAT 331 56074-
GCCATTTGAG 55628_268_303_F 2846 PARC_X95819_33_58_F
TCCAAAAAAATCAGCGCGTACAGTGG 302 2847 PARC_X95819_65_92_F
TACTTGGTAAATACCACCCACATGGT 199 GA 2848 PARC_X95819_69_93_F
TGGTAAATACCACCCACATGGTGAC 596 2849 PARC_NC003997-
TTCCGTAAGTCGGCTAAAACAGTCG 668 3362578- 3365001_181_205_F 2850
PARC_NC003997- TGTAACTATCACCCGCACGGTGAT 621 3362578-
3365001_217_240_F 2851 PARC_NC003997- TGTAACTATCACCCGCACGGTGAT 621
3362578- 3365001_217_240_F 2852 GYRA_AY642140_-
TAAATCTGCCCGTGTCGTTGGTGAC 150 1_24_F 2853 GYRA_AY642140_26_54_F
TAATCGGTAAATATCACCCGCATGGT 166
GAC 2854 GYRA_AY642140_26_54_F TAATCGGTAAATATCACCCGCATGGT 166 GAC
2860 CYA_AF065404_1348_1379_F TCCAACGAAGTACAATACAAGACAAA 305 AGAAGG
2861 LEF_BA_AF065404_751_781_F TCGAAAGCTTTTGCATATTATATCGA 354 GCCAC
2862 LEF_BA_AF065404_762_788_F TGCATATTATATCGAGCCACAGCATCG 498 2917
MUTS_AY698802_106_125_F TCCGCTGAATCTGTCGCCGC 326 2918
MUTS_AY698802_172_192_F TACCTATATGCGCCAGACCGC 187 2919
MUTS_AY698802_228_252_F TACCGGCGCAAAAAGTCGAGATTGG 186 2920
MUTS_AY698802_315_342_F TCTTTATGGTGGAGATGACTGAAACC 419 GA 2921
MUTS_AY698802_394_411_F TGGGCGTGGAACGTCCAC 585 2922 AB_MLST-11-
TGGGcGATGCTGCgAAATGGTTAAAA 583 OIF007_991_1018_F GA 2927
GAPA_NC002505_694_721_F TCAATGAACGACCAACAAGTGATTGA 259 TG 2928
GAPA_NC002505_694_721_2_F TCGATGAACGACCAACAAGTGATTGA 361 TG 2929
GAPA_NC002505_694_721_2_F TCGATGAACGACCAACAAGTGATTGA 361 TG 2932
INFB_EC_1364_1394_F TTGCTCGTGGTGCACAAGTAACGGAT 688 ATTAC 2933
INFB_EC_1364_1394_2_F TTGCTCGTGGTGCAIAAGTAACGGAT 689 ATIAC 2934
INFB_EC_80_110_F TTGCCCGCGGTGCGGAAGTAACCGAT 685 ATTAC 2949
ACS_NC002516- TCGGCGCCTGCCTGATGA 376 970624- 971013_299_316_F 2950
ARO_NC002516-26883- TCACCGTGCCGTTCAAGGAAGAG 267 27380_4_26_F 2951
ARO_NC002516-26883- TTTCGAAGGGCCTTTCGACCTG 705 27380_356_377_F 2952
GUA_NC002516- TGGACTCCTCGGTGGTCGC 551 4226546- 4226174_23_41_F 2953
GUA_NC002516- TGACCAGGTGATGGCCATGTTCG 448 4226546-
4226174_120_142_F 2954 GUA_NC002516- TTTTGAAGGTGATCCGTGCCAACG 710
4226546- 4226174_155_178_F 2955 GUA_NC002516- TTCCTCGGCCGCCTGGC 670
4226546- 4226174_190_206_F 2956 GUA_NC002516-
TCGGCCGCACCTTCATCGAAGT 374 4226546- 4226174_242_263_F 2957
MUT_NC002516- TGGAAGTCATCAAGCGCCTGGC 545 5551158- 5550717_5_26_F
2958 MUT_NC002516- TCGAGCAGGCGCTGCCG 358 5551158- 5550717_152_168_F
2959 NUO_NC002516- TCAACCTCGGCCCGAACCA 249 2984589- 2984954_8_26_F
2960 NUO_NC002516- TACTCTCGGTGGAGAAGCTCGC 195 2984589-
2984954_218_239_F 2961 PPS_NC002516- TCCACGGTCATGGAGCGCTA 311
1915014- 1915383_44_63_F 2962 PPS_NC002516- TCGCCATCGTCACCAACCG 365
1915014- 1915383_240_258_F 2963 TRP_NC002516- TGCTGGTACGGGTCGAGGA
527 671831- 672273_24_42_F 2964 TRP_NC002516-
TGCACATCGTGTCCAACGTCAC 490 671831- 672273_261_282_F 2972
AB_MLST-11- TGGGIGATGCTGCIAAATGGTTAAAA 592 OIF007_1007_1034_F GA
2993 OMPU_NC002505- TTCCCACCGATATCATGGCTTACCAC 667 674828- GG
675880_428_455_F 2994 GAPA_NC002505- TCCTCAATGAACGAICAACAAGTGAT 335
506780- TGATG 507937_691_721_F 2995 GAPA_NC002505-
TCCTCIATGAACGAICAACAAGTGAT 339 506780- TGATG 507937_691_721_2_F
2996 GAPA_NC002505- TCTCGATGAACGACCAACAAGTGATT 396 506780- GATG
507937_692_721_F 2997 GAPA_NC002505- TCCTCGATGAACGAICAACAAGTIAT 337
506780- TGATG 507937_691_721_3_F 2998 GAPA_NC002505-
TCCTCAATGAATGATCAACAAGTGAT 336 506780- TGATG 507937_691_721_4_F
2999 GAPA_NC002505- TCCTCIATGAAIGAICAACAAGTIAT 340 506780- TGATG
507937_691_721_5_F 3000 GAPA_NC002505- TCCTCGATGAATGAICAACAAGTIAT
338 506780- TGATG 507937_691_721_6_F 3001 CTXB_NC002505-
TCAGCATATGCACATGGAACACCTCA 275 1566967- 1567341_46_71_F 3002
CTXB_NC002505- TCAGCATATGCACATGGAACACCTC 274 1566967-
1567341_46_70_F 3003 CTXB_NC002505- TCAGCATATGCACATGGAACACCTC 274
1566967- 1567341_46_70_F 3004 TUFB_NC002758- TACAGGCCGTGTTGAACGTGG
180 615038- 616222_684_704_F 3005 TUFB_NC002758-
TGCCGTGTTGAACGTGGTCAAAT 503 615038- 616222_688_710_F 3006
TUFB_NC002758- TGTGGTCAAATCAAAGTTGGTGAAGAA 638 615038-
616222_700_726_F 3007 TUFB_NC002758- TGGTCAAATCAAAGTTGGTGAAGAA 607
615038- 616222_702_726_F 3008 TUFB_NC002758-
TGAACGTGGTCAAATCAAAGTTGGTG 431 615038- AAGAA 616222_696_726_F 3009
TUFB_NC002758- TCGTGTTGAACGTGGTCAAATCAAAGT 386 615038-
616222_690_716_F 3010 MECI-R_NC003923- TCACATATCGTGAGCAATGAACTG 261
41798-41609_36_59_F 3011 MECI-R_NC003923-
TGGGCGTGAGCAATGAACTGATTATAC 584 41798-41609_40_66_F 3012
MECI-R_NC003923- TGGACACATATCGTGAGCAATGAACT 549 41798- GA
41609_33_60_2_F 3013 MECI-R_NC003923- TGGGTTTACACATATCGTGAGCAATG
595 41798-41609_29_60_F AACTGA 3014 MUPR_X75439_2490_2514_F
TGGGCTCTTTCTCGCTTAAACACCT 587 3015 MUPR_X75439_2490_2513_F
TGGGCTCTTTCTCGCTTAAACACC 586 3016 MUPR_X75439_2482_2510_F
TAGATAATTGGGCTCTTTCTCGCTTA 205 AAC 3017 MUPR_X75439_2490_2514_F
TGGGCTCTTTCTCGCTTAAACACCT 587 3018 MUPR_X75439_2482_2510_F
TAGATAATTGGGCTCTTTCTCGCTTA 205 AAC 3019 MUPR_X75439_2490_2514_F
TGGGCTCTTTCTCGCTTAAACACCT 587 3020 AROE_NC003923-
TGATGGCAAGTGGATAGGGTATAATA 474 1674726- CAG 1674277_204_232_F 3021
AROE_NC003923- TGGCGAGTGGATAGGGTATAATACAG 570 1674726-
1674277_207_232_F 3022 AROE_NC003923- TGGCpAAGTpGGATpAGGGTpATpAA
572 1674726- TpACpAG 1674277_207_232P_F 3023 ARCC_NC003923-
TCTGAAATGAATAGTGATAGAACTGT 398 2725050- AGGCAC 2724595_124_155_F
3024 ARCC_NC003923- TGAATAGTGATAGAACTGTAGGCACA 437 2725050- ATCGT
2724595_131_161_F 3025 ARCC_NC003923- TGAATAGTGATAGAACTGTAGGCACA
437 2725050- ATCGT 2724595_131_161_F 3026 PTA_NC003923-
TACAATGCTTGTTTATGCTGGTAAAG 177 628885- CAG 629355_231_259_F 3027
PTA_NC003923- TACAATGCTTGTTTATGCTGGTAAAG 177 628885- CAG
629355_231_259_F 3028 PTA_NC003923- TCTTGTTTATGCTGGTAAAGCAGATGG 418
628885- 629355_237_263_F Primer Reverse Pair SEQ Number Reverse
Primer Name Reverse Sequence ID NO: 1 16S_EC_1175_1195_R
GACGTCATCCCCACCTTCCTC 809 2 16S_EC_1175_1197_R
TTGACGTCATCCCCACCTTCCTC 1398 3 16S_EC_1175_1196_R
TGACGTCATCCCCACCTTCCTC 1159
4 16S_EC_1303_1323_R CGAGTTGCAGACTGCGATCCG 787 5 16S_EC_1389_1407_R
GACGGGCGGTGTGTACAAG 806 6 16S_EC_105_126_R TACGCATTACTCACCCGTCCGC
897 7 16S_EC_101_120_R TTACTCACCCGTCCGCCGCT 1365 8 16S_EC_104_120_R
TTACTCACCCGTCCGCC 1364 9 16S_EC_774_795_R GTATCTAATCCTGTTTGCTCCC
839 10 16S_EC_789_809_R CGTGGACTACCAGGGTATCTA 798 11
16S_EC_880_897_R GGCCGTACTCCCCAGGCG 830 12 16S_EC_880_897_2_R
GGCCGTACTCCCCAGGCG 830 13 16S_EC_880_894_R CGTACTCCCCAGGCG 796 14
16S_EC_1054_1073_R ACGAGCTGACGACAGCCATG 735 15 16S_EC_1061_1078_R
ACGACACGAGCTGACGAC 734 16 23S_EC_1906_1924_R GACCGTTATAGTTACGGCC
805 17 23S_EC_2744_2761_R TGCTTAGATGCTTTCAGC 1252 18
23S_EC_2751_2767_R GTTTCATGCTTAGATGCTTTCAGC 846 19 23S_EC_551_571_R
ACAAAAGGTACGCCGTCACCC 717 20 23S_EC_551_571_2_R
ACAAAAGGCACGCCATCACCC 716 21 23S_EC_1059_1077_R TGGCTGCTTCTAAGCCAAC
1282 22 CAPC_BA_180_205_R TGAATCTTGAAACACCATACGTAACG 1150 23
CAPC_BA_185_205_R TGAATCTTGAAACACCATACG 1149 24 CAPC_BA_349_376_R
GTAACCCTTGTCTTTGAATTGTATTTGC 837 25 CAPC_BA_358_377_R
GGTAACCCTTGTCTTTGAAT 834 26 CAPC_BA_361_378_R TGGTAACCCTTGTCTTTG
1298 27 CAPC_BA_361_378_R TGGTAACCCTTGTCTTTG 1298 28
CYA_BA_1112_1130_R TGTTGACCATGCTTCTTAG 1352 29 CYA_BA_1447_1426_R
CTTCTACATTTTTAGCCATCAC 800 30 CYA_BA_1448_1467_R
TGTTAACGGCTTCAAGACCC 1342 31 CYA_BA_1447_1461_R CGGCTTCAAGACCCC 794
32 CYA_BA_999_1026_R ACCACTTTTAATAAGGTTTGTAGCTAAC 728 33
CYA_BA_1003_1025_R CCACTTTTAATAAGGTTTGTAGC 768 34
INFB_EC_1439_1467_R TGCTGCTTTCGCATGGTTAATTGCTTCAA 1248 35
LEF_BA_1119_1135_R GAATATCAATTTGTAGC 803 36 LEF_BA_1119_1149_R
AGATAAAGAATCACGAATATCAATTTGT 745 AGC 37 LEF_BA_843_872_R
TCTTCCAAGGATAGATTTATTTCTTGTT 1135 CG 38 LEF_BA_843_865_R
AGGATAGATTTATTTCTTGTTCG 748 39 LEF_BA_883_900_R TCTTGACAGCATCCGTTG
1140 40 LEF_BA_939_958_R CAGATAAAGAATCGCTCCAG 762 41
PAG_BA_190_209_R CCTGTAGTAGAAGAGGTAAC 781 42 PAG_BA_187_210_R
CCCTGTAGTAGAAGAGGTAACCAC 774 43 PAG_BA_326_344_R
TGATTATCAGCGGAAGTAG 1186 44 PAG_BA_755_772_R CCGTGCTCCATTTTTCAG 778
45 PAG_BA_849_868_R TCGGATAAGCTGCCACAAGG 1089 46 PAG_BA_849_868_R
TCGGATAAGCTGCCACAAGG 1089 47 RPOC_EC_1095_1124_R
TCAAGCGCCATTTCTTTTGGTAAACCAC 959 AT 48 RPOC_EC_1095_1124_2_R
TCAAGCGCCATCTCTTTCGGTAATCCAC 958 AT 49 RPOC_EC_213_232_R
GGCGCTTGTACTTACCGCAC 831 50 RPOC_EC_2225_2246_R
TTGGCCATCAGGCCACGCATAC 1414 51 RPOC_EC_2225_2246_2_R
TTGGCCATCAGACCACGCATAC 1413 52 RPOC_EC_2313_2337_R
CGCACCGTGGGTTGAGATGAAGTAC 790 53 RPOC_EC_2313_2337_2_R
CGCACCATGCGTAGAGATGAAGTAC 789 54 RPOC_EC_865_889_R
GTTTTTCGTTGCGTACGATGATGTC 847 55 RPOC_EC_865_891_R
ACGTTTTTCGTTTTGAACGATAATGCT 741 56 RPOC_EC_1036_1059_R
CGAACGGCCTGAGTAGTCAACACG 785 57 RPOC_EC_1036_1059_2_R
CGAACGGCCAGAGTAGTCAACACG 784 58 SSPE_BA_197_222_R
TGCACGTCTGTTTCAGTTGCAAATTC 1201 59 TUFB_EC_283_303_R
GCCGTCCATCTGAGCAGCACC 815 60 TUFB_EC_283_303_2_R
GCCGTCCATTTGAGCAGCACC 816 61 TUFB_EC_1045_1068_R
GTTGTCGCCAGGCATAACCATTTC 845 62 TUFB_EC_1045_1068_2_R
GTTGTCACCAGGCATTACCATTTC 844 63 TUFB_EC_1033_1062_R
TCCAGGCATTACCATTTCTACTCCTTCT 1006 GG 66 RPLB_EC_739_762_R
TCCAAGTGCTGGTTTACCCCATGG 999 67 RPLB_EC_736_757_R
GTGCTGGTTTACCCCATGGAGT 842 68 RPOC_EC_1097_1126_R
ATTCAAGAGCCATTTCTTTTGGTAAACC 754 AC 69 RPOB_EC_3836_3865_R
TTTCTTGAAGAGTATGAGCTGCTCCGTA 1435 AG 70 RPLB_EC_743_771_R
TGTTTTGTATCCAAGTGCTGGTTTACCCC 1356 71 VALS_EC_1195_1218_R
CGGTACGAACTGGATGTCGCCGTT 795 72 RPOB_EC_1909_1929_R
GCTGGATTCGCCTTTGCTACG 825 73 RPLB_EC_735_761_R
CCAAGTGCTGGTTTACCCCATGGAGTA 767 74 RPLB_EC_737_762_R
TCCAAGTGCTGGTTTACCCCATGGAG 1000 75 SP101_SPET11_92_116_R
CCTACCCAACGTTCACCAAGGGCAG 779 76 SP101_SPET11_213_238_R
TGTGGCCGATTTCACCACCTGCTCCT 1340 77 SP101_SPET11_308_333_R
TGCCACTTTGACAACTCCTGTTGCTG 1209 78 SP101_SPET11_355_380_R
GCTGCTTTGATGGCTGAATCCCCTTC 824 79 SP101_SPET11_423_441_R
ATCCCCTGCTTCTGCTGCC 753 80 SP101_SPET11_448_473_R
CCAACCTTTTCCACAACAGAATCAGC 766 81 SP101_SPET11_686_714_R
CCCATTTTTTCACGCATGCTGAAAATATC 772 82 SP101_SPET11_756_784_R
GATTGGCGATAAAGTGATATTTTCTAAAA 813 83 SP101_SPET11_871_896_R
GCCCACCAGAAAGACTAGCAGGATAA 814 84 SP101_SPET11_988_1012_R
CATGACAGCCAAGACCTCACCCACC 763 85 SP101_SPET11_1251_1277_R
GACCCCAACCTGGCCTTTTGTCGTTGA 804 86 SP101_SPET11_1403_1431_R
AAACTATTTTTTTAGCTATACTCGAACAC 711 87 SP101_SPET11_1486_1515_R
GGATAATTGGTCGTAACAAGGGATAGTG 828 AG 88 SP101_SPET11_1783_1808_R
ATATGATTATCATTGAACTGCGGCCG 752 89 SP101_SPET11_1808_1835_R
GCGTGACGACCTTCTTGAATTGTAATCA 821 90 SP101_SPET11_1901_1927_R
TTGGACCTGTAATCAGCTGAATACTGG 1412 91 SP101_SPET11_2062_2083_R
ATTGCCCAGAAATCAAATCATC 755 92 SP101_SPET11_2375_2397_R
TCTGGGTGACCTGGTGTTTTAGA 1131 93 SP101_SPET11_2470_2497_R
AGCTGCTAGATGAGCTTCTGCCATGGCC 747 94 SP101_SPET11_2543_2570_R
CCATAAGGTCACCGTCACCATTCAAAGC 770 95 SP101_SPET11_3023_3045_R
GGAATTTACCAGCGATAGACACC 827 96 SP101_SPET11_3168_3196_R
AATCGACGACCATCTTGGAAAGATTTCTC 715 97 SP101_SPET11_3480_3506_R
CCAGCAGTTACTGTCCCCTCATCTTTG 769 98 SP101_SPET11_3605_3629_R
GGGTCTACACCTGCACTTGCATAAC 832 111 RPOB_EC_3829_3858_R
CGTATAAGCTGCACCATAAGCTTGTAAT 797 GC 112 VALS_EC_1920_1943_R
GCGTTCCACAGCTTGTTGCAGAAG 822 113 RPOB_EC_1438_1455_R
TTCGCTCTCGGCCTGGCC 1386 114 TUFB_EC_284_309_R
TATAGCACCATCCATCTGAGCGGCAC 930 115 DNAK_EC_503_522_R
CGCGGTCGGCTCGTTGATGA 792 116 VALS_EC_1948_1970_R
TCGCAGTTCATCAGCACGAAGCG 1075 117 TUFB_EC_849_867_R
GCGCTCCACGTCTTCACGC 819 118 23S_EC_2745_2765_R
TTCGTGCTTAGATGCTTTCAG 1389 119 16S_EC_1061_1078_2P_R
ACGACACGAGCpTpGACGAC 733 120 16S_EC_1064_1075_2P_R ACACGAGCpTpGAC
727 121 16S_EC_1064_1075_R ACACGAGCTGAC 727 122 23S_EC_40_59_R
ACGTCCTTCATCGCCTCTGA 740 123 23S_EC_430_450_R CTATCGGTCAGTCAGGAGTAT
799 124 23S_EC_891_910_R TTGCATCGGGTTGGTAAGTC 1403 125
23S_EC_1424_1442_R AACATAGCCTTCTCCGTCC 712 126 23S_EC_1908_1931_R
TACCTTAGGACCGTTATAGTTACG 893 127 23S_EC_2475_2494_R
CCAAACACCGCCGTCGATAT 765 128 23S_EC_2833_2852_R
GCTTACACACCCGGCCTATC 826 129 TRNA_ASP- GCGTGACAGGCAGGTATTC 820
RRNH_EC_23_41.2_R 131 16S_EC_508_525_R GCTGCTGGCACGGAGTTA 823 132
16S_EC_1041_1058_R CCATGCAGCACCTGTCTC 771 133 16S_EC_1493_1512_R
ACGGTTACCTTGTTACGACT 739 134 TRNA_ALA- CCTCCTGCGTGCAAAGC 780
RRNH_EC_30_46.2_R 135 16S_EC_1061_1078.2_R ACAACACGAGCTGACGAC 719
137 16S_EC_1061_1078.2_I14_R ACAACACGAGCTGICGAC 721 138
16S_EC_1061_1078.2_I12_R ACAACACGAGCIGACGAC 718 139
16S_EC_1061_1078.2_I11_R ACAACACGAGITGACGAC 722
140 16S_EC_1061_1078.2_I16_R ACAACACGAGCTGACIAC 720 141
16S_EC_1061_1078.2_2I_R ACAACACGAICTIACGAC 723 142
16S_EC_1061_1078.2_3I_R ACAACACIAICTIACGAC 724 143
16S_EC_1061_1078.2_4I_R ACAACACIAICTIACIAC 725 147
23S_EC_2741_2760_R ACTTAGATGCTTTCAGCGGT 743 158 16S_EC_880_894_R
CGTACTCCCCAGGCG 796 159 16S_EC_1174_1188_R TCCCCACCTTCCTCC 1019 215
SSPE_BA_197_216_R TCTGTTTCAGTTGCAAATTC 1132 220 GROL_EC_1039_1060_R
CAATCTGCTGACGGATCTGAGC 759 221 INFB_EC_1174_1191_R
CATGATGGTCACAACCGG 764 222 HFLB_EC_1144_1168_R
CTTTCGCTTTCTCGAACTCAACCAT 802 223 INFB_EC_2038_2058_R
AACTTCGCCTTCGGTCATGTT 713 224 GROL_EC_328_350_R
TTCAGGTCCATCGGGTTCATGCC 1377 225 VALS_EC_1195_1214_R
ACGAACTGGATGTCGCCGTT 732 226 16S_EC_683_700_R CGCATTTCACCGCTACAC
791 227 RPOC_EC_1295_1315_R GTTCAAATGCCTGGATACCCA 843 228
16S_EC_880_894_R CGTACTCCCCAGGCG 796 229 RPOC_EC_1623_1643_R
ACGCGGGCATGCAGAGATGCC 737 230 16S_EC_1177_1196_R
TGACGTCATCCCCACCTTCC 1158 231 16S_EC_1525_1541_R AAGGAGGTGATCCAGCC
714 232 16S_EC_1389_1407_R GACGGGCGGTGTGTACAAG 808 233
23S_EC_115_130_R GGGTTTCCCCATTCGG 833 234 23S_EC_242_256_R
TTCGCTCGCCGCTAC 1385 235 23S_EC_1686_1703_R CCTTCTCCCGAAGTTACG 782
236 23S_EC_1828_1842_R CACCGGGCAGGCGTC 760 237 23S_EC_1929_1949_R
CCGACAAGGAATTTCGCTACC 775 238 23S_EC_2490_2511_R
AGCCGACATCGAGGTGCCAAAC 746 239 23S_EC_2653_2669_R CCGGTCCTCTCGTACTA
777 240 23S_EC_2737_2758_R TTAGATGCTTTCAGCACTTATC 1369 241
23S_BS_5_21_R GTGCGCCCTTTCTAACTT 841 242 16S_EC_342_358_R
ACTGCTGCCTCCCGTAG 742 243 16S_EC_556_575_R CTTTACGCCCAGTAATTCCG 801
244 16S_EC_774_795_R GTATCTAATCCTGTTTGCTCCC 839 245
16S_EC_967_985_R GGTAAGGTTCTTCGCGTTG 835 246 16S_EC_1220_1240_R
ATTGTAGCACGTGTGTAGCCC 757 247 16S_EC_1525_1541_R AAGGAGGTGATCCAGCC
714 248 16S_EC_1525_1541_R AAGGAGGTGATCCAGCC 714 249
23S_EC_1919_1936_R TCGCTACCTTAGGACCGT 1080 250 16S_EC_1494_1513_R
CACGGCTACCTTGTTACGAC 761 251 16S_EC_1486_1505_R
CCTTGTTACGACTTCACCCC 783 252 16S_EC_1485_1506_R
ACCTTGTTACGACTTCACCCCA 731 253 16S_EC_909_929_R
CCCCCGTCAATTCCTTTGAGT 773 254 16S_EC_886_904_R GCCTTGCGACCGTACTCCC
817 255 16S_EC_882_899_R GCGACCGTACTCCCCAGG 818 256
16S_EC_1174_1195_R GACGTCATCCCCACCTTCCTCC 810 257
23S_EC_2658_2677_R AGTCCATCCCGGTCCTCTCG 749 258 RNASEP_SA_358_379_R
ATAAGCCATGTTCTGTTCCATC 750 258 RNASEP_EC_345_362_R
ATAAGCCGGGTTCTGTCG 751 258 RNASEP_BS_363_384_R
GTAAGCCATGTTTTGTTCCATC 838 258 RNASEP_SA_358_379_R
ATAAGCCATGTTCTGTTCCATC 750 258 RNASEP_EC_345_362_R
ATAAGCCGGGTTCTGTCG 751 258 RNASEP_BS_363_384_R
GTAAGCCATGTTTTGTTCCATC 838 258 RNASEP_SA_358_379_R
ATAAGCCATGTTCTGTTCCATC 750 258 RNASEP_EC_345_362_R
ATAAGCCGGGTTCTGTCG 751 258 RNASEP_BS_363_384_R
GTAAGCCATGTTTTGTTCCATC 838 259 RNASEP_BS_363_384_R
GTAAGCCATGTTTTGTTCCATC 838 260 RNASEP_EC_345_362_R
ATAAGCCGGGTTCTGTCG 751 262 RNASEP_SA_358_379_R
ATAAGCCATGTTCTGTTCCATC 750 263 16S_EC_1525_1541_R AAGGAGGTGATCCAGCC
714 264 16S_EC_774_795_R GTATCTAATCCTGTTTGCTCCC 839 265
16S_EC_1177_1196_10G_R TGACGTCATGCCCACCTTCC 1160 266
16S_EC_1177_1196_10G_11G_R TGACGTCATGGCCACCTTCC 1161 268 TRNA_ALA-
AGACCTCCTGCGTGCAAAGC 744 RRNH_EC_30_49_F_MOD 269
16S_EC_1177_1196_R_MOD TGACGTCATCCCCACCTTCC 1158 270
23S_EC_2658_2677_R_MOD AGTCCATCCCGGTCCTCTCG 749 272
16S_EC_1389_1407_R GACGGGCGGTGTGTACAAG 807 273 16S_EC_1303_1323_R
CGAGTTGCAGACTGCGATCCG 788 274 16S_EC_880_894_R CGTACTCCCCAGGCG 796
275 16S_EC_1061_1078_R ACGACACGAGCTGACGAC 734 277
CYA_BA_1426_1447_R CTTCTACATTTTTAGCCATCAC 800 278
16S_EC_1175_1196_R TGACGTCATCCCCACCTTCCTC 1159 279 16S_EC_507_527_R
CGGCTGCTGGCACGAAGTTAG 793 280 GROL_EC_577_596_R
TAGCCGCGGTCGAATTGCAT 914 281 GROL_EC_571_593_R
CCGCGGTCGAATTGCATGCCTTC 776 288 RPOB_EC_3862_3885_R
CGACTTGACGGTTAACATTTCCTG 786 289 RPOB_EC_3862_3888_R
GTCCGACTTGACGGTCAACATTTCCTG 840 290 RPOC_EC_2227_2245_R
ACGCCATCAGGCCACGCAT 736 291 ASPS_EC_521_538_R ACGGCACGAGGTAGTCGC
738 292 RPOC_EC_1437_1455_R GAGCATCAGCGTGCGTGCT 811 293
TUFB_EC_1034_1058_R GGCATCACCATTTCCTTGTCCTTCG 829 294
16S_EC_101_122_R TGTTACTCACCCGTCTGCCACT 1345 295 VALS_EC_705_727_R
TATAACGCACATCGTCAGGGTGA 929 344 16S_EC_1043_1062_R
ACAACCATGCACCACCTGTC 726 346 16S_EC_789_809_TMOD_R
TCGTGGACTACCAGGGTATCTA 1110 347 16S_EC_880_897_TMOD_R
TGGCCGTACTCCCCAGGCG 1278 348 16S_EC_1054_1073_TMOD_R
TACGAGCTGACGACAGCCATG 895 349 23S_EC_1906_1924_TMOD_R
TGACCGTTATAGTTACGGCC 1156 350 CAPC_BA_349_376_TMOD_R
TGTAACCCTTGTCTTTGAATTGTATTTGC 1314 351 CYA_BA_1448_1467_TMOD_R
TTGTTAACGGCTTCAAGACCC 1423 352 INFB_EC_1439_1467_TMOD_R
TTGCTGCTTTCGCATGGTTAATTGCTTC 1411 AA 353 LEF_BA_843_872_TMOD_R
TTCTTCCAAGGATAGATTTATTTCTTGT 1394 TCG 354 RPOC_EC_2313_2337_TMOD_R
TCGCACCGTGGGTTGAGATGAAGTAC 1072 355 SSPE_BA_197_222_TMOD_R
TTGCACGTCTGTTTCAGTTGCAAATTC 1402 356 RPLB_EC_739_762_TMOD_R
TTCCAAGTGCTGGTTTACCCCATGG 1380 357 RPLB_EC_736_757_TMOD_R
TGTGCTGGTTTACCCCATGGAGT 1337 358 VALS_EC_1195_1218_TMOD_R
TCGGTACGAACTGGATGTCGCCGTT 1093 359 RPOB_EC_1909_1929_TMOD_R
TGCTGGATTCGCCTTTGCTACG 1250 360 23S_EC_2745_2765_TMOD_R
TTTCGTGCTTAGATGCTTTCAG 1434 361 16S_EC_1175_1196_TMOD_R
TTGACGTCATCCCCACCTTCCTC 1398 362 RPOB_EC_3862_3888_TMOD_R
TGTCCGACTTGACGGTCAACATTTCCTG 1325 363 RPOC_EC_2227_2245_TMOD_R
TACGCCATCAGGCCACGCAT 898 364 RPOC_EC_1437_1455_TMOD_R
TGAGCATCAGCGTGCGTGCT 1166 367 TUFB_EC_1034_1058_TMOD_R
TGGCATCACCATTTCCTTGTCCTTCG 1276 423 SP101_SPET11_988_1012_TMOD_R
TCATGACAGCCAAGACCTCACCCACC 990 424 SP101_SPET11_1251_1277_TMOD_R
TGACCCCAACCTGGCCTTTTGTCGTTGA 1155 425 SP101_SPET11_213_238_TMOD_R
TTGTGGCCGATTTCACCACCTGCTCCT 1422 426 SP101_SPET11_1403_1431_TMOD_R
TAAACTATTTTTTTAGCTATACTCGAAC 849 AC 427
SP101_SPET11_1486_1515_TMOD_R TGGATAATTGGTCGTAACAAGGGATAGT 1268 GAG
428 SP101_SPET11_1783_1808_TMOD_R TATATGATTATCATTGAACTGCGGCCG 932
429 SP101_SPET11_1808_1835_TMOD_R TGCGTGACGACCTTCTTGAATTGTAATCA
1239 430 SP101_SPET11_1901_1927_TMOD_R TTTGGACCTGTAATCAGCTGAATACTGG
1439 431 SP101_SPET11_2062_2083_TMOD_R TATTGCCCAGAAATCAAATCATC 940
432 SP101_SPET11_308_333_TMOD_R TTGCCACTTTGACAACTCCTGTTGCTG 1404
433 SP101_SPET11_2375_2397_TMOD_R TTCTGGGTGACCTGGTGTTTTAGA 1393 434
SP101_SPET11_2470_2497_TMOD_R TAGCTGCTAGATGAGCTTCTGCCATGGCC 918 435
SP101_SPET11_2543_2570_TMOD_R TCCATAAGGTCACCGTCACCATTCAAAGC 1007
436 SP101_SPET11_355_380_TMOD_R TGCTGCTTTGATGGCTGAATCCCCTTC 1249
437 SP101_SPET11_3023_3045_TMOD_R TGGAATTTACCAGCGATAGACACC 1264 438
SP101_SPET11_3168_3196_TMOD_R TAATCGACGACCATCTTGGAAAGATTTC 875 TC
439 SP101_SPET11_423_441_TMOD_R TATCCCCTGCTTCTGCTGCC 934 440
SP101_SPET11_3480_3506_TMOD_R TCCAGCAGTTACTGTCCCCTCATCTTTG 1005 441
SP101_SPET11_3605_3629_TMOD_R TGGGTCTACACCTGCACTTGCATAAC 1294 442
SP101_SPET11_448_473_TMOD_R TCCAACCTTTTCCACAACAGAATCAGC 998
443 SP101_SPET11_686_714_TMOD_R TCCCATTTTTTCACGCATGCTGAAAATA 1018
TC 444 SP101_SPET11_756_784_TMOD_R TGATTGGCGATAAAGTGATATTTTCTAA
1189 AA 445 SP101_SPET11_871_896_TMOD_R TGCCCACCAGAAAGACTAGCAGGATAA
1217 446 SP101_SPET11_92_116_TMOD_R TCCTACCCAACGTTCACCAAGGGCAG 1044
447 SP101_SPET11_448_471_R TACCTTTTCCACAACAGAATCAGC 894 448
SP101_SPET11_3170_3194_R TCGACGACCATCTTGGAAAGATTTC 1066 449
RPLB_EC_737_758_R TGTGCTGGTTTACCCCATGGAG 1336 481
BONTA_X52066_647_660_R TGTTACTGCTGGAT 1346 482
BONTA_X52066_647_660P_R TG*Tp*TpA*Cp*TpG*Cp*TpGGAT 1146 483
BONTA_X52066_759_775_R TTACTTCTAACCCACTC 1367 484
BONTA_X52066_759_775P_R TTA*Cp*Tp*Tp*Cp*TpAA*Cp*Cp*CpA 1359 *Cp*TpC
485 BONTA_X52066_517_539_R TAACCATTTCGCGTAAGATTCAA 859 486
BONTA_X52066_517_539P_R TAACCA*Tp*Tp*Tp*CpGCGTAAGA*Tp 857 *Tp*CpAA
487 BONTA_X52066_644_671_R TCATGTGCTAATGTTACTGCTGGATCTG 992 608
SSPE_BA_243_255P_R TGCpAGCpTGATpTpGT 1241 609 SSPE_BA_163_177P_R
TGTGCTpTpTpGAATpGCpT 1338 610 SSPE_BA_243_264P_R
TGATTGTTTTGCpAGCpTGATpTpGT 1191 611 SSPE_BA_163_182P_R
TCATTTGTGCTpTpTpGAATpGCpT 995 612 SSPE_BA_196_222P_R
TTGCACGTCpTpGTTTCAGTTGCAAATTC 1401 699 SSPE_BA_202_231_R
TTTCACAGCATGCACGTCTGTTTCAGTT 1431 GC 700 SSPE_BA_243_255_R
TGCAGCTGATTGT 1202 701 SSPE_BA_163_177_R TGTGCTTTGAATGCT 1338 702
SSPE_BA_243_264_R TGATTGTTTTGCAGCTGATTGT 1190 703 SSPE_BA_163_182_R
TCATTTGTGCTTTGAATGCT 995 704 SSPE_BA_242_267_R
TTGTGATTGTTTTGCAGCTGATTGTG 1421 705 SSPE_BA_163_191_R
TCATAACTAGCATTTGTGCTTTGAATGCT 986 706 SSPE_BA_196_222_R
TTGCACGTCTGTTTCAGTTGCAAATTC 1402 770 PLA_AF053945_7434_7462_R
TGTAAATTCCGCAAAGACTTTGGCATTAG 1313 771 PLA_AF053945_7482_7502_R
TGGTCTGAGTACCTCCTTTGC 1304 772 PLA_AF053945_7539_7562_R
TATTGGAAATACCGGCAGCATCTC 943 773 PLA_AF053945_7257_7280_R
TAATGCGATACTGGCCTGCAAGTC 879 774 CAF1_AF053947_33494_33514_R
TGCGGGCTGGTTCAACAAGAG 1235 775 CAF1_AF053947_33595_33621_R
TCCTGTTTTATAGCCGCCAAGAGTAAG 1053 776 CAF1_AF053947_33499_33517_R
TGATGCGGGCTGGTTCAAC 1183 777 CAF1_AF053947_33755_33782_R
TCAAGGTTCTCACCGTTTACCTTAGGAG 962 778 INV_U22457_571_598_R
TGTTAAGTGTGTTGCGGCTGTCTTTATT 1343 779 INV_U22457_753_776_R
TCACGCGACGAGTGCCATCCATTG 976 780 INV_U22457_942_966_R
TGACCCAAAGCTGAAAGCTTTACTG 1154 781 INV_U22457_1619_1643_R
TTGCGTTGCAGATTATCTTTACCAA 1408 782 LL_NC003143_2367073_2367097_R
TCTCATCCCGATATTACCGCCATGA 1123 783 LL_NC003143_2367249_2367271_R
TGGCAACAGCTCAACACCTTTGG 1272 874 RPLB_EC_739_762_TMOD_R
TTCCAAGTGCTGGTTTACCCCATGG 1380 875 RPLB_EC_739_762_TMOD_R
TTCCAAGTGCTGGTTTACCCCATGG 1380 876 MECIA_Y14051_3367_3393_R
TGTGATATGGAGGTGTAGAAGGTGTTA 1333 877 MECA_Y14051_3828_3854_R
TCCCAATCTAACTTCCACATACCATCT 1015 878 MECA_Y14051_3690_3719_R
TGATCCTGAATGTTTATATCTTTAACGC 1181 CT 879 MECA_Y14051_4555_4581_R
TGGATAGACGTCATATGAAGGTGTGCT 1269 880 MECA_Y14051_4586_4610_R
TATTCTTCGTTACTCATGCCATACA 939 881 MECA_Y14051_4765_4793_R
TAACCACCCCAAGATTTATCTTTTTGCCA 858 882 MECA_Y14051_4590_4600P_R
TpACpTpCpATpGCpCpA 1357 883 MECA_Y14051_4600_4610P_R
TpATpTpCpTpTpCpGTpT 1358 902 TRPE_AY094355_1569_1592_R
TGCGCGAGCTTTTATTTGGGTTTC 1231 903 TRPE_AY094355_1551_1580_R
TATTTGGGTTTCATTCCACTCAGATTCT 944 GG 904 TRPE_AY094355_1392_1418_R
TCCTCTTTTCACAGGCTCTACTTCATC 1048 905 TRPE_AY094355_1171_1196_R
TACATCGTTTCGCCCAAGATCAATCA 885 906 TRPE_AY094355_769_791_R
TTCAAAATGCGGAGGCGTATGTG 1372 907 TRPE_AY094355_864_883_R
TGCCCAGGTACAACCTGCAT 1218 908 RECA_AF251469_140_163_R
TTCAAGTGCTTGCTCACCATTGTC 1375 909 RECA_AF251469_277_300_R
TGGCTCATAAGACGCGCTTGTAGA 1280 910 PARC_X95819_201_222_R
TTCGGTATAACGCATCGCAGCA 1387 911 PARC_X95819_192_219_R
GGTATAACGCATCGCAGCAAAAGATTTA 836 912 PARC_X95819_232_260_R
TCGCTCAGCAATAATTCACTATAAGCCGA 1081 913 PARC_X95819_143_170_R
TTCCCCTGACCTTCGATTAAAGGATAGC 1383 914 OMPA_AY485227_364_388_R
GAGCTGCGCCAACGAATAAATCGTC 812 915 OMPA_AY485227_492_519_R
TGCCGTAACATAGAAGTTACCGTTGATT 1223 916 OMPA_AY485227_424_453_R
TACGTCGCCTTTAACTTGGTTATATTCA 901 GC 917 OMPA_AY485227_514_546_R
TCGGGCGTAGTTTTTAGTAATTAAATCA 1092 GAAGT 918 OMPA_AY485227_569_596_R
TCGTCGTATTTATAGTGACCAGCACCTA 1108 919 OMPA_AY485227_658_680_R
TTTAAGCGCCAGAAAGCACCAAC 1425 920 OMPA_AY485227_635_662_R
TCAACACCAGCGTTACCTAAAGTACCTT 954 921 OMPA_AY485227_659_683_R
TCGTTTAAGCGCCAGAAAGCACCAA 1114 922 OMPA_AY485227_739_765_R
TAAGCCAGCAAGAGCTGTATAGTTCCA 871 923 OMPA_AY485227_786_807_R
TACAGGAGCAGCAGGCTTCAAG 884 924 GYRA_AF100557_119_142_R
TCGAACCGAAGTTACCCTGACCAT 1063 925 GYRA_AF100557_178_201_R
TGCCAGCTTAGTCATACGGACTTC 1211 926 GYRB_AB008700_111_140_R
TATTGCGGATCACCATGATGATATTCTT 941 GC 927 GYRB_AB008700_369_395_R
TCGTTGAGATGGTTTTTACCTTCGTTG 1113 928 GYRB_AB008700_466_494_R
TTTGTGAAACAGCGAACATTTTCTTGGTA 1440 929 GYRB_AB008700_611_632_R
TCACGCGCATCATCACCAGTCA 977 930 GYRB_AB008700_862_888_R
ACCTGCAATATCTAATGCACTCTTACG 729 931 WAAA_Z96925_115_138_R
CAAGCGGTTTGCCTCAAATAGTCA 758 932 WAAA_Z96925_394_412_R
TGGCACGAGCCTGACCTGT 1274 939 RPOB_EC_3862_3889_R
TGTCCGACTTGACGGTCAGCATTTCCTG 1326 940 RPOB_EC_3862_3889_2_R
TGTCCGACTTGACGGTTAGCATTTCCTG 1327 941 TUFB_EC_337_362_R
TGGATGTGCTCACGAGTCTGTGGCAT 1271 942 TUFB_EC_337_360_R
TATGTGCTCACGAGTTTGCGGCAT 937 949 GYRB_AB008700_862_888_2_R
TCCTGCAATATCTAATGCACTCTTACG 1050 958 RPOC_EC_2329_2352_R
TGCTAGACCTTTACGTGCACCGTG 1243 959 RPOC_EC_1009_1031_R
TCCAGCAGGTTCTGACGGAAACG 1004 960 RPOC_EC_2380_2403_R
TACTAGACGACGGGTCAGGTAACC 905 961 RPOC_EC_1009_1034_R
TTACCGAGCAGGTTCTGACGGAAACG 1362 962 RPOB_EC_2041_2064_R
TTGACGTTGCATGTTCGAGCCCAT 1399 963 RPOB_EC_1630_1649_R
TCGTCGCGGACTTCGAAGCC 1104 964 INFB_EC_1414_1432_R
TCGGCATCACGCCGTCGTC 1090 965 VALS_EC_1231_1257_R
TTCGCGCATCCAGGAGAAGTACATGTT 1384 978 RPOC_EC_2228_2247_R
TTACGCCATCAGGCCACGCA 1363 1045 CJST_CJ_1774_1799_R
TGAGCGTGTGGAAAAGGACTTGGATG 1170 1046 CJST_CJ_2283_2313_R
TCTCTTTCAAAGCACCATTGCTCATTAT 1126 AGT 1047 CJST_CJ_663_692_R
TTCATTTTCTGGTCCAAAGTAAGCAGTA 1379 TC 1048 CJST_CJ_442_476_R
TCAACTGGTTCAAAAACATTAAGTTGTA 955 ATTGTCC 1049 CJST_CJ_2753_2777_R
TTGCTGCCATAGCAAAGCCTACAGC 1409 1050 CJST_CJ_1406_1433_R
TTTGCTCATGATCTGCATGAAGCATAAA 1437 1051 CJST_CJ_3356_3385_R
TCAAAGAACCCGCACCTAATTCATCATT 951 TA 1052 CJST_CJ_104_137_R
TCCCTTATTTTTCTTTCTACTACCTTCG 1029 GATAAT 1053 CJST_CJ_1166_1198_R
TCCCCTCATGTTTAAATGATCAGGATAA 1022 AAAGC 1054 CJST_CJ_2148_2174_R
TCGATCCGCATCACCATCAAAAGCAAA 1068 1055 CJST_CJ_2979_3007_R
TCCTCCTTGTGCCTCAAAACGCATTTTTA 1045 1056 CJST_CJ_1981_2011_R
TGGTTCTTACTTGCTTTGCATAAACTTT 1309 CCA 1057 CJST_CJ_2283_2316_R
TGAATTCTTTCAAAGCACCATTGCTCAT 1152 TATAGT 1058 CJST_CJ_1724_1752_R
TGCAATGTGTGCTATGTCAGCAAAAAGAT 1198 1059 CJST_CJ_2247_2278_R
TCCACACTGGATTGTAATTTACCTTGTT 1002 CTTT 1060 CJST_CJ_711_743_R
TCCCGAACAATGAGTTGTATCAACTATT 1024 TTTAC 1061 CJST_CJ_443_477_R
TACAACTGGTTCAAAAACATTAAGCTGT 882 AATTGTC 1062 CJST_CJ_2760_2787_R
TGTGCTTTTTTTGCTGCCATAGCAAAGC 1339 1063 CJST_CJ_1349_1379_R
TCGGTTTAAGCTCTACATGATCGTAAGG 1096
ATA 1064 CJST_CJ_1795_1822_R TATGTGTAGTTGAGCTTACTACATGAGC 938 1065
CJST_CJ_2965_2998_R TGCTTCAAAACGCATTTTTACATTTTCG 1253 TTAAAG 1070
RNASEP_BKM_665_686_R TCCGATAAGCCGGATTCTGTGC 1034 1071
RNASEP_BKM_665_687_R TGCCGATAAGCCGGATTCTGTGC 1222 1072
RNASEP_BDP_616_635_R TCGTTTCACCCTGTCATGCCG 1115 1073
23S_BRM_1176_1201_R TCGCAGGCTTACAGAACGCTCTCCTA 1074 1074
23S_BRM_616_635_R TCGGACTCGCTTTCGCTACG 1088 1075
RNASEP_CLB_498_526_R TGCTCTTACCTCACCGTTCCACCCTTACC 1247 1076
RNASEP_CLB_498_522_R TTTACCTCGCCTTTCCACCCTTACC 1426 1077
ICD_CXB_172_194_R TAGGATTTTTCCACGGCGGCATC 921 1078
ICD_CXB_172_194_R TAGGATTTTTCCACGGCGGCATC 921 1079
ICD_CXB_224_247_R TAGCCTTTTCTCCGGCGTAGATCT 916 1080
IS1111A_NC002971_6928_6954_R TAAACGTCCGATACCAATGGTTCGCTC 848 1081
IS1111A_NC002971_7529_7554_R TCAACAACACCTCCTTATTCCCACTC 952 1082
RNASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957 1083
RNASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957 1084
RNASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957 1085
RNASEP_RKP_295_321_R TCTATAGAGTCCGGACTTTCCTCGTGA 1119 1086
RNASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957 1087
OMPB_RKP_972_996_R TCCTGCAGCTCTACCTGCTCCATTA 1051 1088
OMPB_RKP_1288_1315_R TAGCAgCAAAAGTTATCACACCTGCAGT 910 1089
OMPB_RKP_3520_3550_R TGGTTGTAGTTCCTGTAGTTGTTGCATT 1310 AAC 1090
GLTA_RKP_1138_1162_R TGAACATTTGCGACGGTATACCCAT 1147 1091
GLTA_RKP_499_529_R TGGTGGGTATCTTAGCAATCATTCTAAT 1305 AGC 1092
GLTA_RKP_1129_1156_R TTGGCGACGGTATACCCATAGCTTTATA 1415 1093
GLTA_RKP_1138_1162_R TGAACATTTGCGACGGTATACCCAT 1147 1094
GLTA_RKP_1138_1164_R TGTGAACATTTGCGACGGTATACCCAT 1330 1095
GLTA_RKP_505_534_R TGCGATGGTAGGTATCTTAGCAATCATT 1230 CT 1096
CTXA_VBC_194_218_R TGCCTAACAAATCCCGTCTGAGTTC 1226 1097
CTXA_VBC_441_466_R TGTCATCAAGCACCCCAAAATGAACT 1324 1098
RNASEP_VBC_388_414_R TGACTTTCCTCCCCCTTATCAGTCTCC 1163 1099
TOXR_VBC_221_246_R TTCAAAACCTTGCTCTCGCCAAACAA 1370 1100
ASD_FRT_86_116_R TGAGATGTCGAAAAAAACGTTGGCAAAA 1164 TAC 1101
ASD_FRT_129_156_R TCCATATTGTTGCATAAAACCTGTTGGC 1009 1102
GALE_FRT_241_269_R TCACCTACAGCTTTAAAGCCAGCAAAATG 973 1103
GALE_FRT_901_925_R TAGCCTTGGCAACATCAGCAAAACT 915 1104
GALE_FRT_390_422_R TCTTCTGTAAAGGGTGGTTTATTATTCA 1136 TCCCA 1105
IPAH_SGF_301_327_R TCCTTCTGATGCCTGATGGACCAGGAG 1055 1106
IPAH_SGF_172_191_R TTTTCCAGCCATGCAGCGAC 1441 1107
IPAH_SGF_522_540_R TGTCACTCCCGACACGCCA 1322 1111
RNASEP_BRM_542_561_R TGCCTCGCGCAACCTACCCG 1227 1112
RNASEP_BRM_402_428_R TCTCTTACCCCACCCTTTCACCCTTAC 1125 1128
HUPB_CJ_157_188_R TCCCTAATAGTAGAAATAACTGCATCAG 1028 TAGC 1129
HUPB_CJ_157_188_R TCCCTAATAGTAGAAATAACTGCATCAG 1028 TAGC 1130
HUPB_CJ_114_135_R TAGCCCAGCTGTTTGAGCAACT 913 1151 AB_MLST-11-
TTGTACATTTGAAACAATATGCATGACA 1418 OIF007_169_203_R TGTGAAT 1152
AB_MLST-11- TCACAGGTTCTACTTCATCAATAATTTC 969 OIF007_291_324_R
CATTGC 1153 AB_MLST-11- TTGCAATCGACATATCCATTTCACCATG 1400
OIF007_364_393_R CC 1154 AB_MLST-11- TCCGCCAAAAACTCCCCTTTTCACAGG
1036 OIF007_318_344_R 1155 AB_MLST-11- TTCTGCTTGAGGAATAGTGCGTGG
1392 OIF007_587_610_R 1156 AB_MLST-11- TACGTTCTACGATTTCTTCATCAGGTAC
902 OIF007_656_686_R ATC 1157 AB_MLST-11-
TACAACGTGATAAACACGACCAGAAGC 881 OIF007_710_736_R 1158 AB_MLST-11-
TAATGCCGGGTAGTGCAATCCATTCTTC 878 OIF007_1266_1296_R TAG 1159
AB_MLST-11- TGCACCTGCGGTCGAGCG 1199 OIF007_1299_1316_R 1160
AB_MLST-11- TGCCATCCATAATCACGCCATACTGACG 1215 OIF007_1335_1362_R
1161 AB_MLST-11- TGCCAGTTTCCACATTTCACGTTCGTG 1212
OIF007_1422_1448_R 1162 AB_MLST-11- TCGCTTGAGTGTAGTCATGATTGCG 1083
OIF007_1470_1494_R 1163 AB_MLST-11- TCGCTTGAGTGTAGTCATGATTGCG 1083
OIF007_1470_1494_R 1164 AB_MLST-11- TCGCTTGAGTGTAGTCATGATTGCG 1083
OIF007_1470_1494_R 1165 AB_MLST-11- TGAGTCGGGTTCACTTTACCTGGCA 1173
OIF007_1656_1680_R 1166 AB_MLST-11- TGAGTCGGGTTCACTTTACCTGGCA 1173
OIF007_1656_1680_R 1167 AB_MLST-11- TACCGGAAGCACCAGCGACATTAATAG 890
OIF007_1731_1757_R 1168 AB_MLST-11- TGCAACTGAATAGATTGCAGTAAGTTAT
1195 OIF007_1790_1821_R AAGC 1169 AB_MLST-11-
TGAATTATGCAAGAAGTGATCAATTTTC 1151 OIF007_1876_1909_R TCACGA 1170
AB_MLST-11- TGCCGTAACTAACATAAGAGAATTATGC 1224 OIF007_1895_1927_R
AAGAA 1171 AB_MLST-11- TGACGGCATCGATACCACCGTC 1157
OIF007_2097_2118_R 1172 RNASEP_BRM_542_561_2_R TGCCTCGTGCAACCCACCCG
1228 2000 CTXB_NC002505_132_162_R TCCGGCTAGAGATTCTGTATACGACAAT 1039
ATC 2001 FUR_NC002505_205_228_R TCCGCCTTCAAAATGGTGGCGAGT 1037 2002
FUR_NC002505_178_205_R TCACGATACCTGCATCATCAAATTGGTT 974 2003
GAPA_NC002505_646_671_R TCAGAATCGATGCCAAATGCGTCATC 980 2004
GAPA_NC002505_769_798_R TCCTCTATGCAACTTAGTATCAACAGGA 1046 AT 2005
GAPA_NC002505_856_881_R TCCATCGCAGTCACGTTTACTGTTGG 1011 2006
GYRB_NC002505_109_134_R TCCACCACCTCAAAGACCATGTGGTG 1003 2007
GYRB_NC002505_199_225_R TCCGTCATCGCTGACAGAAACTGAGTT 1042 2008
GYRB_NC002505_832_860_R TGGAAACCGGCTAAGTGAGTACCACCATC 1262 2009
GYRB_NC002505_937_957_R TCCTTCACGCGCATCATCACC 1054 2010
GYRB_NC002505_982_1007_R TGGCTTGAGAATTTAGGATCCGGCAC 1283 2011
GYRB_NC002505_1255_1284_R TGAGTCACCCTCCACAATGTATAGTTCA 1172 GA 2012
OMPU_NC002505_154_180_R TGCTTCAGCACGGCCACCAACTTCTAG 1254 2013
OMPU_NC002505_346_369_R TCCGAGACCAGCGTAGGTGTAACG 1033 2014
OMPU_NC002505_544_567_R TCGGTCAGCAAAACGGTAGCTTGC 1094 2015
OMPU_NC002505_625_651_R TAGAGAGTAGCCATCTTCACCGTTGTC 908 2016
OMPU_NC002505_725_751_R TGGGGTAAGACGCGGCTAGCATGTATT 1291 2017
OMPU_NC002505_811_835_R TAGCAGCTAGCTCGTAACCAGTGTA 911 2018
OMPU_NC002505_1033_1053_R TTAGAAGTCGTAACGTGGACC 1368 2019
OMPU_NC002505_1033_1054_R TGGTTAGAAGTCGTAACGTGGACC 1307 2020
TCPA_NC002505_148_170_R TTCTGCGAATCAATCGCACGCTG 1391 2021
TDH_NC004605_357_386_R TGTTGAAGCTGTACTTGACCTGATTTTA 1351 CG 2022
VVHA_NC004460_862_886_R TACCAAAGCGTGCACGATAGTTGAG 887 2023
23S_EC_2746_2770_R TGGGTTTCGCGCTTAGATGCTTTCA 1297 2024
16S_EC_789_811_R TGCGTGGACTACCAGGGTATCTA 1240 2025
16S_EC_880_897_TMOD_R TGGCCGTACTCCCCAGGCG 1278 2026
16S_EC_1052_1074_R TACGAGCTGACGACAGCCATGCA 896 2027
TUFB_EC_1034_1058_2_R TGCATCACCATTTCCTTGTCCTTCG 1204 2028
RPOC_EC_2227_2249_R TGCTAGGCCATCAGGCCACGCAT 1244 2029
RPOB_EC_1909_1929_TMOD_R TGCTGGATTCGCCTTTGCTACG 1250 2030
RPLB_EC_739_763_R TGCCAAGTGCTGGTTTACCCCATGG 1208 2031
RPLB_EC_737_760_R TGGGTGCTGGTTTACCCCATGGAG 1295 2032
INFB_EC_1439_1469_R TGTGCTGCTTTCGCATGGTTAATTGCTT 1335 CAA 2033
VALS_EC_1195_1219_R TGGGTACGAACTGGATGTCGCCGTT 1292 2034
SSPE_BA_197_222_TMOD_R TTGCACGTCTGTTTCAGTTGCAAATTC 1402 2035
RPOC_EC_2313_2338_R TGGCACCGTGGGTTGAGATGAAGTAC 1273 2056
MECI-R_NC003923-41798- TTGTGATATGGAGGTGTAGAAGGTGTTA 1420
41609_86_113_R 2057 AGR-III_NC003923-2108074-
ACCTGCATCCCTAAACGTACTTGC 730 2109507_56_79_R 2058
AGR-III_NC003923-2108074- TACTTCAGCTTCGTCCAATAAAAAATCA 906
2109507_622_653_R CAAT
2059 AGR-III_NC003923-2108074- TGTAGGCAAGTGCATAAGAAATTGATACA 1319
2109507_1070_1098_R 2060 AGR-I_AJ617706_694_726_R
TCCCCATTTAATAATTCCACCTACTATC 1021 ACACT 2061
AGR-I_AJ617706_626_655_R TGGTACTTCAACTTCATCCATTATGAAG 1302 TC 2062
AGR-II_NC002745-2079448- TTGTTTATTGTTTCCATATGCTACACAC 1424
2080879_700_731_R TTTC 2063 AGR-II_NC002745-2079448-
TCGCCATAGCTAAGTTGTTTATTGTTTC 1077 2080879_715_745_R CAT 2064 AGR-
TGCGCTATCAACGATTTTGACAATATAT 1233 IV_AJ617711_1004_1035_R GTGA 2065
AGR-IV_AJ617711_309_335_R TCCCATACCTATGGCGATAACTGTCAT 1017 2066
BLAZ_NC002952(1913827 . . . 1914672)_68_68_R
TGGCCACTTTTATCAGCAACCTTACAGTC 1277 2067 BLAZ_NC002952(1913827 . . .
1914672)_68_68_2_R TAGTCTTTTGGAACACCGTCTTTAATTA 926 AAGT 2068
BLAZ_NC002952(1913827 . . . 1914672)_68_68_3_R
TGGAACACCGTCTTTAATTAAAGTATCT 1263 CC 2069 BLAZ_NC002952(1913827 . .
. 1914672)_68_68_4_R TCTTTTCTTTGCTTAATTTTCCATTTGC 1145 GAT 2070
BLAZ_NC002952(1913827 . . . 1914672)_34_67_R
TTACTTCCTTACCACTTTTAGTATCTAA 1366 AGCATA 2071 BLAZ_NC002952(1913827
. . . 1914672)_40_68_R TGGGGACTTCCTTACCACTTTTAGTATC 1289 TAA 2072
BSA-A_NC003923-1304065- TGCAAGGGAAACCTAGAATTACAAACCCT 1197
1303589_165_193_R 2073 BSA-A_NC003923-1304065-
TGCATAGGGAAGGTAACACCATAGTT 1203 1303589_253_278_R 2074
BSA-A_NC003923-1304065- TAACAACGTTACCTTCGCGATCCACTAA 856
1303589_388_415_R 2075 BSA-A_NC003923-1304065-
TGTTGTGCCGCAGTCAAATATCTAAATA 1353 1303589_317_344_R 2076
BSA-B_NC003923-1917149- TGTGAAGAACTTTCAAATCTGTGAATCCA 1331
1914156_1011_1039_R 2077 BSA-B_NC003923-1917149-
TCTTCTTGAAAAATTGTTGTCCCGAAAC 1138 1914156_1109_1136_R 2078
BSA-B_NC003923-1917149- TGGACTAATAACAATGAGCTCATTGTAC 1267
1914156_1323_1353_R TGA 2079 BSA-B_NC003923-1917149-
TGAATATGTAATGCAAACCAGTCTTTGT 1148 1914156_2186_2216_R CAT 2080
ERMA_NC002952-55890- TGAGTCTACACTTGGCTTAGGATGAAA 1174
56621_487_513_R 2081 ERMA_NC002952-55890-
TGAGCATTTTTATATCCATCTCCACCAT 1167 56621_438_465_R 2082
ERMA_NC002952-55890- TCTTGGCTTAGGATGAAAATATAGTGGT 1143
56621_473_504_R GGTA 2083 ERMA_NC002952-55890-
TCAATACAGAGTCTACACTTGGCTTAGG 964 56621_491_520_R AT 2084
ERMA_NC002952-55890- TGGACGATATTCACGGTTTACCCACTTA 1266
56621_586_615_R TA 2085 ERMA_NC002952-55890-
TTGACATTTGCATGCTTCAAAGCCTG 1397 56621_640_665_R 2086
ERMC_NC005908-2004- TCCGTAGTTTTGCATAATTTATGGTCTA 1041
2738_173_206_R TTTCAA 2087 ERMC_NC005908-2004-
TTTATGGTCTATTTCAATGGCAGTTACG 1429 2738_160_189_R AA 2088
ERMC_NC005908-2004- TATGGTCTATTTCAATGGCAGTTACGA 936 2738_161_187_R
2089 ERMC_NC005908-2004- TCAACTTCTGCCATTAAAAGTAATGCCA 956
2738_425_452_R 2090 ERMC_NC005908-2004-
TGATGGTCTATTTCAATGGCAGTTACGA 1185 2738_159_188_R AA 2091
ERMB_Y13600-625- TCAACAATCAGATAGATGTCAGACGCATG 953 1362_352_380_R
2092 ERMB_Y13600-625- TGCAAGAGCAACCCTAGTGTTCG 1196 1362_415_437_R
2093 ERMB_Y13600-625- TAGGATGAAAGCATTCCGCTGGC 919 1362_471_493_R
2094 ERMB_Y13600-625- TCATCTGTGGTATGGCGGGTAAGTT 989 1362_521_545_R
2095 PVLUK_NC003923-1529595- TGGAAAACTCATGAAATTAAAGTGAAAG 1261
1531285_775_804_R GA 2096 PVLUK_NC003923-1529595-
TCATTAGGTAAAATGTCTGGACATGATC 993 1531285_1095_1125_R CAA 2097
PVLUK_NC003923-1529595- TCTCATGAAAAAGGCTCAGGAGATACAAG 1124
1531285_950_978_R 2098 PVLUK_NC003923-1529595-
TCACACCTGTAAGTGAGAAAAAGGTTGAT 968 1531285_654_682_R 2099
SA442_NC003923-2538576- TTTCCGATGCAACGTAATGAGATTTCA 1433
2538831_98_124_R 2100 SA442_NC003923-2538576-
TCGTATGACCAGCTTCGGTACTACTA 1098 2538831_163_188_R 2101
SA442_NC003923-2538576- TTTATGACCAGCTTCGGTACTACTAAA 1428
2538831_161_187_R 2102 SA442_NC003923-2538576-
TGATAATGAAGGGAAACCTTTTTCACG 1179 2538831_231_257_R 2103
SEA_NC003923-2052219- TCGATCGTGACTCTCTTTATTTTCAGTT 1070
2051456_173_200_R 2104 SEA_NC003923-2052219-
TGTAATTAACCGAAGGTTCTGTAGAAGT 1315 2051456_621_651_R ATG 2105
SEA_NC003923-2052219- TAACCGTTTCCAAAGGTACTGTATTTTGT 861
2051456_464_492_R 2106 SEA_NC003923-2052219-
TAACCGTTTCCAAAGGTACTGTATTTTG 862 2051456_459_492_R TTTACC 2107
SEB_NC002758-2135540- TCATCTGGTTTAGGATCTGGTTGACT 988
2135140_273_298_R 2108 SEB_NC002758-2135540-
TGCAACTCATCTGGTTTAGGATCT 1194 2135140_281_304_R 2109
SEB_NC002758-2135540- TGTGCAGGCATCATGTCATACCAA 1334
2135140_402_402_R 2110 SEB_NC002758-2135540-
TTACCATCTTCAAATACCCGAACAGTAA 1361 2135140_402_402_2_R 2111
SEC_NC003923-851678- TGAGTTTGCACTTCAAAAGAAATTGTGT 1177
852768_620_647_R 2112 SEC_NC003923-851678-
TCAGTTTGCACTTCAAAAGAAATTGTGTT 985 852768_619_647_R 2113
SEC_NC003923-851678- TCGCCTGGTGCAGGCATCATAT 1078 852768_794_815_R
2114 SEC_NC003923-851678- TCTTCACACTTTTAGAATCAACCGTTTT 1133
852768_853_886_R ATTGTC 2115 SED_M28521_741_770_R
TGTACACCATTTATCCACAAATTGATTG 1318 GT 2116 SED_M28521_739_770_R
TGGGCACCATTTATCCACAAATTGATTG 1288 GTAT 2117 SED_M28521_888_911_R
TCGCGCTGTATTTTTCCTCCGAGA 1079 2118 SED_M28521_1022_1048_R
TGTCAATATGAAGGTGCTCTGTGGATA 1320 2119 SEA-SEE_NC002952-2131289-
TCATTTATTTCTTCGCTTTTCTCGCTAC 994 2130703_71_98_R 2120
SEA-SEE_NC002952-2131289- TAAGCACCATATAAGTCTACTTTTTTCC 870
2130703_314_344_R CTT 2121 SEE_NC002952-2131289-
TCTATAGGTACTGTAGTTTGTTTTCCGT 1120 2130703_465_494_R CT 2122
SEE_NC002952-2131289- TTTGCACCTTACCGCCAAAGCT 1436 2130703_586_586_R
2123 SEE_NC002952-2131289- TACCTTACCGCCAAAGCTGTCT 892
2130703_586_586_2_R 2124 SEE_NC002952-2131289-
TCCGTCTATCCACAAGTTAATTGGTACT 1043 2130703_444_471_R 2125
SEG_NC002758-1955100- TAACTCCTCTTCCTTCAACAGGTGGA 863
1954171_321_346_R 2126 SEG_NC002758-1955100-
TGCTTTGTAATCTAGTTCCTGAATAGTA 1260 1954171_671_702_R ACCA 2127
SEG_NC002758-1955100- TGTCTATTGTCGATTGTTACCTGTACAGT 1329
1954171_607_635_R 2128 SEG_NC002758-1955100-
TGATTCAAATGCAGAACCATCAAACTCG 1187 1954171_735_762_R 2129
SEH_NC002953-60024- TAGTGTTGTACCTCCATATAGACATTCA 927
60977_547_576_R GA 2130 SEH_NC002953-60024-
TTCTGAGCTAAATCAGCAGTTGCA 1390 60977_450_473_R 2131
SEH_NC002953-60024- TACCATCTACCCAAACATTAGCACCAA 888 60977_608_634_R
2132 SEH_NC002953-60024- TAGCACCAATCACCCTTTCCTGT 909
60977_594_616_R 2133 SEI_NC002758-1957830-
TCACAAGGACCATTATAATCAATGCCAA 966 1956949_419_446_R 2134
SEI_NC002758-1957830- TGTACAAGGACCATTATAATCAATGCCA 1316
1956949_420_447_R 2135 SEI_NC002758-1957830-
TCTGGCCCCTCCATACATGTATTTAG 1129 1956949_449_474_R 2136
SEI_NC002758-1957830- TGGGTAGGTTTTTATCTGTGACGCCTT 1293
1956949_290_316_R 2137 SEJ_AF053140_1381_1404_R
TCTAGCGGAACAACAGTTCTGATG 1118 2138 SEJ_AF053140_1429_1458_R
TCCTGAAGATCTAGTTCTTGAATGGTTA 1049 CT 2139 SEJ_AF053140_1500_1531_R
TAGTCCTTTCTGAATTTTACCATCAAAG 925 GTAC 2140 SEJ_AF053140_1521_1549_R
TCAGGTATGAAACACGATTAGTCCTTTCT 984 2141 TSST_NC002758-2137564-
TGTAAAAGCAGGGCTATAATAAGGACTC 1312 2138293_278_305_R 2142
TSST_NC002758-2137564- TGCCCTTTTGTAAAAGCAGGGCTAT 1221
2138293_289_313_R
2143 TSST_NC002758-2137564- TACTTTAAGGGGCTATCTTTACCATGAA 907
2138293_448_478_R CCT 2144 TSST_NC002758-2137564-
TAAGTTCCTTCGCTAGTATGTTGGCTT 874 2138293_347_373_R 2145
ARCC_NC003923-2725050- TGAGTTAAAATGCGATTGATTTCAGTTT 1175
2724595_97_128_R CCAA 2146 ARCC_NC003923-2725050-
TCTTCTTCTTTCGTATAAAAAGGACCAA 1137 2724595_214_245_R TTGG 2147
ARCC_NC003923-2725050- TGGTGTTCTAGTATAGATTGAGGTAGTG 1306
2724595_322_353_R GTGA 2148 AROE_NC003923-1674726-
TCGAATTCAGCTAAATACTTTTCAGCAT 1064 1674277_435_464_R CT 2149
AROE_NC003923-1674726- TACCTGCATTAATCGCTTGTTCATCAA 891
1674277_155_181_R 2150 AROE_NC003923-1674726-
TAAGCAATACCTTTACTTGCACCACCTG 869 1674277_308_335_R 2151
GLPF_NC003923-1296927- TGCAACAATTAATGCTCCGACAATTAAA 1193
1297391_382_414_R GGATT 2152 GLPF_NC003923-1296927-
TAAAGACACCGCTGGGTTTAAATGTGCA 850 1297391_81_108_R 2153
GLPF_NC003923-1296927- TCACCGATAAATAAAATACCTAAAGTTA 972
1297391_323_359_R ATGCCATTG 2154 GMK_NC003923-1190906-
TGATATTGAACTGGTGTACCATAATAGT 1180 1191334_166_197_R TGCC 2155
GMK_NC003923-1190906- TCGCTCTCTCAAGTGATCTAAACTTGGAG 1082
1191334_305_333_R 2156 GMK_NC003923-1190906-
TGGGACGTAATCGTATAAATTCATCATT 1284 1191334_403_432_R TC 2157
PTA_NC003923-628885- TGGTACACCTGGTTTCGTTTTGATGATT 1301
629355_314_345_R TGTA 2158 PTA_NC003923-628885-
TGCATTGTACCGAAGTAGTTCACATTGTT 1207 629355_211_239_R 2159
PTA_NC003923-628885- TGTTCTGGATTGATTGCACAATCACCAA 1349
629355_393_422_R AG 2160 TPI_NC003923-830671-
TGAGATGTTGATGATTTACCAGTTCCGA 1165 831072_209_239_R TTG 2161
TPI_NC003923-830671- TGGTACAACATCGTTAGCTTTACCACTT 1300
831072_97_129_R TCACG 2162 TPI_NC003923-830671-
TGGCAGCAATAGTTTGACGTACAAATGC 1275 831072_253_286_R ACACAT 2163
YQI_NC003923-378916- TCGCCAGCTAGCACGATGTCATTTTC 1076
379431_259_284_R 2164 YQI_NC003923-378916-
TTCGTGCTGGATTTTGTCCTTGTCCT 1388 379431_120_145_R 2165
YQI_NC003923-378916- TCCAACCCAGAACCACATACTTTATTCAC 997
379431_193_221_R 2166 YQI_NC003923-378916-
TCCATCTGTTAAACCATCATATACCATG 1013 379431_364_396_R CTATC 2167
BLAZ_(1913827 . . . 1914672)_655_683_R
TGGCCACTTTTATCAGCAACCTTACAGTC 1277 2168 BLAZ_(1913827 . . .
1914672)_628_659_R TAGTCTTTTGGAACACCGTCTTTAATTA 926 AAGT 2169
BLAZ_(1913827 . . . 1914672)_622_651_R TGGAACACCGTCTTTAATTAAAGTATCT
1263 CC 2170 BLAZ_(1913827 . . . 1914672)_553_583_R
TCTTTTCTTTGCTTAATTTTCCATTTGC 1145 GAT 2171 BLAZ_(1913827 . . .
1914672)_121_154_R TTACTTCCTTACCACTTTTAGTATCTAA 1366 AGCATA 2172
BLAZ_(1913827 . . . 1914672)_127_157_R TGGGGACTTCCTTACCACTTTTAGTATC
1289 TAA 2173 BLAZ_NC002952-1913827- TGGCCACTTTTATCAGCAACCTTACAGTC
1277 1914672_655_683_R 2174 BLAZ_NC002952-1913827-
TAGTCTTTTGGAACACCGTCTTTAATTA 926 1914672_628_659_R AAGT 2175
BLAZ_NC002952-1913827- TGGAACACCGTCTTTAATTAAAGTATCT 1263
1914672_622_651_R CC 2176 BLAZ_NC002952-1913827-
TCTTTTCTTTGCTTAATTTTCCATTTGC 1145 1914672_553_583_R GAT 2177
BLAZ_NC002952-1913827- TTACTTCCTTACCACTTTTAGTATCTAA 1366
1914672_121_154_R AGCATA 2178 BLAZ_NC002952-1913827-
TGGGGACTTCCTTACCACTTTTAGTATC 1289 1914672_127_157_R TAA 2247
TUFB_NC002758-615038- TGTCACCAGCTTCAGCGTAGTCTAATAA 1321
616222_793_820_R 2248 TUFB_NC002758-615038-
TGTCACCAGCTTCAGCGTAGTCTAATAA 1321 616222_793_820_R 2249
TUFB_NC002758-615038- TGTCACCAGCTTCAGCGTAGTCTAATAA 1321
616222_793_820_R 2250 TUFB_NC002758-615038-
TGGTTTGTCAGAATCACGTTCTGGAGTT 1311 616222_601_630_R GG 2251
TUFB_NC002758-615038- TAGGCATAACCATTTCAGTACCTTCTGG 922
616222_1030_1060_R TAA 2252 TUFB_NC002758-615038-
TTCCATTTCAACTAATTCTAATAATTCT 1382 616222_424_459_R TCATCGTC 2253
NUC_NC002758-894288- TACGCTAAGCCACGTCCATATTTATCA 899
894974_483_509_R 2254 NUC_NC002758-894288-
TGTTTGTGATGCATTTGCTGAGCTA 1354 894974_165_189_R 2255
NUC_NC002758-894288- TAGTTGAAGTTGCACTATATACTGTTGGA 928
894974_222_250_R 2256 NUC_NC002758-894288-
TAAATGCACTTGCTTCAGGGCCATAT 853 894974_396_421_R 2270
RPOB_EC_3868_3895_R TCACGTCGTCCGACTTCACGGTCAGCAT 979 2271
RPOB_EC_3860_3890_R TCGTCGGACTTAACGGTCAGCATTTCCT 1107 GCA 2272
RPOB_EC_3860_3890_2_R TCGTCCGACTTAACGGTCAGCATTTCCT 1102 GCA 2273
RPOB_EC_3862_3890_R TCGTCGGACTTAACGGTCAGCATTTCCTG 1106 2274
RPOB_EC_3862_3890_2_R TCGTCCGACTTAACGGTCAGCATTTCCTG 1101 2275
RPOB_EC_3865_3890_R TCGTCGGACTTAACGGTCAGCATTTC 1105 2276
RPOB_EC_3865_3890_2_R TCGTCCGACTTAACGGTCAGCATTTC 1100 2309
MUPR_X75439_1744_1773_R TCCCTTCCTTAATATGAGAAGGAAACCA 1030 CT 2310
MUPR_X75439_1413_1441_R TGAGCTGGTGCTATATGAACAATACCAGT 1171 2312
MUPR_X75439_1381_1409_R TATATGAACAATACCAGTTCCTTCTGAGT 931 2313
MUPR_X75439_2548_2574_R TTAATCTGGCTGCGGAAGTGAAATCGT 1360 2314
MUPR_X75439_2605_2630_R TCGTCCTCTCGAATCTCCGATATACC 1103 2315
MUPR_X75439_2711_2740_R TCAGATATAAATGGAACAAATGGAGCCA 981 CT 2316
MUPR_X75439_2867_2890_R TCTGCATTTTTGCGAGCCTGTCTA 1127 2317
MUPR_X75439_977_1007_R TGTACAATAAGGAGTCACCTTATGTCCC 1317 TTA 2318
CTXA_NC002505-1568114- TCGTGCCTAACAAATCCCGTCTGAGTTC 1109
1567341_194_221_R 2319 CTXA_NC002505-1568114-
TCGTGCCTAACAAATCCCGTCTGAGTTC 1109 1567341_194_221_R 2320
CTXA_NC002505-1568114- TAACAAATCCCGTCTGAGTTCCTCTTGCA 855
1567341_186_214_R 2321 CTXA_NC002505-1568114-
TAACAAATCCCGTCTGAGTTCCTCTTGCA 855 1567341_186_214_R 2322
CTXA_NC002505-1568114- TCCCGTCTGAGTTCCTCTTGCATGATCA 1027
1567341_180_207_R 2323 CTXA_NC002505-1568114-
TAACAAATCCCGTCTGAGTTCCTCTTGCA 855 1567341_186_214_R 2324
INV_U22457-74- TGACCCAAAGCTGAAAGCTTTACTG 1154 3772_942_966_R 2325
INV_U22457-74- TAACTGACCCAAAGCTGAAAGCTTTACTG 864 3772_942_970_R
2326 INV_U22457-74- TGGGTTGCGTTGCAGATTATCTTTACCAA 1296
3772_1619_1647_R 2327 INV_U22457-74- TCATAAGGGTTGCGTTGCAGATTATCTT
987 3772_1622_1652_R TAC 2328 ASD_NC006570-439714-
TGATTCGATCATACGAGACATTAAAACT 1188 438608_54_84_R GAG 2329
ASD_NC006570-439714- TCAAAATCTTTTGATTCGATCATACGAG 948
438608_66_95_R AC 2330 ASD_NC006570-439714-
TCCCAATCTTTTGATTCGATCATACGAGA 1016 438608_67_95_R 2331
ASD_NC006570-439714- TCTGCCTGAGATGTCGAAAAAAACGTTG 1128
438608_107_134_R 2332 GALE_AF513299_241_271_R
TCTCACCTACAGCTTTAAAGCCAGCAAA 1122 ATG 2333 GALE_AF513299_245_271_R
TCTCACCTACAGCTTTAAAGCCAGCAA 1121 2334 GALE_AF513299_233_264_R
TACAGCTTTAAAGCCAGCAAAATGAATT 883 ACAG 2335 GALE_AF513299_252_279_R
TTCAACACTCTCACCTACAGCTTTAAAG 1374 2336 PLA_AF053945_7434_7468_R
TACGTATGTAAATTCCGCAAAGACTTTG 900 GCATTAG 2337
PLA_AF053945_7428_7455_R TCCGCAAAGACTTTGGCATTAGGTGTGA 1035 2338
PLA_AF053945_7430_7460_R TAAATTCCGCAAAGACTTTGGCATTAGG 854 TGT 2339
CAF_AF053947_33498_33523_R TAAGAGTGATGCGGGCTGGTTCAACA 866 2340
CAF_AF053947_33483_33507_R TGGTTCAACAAGAGTTGCCGTTGCA 1308 2341
CAF_AF053947_33483_33504_R TTCAACAAGAGTTGCCGTTGCA 1373 2342
CAF_AF053947_33494_33517_R TGATGCGGGCTGGTTCAACAAGAG 1184 2344
GAPA_NC_002505_29_58_R_1 TCCTTTATGCAACTTGGTATCAACAGGA 1060 AT 2472
OMPA_NC000117_145_167_R TCACACCAAGTAGTGCAAGGATC 967
2473 OMPA_NC000117_865_893_R TCAAAACTTGCTCTAGACCATTTAACTCC 947 2474
OMPA_NC000117_757_777_R TGTCGCAGCATCTGTTCCTGC 1328 2475
OMPA_NC000117_1011_1040_R TGACAGGACACAATCTGCATGAAGTCTG 1153 AG 2476
OMPA_NC000117_871_894_R TTCAAAAGTTGCTCGAGACCATTG 1371 2477
OMPA_NC000117_511_534_R TAAAGAGACGTTTGGTAGTTCATTTGC 851 2478
OMPA_NC000117_787_816_R TTGCCATTCATGGTATTTAAGTGTAGCA 1406 GA 2479
OMPA_NC000117_649_672_R TTCTTGAACGCGAGGTTTCGATTG 1395 2480
OMPA_NC000117_417_444_R TCCTTTAAAATAACCGCTAGTAGCTCCT 1058 2481
OMP2_NC000117_71_91_R TCCCGCTGGCAAATAAACTCG 1025 2482
OMP2_NC000117_445_471_R TGGATCACTGCTTACGAACTCAGCTTC 1270 2483
OMP2_NC000117_1396_1419_R TACGTTTGTATCTTCTGCAGAACC 903 2484
OMP2_NC000117_1541_1569_R TCCTTTCAATGTTACAGAAAACTCTACAG 1062 2485
OMP2_NC000117_120_148_R TGTCAGCTAAGCTAATAACGTTTGTAGAG 1323 2486
OMP2_NC000117_240_261_R TTGACATCGTCCCTCTTCACAG 1396 2487
GYRA_NC000117_640_660_R TGCTGTAGGGAAATCAGGGCC 1251 2488
GYRA_NC000117_871_893_R TTGTCAGACTCATCGCGAACATC 1419 2489
GYRA_NC002952_319_345_R TCCATCCATAGAACCAAAGTTACCTTG 1010 2490
GYRA_NC002952_1024_1041_R TCGCAGCGTGCGTGGCAC 1073 2491
GYRA_NC002952_1546_1562_R TTGGTGCGCTTGGCGTA 1416 2492
GYRA_NC002952_124_143_R TGGCGATGCACTGGCTTGAG 1279 2493
GYRA_NC002952_313_333_R TCCGAAGTTGCCCTGGCCGTC 1032 2494
GYRA_NC002952_308_330_R TAAGTTACCTTGCCCGTCAACCA 873 2495
GYRA_NC002952_220_242_R TGCGGGTGATACTTACCGAGTAC 1236 2496
GYRA_NC002952_643_663_R TGCTGTAGGGAAATCAGGGCC 1251 2497
GYRA_NC002952_338_360_R TGCGGCAGCACTATCACCATCCA 1234 2498
GYRA_NC000912_346_370_R TCGAGCCGAAGTTACCCTGTCCGTC 1067 2504
ARCC_NC003923-2725050- TCpTpTpTpCpGTATAAAAAGGACpCpA 1116
2724595_214_239P_R ATpTpGG 2505 PTA_NC003923-628885-
TACpACpCpTGGTpTpTpCpGTpTpTpT 904 629355_314_342P_R pGATGATpTpTpGTA
2517 CJMLST_ST1_1945_1977_R TGTTTTATGTGTAGTTGAGCTTACTACA 1355 TGAGC
2518 CJMLST_ST1_3073_3097_R TCCCCATCTCCGCAAAGACAATAAA 1020 2519
CJMLST_ST1_2447_2481_R TCTACAACACTTGATTGTAATTTGCCTT 1117 GTTCTTT
2520 CJMLST_ST1_725_756_R TCGGAAACAAAGAATTCATTTTCTGGTC 1084 CAAA
2521 CJMLST_ST1_454_487_R TGCTATATGCTACAACTGGTTCAAAAAC 1245 ATTAAG
2522 CJMLST_ST1_1312_1340_R TTTAGCTACTATTCTAGCTGCCATTTCCA 1427 2523
CJMLST_ST1_3656_3685_R TCAAAGAACCAGCACCTAATTCATCATT 950 TA 2524
CJMLST_ST1_55_84_R TGTTCCAATAGCAGTTCCGCCCAAATTG 1348 AT 2525
CJMLST_ST1_1383_1417_R TTTCCCCGATCTAAATTTGGATAAGCCA 1432 TAGGAAA
2526 CJMLST_ST1_2352_2379_R TCCAAACGATCTGCATCACCATCAAAAG 996 2527
CJMLST_ST1_1486_1520_R TGCATGAAGCATAAAAACTGTATCAAGT 1205 GCTTTTA
2528 CJMLST_ST1_3511_3542_R TGCTTGCTCAAATCATCATAAACAATTA 1257 AAGC
2529 CJMLST_ST1_1203_1230_R TAGGATGAGCATTATCAGGGAAAGAATC 920 2530
CJMLST_ST1_2940_2973_R TAGCGATTTCTACTCCTAGAGTTGAAAT 917 TTCAGG 2531
CJMLST_ST1_2131_2162_R TTGGTTCTTACTTGTTTTGCATAAACTT 1417 TCCA 2532
CJMLST_ST1_655_685_R TATTGCTTTTTTTGCTATGCTTCTTGGA 942 CAT 2564
GLTA_NC002163-1604930- TTTTGCTCATGATCTGCATGAAGCATAAA 1443
1604529_352_380_R 2565 UNCA_NC002163-112166-
TCGACCTGGAGGACGACGTAAAATCA 1065 112647_146_171_R 2566
UNCA_NC002163-112166- TGGGATAACATTGGTTGGAATATAAGCA 1285
112647_294_329_R GAAACATC 2567 PGM_NC002163-327773-
TCCATCGCCAGTTTTTGCATAATCGCTA 1012 328270_365_396_R AAAA 2568
TKT_NC002163-1569415- TCAAAACGCATTTTTACATCTTCGTTAA 946
1569873_350_383_R AGGCTA 2570 GLTA_NC002163-1604930-
TGTTCATGTTTAAATGATCAGGATAAAA 1347 1604529_109_142_R AGCACT 2571
TKT_NC002163-1569415- TGCCATAGCAAAGCCTACAGCATT 1214
1569903_139_162_R 2572 TKT_NC002163-1569415-
TACATCTCCTTCGATAGAAATTTCATTG 886 1569903_313_345_R CTATC 2573
TKT_NC002163-1569415- TAAGACAAGGTTTTGTGGATTTTTTAGC 865
1569903_449_481_R TTGTT 2574 TKT_NC002163-1569415-
TTGCCATAGCAAAGCCTACAGCATT 1405 1569903_139_163_R 2575
GLTA_NC002163-1604930- TGCCATTTCCATGTACTCTTCTCTAACA 1216
1604529_139_168_R TT 2576 GLYA_NC002163-367572-
ATTGCTTCTTACTTGCTTAGCATAAATT 756 368079_476_508_R TTCCA 2577
GLYA_NC002163-367572- TGCTCACCTGCTACAACAAGTCCAGCAAT 1246
368079_242_270_R 2578 GLYA_NC002163-367572-
TTCCACCTTGGATACCTGGAAAAATAGC 1381 368079_384_416_R TGAAT 2579
GLYA_NC002163-367572- TCAAGCTCTACACCATAAAAAAAGCTCT 961
368079_52_81_R CA 2580 PGM_NC002163-327746-
TTTGCTCTCCGCCAAAGTTTCCAC 1438 328270_356_379_R 2581
PGM_NC002163-327746- TGCCCCATTGCTCATGATAGTAGCTAC 1219
328270_241_267_R 2582 PGM_NC002163-327746- TGCACGCAAACGCTTTACTTCAGC
1200 328270_79_102_R 2583 UNCA_NC002163-112166-
TGCCCTTTCTAAAAGTCTTGAGTGAAGA 1220 112647_196_225_R TA 2584
UNCA_NC002163-112166- TGCATGCTTACTCAAATCATCATAAACA 1206
112647_88_123_R ATTAAAGC 2585 ASPA_NC002163-96692-
TGCAAAAGTAACGGTTACATCTGCTCCA 1192 97166_403_432_R AT 2586
ASPA_NC002163-96692- TCATGATAGAACTACCTGGTTGCATTTT 991
97166_316_346_R TGG 2587 GLNA_NC002163-658085-
TGAGTTTGAACCATTTCAGAGCGAATAT 1176 657609_340_371_R CTAC 2588
TKT_NC002163-1569415- TCCCCATCTCCGCAAAGACAATAAA 1020
1569903_212_236_R 2589 TKT_NC002163-1569415-
TCCTTGTGCTTCAAAACGCATTTTTACA 1057 1569903_361_393_R TTTTC 2590
GLYA_NC002163-367572- TCCTCTTGGGCCACGCAAAGTTTT 1047
368095_317_340_R 2591 GLYA_NC002163-367572-
TCTTGAGCATTGGTTCTTACTTGTTTTG 1141 368095_485_516_R CATA 2592
PGM_NC002163_116_142_R TCAAACGATCCGCATCACCATCAAAAG 949 2593
PGM_NC002163_247_277_R TCCCCTTTAAAGCACCATTACTCATTAT 1023 AGT 2594
GLNA_NC002163-658085- TCAAAAACAAAGAATTCATTTTCTGGTC 945
657609_148_179_R CAAA 2595 ASPA_NC002163-96685-
TCAAGCTATATGCTACAACTGGTTCAAA 960 97196_467_497_R AAC 2596
ASPA_NC002163-96685- TACAACCTTCGGATAATCAGGATGAGAA 880
97196_95_127_R TTAAT 2597 ASPA_NC002163-96685-
TAAGCTCCCGTATCTTGAGTCGCCTC 872 97196_185_210_R 2598
PGM_NC002163-327746- TCACGATCTAAATTTGGATAAGCCATAG 975
328270_230_261_R GAAA 2599 PGM_NC002163-327746-
TTTTGCTCATGATCTGCATGAAGCATAAA 1443 328270_353_381_R 2600
PGM_NC002163-327746- TGATAAAAAGCACTAAGCGATGAAACAGC 1178
328270_95_123_R 2601 PGM_NC002163-327746-
TCAAGTGCTTTTACTTCTATAGGTTTAA 963 328270_314_345_R GCTC 2602
UNCA_NC002163-112166- TGCTTGCTCTTTCAAGCAGTCTTGAATG 1258
112647_199_229_R AAG 2603 UNCA_NC002163-112166-
TCCGAAACTTGTTTTGTAGCTTTAATTT 1031 112647_430_461_R GAGC 2734
GYRA_AY291534_268_288_R TTGCGCCATACGTACCATCGT 1407 2735
GYRA_AY291534_256_285_R TGCCATACGTACCATCGTTTCATAAACA 1213 GC 2736
GYRA_AY291534_268_288_R TTGCGCCATACGTACCATCGT 1407 2737
GYRA_AY291534_319_346_R TATCGACAGATCCAAAGTTACCATGCCC 935 2738
GYRA_NC002953-7005- TCTTGAGCCATACGTACCATTGC 1142 9668_265_287_R
2739 GYRA_NC002953-7005- TATCCATTGAACCAAAGTTACCTTGGCC 933
9668_316_343_R 2740 GYRA_NC002953-7005-
TAGCCATACGTACCATTGCTTCATAAAT 912 9668_253_283_R AGA 2741
GYRA_NC002953-7005- TCTTGAGCCATACGTACCATTGC 1142 9668_265_287_R
2842 CAPC_AF188935-56074- TGGTAACCCTTGTCTTTGAATTGTATTT 1299
55628_348_378_R GCA 2843 CAPC_AF188935-56074-
TGTAACCCTTGTCTTTGAATpTpGTATp 1314 55628_349_377P_R TpTpGC 2844
CAPC_AF188935-56074- TGTTAATGGTAACCCTTGTCTTTGAATT 1344
55628_349_384_R GTATTTGC
2845 CAPC_AF188935-56074- TAACCCTTGTCTTTGAATTGTATTTGCA 860
55628_337_375_R ATTAATCCTGG 2846 PARC_X95819_121_153_R
TAAAGGATAGCGGTAACTAAATGGCTGA 852 GCCAT 2847 PARC_X95819_157_178_R
TACCCCAGTTCCCCTGACCTTC 889 2848 PARC_X95819_97_128_R
TGAGCCATGAGTACCATGGCTTCATAAC 1169 ATGC 2849 PARC_NC003997-3362578-
TCCAAGTTTGACTTAAACGTACCATCGC 1001 3365001_256_283_R 2850
PARC_NC003997-3362578- TCGTCAACACTACCATTATTACCATGCA 1099
3365001_304_335_R TCTC 2851 PARC_NC003997-3362578-
TGACTTAAACGTACCATCGCTTCATATA 1162 3365001_244_275_R CAGA 2852
GYRA_AY642140_71_100_R TGCTAAAGTCTTGAGCCATACGAACAAT 1242 GG 2853
GYRA_AY642140_121_146_R TCGATCGAACCGAAGTTACCCTGACC 1069 2854
GYRA_AY642140_58_89_R TGAGCCATACGAACAATGGTTTCATAAA 1168 CAGC 2860
CYA_AF065404_1448_1472_R TCAGCTGTTAACGGCTTCAAGACCC 983 2861
LEF_BA_AF065404_843_881_R TCTTTAAGTTCTTCCAAGGATAGATTTA 1144
TTTCTTGTTCG 2862 LEF_BA_AF065404_843_881_R
TCTTTAAGTTCTTCCAAGGATAGATTTA 1144 TTTCTTGTTCG 2917
MUTS_AY698802_172_193_R TGCGGTCTGGCGCATATAGGTA 1237 2918
MUTS_AY698802_228_252_R TCAATCTCGACTTTTTGTGCCGGTA 965 2919
MUTS_AY698802_314_342_R TCGGTTTCAGTCATCTCCACCATAAAGGT 1097 2920
MUTS_AY698802_413_433_R TGCCAGCGACAGACCATCGTA 1210 2921
MUTS_AY698802_497_519_R TCCGGTAACTGGGTCAGCTCGAA 1040 2922
AB_MLST-11- TAGTATCACCACGTACACCCGGATCAGT 923 OIF007_1110_1137_R
2927 GAPA_NC_002505_29_58_R_1 TCCTTTATGCAACTTGGTATCAACAGGA 1060 AT
2928 GAPA_NC002505_769_798_2_R TCCTTTATGCAACTTGGTATCAACCGGA 1061 AT
2929 GAPA_NC002505_769_798_3_R TCCTTTATGCAACTTAGTATCAACCGGA 1059 AT
2932 INFB_EC_1439_1468_R TTGCTGCTTTCGCATGGTTAATCGCTTC 1410 AA 2933
INFB_EC_1439_1468_R TTGCTGCTTTCGCATGGTTAATCGCTTC 1410 AA 2934
INFB_EC_1439_1468_R TTGCTGCTTTCGCATGGTTAATCGCTTC 1410 AA 2949
ACS_NC002516-970624- TGGACCACGCCGAAGAACGG 1265 971013_364_383_R
2950 ARO_NC002516-26883- TGTGTTGTCGCCGCGCAG 1341 27380_111_128_R
2951 ARO_NC002516-26883- TCCTTGGCATACATCATGTCGTAGCA 1056
27380_459_484_R 2952 GUA_NC002516-4226546- TCGGCGAACATGGCCATCAC
1091 4226174_127_146_R 2953 GUA_NC002516-4226546-
TGCTTCTCTTCCGGGTCGGC 1256 4226174_214_233_R 2954
GUA_NC002516-4226546- TGCTTGGTGGCTTCTTCGTCGAA 1259
4226174_265_287_R 2955 GUA_NC002516-4226546- TGCGAGGAACTTCACGTCCTGC
1229 4226174_288_309_R 2956 GUA_NC002516-4226546- TCGTGGGCCTTGCCGGT
1111 4226174_355_371_R 2957 MUT_NC002516-5551158-
TCACGGGCCAGCTCGTCT 978 5550717_99_116_R 2958 MUT_NC002516-5551158-
TCACCATGCGCCCGTTCACATA 971 5550717_256_277_R 2959
NUO_NC002516-2984589- TCGGTGGTGGTAGCCGATCTC 1095 2984954_97_117_R
2960 NUO_NC002516-2984589- TTCAGGTACAGCAGGTGGTTCAGGAT 1376
2984954_301_326_R 2961 PPS_NC002516-1915014-
TCCATTTCCGACACGTCGTTGATCAC 1014 1915383_140_165_R 2962
PPS_NC002516-1915014- TCCTGGCCATCCTGCAGGAT 1052 1915383_341_360_R
2963 TRP_NC002516-671831- TCGATCTCCTTGGCGTCCGA 1071
672273_131_150_R 2964 TRP_NC002516-671831- TGATCTCCATGGCGCGGATCTT
1182 672273_362_383_R 2972 AB_MLST-11- TAGTATCACCACGTACICCIGGATCAGT
924 OIF007_1126_1153_R 2993 OMPU_NC002505_544_567_R
TCGGTCAGCAAAACGGTAGCTTGC 1094 2994 GAPA_NC002505-506780-
TTTTCCCTTTATGCAACTTAGTATCAAC 1442 507937_769_802_R IGGAAT 2995
GAPA_NC002505-506780- TCCATACCTTTATGCAACTTIGTATCAA 1008
507937_769_803_R CIGGAAT 2996 GAPA_NC002505-506780-
TCGGAAATATTCTTTCAATACCTTTATG 1085 507937_785_817_R CAACT 2997
GAPA_NC002505-506780- TCGGAAATATTCTTTCAATACCTTTATG 1085
507937_785_817_R CAACT 2998 GAPA_NC002505-506780-
TCGGAAATATTCTTTCAATICCTTTITG 1087 507937_784_817_R CAACTT 2999
GAPA_NC002505-506780- TCGGAAATATTCTTTCAATACCTTTATG 1086
507937_784_817_2_R CAACTT 3000 GAPA_NC002505-506780-
TTTCAATACCTTTATGCAACTTIGTATC 1430 507937_769_805_R AACIGGAAT 3001
CTXB_NC002505-1566967- TCCCGGCTAGAGATTCTGTATACGA 1026
1567341_139_163_R 3002 CTXB_NC002505-1566967-
TCCGGCTAGAGATTCTGTATACGAAAAT 1038 1567341_132_162_R ATC 3003
CTXB_NC002505-1566967- TGCCGTATACGAAAATATCTTATCATTT 1225
1567341_118_150_R AGCGT 3004 TUFB_NC002758-615038-
TCAGCGTAGTCTAATAATTTACGGAACA 982 616222_778_809_R TTTC 3005
TUFB_NC002758-615038- TGCTTCAGCGTAGTCTAATAATTTACGG 1255
616222_783_813_R AAC 3006 TUFB_NC002758-615038-
TGCGTAGTCTAATAATTTACGGAACATT 1238 616222_778_807_R TC 3007
TUFB_NC002758-615038- TGCGTAGTCTAATAATTTACGGAACATT 1238
616222_778_807_R TC 3008 TUFB_NC002758-615038-
TCACCAGCTTCAGCGTAGTCTAATAATT 970 616222_785_818_R TACGGA 3009
TUFB_NC002758-615038- TCTTCAGCGTAGTCTAATAATTTACGGA 1134
616222_778_812_R ACATTTC 3010 MECI-R_NC003923-41798-
TGTGATATGGAGGTGTAGAAGGTG 1332 41609_89_112_R 3011
MECI-R_NC003923-41798- TGGGATGGAGGTGTAGAAGGTGTTATCA 1287
41609_81_110_R TC 3012 MECI-R_NC003923-41798-
TGGGATGGAGGTGTAGAAGGTGTTATCA 1286 41609_81_110_R TC 3013
MECI-R_NC003923-41798- TGGGGATATGGAGGTGTAGAAGGTGTTA 1290
41609_81_113_R TCATC 3014 MUPR_X75439_2548_2570_R
TCTGGCTGCGGAAGTGAAATCGT 1130 3015 MUPR_X75439_2547_2568_R
TGGCTGCGGAAGTGAAATCGTA 1281 3016 MUPR_X75439_2551_2573_R
TAATCTGGCTGCGGAAGTGAAAT 876 3017 MUPR_X75439_2549_2573_R
TAATCTGGCTGCGGAAGTGAAATCG 877 3018 MUPR_X75439_2559_2589_R
TGGTATATTCGTTAATTAATCTGGCTGC 1303 GGA 3019 MUPR_X75439_2554_2581_R
TCGTTAATTAATCTGGCTGCGGAAGTGA 1112 3020 AROE_NC003923-1674726-
TAAGCAATACCTTTACTTGCACCACCT 868 1674277_309_335_R 3021
AROE_NC003923-1674726- TTCATAAGCAATACCTTTACTTGCACCAC 1378
1674277_311_339_R 3022 AROE_NC003923-1674726-
TAAGCAATACCpTpTpTpACTpTpGCpA 867 1674277_311_335P_R CpCpAC 3023
ARCC_NC003923-2725050- TCTTCTTCTTTCGTATAAAAAGGACCAA 1137
2724595_214_245_R TTGG 3024 ARCC_NC003923-2725050-
TCTTCTTTCGTATAAAAAGGACCAATTG 1139 2724595_212_242_R GTT 3025
ARCC_NC003923-2725050- TGCGCTAATTCTTCAACTTCTTCTTTCGT 1232
2724595_232_260_R 3026 PTA_NC003923-628885-
TGTTCTTGATACACCTGGTTTCGTTTTG 1350 629355_322_351_R AT 3027
PTA_NC003923-628885- TGGTACACCTGGTTTCGTTTTGATGATT 1301
629355_314_345_R TGTA 3028 PTA_NC003923-628885-
TGTTCTTGATACACCTGGTTTCGTTTTG 1350 629355_322_351_R AT
[0371] Primer pair name codes and reference sequences are shown in
Table 3. The primer name code typically represents the gene to
which the given primer pair is targeted. The primer pair name may
include specific coordinates with respect to a reference sequence
defined by an extraction of a section of sequence or defined by a
GenBank gi number, or the corresponding complementary sequence of
the extraction, or the entire GenBank gi number as indicated by the
label "no extraction." Where "no extraction" is indicated for a
reference sequence, the coordinates of a primer pair named to the
reference sequence are with respect to the GenBank gi listing. Gene
abbreviations are shown in bold type in the "Gene Name" column.
[0372] To determine the exact primer hybridization coordinates of a
given pair of primers on a given bioagent nucleic acid sequence and
to determine the sequences, molecular masses and base compositions
of an amplification product to be obtained upon amplification of
nucleic acid of a known bioagent with known sequence information in
the region of interest with a given pair of primers, one with
ordinary skill in bioinformatics is capable of obtaining alignments
of the primers of the present invention with the GenBank gi number
of the relevant nucleic acid sequence of the known bioagent. For
example, the reference sequence GenBank gi numbers (Table 3)
provide the identities of the sequences which can be obtained from
GenBank. Alignments can be done using a bioinformatics tool such as
BLASTn provided to the public by NCBI (Bethesda, Md.).
Alternatively, a relevant GenBank sequence may be downloaded and
imported into custom programmed or commercially available
bioinformatics programs wherein the alignment can be carried out to
determine the primer hybridization coordinates and the sequences,
molecular masses and base compositions of the amplification
product. For example, to obtain the hybridization coordinates of
primer pair number 2095 (SEQ ID NOs: 456:1261), First the forward
primer (SEQ ID NO: 456) is subjected to a BLASTn search on the
publicly available NCBI BLAST website. "RefSeq_Genomic" is chosen
as the BLAST database since the gi numbers refer to genomic
sequences. The BLAST query is then performed. Among the top results
returned is a match to GenBank gi number 21281729 (Accession Number
NC.sub.--003923). The result shown below, indicates that the
forward primer hybridizes to positions 1530282 . . . 1530307 of the
genomic sequence of Staphylococcus aureus subsp. aureus MW2
(represented by gi number 21281729).
Staphylococcus aureus subsp. aureus MW2, complete genome
Length=2820462
[0373] Features in this part of subject sequence: [0374]
Panton-Valentine leukocidin chain F precursor
[0375] Score=52.0 bits (26), Expect=2e-05
[0376] Identities=26/26 (100%), Gaps=0/26 (0%)
[0377] Strand=Plus/Plus
##STR00001##
[0378] The hybridization coordinates of the reverse primer (SEQ ID
NO: 1261) can be determined in a similar manner and thus, the
bioagent identifying amplicon can be defined in terms of genomic
coordinates. The query/subject arrangement of the result would be
presented in Strand=Plus/Minus format because the reverse strand
hybridizes to the reverse complement of the genomic sequence. HThe
preceding sequence analyses are well known to one with ordinary
skill in bioinformatics and thus, Table 3 contains sufficient
information to determine the primer hybridization coordinates of
any of the primers of Table 2 to the applicable reference sequences
described therein.
TABLE-US-00003 TABLE 3 Primer Name Codes and Reference Sequences
Reference GenBank gi Primer name code Gene Name Organism number
16S_EC 16S rRNA (16S ribosomal RNA gene) Escherichia coli 16127994
23S_EC 23S rRNA (23S ribosomal RNA gene) Escherichia coli 16127994
CAPC_BA capC (capsule biosynthesis gene) Bacillus anthracis 6470151
CYA_BA cya (cyclic AMP gene) Bacillus anthracis 4894216 DNAK_EC
dnaK (chaperone dnaK gene) Escherichia coli 16127994 GROL_EC groL
(chaperonin groL) Escherichia coli 16127994 HFLB_EC hflb (cell
division protein peptidase Escherichia coli 16127994 ftsH) INFB_EC
infB (protein chain initiation factor Escherichia coli 16127994
infB gene) LEF_BA lef (lethal factor) Bacillus anthracis 21392688
PAG_BA pag (protective antigen) Bacillus anthracis 21392688 RPLB_EC
rplB (50S ribosomal protein L2) Escherichia coli 16127994 RPOB_EC
rpoB (DNA-directed RNA polymerase beta Escherichia coli 6127994
chain) RPOC_EC rpoC (DNA-directed RNA polymerase Escherichia coli
16127994 beta' chain) SP101ET_SPET_11 Artificial Sequence
Concatenation Artificial 15674250 comprising: Sequence*-- gki
(glucose kinase) partial gene gtr (glutamine transporter protein)
sequences of murI (glutamate racemase) Streptococcus mutS (DNA
mismatch repair protein) pyogenes xpt (xanthine phosphoribosyl
transferase) yqiL (acetyl-CoA-acetyl transferase) tkt
(transketolase) SSPE_BA sspE (small acid-soluble spore Bacillus
anthracis 30253828 protein) TUFB_EC tufB (Elongation factor Tu)
Escherichia coli 16127994 VALS_EC valS (Valyl-tRNA synthetase)
Escherichia coli 16127994 ASPS_EC aspS (Aspartyl-tRNA synthetase)
Escherichia coli 16127994 CAF1_AF053947 caf1 (capsular protein
caf1) Yersinia pestis 2996286 INV_U22457 inv (invasin) Yersinia
pestis 1256565 LL_NC003143 Y. pestis specific chromosomal genes -
Yersinia pestis 16120353 difference region BONTA_X52066 BoNT/A
(neurotoxin type A) Clostridium 40381 botulinum MECA_Y14051 mecA
methicillin resistance gene Staphylococcus 2791983 aureus
TRPE_AY094355 trpE (anthranilate synthase (large Acinetobacter
20853695 component)) baumanii RECA_AF251469 recA (recombinase A)
Acinetobacter 9965210 baumanii GYRA_AF100557 gyrA (DNA gyrase
subunit A) Acinetobacter 4240540 baumanii GYRB_AB008700 gyrB (DNA
gyrase subunit B) Acinetobacter 4514436 baumanii WAAA_Z96925 waaA
(3-deoxy-D-manno-octulosonic-acid Acinetobacter 2765828
transferase) baumanii CJST_CJ Artificial Sequence Concatenation
Artificial 15791399 comprising: Sequence*-- tkt (transketolase)
partial gene glyA (serine hydroxymethyltransferase) sequences of
gltA (citrate synthase) Campylobacter aspA (aspartate ammonia
lyase) jejuni glnA (glutamine synthase) pgm (phosphoglycerate
mutase) uncA (ATP synthetase alpha chain) RNASEP_BDP RNase P
(ribonuclease P) Bordetella 33591275 pertussis RNASEP_BKM RNase P
(ribonuclease P) Burkholderia 53723370 mallei RNASEP_BS RNase P
(ribonuclease P) Bacillus subtilis 16077068 RNASEP_CLB RNase P
(ribonuclease P) Clostridium 18308982 perfringens RNASEP_EC RNase P
(ribonuclease P) Escherichia coli 16127994 RNASEP_RKP RNase P
(ribonuclease P) Rickettsia 15603881 prowazekii RNASEP_SA RNase P
(ribonuclease P) Staphylococcus 15922990 aureus RNASEP_VBC RNase P
(ribonuclease P) Vibrio cholerae 15640032 ICD_CXB icd (isocitrate
dehydrogenase) Coxiella burnetii 29732244 IS1111A multi-locus
IS1111A insertion element Acinetobacter 29732244 baumannii
OMPA_AY485227 ompA (outer membrane protein A) Rickettsia 40287451
prowazekii OMPB_RKP ompB (outer membrane protein B) Rickettsia
15603881 prowazekii GLTA_RKP gltA (citrate synthase) Vibrio
cholerae 15603881 TOXR_VBC toxR (transcription regulator toxR)
Francisella 15640032 tularensis ASD_FRT asd (Aspartate semialdehyde
Francisella 56707187 dehydrogenase) tularensis GALE_FRT galE
(UDP-glucose 4-epimerase) Shigella flexneri 56707187 IPAH_SGF ipaH
(invasion plasmid antigen) Campylobacter 30061571 jejuni HUPB_CJ
hupB (DNA-binding protein Hu-beta) Coxiella burnetii 15791399
AB_MLST Artificial Sequence Concatenation Artificial Sequenced
comprising: Sequence*-- in-house trpE (anthranilate synthase
component partial gene (SEQ ID I)) seguences of NO: 1444) adk
(adenylate kinase) Acinetobacter mutY (adenine glycosylase)
baumannii fumC (fumarate hydratase) efp (elongation factor p) ppa
(pyrophosphate phospho- hydratase MUPR_X75439 mupR (mupriocin
resistance gene) Staphylococcus 438226 aureus PARC_X95819 parC
(topoisomerase IV) Acinetobacter 1212748 baumannii SED_M28521 sed
(enterotoxin D) Staphylococcus 1492109 aureus PLA_AF053945 pla
(plasminogen activator) Yersinia pestis 2996216 SEJ_AF053140 sej
(enterotoxin J) Staphylococcus 3372540 aureus GYRA_NC000912 gyrA
(DNA gyrase subunit A) Mycoplasma 13507739 pneumoniae ACS_NC002516
acsA (Acetyl CoA Synthase) Pseudomonas 15595198 aeruginosa
ARO_NC002516 aroE (shikimate 5-dehydrogenase Pseudomonas 15595198
aeruginosa GUA_NC002516 guaA (GMP synthase) Pseudomonas 15595198
aeruginosa MUT_NC002516 mutL (DNA mismatch repair protein)
Pseudomonas 15595198 aeruginosa NUO_NC002516 nuoD (NADH
dehydrogenase I chain C, D) Pseudomonas 15595198 aeruginosa
PPS_NC002516 ppsA (Phosphoenolpyruvate synthase) Pseudomonas
15595198 aeruginosa TRP_NC002516 trpE (Anthranilate synthetase
Pseudomonas 15595198 component I) aeruginosa OMP2_NC000117 ompB
(outer membrane protein B) Chlamydia 15604717 trachomatis
OMPA_NC000117 ompA (outer membrane protein B) Chlamydia 15604717
trachomatis GYRA_NC000117 gyrA (DNA gyrase subunit A) Chlamydia
15604717 trachomatis CTXA_NC002505 ctxA (Cholera toxin A subunit)
Vibrio cholerae 15640032 CTXB_NC002505 ctxB (Cholera toxin B
subunit) Vibrio cholerae 15640032 FUR_NC002505 fur (ferric uptake
regulator protein) Vibrio cholerae 15640032 GAPA_NC_002505 gapA
(glyceraldehyde-3-phosphate Vibrio cholerae 15640032 dehydrogenase)
GYRB_NC002505 gyrB (DNA gyrase subunit B) Vibrio cholerae 15640032
OMPU_NC002505 ompU (outer membrane protein) Vibrio cholerae
15640032 TCPA_NC002505 tcpA (toxin-coregulated pilus) Vibrio
cholerae 15640032 ASPA_NC002163 aspA (aspartate ammonia lyase)
Campylobacter 15791399 jejuni GLNA_NC002163 glnA (glutamine
synthetase) Campylobacter 15791399 jejuni GLTA_NC002163 gltA
(glutamate synthase) Campylobacter 15791399 jejuni GLYA_NC002163
glyA (serine hydroxymethyltransferase) Campylobacter 15791399
jejuni PGM_NC002163 pgm (phosphoglyceromutase) Campylobacter
15791399 jejuni TKT_NC002163 tkt (transketolase) Campylobacter
15791399 jejuni UNCA_NC002163 uncA (ATP synthetase alpha chain)
Campylobacter 15791399 jejuni AGR-III_NC003923 agr-III (accessory
gene regulator-III) Staphylococcus 21281729 aureus ARCC_NC003923
arcC (carbamate kinase) Staphylococcus 21281729 aureus
AROE_NC003923 aroE (shikimate 5-dehydrogenase Staphylococcus
21281729 aureus BSA-A_NC003923 bsa-a (glutathione peroxidase)
Staphylococcus 21281729 aureus BSA-B_NC003923 bsa-b (epidermin
biosynthesis protein Staphylococcus 21281729 EpiB) aureus
GLPF_NC003923 glpF (glycerol transporter) Staphylococcus 21281729
aureus GMK_NC003923 gmk (guanylate kinase) Staphylococcus 21281729
aureus MECI-R_NC003923 mecR1 (truncated methicillin Staphylococcus
21281729 resistance protein) aureus PTA_NC003923 pta (phosphate
acetyltransferase) Staphylococcus 21281729 aureus PVLUK_NC003923
pvluk (Panton-Valentine leukocidin Staphylococcus 21281729 chain F
precursor) aureus SA442_NC003923 sa442 gene Staphylococcus 21281729
aureus SEA_NC003923 sea (staphylococcal enterotoxin A
Staphylococcus 21281729 precursor) aureus SEC_NC003923 sec4
(enterotoxin type C precursor) Staphylococcus 21281729 aureus
TPI_NC003923 tpi (triosephosphate isomerase) Staphylococcus
21281729 aureus YQI_NC003923 yqi (acetyl-CoA C-acetyltransferase
Staphylococcus 21281729 homologue) aureus GALE_AF513299 galE
(galactose epimerase) Francisella 23506418 tularensis VVHA_NC004460
vVhA (cytotoxin, cytolysin precursor) Vibrio vulnificus 27366463
TDH_NC004605 tdh (thermostable direct hemolysin A) Vibrio 28899855
parahaemolyticus AGR-II_NC002745 agr-II (accessory gene
regulator-II) Staphylococcus 29165615 aureus PARC_NC003997 parC
(topoisomerase IV) Bacillus anthracis 30260195 GYRA_AY291534 gyrA
(DNA gyrase subunit A) Bacillus anthracis 31323274 AGR-I_AJ617706
agr-I (accessory gene regulator-I) Staphylococcus 46019543 aureus
AGR-IV_AJ617711 agr-IV (accessory gene regulator-III)
Staphylococcus 46019563 aureus BLAZ_NC002952 blaZ (beta lactamase
III) Staphylococcus 49482253 aureus ERMA_NC002952 ermA (rRNA
methyltransferase A) Staphylococcus 49482253 aureus ERMB_Y13600
ermB (rRNA methyltransferase B) Staphylococcus 49482253 aureus
SEA-SEE_NC002952 sea (staphylococcal enterotoxin A Staphylococcus
49482253 precursor) aureus SEA-SEE_NC002952 sea (staphylococcal
enterotoxin A Staphylococcus 49482253 precursor) aureus
SEE_NC002952 sea (staphylococcal enterotoxin A Staphylococcus
49482253 precursor) aureus SEH_NC002953 seh (staphylococcal
enterotoxin H) Staphylococcus 49484912 aureus ERMC_NC005908 ermC
(rRNA methyltransferase C) Staphylococcus 49489772 aureus
MUTS_AY698802 mutS (DNA mismatch repair protein) Shigella boydii
52698233 NUC_NC002758 nuc (staphylococcal nuclease) Staphylococcus
57634611 aureus SEB_NC002758 seb (enterotoxin type B precursor)
Staphylococcus 57634611 aureus SEG_NC002758 seg (staphylococcal
enterotoxin G) Staphylococcus 57634611 aureus SEI_NC002758 sei
(staphylococcal enterotoxin I) Staphylococcus 57634611 aureus
TSST_NC002758 tsst (toxic shock syndrome toxin-1) Staphylococcus
57634611 aureus TUFB_NC002758 tufB (Elongation factor Tu)
Staphylococcus 57634611 aureus Note: artificial reference sequences
represent concatenations of partial gene extractions from the
indicated reference gi number. Partial sequences were used to
create the concatenated sequence because complete gene sequences
were not necessary for primer design.
Example 2
Sample Preparation and PCR
[0379] Genomic DNA was prepared from samples using the DNeasy
Tissue Kit (Qiagen, Valencia, Calif.) according to the
manufacturer's protocols.
[0380] All PCR reactions were assembled in 50 .mu.l reaction
volumes in a 96-well microtiter plate format using a Packard MPH
liquid handling robotic platform and M.J. Dyad thermocyclers (MJ
research, Waltham, Mass.) or Eppendorf Mastercycler thermocyclers
(Eppendorf, Westbury, N.Y.). The PCR reaction mixture consisted of
4 units of Amplitaq Gold, 1.times. buffer II (Applied Biosystems,
Foster City, Calif.), 1.5 mM MgCl.sub.2, 0.4 M betaine, 800 .mu.M
dNTP mixture and 250 nM of each primer. The following typical PCR
conditions were used: 95.degree. C. for 10 min followed by 8 cycles
of 95.degree. C. for 30 seconds, 48.degree. C. for 30 seconds, and
72.degree. C. 30 seconds with the 48.degree. C. annealing
temperature increasing 0.9.degree. C. with each of the eight
cycles. The PCR was then continued for 37 additional cycles of
95.degree. C. for 15 seconds, 56.degree. C. for 20 seconds, and
72.degree. C. 20 seconds.
Example 3
Purification of PCR Products for Mass Spectrometry with Ion
Exchange Resin-Magnetic Beads
[0381] For solution capture of nucleic acids with ion exchange
resin linked to magnetic beads, 25 .mu.l of a 2.5 mg/mL suspension
of BioClone amine terminated superparamagnetic beads were added to
25 to 50 .mu.l of a PCR (or RT-PCR) reaction containing
approximately 10 .mu.M of a typical PCR amplification product. The
above suspension was mixed for approximately 5 minutes by vortexing
or pipetting, after which the liquid was removed after using a
magnetic separator. The beads containing bound PCR amplification
product were then washed three times with 50 mM ammonium
bicarbonate/50% MeOH or 100 mM ammonium bicarbonate/50% MeOH,
followed by three more washes with 50% MeOH. The bound PCR amplicon
was eluted with a solution of 25 mM piperidine, 25 mM imidazole,
35% MeOH which included peptide calibration standards.
Example 4
Mass Spectrometry and Base Composition Analysis
[0382] The ESI-FTICR mass spectrometer is based on a Bruker
Daltonics (Billerica, Mass.) Apex II 70e electrospray ionization
Fourier transform ion cyclotron resonance mass spectrometer that
employs an actively shielded 7 Tesla superconducting magnet. The
active shielding constrains the majority of the fringing magnetic
field from the superconducting magnet to a relatively small volume.
Thus, components that might be adversely affected by stray magnetic
fields, such as CRT monitors, robotic components, and other
electronics, can operate in close proximity to the FTICR
spectrometer. All aspects of pulse sequence control and data
acquisition were performed on a 600 MHz Pentium II data station
running Bruker's Xmass software under Windows NT 4.0 operating
system. Sample aliquots, typically 15 .mu.l, were extracted
directly from 96-well microtiter plates using a CTC HTS PAL
autosampler (LEAP Technologies, Carrboro, N.C.) triggered by the
FTICR data station. Samples were injected directly into a 10 .mu.l
sample loop integrated with a fluidics handling system that
supplies the 100 .mu.l/hr flow rate to the ESI source. Ions were
formed via electrospray ionization in a modified Analytica
(Branford, Conn.) source employing an off axis, grounded
electrospray probe positioned approximately 1.5 cm from the
metalized terminus of a glass desolvation capillary. The
atmospheric pressure end of the glass capillary was biased at 6000
V relative to the ESI needle during data acquisition. A
counter-current flow of dry N.sub.2 was employed to assist in the
desolvation process. Ions were accumulated in an external ion
reservoir comprised of an rf-only hexapole, a skimmer cone, and an
auxiliary gate electrode, prior to injection into the trapped ion
cell where they were mass analyzed. Ionization duty cycles greater
than 99% were achieved by simultaneously accumulating ions in the
external ion reservoir during ion detection. Each detection event
consisted of 1M data points digitized over 2.3 s. To improve the
signal-to-noise ratio (S/N), 32 scans were co-added for a total
data acquisition time of 74 s.
[0383] The ESI-TOF mass spectrometer is based on a Bruker Daltonics
MicroTOF.TM.. Ions from the ESI source undergo orthogonal ion
extraction and are focused in a reflectron prior to detection. The
TOF and FTICR are equipped with the same automated sample handling
and fluidics described above. Ions are formed in the standard
MicroTOF.TM. ESI source that is equipped with the same off-axis
sprayer and glass capillary as the FTICR ESI source. Consequently,
source conditions were the same as those described above. External
ion accumulation was also employed to improve ionization duty cycle
during data acquisition. Each detection event on the TOF was
comprised of 75,000 data points digitized over 75 .mu.s.
[0384] The sample delivery scheme allows sample aliquots to be
rapidly injected into the electrospray source at high flow rate and
subsequently be electrosprayed at a much lower flow rate for
improved ESI sensitivity. Prior to injecting a sample, a bolus of
buffer was injected at a high flow rate to rinse the transfer line
and spray needle to avoid sample contamination/carryover. Following
the rinse step, the autosampler injected the next sample and the
flow rate was switched to low flow. Following a brief equilibration
delay, data acquisition commenced. As spectra were co-added, the
autosampler continued rinsing the syringe and picking up buffer to
rinse the injector and sample transfer line. In general, two
syringe rinses and one injector rinse were required to minimize
sample carryover. During a routine screening protocol a new sample
mixture was injected every 106 seconds. More recently a fast wash
station for the syringe needle has been implemented which, when
combined with shorter acquisition times, facilitates the
acquisition of mass spectra at a rate of just under one
spectrum/minute.
[0385] Raw mass spectra were post-calibrated with an internal mass
standard and deconvoluted to monoisotopic molecular masses.
Unambiguous base compositions were derived from the exact mass
measurements of the complementary single-stranded oligonucleotides.
Quantitative results are obtained by comparing the peak heights
with an internal PCR calibration standard present in every PCR well
at 500 molecules per well. Calibration methods are commonly owned
and disclosed in U.S. Provisional Patent Application Ser. No.
60/545,425 which is incorporated herein by reference in
entirety.
Example 5
De Novo Determination of Base Composition of Amplification Products
using Molecular Mass Modified Deoxynucleotide Triphosphates
[0386] Because the molecular masses of the four natural nucleobases
have a relatively narrow molecular mass range (A=313.058,
G=329.052, C=289.046, T=304.046--See Table 4), a persistent source
of ambiguity in assignment of base composition can occur as
follows: two nucleic acid strands having different base composition
may have a difference of about 1 Da when the base composition
difference between the two strands is GA (-15.994) combined with CT
(+15.000). For example, one 99-mer nucleic acid strand having a
base composition of A.sub.27G.sub.30C.sub.21T.sub.21 has a
theoretical molecular mass of 30779.058 while another 99-mer
nucleic acid strand having a base composition of
A.sub.26G.sub.31C.sub.22T.sub.20 has a theoretical molecular mass
of 30780.052. A 1 Da difference in molecular mass may be within the
experimental error of a molecular mass measurement and thus, the
relatively narrow molecular mass range of the four natural
nucleobases imposes an uncertainty factor.
[0387] The present invention provides for a means for removing this
theoretical 1 Da uncertainty factor through amplification of a
nucleic acid with one mass-tagged nucleobase and three natural
nucleobases. The term "nucleobase" as used herein is synonymous
with other terms in use in the art including "nucleotide,"
"deoxynucleotide," "nucleotide residue," "deoxynucleotide residue,"
"nucleotide triphosphate (NTP)," or deoxynucleotide triphosphate
(dNTP).
[0388] Addition of significant mass to one of the 4 nucleobases
(dNTPs) in an amplification reaction, or in the primers themselves,
will result in a significant difference in mass of the resulting
amplification product (significantly greater than 1 Da) arising
from ambiguities arising from the G A combined with CT event (Table
4). Thus, the same the GA (-15.994) event combined with 5-Iodo-CT
(-110.900) event would result in a molecular mass difference of
126.894. If the molecular mass of the base composition
A.sub.27G.sub.305-Iodo-C.sub.21T.sub.21 (33422.958) is compared
with A.sub.26G.sub.315-Iodo-C.sub.22T.sub.20, (33549.852) the
theoretical molecular mass difference is +126.894. The experimental
error of a molecular mass measurement is not significant with
regard to this molecular mass difference. Furthermore, the only
base composition consistent with a measured molecular mass of the
99-mer nucleic acid is A.sub.27G.sub.305-Iodo-C.sub.21T.sub.21. In
contrast, the analogous amplification without the mass tag has 18
possible base compositions.
TABLE-US-00004 TABLE 4 Molecular Masses of Natural Nucleobases and
the Mass-Modified Nucleobase 5-Iodo-C and Molecular Mass
Differences Resulting from Transitions .DELTA. Molecular Nucleobase
Molecular Mass Transition Mass A 313.058 A-->T -9.012 A 313.058
A-->C -24.012 A 313.058 A-->5-Iodo-C 101.888 A 313.058
A-->G 15.994 T 304.046 T-->A 9.012 T 304.046 T-->C -15.000
T 304.046 T-->5-Iodo-C 110.900 T 304.046 T-->G 25.006 C
289.046 C-->A 24.012 C 289.046 C-->T 15.000 C 289.046
C-->G 40.006 5-Iodo-C 414.946 5-Iodo-C-->A -101.888 5-Iodo-C
414.946 5-Iodo-C-->T -110.900 5-Iodo-C 414.946 5-Iodo-C-->G
-85.894 G 329.052 G-->A -15.994 G 329.052 G-->T -25.006 G
329.052 G-->C -40.006 G 329.052 G-->5-Iodo-C 85.894
[0389] Mass spectra of bioagent-identifying amplicons were analyzed
independently using a maximum-likelihood processor, such as is
widely used in radar signal processing. This processor, referred to
as GenX, first makes maximum likelihood estimates of the input to
the mass spectrometer for each primer by running matched filters
for each base composition aggregate on the input data. This
includes the GenX response to a calibrant for each primer.
[0390] The algorithm emphasizes performance predictions culminating
in probability-of-detection versus probability-of-false-alarm plots
for conditions involving complex backgrounds of naturally occurring
organisms and environmental contaminants. Matched filters consist
of a priori expectations of signal values given the set of primers
used for each of the bioagents. A genomic sequence database is used
to define the mass base count matched filters. The database
contains the sequences of known bacterial bioagents and includes
threat organisms as well as benign background organisms. The latter
is used to estimate and subtract the spectral signature produced by
the background organisms. A maximum likelihood detection of known
background organisms is implemented using matched filters and a
running-sum estimate of the noise covariance. Background signal
strengths are estimated and used along with the matched filters to
form signatures which are then subtracted. The maximum likelihood
process is applied to this "cleaned up" data in a similar manner
employing matched filters for the organisms and a running-sum
estimate of the noise-covariance for the cleaned up data.
[0391] The amplitudes of all base compositions of
bioagent-identifying amplicons for each primer are calibrated and a
final maximum likelihood amplitude estimate per organism is made
based upon the multiple single primer estimates. Models of all
system noise are factored into this two-stage maximum likelihood
calculation. The processor reports the number of molecules of each
base composition contained in the spectra. The quantity of
amplification product corresponding to the appropriate primer set
is reported as well as the quantities of primers remaining upon
completion of the amplification reaction.
[0392] Base count blurring can be carried out as follows.
"Electronic PCR" can be conducted on nucleotide sequences of the
desired bioagents to obtain the different expected base counts that
could be obtained for each primer pair. See for example,
ncbi.nlm.nih.gov/sutils/e-pcr/; Schuler, Genome Res. 7:541-50,
1997. In one illustrative embodiment, one or more spreadsheets,
such as Microsoft Excel workbooks contain a plurality of
worksheets. First in this example, there is a worksheet with a name
similar to the workbook name; this worksheet contains the raw
electronic PCR data. Second, there is a worksheet named "filtered
bioagents base count" that contains bioagent name and base count;
there is a separate record for each strain after removing sequences
that are not identified with a genus and species and removing all
sequences for bioagents with less than 10 strains. Third, there is
a worksheet, "Sheet 1" that contains the frequency of
substitutions, insertions, or deletions for this primer pair. This
data is generated by first creating a pivot table from the data in
the "filtered bioagents base count" worksheet and then executing an
Excel VBA macro. The macro creates a table of differences in base
counts for bioagents of the same species, but different strains.
One of ordinary skill in the art may understand additional pathways
for obtaining similar table differences without undo
experimentation.
[0393] Application of an exemplary script, involves the user
defining a threshold that specifies the fraction of the strains
that are represented by the reference set of base counts for each
bioagent. The reference set of base counts for each bioagent may
contain as many different base counts as are needed to meet or
exceed the threshold. The set of reference base counts is defined
by taking the most abundant strain's base type composition and
adding it to the reference set and then the next most abundant
strain's base type composition is added until the threshold is met
or exceeded. The current set of data was obtained using a threshold
of 55%, which was obtained empirically.
[0394] For each base count not included in the reference base count
set for that bioagent, the script then proceeds to determine the
manner in which the current base count differs from each of the
base counts in the reference set. This difference may be
represented as a combination of substitutions, Si=Xi, and
insertions, Ii=Yi, or deletions, Di=Zi. If there is more than one
reference base count, then the reported difference is chosen using
rules that aim to minimize the number of changes and, in instances
with the same number of changes, minimize the number of insertions
or deletions. Therefore, the primary rule is to identify the
difference with the minimum sum (Xi+yi) or (Xi+Zi), e.g., one
insertion rather than two substitutions: If there are two or more
differences with the minimum sum, then the one that will be
reported is the one that contains the most substitutions.
[0395] Differences between a base count and a reference composition
are categorized as one, two, or more substitutions, one, two, or
more insertions, one, two, or more deletions, and combinations of
substitutions and insertions or deletions. The different classes of
nucleobase changes and their probabilities of occurrence have been
delineated in U.S. Patent Application Publication No. 2004209260
(U.S. application Ser. No. 10/418,514) which is incorporated herein
by reference in entirety.
Example 6
Use of Broad Range Survey and Division Wide Primer Pairs for
Identification of Bacteria in an Epidemic Surveillance
Investigation
[0396] This investigation employed a set of 16 primer pairs which
is herein designated the "surveillance primer set" and comprises
broad range survey primer pairs, division wide primer pairs and a
single Bacillus clade primer pair. The surveillance primer set is
shown in Table 5 and consists of primer pairs originally listed in
Table 2. This surveillance set comprises primers with T
modifications (note TMOD designation in primer names) which
constitutes a functional improvement with regard to prevention of
non-templated adenylation (vide supra) relative to originally
selected primers which are displayed below in the same row. Primer
pair 449 (non-T modified) has been modified twice. Its predecessors
are primer pairs 70 and 357, displayed below in the same row.
Primer pair 360 has also been modified twice and its predecessors
are primer pairs 17 and 118.
TABLE-US-00005 TABLE 5 Bacterial Primer Pairs of the Surveillance
Primer Set Forward Reverse Primer Primer Primer Pair (SEQ ID (SEQ
ID No. Forward Primer Name NO:) Reverse Primer Name NO:) Target
Gene 346 16S_EC_713_732_TMOD_F 202 16S_EC_789_809_TMOD_R 1110 16S
rRNA 10 16S_EC_713_732_F 21 16S_EC_789_809 798 16S rRNA 347
16S_EC_785_806_TMOD_F 560 16S_EC_880_897_TMOD_R 1278 16S rRNA 11
16S_EC_785_806_F 118 16S_EC_880_897_R 830 16S rRNA 348
16S_EC_960_981_TMOD_F 706 16S_EC_1054_1073_TMOD_R 895 16S rRNA 14
16S_EC_960_981_F 672 16S_EC_1054_1073_R 735 16S rRNA 349
23S_EC_1826_1843_TMOD_F 401 23S_EC_1906_1924_TMOD_R 1156 23S rRNA
16 23S_EC_1826_1843_F 80 23S_EC_1906_1924_R 805 23S rRNA 352
INFB_EC_1365_1393_TMOD_F 687 INFB_EC_1439_1467_TMOD_R 1411 infB 34
INFB_EC_1365_1393_F 524 INFB_EC_1439_1467_R 1248 infB 354
RPOC_EC_2218_2241_TMOD_F 405 RPOC_EC_2313_2337_TMOD_R 1072 rpoC 52
RPOC_EC_2218_2241_F 81 RPOC_EC_2313_2337_R 790 rpoC 355
SSPE_BA_115_137_TMOD_F 255 SSPE_BA_197_222_TMOD_R 1402 sspE 58
SSPE_BA_115_137_F 45 SSPE_BA_197_222_R 1201 sspE 356
RPLB_EC_650_679_TMOD_F 232 RPLB_EC_739_762_TMOD_R 592 rplB 66
RPLB_EC_650_679_F 98 RPLB_EC_739_762_R 999 rplB 358
VALS_EC_1105_1124_TMOD_F 385 VALS_EC_1195_1218_TMOD_R 1093 valS 71
VALS_EC_1105_1124_F 77 VALS_EC_1195_1218_R 795 valS 359
RPOB_EC_1845_1866_TMOD_F 659 RPOB_EC_1909_1929_TMOD_R 1250 rpoB 72
RPOB_EC_1845_1866_F 233 RPOB_EC_1909_1929_R 825 rpoB 360
23S_EC_2646_2667_TMOD_F 409 23S_EC_2745_2765_TMOD_R 1434 23S rRNA
118 23S_EC_2646_2667_F 84 23S_EC_2745_2765_R 1389 23S rRNA 17
23S_EC_2645_2669_F 408 23S_EC_2744_2761_R 1252 23S rRNA 361
16S_EC_1090_1111_2_TMOD_F 697 16S_EC_1175_1196_TMOD_R 1398 16S rRNA
3 16S_EC_1090_1111_2_F 651 16S_EC_1175_1196_R 1159 16S rRNA 362
RPOB_EC_3799_3821_TMOD_F 581 RPOB_EC_3862_3888_TMOD_R 1325 rpoB 289
RPOB_EC_3799_3821_F 124 RPOB_EC_3862_3888_R 840 rpoB 363
RPOC_EC_2146_2174_TMOD_F 284 RPOC_EC_2227_2245_TMOD_R 898 rpoC 290
RPOC_EC_2146_2174_F 52 RPOC_EC_2227_2245_R 736 rpoC 367
TUFB_EC_957_979_TMOD_F 308 TUFB_EC_1034_1058_TMOD_R 1276 tufB 293
TUFB_EC_957_979_F 55 TUFB_EC_1034_1058_R 829 tufB 449
RPLB_EC_690_710_F 309 RPLB_EC_737_758_R 1336 rplB 357
RPLB_EC_688_710_TMOD_F 296 RPLB_EC_736_757_TMOD_R 1337 rplB 67
RPLB_EC_688_710_F 54 RPLB_EC_736_757_R 842 rplB
[0397] The 16 primer pairs of the surveillance set are used to
produce bioagent identifying amplicons whose base compositions are
sufficiently different amongst all known bacteria at the species
level to identify, at a reasonable confidence level, any given
bacterium at the species level. As shown in Tables 6A-E, common
respiratory bacterial pathogens can be distinguished by the base
compositions of bioagent identifying amplicons obtained using the
16 primer pairs of the surveillance set. In some cases,
triangulation identification improves the confidence level for
species assignment. For example, nucleic acid from Streptococcus
pyogenes can be amplified by nine of the sixteen surveillance
primer pairs and Streptococcus pneumoniae can be amplified by ten
of the sixteen surveillance primer pairs. The base compositions of
the bioagent identifying amplicons are identical for only one of
the analogous bioagent identifying amplicons and differ in all of
the remaining analogous bioagent identifying amplicons by up to
four bases per bioagent identifying amplicon. The resolving power
of the surveillance set was confirmed by determination of base
compositions for 120 isolates of respiratory pathogens representing
70 different bacterial species and the results indicated that
natural variations (usually only one or two base substitutions per
bioagent identifying amplicon) amongst multiple isolates of the
same species did not prevent correct identification of major
pathogenic organisms at the species level.
[0398] Bacillus anthracis is a well known biological warfare agent
which has emerged in domestic terrorism in recent years. Since it
was envisioned to produce bioagent identifying amplicons for
identification of Bacillus anthracis, additional drill-down
analysis primers were designed to target genes present on virulence
plasmids of Bacillus anthracis so that additional confidence could
be reached in positive identification of this pathogenic organism.
Three drill-down analysis primers were designed and are listed in
Tables 2 and 6. In Table 6, the drill-down set comprises primers
with T modifications (note TMOD designation in primer names) which
constitutes a functional improvement with regard to prevention of
non-templated adenylation (vide supra) relative to originally
selected primers which are displayed below in the same row.
TABLE-US-00006 TABLE 6 Drill-Down Primer Pairs for Confirmation of
Identification of Bacillus anthracis Forward Reverse Primer Primer
Primer Pair (SEQ ID (SEQ ID No. Forward Primer Name NO:) Reverse
Primer Name NO:) Target Gene 350 CAPC_BA_274_303_TMOD_F 476
CAPC_BA_349_376_TMOD_R 1314 capC 24 CAPC_BA_274_303_F 109
CAPC_BA_349_376_R 837 capC 351 CYA_BA_1353_1379_TMOD_F 355
CYA_BA_1448_1467_TMOD_R 1423 cyA 30 CYA_BA_1353_1379_F 64
CYA_BA_1448_1467_R 1342 cyA 353 LEF_BA_756_781_TMOD_F 220
LEF_BA_843_872_TMOD_R 1394 lef 37 LEF_BA_756_781_F 26
LEF_BA_843_872_R 1135 lef
[0399] Phylogenetic coverage of bacterial space of the sixteen
surveillance primers of Table 5 and the three Bacillus anthracis
drill-down primers of Table 6 is shown in FIG. 3 which lists common
pathogenic bacteria. FIG. 3 is not meant to be comprehensive in
illustrating all species identified by the primers. Only pathogenic
bacteria are listed as representative examples of the bacterial
species that can be identified by the primers and methods of the
present invention. Nucleic acid of groups of bacteria enclosed
within the polygons of FIG. 3 can be amplified to obtain bioagent
identifying amplicons using the primer pair numbers listed in the
upper right hand corner of each polygon. Primer coverage for
polygons within polygons is additive. As an illustrative example,
bioagent identifying amplicons can be obtained for Chlamydia
trachomatis by amplification with, for example, primer pairs
346-349, 360 and 361, but not with any of the remaining primers of
the surveillance primer set. On the other hand, bioagent
identifying amplicons can be obtained from nucleic acid originating
from Bacillus anthracis (located within 5 successive polygons)
using, for example, any of the following primer pairs: 346-349,
360, 361 (base polygon), 356, 449 (second polygon), 352 (third
polygon), 355 (fourth polygon), 350, 351 and 353 (fifth polygon).
Multiple coverage of a given organism with multiple primers
provides for increased confidence level in identification of the
organism as a result of enabling broad triangulation
identification.
[0400] In Tables 7A-E, base compositions of respiratory pathogens
for primer target regions are shown. Two entries in a cell,
represent variation in ribosomal DNA operons. The most predominant
base composition is shown first and the minor (frequently a single
operon) is indicated by an asterisk (*). Entries with NO DATA mean
that the primer would not be expected to prime this species due to
mismatches between the primer and target region, as determined by
theoretical PCR.
TABLE-US-00007 TABLE 7A Base Compositions of Common Respiratory
Pathogens for Bioagent Identifying Amplicons Corresponding to
Primer Pair Nos: 346, 347 and 348 Primer 346 Primer 347 Primer 348
Organism Strain [A G C T] [A G C T] [A G C T] Klebsiella MGH78578
[29 32 25 13] [23 38 28 26] [26 32 28 30] pneumoniae [29 31 25 13]*
[23 37 28 26]* [26 31 28 30]* Yersinia pestis CO-92 Biovar [29 32
25 13] [22 39 28 26] [29 30 28 29] Orientalis [30 30 27 29]*
Yersinia pestis KIM5 P12 (Biovar [29 32 25 13] [22 39 28 26] [29 30
28 29] Mediaevalis) Yersinia pestis 91001 [29 32 25 13] [22 39 28
26] [29 30 28 29] [30 30 27 29]* Haemophilus KW20 [28 31 23 17] [24
37 25 27] [29 30 28 29] influenzae Pseudomonas PAO1 [30 31 23 15]
[26 36 29 24] [26 32 29 29] aeruginosa [27 36 29 23]* Pseudomonas
Pf0-1 [30 31 23 15] [26 35 29 25] [28 31 28 29] fluorescens
Pseudomonas KT2440 [30 31 23 15] [28 33 27 27] [27 32 29 28] putida
Legionella Philadelphia-1 [30 30 24 15] [33 33 23 27] [29 28 28 31]
pneumophila Francisella schu 4 [32 29 22 16] [28 38 26 26] [25 32
28 31] tularensis Bordetella Tohama I [30 29 24 16] [23 37 30 24]
[30 32 30 26] pertussis Burkholderia J2315 [29 29 27 14] [27 32 26
29] [27 36 31 24] cepacia [20 42 35 19]* Burkholderia K96243 [29 29
27 14] [27 32 26 29] [27 36 31 24] pseudomallei Neisseria FA 1090,
ATCC [29 28 24 18] [27 34 26 28] [24 36 29 27] gonorrhoeae 700825
Neisseria MC58 (serogroup B) [29 28 26 16] [27 34 27 27] [25 35 30
26] meningitidis Neisseria serogroup C, FAM18 [29 28 26 16] [27 34
27 27] [25 35 30 26] meningitidis Neisseria Z2491 (serogroup A) [29
28 26 16] [27 34 27 27] [25 35 30 26] meningitidis Chlamydophila
TW-183 [31 27 22 19] NO DATA [32 27 27 29] pneumoniae Chlamydophila
AR39 [31 27 22 19] NO DATA [32 27 27 29] pneumoniae Chlamydophila
CWL029 [31 27 22 19] NO DATA [32 27 27 29] pneumoniae Chlamydophila
J138 [31 27 22 19] NO DATA [32 27 27 29] pneumoniae Corynebacterium
NCTC13129 [29 34 21 15] [22 38 31 25] [22 33 25 34] diphtheriae
Mycobacterium k10 [27 36 21 15] [22 37 30 28] [21 36 27 30] avium
Mycobacterium 104 [27 36 21 15] [22 37 30 28] [21 36 27 30] avium
Mycobacterium CSU#93 [27 36 21 15] [22 37 30 28] [21 36 27 30]
tuberculosis Mycobacterium CDC 1551 [27 36 21 15] [22 37 30 28] [21
36 27 30] tuberculosis Mycobacterium H37Rv (lab strain) [27 36 21
15] [22 37 30 28] [21 36 27 30] tuberculosis Mycoplasma M129 [31 29
19 20] NO DATA NO DATA pneumoniae Staphylococcus MRSA252 [27 30 21
21] [25 35 30 26] [30 29 30 29] aureus [29 31 30 29]*
Staphylococcus MSSA476 [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [30 29 29 30]* Staphylococcus COL [27 30 21 21] [25 35 30
26] [30 29 30 29] aureus [30 29 29 30]* Staphylococcus Mu50 [27 30
21 21] [25 35 30 26] [30 29 30 29] aureus [30 29 29 30]*
Staphylococcus MW2 [27 30 21 21] [25 35 30 26] [30 29 30 29] aureus
[30 29 29 30]* Staphylococcus N315 [27 30 21 21] [25 35 30 26] [30
29 30 29] aureus [30 29 29 30]* Staphylococcus NCTC 8325 [27 30 21
21] [25 35 30 26] [30 29 30 29] aureus [25 35 31 26]* [30 29 29 30]
Streptococcus NEM316 [26 32 23 18] [24 36 31 25] [25 32 29 30]
agalactiae [24 36 30 26]* Streptococcus NC_002955 [26 32 23 18] [23
37 31 25] [29 30 25 32] equi Streptococcus MGAS8232 [26 32 23 18]
[24 37 30 25] [25 31 29 31] pyogenes Streptococcus MGAS315 [26 32
23 18] [24 37 30 25] [25 31 29 31] pyogenes Streptococcus SSI-1 [26
32 23 18] [24 37 30 25] [25 31 29 31] pyogenes Streptococcus
MGAS10394 [26 32 23 18] [24 37 30 25] [25 31 29 31] pyogenes
Streptococcus Manfredo (M5) [26 32 23 18] [24 37 30 25] [25 31 29
31] pyogenes Streptococcus SF370 (M1) [26 32 23 18] [24 37 30 25]
[25 31 29 31] pyogenes Streptococcus 670 [26 32 23 18] [25 35 28
28] [25 32 29 30] pneumoniae Streptococcus R6 [26 32 23 18] [25 35
28 28] [25 32 29 30] pneumoniae Streptococcus TIGR4 [26 32 23 18]
[25 35 28 28] [25 32 30 29] pneumoniae Streptococcus NCTC7868 [25
33 23 18] [24 36 31 25] [25 31 29 31] gordonii Streptococcus NCTC
12261 [26 32 23 18] [25 35 30 26] [25 32 29 30] mitis [24 31 35
29]* Streptococcus UA159 [24 32 24 19] [25 37 30 24] [28 31 26 31]
mutans
TABLE-US-00008 TABLE 7B Base Compositions of Common Respiratory
Pathogens for Bioagent Identifying Amplicons Corresponding to
Primer Pair Nos: 349, 360, and 356 Primer 349 Primer 360 Primer 356
Organism Strain [A G C T] [A G C T] [A G C T] Klebsiella MGH78578
[25 31 25 22] [33 37 25 27] NO DATA pneumoniae Yersinia pestis
CO-92 Biovar [25 31 27 20] [34 35 25 28] NO DATA Orientalis [25 32
26 20]* Yersinia pestis KIM5 P12 (Biovar [25 31 27 20] [34 35 25
28] NO DATA Mediaevalis) [25 32 26 20]* Yersinia pestis 91001 [25
31 27 20] [34 35 25 28] NO DATA Haemophilus KW20 [28 28 25 20] [32
38 25 27] NO DATA influenzae Pseudomonas PAO1 [24 31 26 20] [31 36
27 27] NO DATA aeruginosa [31 36 27 28]* Pseudomonas Pf0-1 NO DATA
[30 37 27 28] NO DATA fluorescens [30 37 27 28] Pseudomonas KT2440
[24 31 26 20] [30 37 27 28] NO DATA putida Legionella
Philadelphia-1 [23 30 25 23] [30 39 29 24] NO DATA pneumophila
Francisella schu 4 [26 31 25 19] [32 36 27 27] NO DATA tularensis
Bordetella Tohama I [21 29 24 18] [33 36 26 27] NO DATA pertussis
Burkholderia J2315 [23 27 22 20] [31 37 28 26] NO DATA cepacia
Burkholderia K96243 [23 27 22 20] [31 37 28 26] NO DATA
pseudomallei Neisseria FA 1090, ATCC 700825 [24 27 24 17] [34 37 25
26] NO DATA gonorrhoeae Neisseria MC58 (serogroup B) [25 27 22 18]
[34 37 25 26] NO DATA meningitidis Neisseria serogroup C, FAM18 [25
26 23 18] [34 37 25 26] NO DATA meningitidis Neisseria Z2491
(serogroup A) [25 26 23 18] [34 37 25 26] NO DATA meningitidis
Chlamydophila TW-183 [30 28 27 18] NO DATA NO DATA pneumoniae
Chlamydophila AR39 [30 28 27 18] NO DATA NO DATA pneumoniae
Chlamydophila CWL029 [30 28 27 18] NO DATA NO DATA pneumoniae
Chlamydophila J138 [30 28 27 18] NO DATA NO DATA pneumoniae
Corynebacterium NCTC13129 NO DATA [29 40 28 25] NO DATA diphtheriae
Mycobacterium k10 NO DATA [33 35 32 22] NO DATA avium Mycobacterium
104 NO DATA [33 35 32 22] NO DATA avium Mycobacterium CSU#93 NO
DATA [30 36 34 22] NO DATA tuberculosis Mycobacterium CDC 1551 NO
DATA [30 36 34 22] NO DATA tuberculosis Mycobacterium H37Rv (lab
strain) NO DATA [30 36 34 22] NO DATA tuberculosis Mycoplasma M129
[28 30 24 19] [34 31 29 28] NO DATA pneumoniae Staphylococcus
MRSA252 [26 30 25 20] [31 38 24 29] [33 30 31 27] aureus
Staphylococcus MSSA476 [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus Staphylococcus COL [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus Staphylococcus Mu50 [26 30 25 20] [31 38 24 29] [33 30 31
27] aureus Staphylococcus MW2 [26 30 25 20] [31 38 24 29] [33 30 31
27] aureus Staphylococcus N315 [26 30 25 20] [31 38 24 29] [33 30
31 27] aureus Staphylococcus NCTC 8325 [26 30 25 20] [31 38 24 29]
[33 30 31 27] aureus Streptococcus NEM316 [28 31 22 20] [33 37 24
28] [37 30 28 26] agalactiae Streptococcus NC_002955 [28 31 23 19]
[33 38 24 27] [37 31 28 25] equi Streptococcus MGAS8232 [28 31 23
19] [33 37 24 28] [38 31 29 23] pyogenes Streptococcus MGAS315 [28
31 23 19] [33 37 24 28] [38 31 29 23] pyogenes Streptococcus SSI-1
[28 31 23 19] [33 37 24 28] [38 31 29 23] pyogenes Streptococcus
MGAS10394 [28 31 23 19] [33 37 24 28] [38 31 29 23] pyogenes
Streptococcus Manfredo (M5) [28 31 23 19] [33 37 24 28] [38 31 29
23] pyogenes Streptococcus SF370 (M1) [28 31 23 19] [33 37 24 28]
[38 31 29 23] pyogenes [28 31 22 20]* Streptococcus 670 [28 31 22
20] [34 36 24 28] [37 30 29 25] pneumoniae Streptococcus R6 [28 31
22 20] [34 36 24 28] [37 30 29 25] pneumoniae Streptococcus TIGR4
[28 31 22 20] [34 36 24 28] [37 30 29 25] pneumoniae Streptococcus
NCTC7868 [28 32 23 20] [34 36 24 28] [36 31 29 25] gordonii
Streptococcus NCTC 12261 [28 31 22 20] [34 36 24 28] [37 30 29 25]
mitis [29 30 22 20]* Streptococcus UA159 [26 32 23 22] [34 37 24
27] NO DATA mutans
TABLE-US-00009 TABLE 7C Base Compositions of Common Respiratory
Pathogens for Bioagent Identifying Amplicons Corresponding to
Primer Pair Nos: 449, 354, and 352 Primer 449 Primer 354 Primer 352
Organism Strain [A G C T] [A G C T] [A G C T] Klebsiella MGH78578
NO DATA [27 33 36 26] NO DATA pneumoniae Yersinia pestis CO-92
Biovar NO DATA [29 31 33 29] [32 28 20 25] Orientalis Yersinia
pestis KIM5 P12 (Biovar NO DATA [29 31 33 29] [32 28 20 25]
Mediaevalis) Yersinia pestis 91001 NO DATA [29 31 33 29] NO DATA
Haemophilus KW20 NO DATA [30 29 31 32] NO DATA influenzae
Pseudomonas PAO1 NO DATA [26 33 39 24] NO DATA aeruginosa
Pseudomonas Pf0-1 NO DATA [26 33 34 29] NO DATA fluorescens
Pseudomonas KT2440 NO DATA [25 34 36 27] NO DATA putida Legionella
Philadelphia-1 NO DATA NO DATA NO DATA pneumophila Francisella schu
4 NO DATA [33 32 25 32] NO DATA tularensis Bordetella Tohama I NO
DATA [26 33 39 24] NO DATA pertussis Burkholderia J2315 NO DATA [25
37 33 27] NO DATA cepacia Burkholderia K96243 NO DATA [25 37 34 26]
NO DATA pseudomallei Neisseria FA 1090, ATCC 700825 [17 23 22 10]
[29 31 32 30] NO DATA gonorrhoeae Neisseria MC58 (serogroup B) NO
DATA [29 30 32 31] NO DATA meningitidis Neisseria serogroup C,
FAM18 NO DATA [29 30 32 31] NO DATA meningitidis Neisseria Z2491
(serogroup A) NO DATA [29 30 32 31] NO DATA meningitidis
Chlamydophila TW-183 NO DATA NO DATA NO DATA pneumoniae
Chlamydophila AR39 NO DATA NO DATA NO DATA pneumoniae Chlamydophila
CWL029 NO DATA NO DATA NO DATA pneumoniae Chlamydophila J138 NO
DATA NO DATA NO DATA pneumoniae Corynebacterium NCTC13129 NO DATA
NO DATA NO DATA diphtheriae Mycobacterium k10 NO DATA NO DATA NO
DATA avium Mycobacterium 104 NO DATA NO DATA NO DATA avium
Mycobacterium CSU#93 NO DATA NO DATA NO DATA tuberculosis
Mycobacterium CDC 1551 NO DATA NO DATA NO DATA tuberculosis
Mycobacterium H37Rv (lab strain) NO DATA NO DATA NO DATA
tuberculosis Mycoplasma M129 NO DATA NO DATA NO DATA pneumoniae
Staphylococcus MRSA252 [17 20 21 17] [30 27 30 35] [36 24 19 26]
aureus Staphylococcus MSSA476 [17 20 21 17] [30 27 30 35] [36 24 19
26] aureus Staphylococcus COL [17 20 21 17] [30 27 30 35] [35 24 19
27] aureus Staphylococcus Mu50 [17 20 21 17] [30 27 30 35] [36 24
19 26] aureus Staphylococcus MW2 [17 20 21 17] [30 27 30 35] [36 24
19 26] aureus Staphylococcus N315 [17 20 21 17] [30 27 30 35] [36
24 19 26] aureus Staphylococcus NCTC 8325 [17 20 21 17] [30 27 30
35] [35 24 19 27] aureus Streptococcus NEM316 [22 20 19 14] [26 31
27 38] [29 26 22 28] agalactiae Streptococcus NC_002955 [22 21 19
13] NO DATA NO DATA equi Streptococcus MGAS8232 [23 21 19 12] [24
32 30 36] NO DATA pyogenes Streptococcus MGAS315 [23 21 19 12] [24
32 30 36] NO DATA pyogenes Streptococcus SSI-1 [23 21 19 12] [24 32
30 36] NO DATA pyogenes Streptococcus MGAS10394 [23 21 19 12] [24
32 30 36] NO DATA pyogenes Streptococcus Manfredo (M5) [23 21 19
12] [24 32 30 36] NO DATA pyogenes Streptococcus SF370 (M1) [23 21
19 12] [24 32 30 36] NO DATA pyogenes Streptococcus 670 [22 20 19
14] [25 33 29 35] [30 29 21 25] pneumoniae Streptococcus R6 [22 20
19 14] [25 33 29 35] [30 29 21 25] pneumoniae Streptococcus TIGR4
[22 20 19 14] [25 33 29 35] [30 29 21 25] pneumoniae Streptococcus
NCTC7868 [21 21 19 14] NO DATA [29 26 22 28] gordonii Streptococcus
NCTC 12261 [22 20 19 14] [26 30 32 34] NO DATA mitis Streptococcus
UA159 NO DATA NO DATA NO DATA mutans
TABLE-US-00010 TABLE 7D Base Compositions of Common Respiratory
Pathogens for Bioagent Identifying Amplicons Corresponding to
Primer Pair Nos: 355, 358, and 359 Primer 355 Primer 358 Primer 359
Organism Strain [A G C T] [A G C T] [A G C T] Klebsiella MGH78578
NO DATA [24 39 33 20] [25 21 24 17] pneumoniae Yersinia pestis
CO-92 Biovar NO DATA [26 34 35 21] [23 23 19 22] Orientalis
Yersinia pestis KIM5 P12 (Biovar NO DATA [26 34 35 21] [23 23 19
22] Mediaevalis) Yersinia pestis 91001 NO DATA [26 34 35 21] [23 23
19 22] Haemophilus KW20 NO DATA NO DATA NO DATA influenzae
Pseudomonas PAO1 NO DATA NO DATA NO DATA aeruginosa Pseudomonas
Pf0-1 NO DATA NO DATA NO DATA fluorescens Pseudomonas KT2440 NO
DATA [21 37 37 21] NO DATA putida Legionella Philadelphia-1 NO DATA
NO DATA NO DATA pneumophila Francisella schu 4 NO DATA NO DATA NO
DATA tularensis Bordetella Tohama I NO DATA NO DATA NO DATA
pertussis Burkholderia J2315 NO DATA NO DATA NO DATA cepacia
Burkholderia K96243 NO DATA NO DATA NO DATA pseudomallei Neisseria
FA 1090, ATCC 700825 NO DATA NO DATA NO DATA gonorrhoeae Neisseria
MC58 (serogroup B) NO DATA NO DATA NO DATA meningitidis Neisseria
serogroup C, FAM18 NO DATA NO DATA NO DATA meningitidis Neisseria
Z2491 (serogroup A) NO DATA NO DATA NO DATA meningitidis
Chlamydophila TW-183 NO DATA NO DATA NO DATA pneumoniae
Chlamydophila AR39 NO DATA NO DATA NO DATA pneumoniae Chlamydophila
CWL029 NO DATA NO DATA NO DATA pneumoniae Chlamydophila J138 NO
DATA NO DATA NO DATA pneumoniae Corynebacterium NCTC13129 NO DATA
NO DATA NO DATA diphtheriae Mycobacterium k10 NO DATA NO DATA NO
DATA avium Mycobacterium 104 NO DATA NO DATA NO DATA avium
Mycobacterium CSU#93 NO DATA NO DATA NO DATA tuberculosis
Mycobacterium CDC 1551 NO DATA NO DATA NO DATA tuberculosis
Mycobacterium H37Rv (lab strain) NO DATA NO DATA NO DATA
tuberculosis Mycoplasma M129 NO DATA NO DATA NO DATA pneumoniae
Staphylococcus MRSA252 NO DATA NO DATA NO DATA aureus
Staphylococcus MSSA476 NO DATA NO DATA NO DATA aureus
Staphylococcus COL NO DATA NO DATA NO DATA aureus Staphylococcus
Mu50 NO DATA NO DATA NO DATA aureus Staphylococcus MW2 NO DATA NO
DATA NO DATA aureus Staphylococcus N315 NO DATA NO DATA NO DATA
aureus Staphylococcus NCTC 8325 NO DATA NO DATA NO DATA aureus
Streptococcus NEM316 NO DATA NO DATA NO DATA agalactiae
Streptococcus NC_002955 NO DATA NO DATA NO DATA equi Streptococcus
MGAS8232 NO DATA NO DATA NO DATA pyogenes Streptococcus MGAS315 NO
DATA NO DATA NO DATA pyogenes Streptococcus SSI-1 NO DATA NO DATA
NO DATA pyogenes Streptococcus MGAS10394 NO DATA NO DATA NO DATA
pyogenes Streptococcus Manfredo (M5) NO DATA NO DATA NO DATA
pyogenes Streptococcus SF370 (M1) NO DATA NO DATA NO DATA pyogenes
Streptococcus 670 NO DATA NO DATA NO DATA pneumoniae Streptococcus
R6 NO DATA NO DATA NO DATA pneumoniae Streptococcus TIGR4 NO DATA
NO DATA NO DATA pneumoniae Streptococcus NCTC7868 NO DATA NO DATA
NO DATA gordonii Streptococcus NCTC 12261 NO DATA NO DATA NO DATA
mitis Streptococcus UA159 NO DATA NO DATA NO DATA mutans
TABLE-US-00011 TABLE 7E Base Compositions of Common Respiratory
Pathogens for Bioagent Identifying Amplicons Corresponding to
Primer Pair Nos: 362, 363, and 367 Primer 362 Primer 363 Primer 367
Organism Strain [A G C T] [A G C T] [A G C T] Klebsiella MGH78578
[21 33 22 16] [16 34 26 26] NO DATA pneumoniae Yersinia pestis
CO-92 Biovar [20 34 18 20] NO DATA NO DATA Orientalis Yersinia
pestis KIM5 P12 (Biovar [20 34 18 20] NO DATA NO DATA Mediaevalis)
Yersinia pestis 91001 [20 34 18 20] NO DATA NO DATA Haemophilus
KW20 NO DATA NO DATA NO DATA influenzae Pseudomonas PAO1 [19 35 21
17] [16 36 28 22] NO DATA aeruginosa Pseudomonas Pf0-1 NO DATA [18
35 26 23] NO DATA fluorescens Pseudomonas KT2440 NO DATA [16 35 28
23] NO DATA putida Legionella Philadelphia-1 NO DATA NO DATA NO
DATA pneumophila Francisella schu 4 NO DATA NO DATA NO DATA
tularensis Bordetella Tohama I [20 31 24 17] [15 34 32 21] [26 25
34 19] pertussis Burkholderia J2315 [20 33 21 18] [15 36 26 25] [25
27 32 20] cepacia Burkholderia K96243 [19 34 19 20] [15 37 28 22]
[25 27 32 20] pseudomallei Neisseria FA 1090, ATCC 700825 NO DATA
NO DATA NO DATA gonorrhoeae Neisseria MC58 (serogroup B) NO DATA NO
DATA NO DATA meningitidis Neisseria serogroup C, FAM18 NO DATA NO
DATA NO DATA meningitidis Neisseria Z2491 (serogroup A) NO DATA NO
DATA NO DATA meningitidis Chlamydophila TW-183 NO DATA NO DATA NO
DATA pneumoniae Chlamydophila AR39 NO DATA NO DATA NO DATA
pneumoniae Chlamydophila CWL029 NO DATA NO DATA NO DATA pneumoniae
Chlamydophila J138 NO DATA NO DATA NO DATA pneumoniae
Corynebacterium NCTC13129 NO DATA NO DATA NO DATA diphtheriae
Mycobacterium k10 [19 34 23 16] NO DATA [24 26 35 19] avium
Mycobacterium 104 [19 34 23 16] NO DATA [24 26 35 19] avium
Mycobacterium CSU#93 [19 31 25 17] NO DATA [25 25 34 20]
tuberculosis Mycobacterium CDC 1551 [19 31 24 18] NO DATA [25 25 34
20] tuberculosis Mycobacterium H37Rv (lab strain) [19 31 24 18] NO
DATA [25 25 34 20] tuberculosis Mycoplasma M129 NO DATA NO DATA NO
DATA pneumoniae Staphylococcus MRSA252 NO DATA NO DATA NO DATA
aureus Staphylococcus MSSA476 NO DATA NO DATA NO DATA aureus
Staphylococcus COL NO DATA NO DATA NO DATA aureus Staphylococcus
Mu50 NO DATA NO DATA NO DATA aureus Staphylococcus MW2 NO DATA NO
DATA NO DATA aureus Staphylococcus N315 NO DATA NO DATA NO DATA
aureus Staphylococcus NCTC 8325 NO DATA NO DATA NO DATA aureus
Streptococcus NEM316 NO DATA NO DATA NO DATA agalactiae
Streptococcus NC_002955 NO DATA NO DATA NO DATA equi Streptococcus
MGAS8232 NO DATA NO DATA NO DATA pyogenes Streptococcus MGAS315 NO
DATA NO DATA NO DATA pyogenes Streptococcus SSI-1 NO DATA NO DATA
NO DATA pyogenes Streptococcus MGAS10394 NO DATA NO DATA NO DATA
pyogenes Streptococcus Manfredo (M5) NO DATA NO DATA NO DATA
pyogenes Streptococcus SF370 (M1) NO DATA NO DATA NO DATA pyogenes
Streptococcus 670 NO DATA NO DATA NO DATA pneumoniae Streptococcus
R6 [20 30 19 23] NO DATA NO DATA pneumoniae Streptococcus TIGR4 [20
30 19 23] NO DATA NO DATA pneumoniae Streptococcus NCTC7868 NO DATA
NO DATA NO DATA gordonii Streptococcus NCTC 12261 NO DATA NO DATA
NO DATA mitis Streptococcus UA159 NO DATA NO DATA NO DATA
mutans
[0401] Four sets of throat samples from military recruits at
different military facilities taken at different time points were
analyzed using the primers of the present invention. The first set
was collected at a military training center from November 1 to Dec.
20, 2002 during one of the most severe outbreaks of pneumonia
associated with group A Streptococcus in the United States since
1968. During this outbreak, fifty-one throat swabs were taken from
both healthy and hospitalized recruits and plated on blood agar for
selection of putative group A Streptococcus colonies. A second set
of 15 original patient specimens was taken during the height of
this group A Streptococcus-associated respiratory disease outbreak.
The third set were historical samples, including twenty-seven
isolates of group A Streptococcus, from disease outbreaks at this
and other military training facilities during previous years. The
fourth set of samples was collected from five geographically
separated military facilities in the continental U.S. in the winter
immediately following the severe November/December 2002
outbreak.
[0402] Pure colonies isolated from group A Streptococcus-selective
media from all four collection periods were analyzed with the
surveillance primer set. All samples showed base compositions that
precisely matched the four completely sequenced strains of
Streptococcus pyogenes. Shown in FIG. 4 is a 3D diagram of base
composition (axes A, G and C) of bioagent identifying amplicons
obtained with primer pair number 14 (a precursor of primer pair
number 348 which targets 16S rRNA). The diagram indicates that the
experimentally determined base compositions of the clinical samples
closely match the base compositions expected for Streptococcus
pyogenes and are distinct from the expected base compositions of
other organisms.
[0403] In addition to the identification of Streptococcus pyogenes,
other potentially pathogenic organisms were identified
concurrently. Mass spectral analysis of a sample whose nucleic acid
was amplified by primer pair number 349 (SEQ ID NOs: 401:1156)
exhibited signals of bioagent identifying amplicons with molecular
masses that were found to correspond to analogous base compositions
of bioagent identifying amplicons of Streptococcus pyogenes (A27
G32 C24 T18), Neisseria meningitidis (A25 G27 C22 T18), and
Haemophilus influenzae (A28 G28 C25 T20) (see FIG. 5 and Table 7B).
These organisms were present in a ratio of 4:5:20 as determined by
comparison of peak heights with peak height of an internal PCR
calibration standard as described in commonly owned U.S. Patent
Application Ser. No. 60/545,425 which is incorporated herein by
reference in its entirety.
[0404] Since certain division-wide primers that target housekeeping
genes are designed to provide coverage of specific divisions of
bacteria to increase the confidence level for identification of
bacterial species, they are not expected to yield bioagent
identifying amplicons for organisms outside of the specific
divisions. For example, primer pair number 356 (SEQ ID NOs:
449:1380) primarily amplifies the nucleic acid of members of the
classes Bacilli and Clostridia and is not expected to amplify
proteobacteria such as Neisseria meningitidis and Haemophilus
influenzae. As expected, analysis of the mass spectrum of
amplification products obtained with primer pair number 356 does
not indicate the presence of Neisseria meningitidis and Haemophilus
influenzae but does indicate the presence of Streptococcus pyogenes
(FIGS. 3 and 6, Table 7B). Thus, these primers or types of primers
can confirm the absence of particular bioagents from a sample.
[0405] The 15 throat swabs from military recruits were found to
contain a relatively small set of microbes in high abundance. The
most common were Haemophilus influenza, Neisseria meningitides, and
Streptococcus pyogenes. Staphylococcus epidermidis, Moraxella
cattarhalis, Corynebacterium pseudodiphtheriticum, and
Staphylococcus aureus were present in fewer samples. An equal
number of samples from healthy volunteers from three different
geographic locations, were identically analyzed. Results indicated
that the healthy volunteers have bacterial flora dominated by
multiple, commensal non-beta-hemolytic Streptococcal species,
including the viridans group streptococci (S. parasangunis, S.
vestibularis, S. mitis, S. oralis and S. pneumoniae; data not
shown), and none of the organisms found in the military recruits
were found in the healthy controls at concentrations detectable by
mass spectrometry. Thus, the military recruits in the midst of a
respiratory disease outbreak had a dramatically different microbial
population than that experienced by the general population in the
absence of epidemic disease.
Example 7
Triangulation Genotyping Analysis for Determination of emm-Type of
Streptococcus pyogenes in Epidemic Surveillance
[0406] As a continuation of the epidemic surveillance investigation
of Example 6, determination of sub-species characteristics
(genotyping) of Streptococcus pyogenes, was carried out based on a
strategy that generates strain-specific signatures according to the
rationale of Multi-Locus Sequence Typing (MLST). In classic MLST
analysis, internal fragments of several housekeeping genes are
amplified and sequenced (Enright et al. Infection and Immunity,
2001, 69, 2416-2427). In classic MLST analysis, internal fragments
of several housekeeping genes are amplified and sequenced. In the
present investigation, bioagent identifying amplicons from
housekeeping genes were produced using drill-down primers and
analyzed by mass spectrometry. Since mass spectral analysis results
in molecular mass, from which base composition can be determined,
the challenge was to determine whether resolution of emm
classification of strains of Streptococcus pyogenes could be
determined.
[0407] For the purpose of development of a triangulation genotyping
assay, an alignment was constructed of concatenated alleles of
seven MLST housekeeping genes (glucose kinase (gki), glutamine
transporter protein (gtr), glutamate racemase (murI), DNA mismatch
repair protein (mutS), xanthine phosphoribosyl transferase (xpt),
and acetyl-CoA acetyl transferase (yqiL)) from each of the 212
previously emm-typed strains of Streptococcus pyogenes. From this
alignment, the number and location of primer pairs that would
maximize strain identification via base composition was determined.
As a result, 6 primer pairs were chosen as standard drill-down
primers for determination of emm-type of Streptococcus pyogenes.
These six primer pairs are displayed in Table 8. This drill-down
set comprises primers with T modifications (note TMOD designation
in primer names) which constitutes a functional improvement with
regard to prevention of non-templated adenylation (vide supra)
relative to originally selected primers which are displayed below
in the same row.
TABLE-US-00012 TABLE 8 Triangulation Genotyping Analysis Primer
Pairs for Group A Streptococcus Drill-Down Forward Primer Primer
(SEQ Reverse Primer Target Pair No. Forward Primer Name ID NO:)
Reverse Primer Name (SEQ ID NO:) Gene 442
SP101_SPET11_358_387_TMOD_F 588 SP101_SPET11_448_473_TMOD_R 998 gki
80 SP101_SPET11_358_387_F 126 SP101_SPET11_448_473_TMOD_R 766 gki
443 SP101_SPET11_600_629_TMOD_F 348 SP101_SPET11_686_714_TMOD_R
1018 gtr 81 SP101_SPET11_600_629_F 62 SP101_SPET11_686_714_R 772
gtr 426 SP101_SPET11_1314_1336_TMOD_F 363
SP101_SPET11_1403_1431_TMOD_R 849 murI 86 SP101_SPET11_1314_1336_F
68 SP101_SPET11_1403_1431_R 711 murI 430
SP101_SPET11_1807_1835_TMOD_F 235 SP101_SPET11_1901_1927_TMOD_R
1439 mutS 90 SP101_SPET11_1807_1835_F 33 SP101_SPET11_1901_1927_R
1412 mutS 438 SP101_SPET11_3075_3103_TMOD_F 473
SP101_SPET11_3168_3196_TMOD_R 875 xpt 96 SP101_SPET11_3075_3103_F
108 SP101_SPET11_3168_3196_R 715 xpt 441
SP101_SPET11_3511_3535_TMOD_F 531 SP101_SPET11_3605_3629_TMOD_R
1294 yqiL 98 SP101_SPET11_3511_3535_F 116 SP101_SPET11_3605_3629_R
832 yqiL
[0408] The primers of Table 8 were used to produce bioagent
identifying amplicons from nucleic acid present in the clinical
samples. The bioagent identifying amplicons which were subsequently
analyzed by mass spectrometry and base compositions corresponding
to the molecular masses were calculated.
[0409] Of the 51 samples taken during the peak of the
November/December 2002 epidemic (Table 9A-C rows 1-3), all except
three samples were found to represent emm3, a Group A Streptococcus
genotype previously associated with high respiratory virulence. The
three outliers were from samples obtained from healthy individuals
and probably represent non-epidemic strains. Archived samples
(Tables 9A-C rows 5-13) from historical collections showed a
greater heterogeneity of base compositions and emm types as would
be expected from different epidemics occurring at different places
and dates. The results of the mass spectrometry analysis and emm
gene sequencing were found to be concordant for the epidemic and
historical samples.
TABLE-US-00013 TABLE 9A Base Composition Analysis of Bioagent
Identifying Amplicons of Group A Streptococcus samples from Six
Military Installations Obtained with Primer Pair Nos. 426 and 430
emm-type by murI mutS # of Mass emm-Gene Location (Primer Pair
(Primer Pair Instances Spectrometry Sequencing (sample) Year No.
426) No. 430) 48 3 3 MCRD San 2002 A39 G25 C20 T34 A38 G27 C23 T33
2 6 6 Diego A40 G24 C20 T34 A38 G27 C23 T33 1 28 28 (Cultured) A39
G25 C20 T34 A38 G27 C23 T33 15 3 ND A39 G25 C20 T34 A38 G27 C23 T33
6 3 3 NHRC San 2003 A39 G25 C20 T34 A38 G27 C23 T33 3 5, 58 5
Diego- A40 G24 C20 T34 A38 G27 C23 T33 6 6 6 Archive A40 G24 C20
T34 A38 G27 C23 T33 1 11 11 (Cultured) A39 G25 C20 T34 A38 G27 C23
T33 3 12 12 A40 G24 C20 T34 A38 G26 C24 T33 1 22 22 A39 G25 C20 T34
A38 G27 C23 T33 3 25, 75 75 A39 G25 C20 T34 A38 G27 C23 T33 4
44/61, 82, 9 44/61 A40 G24 C20 T34 A38 G26 C24 T33 2 53, 91 91 A39
G25 C20 T34 A38 G27 C23 T33 1 2 2 Ft. 2003 A39 G25 C20 T34 A38 G27
C24 T32 2 3 3 Leonard A39 G25 C20 T34 A38 G27 C23 T33 1 4 4 Wood
A39 G25 C20 T34 A38 G27 C23 T33 1 6 6 (Cultured) A40 G24 C20 T34
A38 G27 C23 T33 11 25 or 75 75 A39 G25 C20 T34 A38 G27 C23 T33 1
25, 75, 33, 75 A39 G25 C20 T34 A38 G27 C23 T33 34, 4, 52, 84 1
44/61 or 82 44/61 A40 G24 C20 T34 A38 G26 C24 T33 or 9 2 5 or 58 5
A40 G24 C20 T34 A38 G27 C23 T33 3 1 1 Ft. Sill 2003 A40 G24 C20 T34
A38 G27 C23 T33 2 3 3 (Cultured) A39 G25 C20 T34 A38 G27 C23 T33 1
4 4 A39 G25 C20 T34 A38 G27 C23 T33 1 28 28 A39 G25 C20 T34 A38 G27
C23 T33 1 3 3 Ft. 2003 A39 G25 C20 T34 A38 G27 C23 T33 1 4 4
Benning A39 G25 C20 T34 A38 G27 C23 T33 3 6 6 (Cultured) A40 G24
C20 T34 A38 G27 C23 T33 1 11 11 A39 G25 C20 T34 A38 G27 C23 T33 1
13 94** A40 G24 C20 T34 A38 G27 C23 T33 1 44/61 or 82 82 A40 G24
C20 T34 A38 G26 C24 T33 or 9 1 5 or 58 58 A40 G24 C20 T34 A38 G27
C23 T33 1 78 or 89 89 A39 G25 C20 T34 A38 G27 C23 T33 2 5 or 58 ND
Lackland 2003 A40 G24 C20 T34 A38 G27 C23 T33 1 2 AFB A39 G25 C20
T34 A38 G27 C24 T32 1 81 or 90 (Throat A40 G24 C20 T34 A38 G27 C23
T33 1 78 Swabs) A38 G26 C20 T34 A38 G27 C23 T33 3*** No detection
No detection No detection 7 3 ND MCRD San 2002 A39 G25 C20 T34 A38
G27 C23 T33 1 3 ND Diego No detection A38 G27 C23 T33 1 3 ND
(Throat No detection No detection 1 3 ND Swabs) No detection No
detection 2 3 ND No detection A38 G27 C23 T33 3 No detection ND No
detection No detection
TABLE-US-00014 TABLE 9B Base Composition Analysis of Bioagent
Identifying Amplicons of Group A Streptococcus samples from Six
Military Installations Obtained with Primer Pair Nos. 438 and 441
emm-type by xpt yqiL # of Mass emm-Gene Location (Primer Pair
(Primer Pair Instances Spectrometry Sequencing (sample) Year No.
438) No. 441) 48 3 3 MCRD San 2002 A30 G36 C20 T36 A40 G29 C19 T31
2 6 6 Diego A30 G36 C20 T36 A40 G29 C19 T31 1 28 28 (Cultured) A30
G36 C20 T36 A41 G28 C18 T32 15 3 ND A30 G36 C20 T36 A40 G29 C19 T31
6 3 3 NHRC San 2003 A30 G36 C20 T36 A40 G29 C19 T31 3 5, 58 5
Diego- A30 G36 C20 T36 A40 G29 C19 T31 6 6 6 Archive A30 G36 C20
T36 A40 G29 C19 T31 1 11 11 (Cultured) A30 G36 C20 T36 A40 G29 C19
T31 3 12 12 A30 G36 C19 T37 A40 G29 C19 T31 1 22 22 A30 G36 C20 T36
A40 G29 C19 T31 3 25, 75 75 A30 G36 C20 T36 A40 G29 C19 T31 4
44/61, 82, 9 44/61 A30 G36 C20 T36 A41 G28 C19 T31 2 53, 91 91 A30
G36 C19 T37 A40 G29 C19 T31 1 2 2 Ft. 2003 A30 G36 C20 T36 A40 G29
C19 T31 2 3 3 Leonard A30 G36 C20 T36 A40 G29 C19 T31 1 4 4 Wood
A30 G36 C19 T37 A41 G28 C19 T31 1 6 6 (Cultured) A30 G36 C20 T36
A40 G29 C19 T31 11 25 or 75 75 A30 G36 C20 T36 A40 G29 C19 T31 1
25, 75, 33, 75 A30 G36 C19 T37 A40 G29 C19 T31 34, 4, 52, 84 1
44/61 or 82 44/61 A30 G36 C20 T36 A41 G28 C19 T31 or 9 2 5 or 58 5
A30 G36 C20 T36 A40 G29 C19 T31 3 1 1 Ft. Sill 2003 A30 G36 C19 T37
A40 G29 C19 T31 2 3 3 (Cultured) A30 G36 C20 T36 A40 G29 C19 T31 1
4 4 A30 G36 C19 T37 A41 G28 C19 T31 1 28 28 A30 G36 C20 T36 A41 G28
C18 T32 1 3 3 Ft. 2003 A30 G36 C20 T36 A40 G29 C19 T31 1 4 4
Benning A30 G36 C19 T37 A41 G28 C19 T31 3 6 6 (Cultured) A30 G36
C20 T36 A40 G29 C19 T31 1 11 11 A30 G36 C20 T36 A40 G29 C19 T31 1
13 94** A30 G36 C20 T36 A41 G28 C19 T31 1 44/61 or 82 82 A30 G36
C20 T36 A41 G28 C19 T31 or 9 1 5 or 58 58 A30 G36 C20 T36 A40 G29
C19 T31 1 78 or 89 89 A30 G36 C20 T36 A41 G28 C19 T31 2 5 or 58 ND
Lackland 2003 A30 G36 C20 T36 A40 G29 C19 T31 1 2 AFB A30 G36 C20
T36 A40 G29 C19 T31 1 81 or 90 (Throat A30 G36 C20 T36 A40 G29 C19
T31 1 78 Swabs) A30 G36 C20 T36 A41 G28 C19 T31 3*** No detection
No detection No detection 7 3 ND MCRD San 2002 A30 G36 C20 T36 A40
G29 C19 T31 1 3 ND Diego A30 G36 C20 T36 A40 G29 C19 T31 1 3 ND
(Throat A30 G36 C20 T36 No detection 1 3 ND Swabs) No detection A40
G29 C19 T31 2 3 ND A30 G36 C20 T36 A40 G29 C19 T31 3 No detection
ND No detection No detection
TABLE-US-00015 TABLE 9C Base Composition Analysis of Bioagent
Identifying Amplicons of Group A Streptococcus samples from Six
Military Installations Obtained with Primer Pair Nos. 438 and 441
emm-type by gki gtr # of Mass emm-Gene Location (Primer Pair
((Primer Pair Instances Spectrometry Sequencing (sample) Year No.
442) No. 443) 48 3 3 MCRD San 2002 A32 G35 C17 T32 A39 G28 C16 T32
2 6 6 Diego A31 G35 C17 T33 A39 G28 C15 T33 1 28 28 (Cultured) A30
G36 C17 T33 A39 G28 C16 T32 15 3 ND A32 G35 C17 T32 A39 G28 C16 T32
6 3 3 NHRC San 2003 A32 G35 C17 T32 A39 G28 C16 T32 3 5, 58 5
Diego- A30 G36 C20 T30 A39 G28 C15 T33 6 6 6 Archive A31 G35 C17
T33 A39 G28 C15 T33 1 11 11 (Cultured) A30 G36 C20 T30 A39 G28 C16
T32 3 12 12 A31 G35 C17 T33 A39 G28 C15 T33 1 22 22 A31 G35 C17 T33
A38 G29 C15 T33 3 25, 75 75 A30 G36 C17 T33 A39 G28 C15 T33 4
44/61, 82, 9 44/61 A30 G36 C18 T32 A39 G28 C15 T33 2 53, 91 91 A32
G35 C17 T32 A39 G28 C16 T32 1 2 2 Ft. 2003 A30 G36 C17 T33 A39 G28
C15 T33 2 3 3 Leonard A32 G35 C17 T32 A39 G28 C16 T32 1 4 4 Wood
A31 G35 C17 T33 A39 G28 C15 T33 1 6 6 (Cultured) A31 G35 C17 T33
A39 G28 C15 T33 11 25 or 75 75 A30 G36 C17 T33 A39 G28 C15 T33 1
25, 75, 33, 75 A30 G36 C17 T33 A39 G28 C15 T33 34, 4, 52, 84 1
44/61 or 82 44/61 A30 G36 C18 T32 A39 G28 C15 T33 or 9 2 5 or 58 5
A30 G36 C20 T30 A39 G28 C15 T33 3 1 1 Ft. Sill 2003 A30 G36 C18 T32
A39 G28 C15 T33 2 3 3 (Cultured) A32 G35 C17 T32 A39 G28 C16 T32 1
4 4 A31 G35 C17 T33 A39 G28 C15 T33 1 28 28 A30 G36 C17 T33 A39 G28
C16 T32 1 3 3 Ft. 2003 A32 G35 C17 T32 A39 G28 C16 T32 1 4 4
Benning A31 G35 C17 T33 A39 G28 C15 T33 3 6 6 (Cultured) A31 G35
C17 T33 A39 G28 C15 T33 1 11 11 A30 G36 C20 T30 A39 G28 C16 T32 1
13 94** A30 G36 C19 T31 A39 G28 C15 T33 1 44/61 or 82 82 A30 G36
C18 T32 A39 G28 C15 T33 or 9 1 5 or 58 58 A30 G36 C20 T30 A39 G28
C15 T33 1 78 or 89 89 A30 G36 C18 T32 A39 G28 C15 T33 2 5 or 58 ND
Lackland 2003 A30 G36 C20 T30 A39 G28 C15 T33 1 2 AFB A30 G36 C17
T33 A39 G28 C15 T33 1 81 or 90 (Throat A30 G36 C17 T33 A39 G28 C15
T33 1 78 Swabs) A30 G36 C18 T32 A39 G28 C15 T33 3*** No detection
No detection No detection 7 3 ND MCRD San 2002 A32 G35 C17 T32 A39
G28 C16 T32 1 3 ND Diego No detection No detection 1 3 ND (Throat
A32 G35 C17 T32 A39 G28 C16 T32 1 3 ND Swabs) A32 G35 C17 T32 No
detection 2 3 ND A32 G35 C17 T32 No detection 3 No detection ND No
detection No detection
Example 8
Design of Calibrant Polynucleotides based on Bioagent Identifying
Amplicons for Identification of Species of Bacteria (Bacterial
Bioagent Identifying Amplicons)
[0410] This example describes the design of 19 calibrant
polynucleotides based on bacterial bioagent identifying amplicons
corresponding to the primers of the broad surveillance set (Table
5) and the Bacillus anthracis drill-down set (Table 6).
[0411] Calibration sequences were designed to simulate bacterial
bioagent identifying amplicons produced by the T modified primer
pairs shown in Tables 5 and 6 (primer names have the designation
"TMOD"). The calibration sequences were chosen as a representative
member of the section of bacterial genome from specific bacterial
species which would be amplified by a given primer pair. The model
bacterial species upon which the calibration sequences are based
are also shown in Table 10. For example, the calibration sequence
chosen to correspond to an amplicon produced by primer pair no. 361
is SEQ ID NO: 1445. In Table 10, the forward (_F) or reverse (_R)
primer name indicates the coordinates of an extraction representing
a gene of a standard reference bacterial genome to which the primer
hybridizes e.g.: the forward primer name
16S_EC.sub.--713.sub.--732_TMOD_F indicates that the forward primer
hybridizes to residues 713-732 of the gene encoding 16S ribosomal
RNA in an E. coli reference sequence (in this case, the reference
sequence is an extraction consisting of residues 4033120-4034661 of
the genomic sequence of E. coli K12 (GenBank gi number 16127994).
Additional gene coordinate reference information is shown in Table
11. The designation "TMOD" in the primer names indicates that the
5' end of the primer has been modified with a non-matched template
T residue which prevents the PCR polymerase from adding
non-templated adenosine residues to the 5' end of the amplification
product, an occurrence which may result in miscalculation of base
composition from molecular mass data (vide supra).
[0412] The 19 calibration sequences described in Tables 10 and 11
were combined into a single calibration polynucleotide sequence
(SEQ ID NO: 1464--which is herein designated a "combination
calibration polynucleotide") which was then cloned into a
pCR.RTM.-Blunt vector (Invitrogen, Carlsbad, Calif.). This
combination calibration polynucleotide can be used in conjunction
with the primers of Tables 5 or 6 as an internal standard to
produce calibration amplicons for use in determination of the
quantity of any bacterial bioagent. Thus, for example, when the
combination calibration polynucleotide vector is present in an
amplification reaction mixture, a calibration amplicon based on
primer pair 346 (16S rRNA) will be produced in an amplification
reaction with primer pair 346 and a calibration amplicon based on
primer pair 363 (rpoC) will be produced with primer pair 363.
Coordinates of each of the 19 calibration sequences within the
calibration polynucleotide (SEQ ID NO: 1464) are indicated in Table
11.
TABLE-US-00016 TABLE 10 Bacterial Primer Pairs for Production of
Bacterial Bioagent Identifying Amplicons and Corresponding
Representative Calibration Sequences Forward Reverse Calibration
Primer Primer Calibration Sequence Primer (SEQ ID (SEQ ID Sequence
Model (SEQ ID Pair No. Forward Primer Name NO:) Reverse Primer Name
NO:) Species NO:) 361 16S_EC_1090_1111_2_TMOD_F 697
16S_EC_1175_1196_TMOD_R 1398 Bacillus 1445 anthracis 346
16S_EC_713_732_TMOD_F 202 16S_EC_789_809_TMOD_R 1110 Bacillus 1446
anthracis 347 16S_EC_785_806_TMOD_F 560 16S_EC_880_897_TMOD_R 1278
Bacillus 1447 anthracis 348 16S_EC_960_981_TMOD_F 706
16S_EC_1054_1073_TMOD_R 895 Bacillus 1448 anthracis 349
23S_EC_1826_1843_TMOD_F 401 23S_EC_1906_1924_TMOD_R 1156 Bacillus
1449 anthracis 360 23S_EC_2646_2667_TMOD_F 409
23S_EC_2745_2765_TMOD_R 1434 Bacillus 1450 anthracis 350
CAPC_BA_274_303_TMOD_F 476 CAPC_BA_349_376_TMOD_R 1314 Bacillus
1451 anthracis 351 CYA_BA_1353_1379_TMOD_F 355
CYA_BA_1448_1467_TMOD_R 1423 Bacillus 1452 anthracis 352
INFB_EC_1365_1393_TMOD_F 687 INFB_EC_1439_1467_TMOD_R 1411 Bacillus
1453 anthracis 353 LEF_BA_756_781_TMOD_F 220 LEF_BA_843_872_TMOD_R
1394 Bacillus 1454 anthracis 356 RPLB_EC_650_679_TMOD_F 449
RPLB_EC_739_762_TMOD_R 1380 Clostridium 1455 botulinum 449
RPLB_EC_690_710_F 309 RPLB_EC_737_758_R 1336 Clostridium 1456
botulinum 359 RPOB_EC_1845_1866_TMOD_F 659 RPOB_EC_1909_1929_TMOD_R
1250 Yersinia 1457 Pestis 362 RPOB_EC_3799_3821_TMOD_F 581
RPOB_EC_3862_3888_TMOD_R 1325 Burkholderia 1458 mallei 363
RPOC_EC_2146_2174_TMOD_F 284 RPOC_EC_2227_2245_TMOD_R 898
Burkholderia 1459 mallei 354 RPOC_EC_2218_2241_TMOD_F 405
RPOC_EC_2313_2337_TMOD_R 1072 Bacillus 1460 anthracis 355
SSPE_BA_115_137_TMOD_F 255 SSPE_BA_197_222_TMOD_R 1402 Bacillus
1461 anthracis 367 TUFB_EC_957_979_TMOD_F 308
TUFB_EC_1034_1058_TMOD_R 1276 Burkholderia 1462 mallei 358
VALS_EC_1105_1124_TMOD_F 385 VALS_EC_1195_1218_TMOD_R 1093 Yersinia
1463 Pestis
TABLE-US-00017 TABLE 11 Primer Pair Gene Coordinate References and
Calibration Polynucleotide Sequence Coordinates within the
Combination Calibration Polynucleotide Coordinates of Gene
Extraction Calibration Sequence in Bacterial Coordinates Reference
GenBank GI Combination Calibration Gene and of Genomic or Plasmid
No. of Genomic (G) or Primer Polynucleotide (SEQ ID Species
Sequence Plasmid (P) Sequence Pair No. NO: 1464) 16S E. coli
4033120 . . . 4034661 16127994 (G) 346 16 . . . 109 16S E. coli
4033120 . . . 4034661 16127994 (G) 347 83 . . . 190 16S E. coli
4033120 . . . 4034661 16127994 (G) 348 246 . . . 353 16S E. coli
4033120 . . . 4034661 16127994 (G) 361 368 . . . 469 23S E. coli
4166220 . . . 4169123 16127994 (G) 349 743 . . . 837 23S E. coli
4166220 . . . 4169123 16127994 (G) 360 865 . . . 981 rpoB E. coli.
4178823 . . . 4182851 16127994 (G) 359 1591 . . . 1672 (complement
strand) rpoB E. coli 4178823 . . . 4182851 16127994 (G) 362 2081 .
. . 2167 (complement strand) rpoC E. coli 4182928 . . . 4187151
16127994 (G) 354 1810 . . . 1926 rpoC E. coli 4182928 . . . 4187151
16127994 (G) 363 2183 . . . 2279 infB E. coli 3313655 . . . 3310983
16127994 (G) 352 1692 . . . 1791 (complement strand) tufB E. coli
4173523 . . . 4174707 16127994 (G) 367 2400 . . . 2498 rplB E. coli
3449001 . . . 3448180 16127994 (G) 356 1945 . . . 2060 rplB E. coli
3449001 . . . 3448180 16127994 (G) 449 1986 . . . 2055 valS E. coli
4481405 . . . 4478550 16127994 (G) 358 1462 . . . 1572 (complement
strand) capC 56074 . . . 55628 6470151 (P) 350 2517 . . . 2616 B.
anthracis (complement strand) cya 156626 . . . 154288 4894216 (P)
351 1338 . . . 1449 B. anthracis (complement strand) lef 127442 . .
. 129921 4894216 (P) 353 1121 . . . 1234 B. anthracis sspE 226496 .
. . 226783 30253828 (G) 355 1007-1104 B. anthracis
Example 9
Use of a Calibration Polynucleotide for Determining the Quantity of
Bacillus Anthracis in a Sample Containing a Mixture of Microbes
[0413] The process described in this example is shown in FIG. 2.
The capC gene is a gene involved in capsule synthesis which resides
on the pX02 plasmid of Bacillus anthracis. Primer pair number 350
(see Tables 10 and 11) was designed to identify Bacillus anthracis
via production of a bacterial bioagent identifying amplicon. Known
quantities of the combination calibration polynucleotide vector
described in Example 8 were added to amplification mixtures
containing bacterial bioagent nucleic acid from a mixture of
microbes which included the Ames strain of Bacillus anthracis. Upon
amplification of the bacterial bioagent nucleic acid and the
combination calibration polynucleotide vector with primer pair no.
350, bacterial bioagent identifying amplicons and calibration
amplicons were obtained and characterized by mass spectrometry. A
mass spectrum measured for the amplification reaction is shown in
FIG. 7. The molecular masses of the bioagent identifying amplicons
provided the means for identification of the bioagent from which
they were obtained (Ames strain of Bacillus anthracis) and the
molecular masses of the calibration amplicons provided the means
for their identification as well. The relationship between the
abundance (peak height) of the calibration amplicon signals and the
bacterial bioagent identifying amplicon signals provides the means
of calculation of the copies of the pX02 plasmid of the Ames strain
of Bacillus anthracis. Methods of calculating quantities of
molecules based on internal calibration procedures are well known
to those of ordinary skill in the art.
[0414] Averaging the results of 10 repetitions of the experiment
described above, enabled a calculation that indicated that the
quantity of Ames strain of Bacillus anthracis present in the sample
corresponds to approximately 10 copies of pX02 plasmid.
Example 10
Triangulation Genotyping Analysis of Campylobacter Species
[0415] A series of triangulation genotyping analysis primers were
designed as described in Example 1 with the objective of
identification of different strains of Campylobacter jejuni. The
primers are listed in Table 12 with the designation "CJST_CJ."
Housekeeping genes to which the primers hybridize and produce
bioagent identifying amplicons include: tkt (transketolase), glyA
(serine hydroxymethyltransferase), gltA (citrate synthase), aspA
(aspartate ammonia lyase), glnA (glutamine synthase), pgm
(phosphoglycerate mutase), and uncA (ATP synthetase alpha
chain).
TABLE-US-00018 TABLE 12 Campylobacter Genotyping Primer Pairs
Primer Pair Forward Primer Reverse Primer No. Forward Primer Name
(SEQ ID NO:) Reverse Primer Name (SEQ ID NO:) Target Gene 1053
CJST_CJ_1080_1110_F 681 CJST_CJ_1166_1198_R 1022 gltA 1047
CJST_CJ_584_616_F 315 CJST_CJ_663_692_R 1379 glnA 1048
CJST_CJ_360_394_F 346 CJST_CJ_442_476_R 955 aspA 1049
CJST_CJ_2636_2668_F 504 CJST_CJ_2753_2777_R 1409 tkt 1054
CJST_CJ_2060_2090_F 323 CJST_CJ_2148_2174_R 1068 pgm 1064
CJST_CJ_1680_1713_F 479 CJST_CJ_1795_1822_R 938 glyA
[0416] The primers were used to amplify nucleic acid from 50 food
product samples provided by the USDA, 25 of which contained
Campylobacter jejuni and 25 of which contained Campylobacter coli.
Primers used in this study were developed primarily for the
discrimination of Campylobacter jejuni clonal complexes and for
distinguishing Campylobacter jejuni from Campylobacter coli. Finer
discrimination between Campylobacter coli types is also possible by
using specific primers targeted to loci where closely-related
Campylobacter coli isolates demonstrate polymorphisms between
strains. The conclusions of the comparison of base composition
analysis with sequence analysis are shown in Tables 13A-C.
TABLE-US-00019 TABLE 13A Results of Base Composition Analysis of 50
Campylobacter Samples with Drill-down MLST Primer Pair Nos: 1048
and 1047 MLST type or MLST Type or Base Composition of Base
Composition of Clonal Complex by Clonal Complex Bioagent
Identifying Bioagent Identifying Isolate Base Composition by
Sequence Amplicon Obtained with Amplicon Obtained with Group
Species origin analysis analysis Strain Primer Pair No: 1048 (aspA)
Primer Pair No: 1047 (glnA) J-1 C. Goose ST 690/ ST 991 RM3673 A30
G25 C16 T46 A47 G21 C16 T25 jejuni 692/707/991 J-2 C. Human Complex
ST 356, RM4192 A30 G25 C16 T46 A48 G21 C17 T23 jejuni 206/48/353
complex 353 J-3 C. Human Complex ST 436 RM4194 A30 G25 C15 T47 A48
G21 C18 T22 jejuni 354/179 J-4 C. Human Complex 257 ST 257, RM4197
A30 G25 C16 T46 A48 G21 C18 T22 jejuni complex 257 J-5 C. Human
Complex 52 ST 52, RM4277 A30 G25 C16 T46 A48 G21 C17 T23 jejuni
complex 52 J-6 C. Human Complex 443 ST 51, RM4275 A30 G25 C15 T47
A48 G21 C17 T23 jejuni complex 443 RM4279 A30 G25 C15 T47 A48 G21
C17 T23 J-7 C. Human Complex 42 ST 604, RM1864 A30 G25 C15 T47 A48
G21 C18 T22 jejuni complex 42 J-8 C. Human Complex ST 362, RM3193
A30 G25 C15 T47 A48 G21 C18 T22 jejuni 42/49/362 complex 362 J-9 C.
Human Complex ST 147, RM3203 A30 G25 C15 T47 A47 G21 C18 T23 jejuni
45/283 Complex 45 C. Human Consistent with 74 ST 828 RM4183 A31 G27
C20 T39 A48 G21 C16 T24 jejuni closely related C-1 C. coli sequence
types ST 832 RM1169 A31 G27 C20 T39 A48 G21 C16 T24 (none belong to
a ST 1056 RM1857 A31 G27 C20 T39 A48 G21 C16 T24 Poultry clonal
complex) ST 889 RM1166 A31 G27 C20 T39 A48 G21 C16 T24 ST 829
RM1182 A31 G27 C20 T39 A48 G21 C16 T24 ST 1050 RM1518 A31 G27 C20
T39 A48 G21 C16 T24 ST 1051 RM1521 A31 G27 C20 T39 A48 G21 C16 T24
ST 1053 RM1523 A31 G27 C20 T39 A48 G21 C16 T24 ST 1055 RM1527 A31
G27 C20 T39 A48 G21 C16 T24 ST 1017 RM1529 A31 G27 C20 T39 A48 G21
C16 T24 ST 860 RM1840 A31 G27 C20 T39 A48 G21 C16 T24 ST 1063
RM2219 A31 G27 C20 T39 A48 G21 C16 T24 ST 1066 RM2241 A31 G27 C20
T39 A48 G21 C16 T24 ST 1067 RM2243 A31 G27 C20 T39 A48 G21 C16 T24
ST 1068 RM2439 A31 G27 C20 T39 A48 G21 C16 T24 Swine ST 1016 RM3230
A31 G27 C20 T39 A48 G21 C16 T24 ST 1069 RM3231 A31 G27 C20 T39 A48
G21 C16 T24 ST 1061 RM1904 A31 G27 C20 T39 A48 G21 C16 T24 Unknown
ST 825 RM1534 A31 G27 C20 T39 A48 G21 C16 T24 ST 901 RM1505 A31 G27
C20 T39 A48 G21 C16 T24 C-2 C. coli Human ST 895 ST 895 RM1532 A31
G27 C19 T40 A48 G21 C16 T24 C-3 C. coli Poultry Consistent with 63
ST 1064 RM2223 A31 G27 C20 T39 A48 G21 C16 T24 closely related ST
1082 RM1178 A31 G27 C20 T39 A48 G21 C16 T24 sequence types ST 1054
RM1525 A31 G27 C20 T39 A48 G21 C16 T24 (none belong to a ST 1049
RM1517 A31 G27 C20 T39 A48 G21 C16 T24 Marmoset clonal complex) ST
891 RM1531 A31 G27 C20 T39 A48 G21 C16 T24
TABLE-US-00020 TABLE 13B Results of Base Composition Analysis of 50
Campylobacter Samples with Drill-down MLST Primer Pair Nos: 1053
and 1064 MLST type or MLST Type or Base Composition of Base
Composition of Clonal Complex by Clonal Complex Bioagent
Identifying Bioagent Identifying Isolate Base Composition by
Sequence Amplicon Obtained with Amplicon Obtained with Group
Species origin analysis analysis Strain Primer Pair No: 1053 (gltA)
Primer Pair No: 1064 (glyA) J-1 C. Goose ST 690/ ST 991 RM3673 A24
G25 C23 T47 A40 G29 C29 T45 jejuni 692/707/991 J-2 C. Human Complex
ST 356, RM4192 A24 G25 C23 T47 A40 G29 C29 T45 jejuni 206/48/353
complex 353 J-3 C. Human Complex ST 436 RM4194 A24 G25 C23 T47 A40
G29 C29 T45 jejuni 354/179 J-4 C. Human Complex 257 ST 257, RM4197
A24 G25 C23 T47 A40 G29 C29 T45 jejuni complex 257 J-5 C. Human
Complex 52 ST 52, RM4277 A24 G25 C23 T47 A39 G30 C26 T48 jejuni
complex 52 J-6 C. Human Complex 443 ST 51, RM4275 A24 G25 C23 T47
A39 G30 C28 T46 jejuni complex 443 RM4279 A24 G25 C23 T47 A39 G30
C28 T46 J-7 C. Human Complex 42 ST 604, RM1864 A24 G25 C23 T47 A39
G30 C26 T48 jejuni complex 42 J-8 C. Human Complex ST 362, RM3193
A24 G25 C23 T47 A38 G31 C28 T46 jejuni 42/49/362 complex 362 J-9 C.
Human Complex ST 147, RM3203 A24 G25 C23 T47 A38 G31 C28 T46 jejuni
45/283 Complex 45 C. Human Consistent with 74 ST 828 RM4183 A23 G24
C26 T46 A39 G30 C27 T47 jejuni closely related C-1 C. coli sequence
types ST 832 RM1169 A23 G24 C26 T46 A39 G30 C27 T47 (none belong to
a ST 1056 RM1857 A23 G24 C26 T46 A39 G30 C27 T47 Poultry clonal
complex) ST 889 RM1166 A23 G24 C26 T46 A39 G30 C27 T47 ST 829
RM1182 A23 G24 C26 T46 A39 G30 C27 T47 ST 1050 RM1518 A23 G24 C26
T46 A39 G30 C27 T47 ST 1051 RM1521 A23 G24 C26 T46 A39 G30 C27 T47
ST 1053 RM1523 A23 G24 C26 T46 A39 G30 C27 T47 ST 1055 RM1527 A23
G24 C26 T46 A39 G30 C27 T47 ST 1017 RM1529 A23 G24 C26 T46 A39 G30
C27 T47 ST 860 RM1840 A23 G24 C26 T46 A39 G30 C27 T47 ST 1063
RM2219 A23 G24 C26 T46 A39 G30 C27 T47 ST 1066 RM2241 A23 G24 C26
T46 A39 G30 C27 T47 ST 1067 RM2243 A23 G24 C26 T46 A39 G30 C27 T47
ST 1068 RM2439 A23 G24 C26 T46 A39 G30 C27 T47 Swine ST 1016 RM3230
A23 G24 C26 T46 A39 G30 C27 T47 ST 1069 RM3231 A23 G24 C26 T46 NO
DATA ST 1061 RM1904 A23 G24 C26 T46 A39 G30 C27 T47 Unknown ST 825
RM1534 A23 G24 C26 T46 A39 G30 C27 T47 ST 901 RM1505 A23 G24 C26
T46 A39 G30 C27 T47 C-2 C. coli Human ST 895 ST 895 RM1532 A23 G24
C26 T46 A39 G30 C27 T47 C-3 C. coli Poultry Consistent with 63 ST
1064 RM2223 A23 G24 C26 T46 A39 G30 C27 T47 closely related ST 1082
RM1178 A23 G24 C26 T46 A39 G30 C27 T47 sequence types ST 1054
RM1525 A23 G24 C25 T47 A39 G30 C27 T47 (none belong to a ST 1049
RM1517 A23 G24 C26 T46 A39 G30 C27 T47 Marmoset clonal complex) ST
891 RM1531 A23 G24 C26 T46 A39 G30 C27 T47
TABLE-US-00021 TABLE 13C Results of Base Composition Analysis of 50
Campylobacter Samples with Drill-down MLST Primer Pair Nos: 1054
and 1049 MLST type or MLST Type or Base Composition of Base
Composition of Clonal Complex by Clonal Complex Bioagent
Identifying Bioagent Identifying Isolate Base Composition by
Sequence Amplicon Obtained with Amplicon Obtained with Group
Species origin analysis analysis Strain Primer Pair No: 1054 (pgm)
Primer Pair No: 1049 (tkt) J-1 C. Goose ST 690/ ST 991 RM3673 A26
G33 C18 T38 A41 G28 C35 T38 jejuni 692/707/991 J-2 C. Human Complex
ST 356, RM4192 A26 G33 C19 T37 A41 G28 C36 T37 jejuni 206/48/353
complex 353 J-3 C. Human Complex ST 436 RM4194 A27 G32 C19 T37 A42
G28 C36 T36 jejuni 354/179 J-4 C. Human Complex 257 ST 257, RM4197
A27 G32 C19 T37 A41 G29 C35 T37 jejuni complex 257 J-5 C. Human
Complex 52 ST 52, RM4277 A26 G33 C18 T38 A41 G28 C36 T37 jejuni
complex 52 J-6 C. Human Complex 443 ST 51, RM4275 A27 G31 C19 T38
A41 G28 C36 T37 jejuni complex 443 RM4279 A27 G31 C19 T38 A41 G28
C36 T37 J-7 C. Human Complex 42 ST 604, RM1864 A27 G32 C19 T37 A42
G28 C35 T37 jejuni complex 42 J-8 C. Human Complex ST 362, RM3193
A26 G33 C19 T37 A42 G28 C35 T37 jejuni 42/49/362 complex 362 J-9 C.
Human Complex ST 147, RM3203 A28 G31 C19 T37 A43 G28 C36 T35 jejuni
45/283 Complex 45 C. Human Consistent with 74 ST 828 RM4183 A27 G30
C19 T39 A46 G28 C32 T36 jejuni closely related C-1 C. coli sequence
types ST 832 RM1169 A27 G30 C19 T39 A46 G28 C32 T36 (none belong to
a ST 1056 RM1857 A27 G30 C19 T39 A46 G28 C32 T36 Poultry clonal
complex) ST 889 RM1166 A27 G30 C19 T39 A46 G28 C32 T36 ST 829
RM1182 A27 G30 C19 T39 A46 G28 C32 T36 ST 1050 RM1518 A27 G30 C19
T39 A46 G28 C32 T36 ST 1051 RM1521 A27 G30 C19 T39 A46 G28 C32 T36
ST 1053 RM1523 A27 G30 C19 T39 A46 G28 C32 T36 ST 1055 RM1527 A27
G30 C19 T39 A46 G28 C32 T36 ST 1017 RM1529 A27 G30 C19 T39 A46 G28
C32 T36 ST 860 RM1840 A27 G30 C19 T39 A46 G28 C32 T36 ST 1063
RM2219 A27 G30 C19 T39 A46 G28 C32 T36 ST 1066 RM2241 A27 G30 C19
T39 A46 G28 C32 T36 ST 1067 RM2243 A27 G30 C19 T39 A46 G28 C32 T36
ST 1068 RM2439 A27 G30 C19 T39 A46 G28 C32 T36 Swine ST 1016 RM3230
A27 G30 C19 T39 A46 G28 C32 T36 ST 1069 RM3231 A27 G30 C19 T39 A46
G28 C32 T36 ST 1061 RM1904 A27 G30 C19 T39 A46 G28 C32 T36 Unknown
ST 825 RM1534 A27 G30 C19 T39 A46 G28 C32 T36 ST 901 RM1505 A27 G30
C19 T39 A46 G28 C32 T36 C-2 C. coli Human ST 895 ST 895 RM1532 A27
G30 C19 T39 A45 G29 C32 T36 C-3 C. coli Poultry Consistent with 63
ST 1064 RM2223 A27 G30 C19 T39 A45 G29 C32 T36 closely related ST
1082 RM1178 A27 G30 C19 T39 A45 G29 C32 T36 sequence types ST 1054
RM1525 A27 G30 C19 T39 A45 G29 C32 T36 (none belong to a ST 1049
RM1517 A27 G30 C19 T39 A45 G29 C32 T36 Marmoset clonal complex) ST
891 RM1531 A27 G30 C19 T39 A45 G29 C32 T36
[0417] The base composition analysis method was successful in
identification of 12 different strain groups. Campylobacter jejuni
and Campylobacter coli are generally differentiated by all loci.
Ten clearly differentiated Campylobacter jejuni isolates and 2
major Campylobacter coli groups were identified even though the
primers were designed for strain typing of Campylobacter jejuni.
One isolate (RM4183) which was designated as Campylobacter jejuni
was found to group with Campylobacter coli and also appears to
actually be Campylobacter coli by full MLST sequencing.
Example 11
Identification of Acinetobacter baumannii Using Broad Range Survey
and Division-Wide Primers in Epidemiological Surveillance
[0418] To test the capability of the broad range survey and
division-wide primer sets of Table 5 in identification of
Acinetobacter species, 183 clinical samples were obtained from
individuals participating in, or in contact with individuals
participating in Operation Iraqi Freedom (including US service
personnel, US civilian patients at the Walter Reed Army Institute
of Research (WRAIR), medical staff, Iraqi civilians and enemy
prisoners. In addition, 34 environmental samples were obtained from
hospitals in Iraq, Kuwait, Germany, the United States and the USNS
Comfort, a hospital ship.
[0419] Upon amplification of nucleic acid obtained from the
clinical samples, primer pairs 346-349, 360, 361, 354, 362 and 363
(Table 5) all produced bacterial bioagent amplicons which
identified Acinetobacter baumannii in 215 of 217 samples. The
organism Klebsiella pneumoniae was identified in the remaining two
samples. In addition, 14 different strain types (containing single
nucleotide polymorphisms relative to a reference strain of
Acinetobacter baumannii) were identified and assigned arbitrary
numbers from 1 to 14. Strain type 1 was found in 134 of the sample
isolates and strains 3 and 7 were found in 46 and 9 of the isolates
respectively.
[0420] The epidemiology of strain type 7 of Acinetobacter baumannii
was investigated. Strain 7 was found in 4 patients and 5
environmental samples (from field hospitals in Iraq and Kuwait).
The index patient infected with strain 7 was a pre-war patient who
had a traumatic amputation in March of 2003 and was treated at a
Kuwaiti hospital. The patient was subsequently transferred to a
hospital in Germany and then to WRAIR. Two other patients from
Kuwait infected with strain 7 were found to be non-infectious and
were not further monitored. The fourth patient was diagnosed with a
strain 7 infection in September of 2003 at WRAIR. Since the fourth
patient was not related involved in Operation Iraqi Freedom, it was
inferred that the fourth patient was the subject of a nosocomial
infection acquired at WRAIR as a result of the spread of strain 7
from the index patient.
[0421] The epidemiology of strain type 3 of Acinetobacter baumannii
was also investigated. Strain type 3 was found in 46 samples, all
of which were from patients (US service members, Iraqi civilians
and enemy prisoners) who were treated on the USNS Comfort hospital
ship and subsequently returned to Iraq or Kuwait. The occurrence of
strain type 3 in a single locale may provide evidence that at least
some of the infections at that locale were a result of nosocomial
infections.
[0422] This example thus illustrates an embodiment of the present
invention wherein the methods of analysis of bacterial bioagent
identifying amplicons provide the means for epidemiological
surveillance.
Example 12
Selection and Use of Triangulation Genotyping Analysis Primer Pairs
for Acinetobacter baumanii
[0423] To combine the power of high-throughput mass spectrometric
analysis of bioagent identifying amplicons with the sub-species
characteristic resolving power provided by triangulation genotyping
analysis, an additional 21 primer pairs were selected based on
analysis of housekeeping genes of the genus Acinetobacter. Genes to
which the drill-down triangulation genotyping analysis primers
hybridize for production of bacterial bioagent identifying
amplicons include anthranilate synthase component I (trpE),
adenylate kinase (adk), adenine glycosylase (mutY), fumarate
hydratase (fumC), and pyrophosphate phospho-hydratase (ppa). These
21 primer pairs are indicated with reference to sequence listings
in Table 14. Primer pair numbers 1151-1154 hybridize to and amplify
segments of trpE. Primer pair numbers 1155-1157 hybridize to and
amplify segments of adk. Primer pair numbers 1158-1164 hybridize to
and amplify segments of mutY. Primer pair numbers 1165-1170
hybridize to and amplify segments of fumC. Primer pair number 1171
hybridizes to and amplifies a segment of ppa. Primer pair numbers:
2846-2848 hybridize to and amplify segments of the parC gene of DNA
topoisomerase which include a codon known to confer quinolone drug
resistance upon sub-types of Acinetobacter baumannii. Primer pair
numbers 2852-2854 hybridize to and amplify segments of the gyrA
gene of DNA gyrase which include a codon known to confer quinolone
drug resistance upon sub-types of Acinetobacter baumannii. Primer
pair numbers 2922 and 2972 are speciating primers which are useful
for identifying different species members of the genus
Acinetobacter. The primer names given in Table 14A (with the
exception of primer pair numbers 2846-2848, 2852-2854) indicate the
coordinates to which the primers hybridize to a reference sequence
which comprises a concatenation of the genes TrpE, efp (elongation
factor p), adk, mutT, fumC, and ppa. For example, the forward
primer of primer pair 1151 is named
AB_MLST-11-OIF007.sub.--62.sub.--91_F because it hybridizes to the
Acinetobacter primer reference sequence of strain type 11 in sample
007 of Operation Iraqi Freedom (OIF) at positions 62 to 91. DNA was
sequenced from strain type 11 and from this sequence data and an
artificial concatenated sequence of partial gene extractions was
assembled for use in design of the triangulation genotyping
analysis primers. The stretches of arbitrary residues "N"s in the
concatenated sequence were added for the convenience of separation
of the partial gene extractions (40N for AB_MLST (SEQ ID NO:
1444)).
[0424] The hybridization coordinates of primer pair numbers
2846-2848 are with respect to GenBank Accession number X95819. The
hybridization coordinates of primer pair numbers 2852-2854 are with
respect to GenBank Accession number AY642140. Sequence residue "I"
appearing in the forward and reverse primers of primer pair number
2972 represents inosine.
TABLE-US-00022 TABLE 14A Triangulation Genotyping Analysis Primer
Pairs for Identification of Sub-species characteristics (Strain
Type) of Members of the Bacterial Genus Acinetobacter Primer
Forward Primer Reverse Primer Pair No. Forward Primer Name (SEQ ID
NO:) Reverse Primer Name (SEQ ID NO:) 1151
AB_MLST-11-OIF007_62_91_F 454 AB_MLST-11-OIF007_169_203_R 1418 1152
AB_MLST-11-OIF007_185_214_F 243 AB_MLST-11-OIF007_291_324_R 969
1153 AB_MLST-11-OIF007_260_289_F 541 AB_MLST-11-OIF007_364_393_R
1400 1154 AB_MLST-11-OIF007_206_239_F 436
AB_MLST-11-OIF007_318_344_R 1036 1155 AB_MLST-11-OIF007_522_552_F
378 AB_MLST-11-OIF007_587_610_R 1392 1156
AB_MLST-11-OIF007_547_571_F 250 AB_MLST-11-OIF007_656_686_R 902
1157 AB_MLST-11-OIF007_601_627_F 256 AB_MLST-11-OIF007_710_736_R
881 1158 AB_MLST-11-OIF007_1202_1225_F 384
AB_MLST-11-OIF007_1266_1296_R 878 1159
AB_MLST-11-OIF007_1202_1225_F 384 AB_MLST-11-OIF007_1299_1316_R
1199 1160 AB_MLST-11-OIF007_1234_1264_F 694
AB_MLST-11-OIF007_1335_1362_R 1215 1161
AB_MLST-11-OIF007_1327_1356_F 225 AB_MLST-11-OIF007_1422_1448_R
1212 1162 AB_MLST-11-OIF007_1345_1369_F 383
AB_MLST-11-OIF007_1470_1494_R 1083 1163
AB_MLST-11-OIF007_1351_1375_F 662 AB_MLST-11-OIF007_1470_1494_R
1083 1164 AB_MLST-11-OIF007_1387_1412_F 422
AB_MLST-11-OIF007_1470_1494_R 1083 1165
AB_MLST-11-OIF007_1542_1569_F 194 AB_MLST-11-OIF007_1656_1680_R
1173 1166 AB_MLST-11-OIF007_1566_1593_F 684
AB_MLST-11-OIF007_1656_1680_R 1173 1167
AB_MLST-11-OIF007_1611_1638_F 375 AB_MLST-11-OIF007_1731_1757_R 890
1168 AB_MLST-11-OIF007_1726_1752_F 182
AB_MLST-11-OIF007_1790_1821_R 1195 1169
AB_MLST-11-OIF007_1792_1826_F 656 AB_MLST-11-OIF007_1876_1909_R
1151 1170 AB_MLST-11-OIF007_1792_1826_F 656
AB_MLST-11-OIF007_1895_1927_R 1224 1171
AB_MLST-11-OIF007_1970_2002_F 618 AB_MLST-11-OIF007_2097_2118_R
1157 2846 PARC_X95819_33_58_F 302 PARC_X95819_121_153_R 852 2847
PARC_X95819_33_58_F 199 PARC_X95819_157_178_R 889 2848
PARC_X95819_33_58_F 596 PARC_X95819_97_128_R 1169 2852
GYRA_AY642140_-1_24_F 150 GYRA_AY642140_71_100_R 1242 2853
GYRA_AY642140_26_54_F 166 GYRA_AY642140_121_146_R 1069 2854
GYRA_AY642140_26_54_F 166 GYRA_AY642140_58_89_R 1168 2922
AB_MLST-11-OIF007_991_1018_F 583 AB_MLST-11-OIF007_1110_1137_R 923
2972 AB_MLST-11-OIF007_1007_1034_F 592
AB_MLST-11-OIF007_1126_1153_R 924
TABLE-US-00023 TABLE 14B Triangulation Genotyping Analysis Primer
Pairs for Identification of Sub-species characteristics (Strain
Type) of Members of the Bacterial Genus Acinetobacter Forward
Reverse Primer Primer Primer Pair (SEQ ID (SEQ ID No. NO:) SEQUENCE
NO:) SEQUENCE 1151 454 TGAGATTGCTGAACATTTAATGCTGATTGA 1418
TTGTACATTTGAAACAATATGCATGACATGTGAAT 1152 243
TATTGTTTCAAATGTACAAGGTGAAGTGCG 969
TCACAGGTTCTACTTCATCAATAATTTCCATTGC 1153 541
TGGAACGTTATCAGGTGCCCCAAAAATTCG 1400 TTGCAATCGACATATCCATTTCACCATGCC
1154 436 TGAAGTGCGTGATGATATCGATGCACTTGATGTA 1036
TCCGCCAAAAACTCCCCTTTTCACAGG 1155 378
TCGGTTTAGTAAAAGAACGTATTGCTCAACC 1392 TTCTGCTTGAGGAATAGTGCGTGG 1156
250 TCAACCTGACTGCGTGAATGGTTGT 902 TACGTTCTACGATTTCTTCATCAGGTACATC
1157 256 TCAAGCAGAAGCTTTGGAAGAAGAAGG 881
TACAACGTGATAAACACGACCAGAAGC 1158 384 TCGTGCCCGCAATTTGCATAAAGC 878
TAATGCCGGGTAGTGCAATCCATTCTTCTAG 1159 384 TCGTGCCCGCAATTTGCATAAAGC
1199 TGCACCTGCGGTCGAGCG 1160 694 TTGTAGCACAGCAAGGCAAATTTCCTGAAAC
1215 TGCCATCCATAATCACGCCATACTGACG 1161 225
TAGGTTTACGTCAGTATGGCGTGATTATGG 1212 TGCCAGTTTCCACATTTCACGTTCGTG
1162 383 TCGTGATTATGGATGGCAACGTGAA 1083 TCGCTTGAGTGTAGTCATGATTGCG
1163 662 TTATGGATGGCAACGTGAAACGCGT 1083 TCGCTTGAGTGTAGTCATGATTGCG
1164 422 TCTTTGCCATTGAAGATGACTTAAGC 1083 TCGCTTGAGTGTAGTCATGATTGCG
1165 194 TACTAGCGGTAAGCTTAAACAAGATTGC 1173
TGAGTCGGGTTCACTTTACCTGGCA 1166 684 TTGCCAATGATATTCGTTGGTTAGCAAG
1173 TGAGTCGGGTTCACTTTACCTGGCA 1167 375
TCGGCGAAATCCGTATTCCTGAAAATGA 890 TACCGGAAGCACCAGCGACATTAATAG 1168
182 TACCACTATTAATGTCGCTGGTGCTTC 1195
TGCAACTGAATAGATTGCAGTAAGTTATAAGC 1169 656
TTATAACTTACTGCAATCTATTCAGTTGCTTGGTG 1151
TGAATTATGCAAGAAGTGATCAATTTTCTCACGA 1170 656
TTATAACTTACTGCAATCTATTCAGTTGCTTGGTG 1224
TGCCGTAACTAACATAAGAGAATTATGCAAGAA 1171 618
TGGTTATGTACCAAATACTTTGTCTGAAGATGG 1157 TGACGGCATCGATACCACCGTC 2846
302 TCCAAAAAAATCAGCGCGTACAGTGG 852
TAAAGGATAGCGGTAACTAAATGGCTGAGCCAT 2847 199
TACTTGGTAAATACCACCCACATGGTGA 889 TACCCCAGTTCCCCTGACCTTC 2848 596
TGGTAAATACCACCCACATGGTGAC 1169 TGAGCCATGAGTACCATGGCTTCATAACATGC
2852 150 TAAATCTGCCCGTGTCGTTGGTGAC 1242
TGCTAAAGTCTTGAGCCATACGAACAATGG 2853 166
TAATCGGTAAATATCACCCGCATGGTGAC 1069 TCGATCGAACCGAAGTTACCCTGACC 2854
166 TAATCGGTAAATATCACCCGCATGGTGAC 1168
TGAGCCATACGAACAATGGTTTCATAAACAGC 2922 583
TGGGCGATGCTGCGAAATGGTTAAAAGA 923 TAGTATCACCACGTACACCCGGATCAGT 2972
592 TGGGIGATGCTGCIAAATGGTTAAAAGA 924
TAGTATCACCACGTACICCIGGATCAGT
[0425] Analysis of bioagent identifying amplicons obtained using
the primers of Table 14B for over 200 samples from Operation Iraqi
Freedom resulted in the identification of 50 distinct strain type
clusters. The largest cluster, designated strain type 11 (ST11)
includes 42 sample isolates, all of which were obtained from US
service personnel and Iraqi civilians treated at the 28.sup.th
Combat Support Hospital in Baghdad. Several of these individuals
were also treated on the hospital ship USNS Comfort. These
observations are indicative of significant epidemiological
correlation/linkage.
[0426] All of the sample isolates were tested against a broad panel
of antibiotics to characterize their antibiotic resistance
profiles. As an example of a representative result from antibiotic
susceptibility testing, ST11 was found to consist of four different
clusters of isolates, each with a varying degree of
sensitivity/resistance to the various antibiotics tested which
included penicillins, extended spectrum penicillins,
cephalosporins, carbepenem, protein synthesis inhibitors, nucleic
acid synthesis inhibitors, anti-metabolites, and anti-cell membrane
antibiotics. Thus, the genotyping power of bacterial bioagent
identifying amplicons, particularly drill-down bacterial bioagent
identifying amplicons, has the potential to increase the
understanding of the transmission of infections in combat
casualties, to identify the source of infection in the environment,
to track hospital transmission of nosocomial infections, and to
rapidly characterize drug-resistance profiles which enable
development of effective infection control measures on a time-scale
previously not achievable.
Example 13
Triangulation Genotyping Analysis and Codon Analysis of
Acinetobacter baumannii Samples from Two Health Care Facilities
[0427] In this investigation, 88 clinical samples were obtained
from Walter Reed Hospital and 95 clinical samples were obtained
from Northwestern Medical Center. All samples from both healthcare
facilities were suspected of containing sub-types of Acinetobacter
baumannii, at least some of which were expected to be resistant to
quinolone drugs. Each of the 183 samples was analyzed by the method
of the present invention. DNA was extracted from each of the
samples and amplified with eight triangulation genotyping analysis
primer pairs represented by primer pair numbers: 1151, 1156, 1158,
1160, 1165, 1167, 1170, and 1171. The DNA was also amplified with
speciating primer pair number 2922 and codon analysis primer pair
numbers 2846-2848 which interrogate a codon present in the parC
gene, and primer pair numbers 2852-2854 which bracket a codon
present in the gyrA gene. The parC and gyrA codon mutations are
both responsible for causing drug resistance in Acinetobacter
baumannii. During evolution of drug resistant strains, the gyrA
mutation usually occurs before the parC mutation. Amplification
products were measured by ESI-TOF mass spectrometry as indicated in
Example 4. The base compositions of the amplification products were
calculated from the average molecular masses of the amplification
products and are shown in Tables 15-18. The entries in each of the
tables are grouped according to strain type number, which is an
arbitrary number assigned to Acinetobacter baumannii strains in the
order of observance beginning from the triangulation genotyping
analysis OIF genotyping study described in Example 12. For example,
strain type 11 which appears in samples from the Walter Reed
Hospital is the same strain as the strain type 11 mentioned in
Example 12. Ibis# refers to the order in which each sample was
analyzed. Isolate refers to the original sample isolate numbering
system used at the location from which the samples were obtained
(either Walter Reed Hospital or Northwestern Medical Center).
ST=strain type. ND=not detected. Base compositions highlighted with
bold type indicate that the base composition is a unique base
composition for the amplification product obtained with the pair of
primers indicated.
TABLE-US-00024 TABLE 15A Base Compositions of Amplification
Products of 88 A. baumannii Samples Obtained from Walter Reed
Hospital and Amplified with Codon Analysis Primer Pairs Targeting
the gyrA Gene PP No: 2852 PP No: 2853 PP No: 2854 Species Ibis#
Isolate ST gyrA gyrA gyrA A. baumannii 20 1082 1 A25G23C22T31
A29G28C22T42 A17G13C14T20 A. baumannii 13 854 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 22 1162 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 27 1230 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 31 1367 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 37 1459 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 55 1700 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 64 1777 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 73 1861 10 A25G23C21T32
A29G28C21T43 A17G13C13T21 A. baumannii 74 1877 10 ND A29G28C21T43
A17G13C13T21 A. baumannii 86 1972 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 3 684 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 6 720 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 7 726 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 19 1079 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 21 1123 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 23 1188 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 33 1417 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 34 1431 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 38 1496 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 40 1523 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 42 1640 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 50 1666 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 51 1668 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 52 1695 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 65 1781 11 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 44 1649 12 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 49A 1658.1 12 A25G23C22T31 A29G28C21T43
A17G13C13T21 A. baumannii 49B 1658.2 12 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 56 1707 12 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 80 1893 12 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 5 693 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 8 749 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 10 839 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 14 865 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 16 888 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 29 1326 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 35 1440 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 41 1524 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 46 1652 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 47 1653 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 48 1657 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 57 1709 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 61 1727 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 63 1762 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 67 1806 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 75 1881 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 77 1886 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 1 649 46 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 2 653 46 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 39 1497 16 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 24 1198 15 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 28 1243 15 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 43 1648 15 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 62 1746 15 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 4 689 15 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 68 1822 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 69 1823A 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 70 1823B 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 71 1826 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 72 1860 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 81 1924 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 82 1929 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 85 1966 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 11 841 3 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. baumannii 32 1415 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 45 1651 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 54 1697 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 58 1712 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 60 1725 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 66 1802 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 76 1883 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 78 1891 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 79 1892 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 83 1947 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 84 1964 24 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 53 1696 24 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. baumannii 36 1458 49 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 59 1716 9 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. baumannii 9 805 30 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. baumannii 18 967 39 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. baumannii 30 1322 48 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. baumannii 26 1218 50 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. sp. 13TU 15 875 A1 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. sp. 13TU 17 895 A1 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. sp. 3 12 853 B7 A25G22C22T32 A30G29C22T40
A17G13C14T20 A. johnsonii 25 1202 NEW1 A25G22C22T32 A30G29C22T40
A17G13C14T20 A. sp. 2082 87 2082 NEW2 A25G22C22T32 A31G28C22T40
A17G13C14T20
TABLE-US-00025 TABLE 15B Base Compositions Determined from A.
baumannii DNA Samples Obtained from Walter Reed Hospital and
Amplified with Codon Analysis Primer Pairs Targeting the parC Gene
PP No: 2846 PP No: 2847 PP No: 2848 Species Ibis# Isolate ST parC
parC parC A. baumannii 20 1082 1 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 13 854 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 22 1162 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 27 1230 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 31 1367 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 37 1459 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 55 1700 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 64 1777 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 73 1861 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 74 1877 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 86 1972 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 3 684 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 6 720 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 7 726 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 19 1079 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 21 1123 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 23 1188 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 33 1417 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 34 1431 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 38 1496 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 40 1523 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 42 1640 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 50 1666 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 51 1668 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 52 1695 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 65 1781 11 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 44 1649 12 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 49A 1658.1 12 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 49B 1658.2 12 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 56 1707 12 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 80 1893 12 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 5 693 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 8 749 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 10 839 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 14 865 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 16 888 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 29 1326 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 35 1440 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 41 1524 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 46 1652 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 47 1653 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 48 1657 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 57 1709 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 61 1727 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 63 1762 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 67 1806 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 75 1881 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 77 1886 14 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 1 649 46 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 2 653 46 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 39 1497 16 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 24 1198 15 A33G26C28T34 A29G29C23T33
A16G14C14T16 A. baumannii 28 1243 15 A33G26C28T34 A29G29C23T33
A16G14C14T16 A. baumannii 43 1648 15 A33G26C28T34 A29G29C23T33
A16G14C14T16 A. baumannii 62 1746 15 A33G26C28T34 A29G29C23T33
A16G14C14T16 A. baumannii 4 689 15 A34G25C29T33 A30G27C26T31
A16G14C15T15 A. baumannii 68 1822 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 69 1823A 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 70 1823B 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 71 1826 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 72 1860 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 81 1924 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 82 1929 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 85 1966 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 11 841 3 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 32 1415 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 45 1651 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 54 1697 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 58 1712 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 60 1725 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 66 1802 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 76 1883 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 78 1891 24 A34G25C29T33 A30G27C26T31
A16G14C15T15 A. baumannii 79 1892 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 83 1947 24 A34G25C29T33 A30G27C26T31
A16G14C15T15 A. baumannii 84 1964 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 53 1696 24 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 36 1458 49 A34G26C29T32 A30G28C24T32
A16G14C15T15 A. baumannii 59 1716 9 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 9 805 30 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 18 967 39 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 30 1322 48 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. baumannii 26 1218 50 A33G26C29T33 A29G28C26T31
A16G14C15T15 A. sp. 13TU 15 875 A1 A32G26C28T35 A28G28C24T34
A16G14C15T15 A. sp. 13TU 17 895 A1 A32G26C28T35 A28G28C24T34
A16G14C15T15 A. sp. 3 12 853 B7 A29G26C27T39 A26G32C21T35
A16G14C15T15 A. johnsonii 25 1202 NEW1 A32G28C26T35 A29G29C22T34
A16G14C15T15 A. sp. 2082 87 2082 NEW2 A33G27C26T35 A31G28C20T35
A16G14C15T15
TABLE-US-00026 TABLE 16A Base Compositions Determined from A.
baumannii DNA Samples Obtained from Northwestern Medical Center and
Amplified with Codon Analysis Primer Pairs Targeting the gyrA Gene
PP No: 2852 PP No: 2853 PP No: 2854 Species Ibis# Isolate ST gyrA
gyrA gyrA A. baumannii 54 536 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 87 665 3 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 8 80 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 9 91 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 10 92 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 11 131 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 12 137 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 21 218 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 26 242 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 94 678 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 1 9 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 2 13 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 3 19 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 4 24 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 5 36 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 6 39 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 13 139 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 15 165 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 16 170 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 17 186 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 20 202 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 22 221 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 24 234 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 25 239 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 33 370 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 34 389 10 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 19 201 14 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 27 257 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 29 301 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 31 354 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 36 422 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 37 424 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 38 434 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 39 473 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 40 482 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 44 512 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 45 516 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 47 522 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 48 526 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 50 528 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 52 531 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 53 533 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 56 542 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 59 550 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 62 556 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 64 557 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 70 588 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 73 603 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 74 605 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 75 606 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 77 611 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 79 622 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 83 643 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 85 653 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 89 669 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 93 674 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 23 228 51 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 32 369 52 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 35 393 52 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 30 339 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 41 485 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 42 493 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 43 502 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 46 520 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 49 527 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 51 529 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 65 562 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 68 579 53 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 57 546 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 58 548 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 60 552 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 61 555 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 63 557 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 66 570 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 67 578 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 69 584 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 71 593 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 72 602 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 76 609 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 78 621 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 80 625 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 81 628 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 82 632 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 84 649 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 86 655 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 88 668 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 90 671 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 91 672 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 92 673 54 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 18 196 55 A25G23C22T31 A29G28C21T43
A17G13C13T21 A. baumannii 55 537 27 A25G23C21T32 A29G28C21T43
A17G13C13T21 A. baumannii 28 263 27 A25G23C22T31 A29G28C22T42
A17G13C14T20 A. sp. 3 14 164 B7 A25G22C22T32 A30G29C22T40
A17G13C14T20 mixture 7 71 -- ND ND A17G13C15T19
TABLE-US-00027 TABLE 16B Base Compositions Determined from A.
baumannii DNA Samples Obtained from Northwestern Medical Center and
Amplified with Codon Analysis Primer Pairs Targeting the parC Gene
PP No: 2846 PP No: 2847 PP No: 2848 Species Ibis# Isolate ST parC
parC parC A. baumannii 54 536 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 87 665 3 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 8 80 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 9 91 10 A33G26C28T34 A29G28C25T32
A16G14C14T16 A. baumannii 10 92 10 A33G26C28T34 A29G28C25T32 ND A.
baumannii 11 131 10 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 12 137 10 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 21 218 10 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 26 242 10 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 94 678 10 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 1 9 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 2 13 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 3 19 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 4 24 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 5 36 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 6 39 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 13 139 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 15 165 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 16 170 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 17 186 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 20 202 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 22 221 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 24 234 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 25 239 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 33 370 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 34 389 10 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 19 201 14 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 27 257 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 29 301 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 31 354 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 36 422 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 37 424 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 38 434 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 39 473 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 40 482 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 44 512 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 45 516 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 47 522 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 48 526 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 50 528 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 52 531 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 53 533 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 56 542 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 59 550 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 62 556 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 64 557 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 70 588 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 73 603 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 74 605 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 75 606 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 77 611 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 79 622 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 83 643 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 85 653 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 89 669 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 93 674 51 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 23 228 51 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 32 369 52 A34G25C28T34 A30G27C25T32 A16G14C14T16 A.
baumannii 35 393 52 A34G25C28T34 A30G27C25T32 A16G14C14T16 A.
baumannii 30 339 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 41 485 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 42 493 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 43 502 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 46 520 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 49 527 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 51 529 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 65 562 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 68 579 53 A34G25C29T33 A30G27C26T31 A16G14C15T15 A.
baumannii 57 546 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 58 548 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 60 552 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 61 555 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 63 557 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 66 570 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 67 578 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 69 584 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 71 593 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 72 602 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 76 609 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 78 621 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 80 625 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 81 628 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 82 632 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 84 649 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 86 655 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 88 668 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 90 671 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 91 672 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 92 673 54 A33G26C28T34 A29G28C25T32 A16G14C14T16 A.
baumannii 18 196 55 A33G27C28T33 A29G28C25T31 A15G14C15T16 A.
baumannii 55 537 27 A33G26C29T33 A29G28C26T31 A16G14C15T15 A.
baumannii 28 263 27 A33G26C29T33 A29G28C26T31 A16G14C15T15 A. sp. 3
14 164 B7 A35G25C29T32 A30G28C17T39 A16G14C15T15 mixture 7 71 -- ND
ND A17G14C15T14
TABLE-US-00028 TABLE 17A Base Compositions Determined from A.
baumannii DNA Samples Obtained from Walter Reed Hospital and
Amplified with Speciating Primer Pair No. 2922 and Triangulation
Genotyping Analysis Primer Pair Nos. 1151 and 1156 PP No: 2922 PP
No: 1151 PP No: 1156 Species Ibis# Isolate ST efp trpE Adk A.
baumannii 20 1082 1 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 13 854 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 22 1162 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 27 1230 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 31 1367 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 37 1459 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 55 1700 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 64 1777 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 73 1861 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 74 1877 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 86 1972 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 3 684 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 6 720 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 7 726 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 19 1079 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 21 1123 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 23 1188 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 33 1417 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 34 1431 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 38 1496 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 40 1523 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 42 1640 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 50 1666 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 51 1668 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 52 1695 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 65 1781 11 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 44 1649 12 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 49A 1658.1 12 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 49B 1658.2 12 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 56 1707 12 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 80 1893 12 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 5 693 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A.
baumannii 8 749 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A.
baumannii 10 839 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A.
baumannii 14 865 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A.
baumannii 16 888 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A.
baumannii 29 1326 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A.
baumannii 35 1440 14 A44G35C25T43 ND A44G32C27T37 A. baumannii 41
1524 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 46 1652
14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 47 1653 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 48 1657 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 57 1709 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 61 1727 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 63 1762 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 67 1806 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 75 1881 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 77 1886 14
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 1 649 46
A44G35C25T43 A44G35C22T41 A44G32C26T38 A. baumannii 2 653 46
A44G35C25T43 A44G35C22T41 A44G32C26T38 A. baumannii 39 1497 16
A44G35C25T43 A44G35C22T41 A44G32C27T37 A. baumannii 24 1198 15
A44G35C25T43 A44G35C22T41 A44G32C26T38 A. baumannii 28 1243 15
A44G35C25T43 A44G35C22T41 A44G32C26T38 A. baumannii 43 1648 15
A44G35C25T43 A44G35C22T41 A44G32C26T38 A. baumannii 62 1746 15
A44G35C25T43 A44G35C22T41 A44G32C26T38 A. baumannii 4 689 15
A44G35C25T43 A44G35C22T41 A44G32C26T38 A. baumannii 68 1822 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 69 1823A 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 70 1823B 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 71 1826 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 72 1860 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 81 1924 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 82 1929 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 85 1966 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 11 841 3
A44G35C24T44 A44G35C22T41 A44G32C26T38 A. baumannii 32 1415 24
A44G35C25T43 A43G36C20T43 A44G32C27T37 A. baumannii 45 1651 24
A44G35C25T43 A43G36C20T43 A44G32C27T37 A. baumannii 54 1697 24
A44G35C25T43 A43G36C20T43 A44G32C27T37 A. baumannii 58 1712 24
A44G35C25T43 A43G36C20T43 A44G32C27T37 A. baumannii 60 1725 24
A44G35C25T43 A43G36C20T43 A44G32C27T37 A. baumannii 66 1802 24
A44G35C25T43 A43G36C20T43 A44G32C27T37 A. baumannii 76 1883 24 ND
A43G36C20T43 A44G32C27T37 A. baumannii 78 1891 24 A44G35C25T43
A43G36C20T43 A44G32C27T37 A. baumannii 79 1892 24 A44G35C25T43
A43G36C20T43 A44G32C27T37 A. baumannii 83 1947 24 A44G35C25T43
A43G36C20T43 A44G32C27T37 A. baumannii 84 1964 24 A44G35C25T43
A43G36C20T43 A44G32C27T37 A. baumannii 53 1696 24 A44G35C25T43
A43G36C20T43 A44G32C27T37 A. baumannii 36 1458 49 A44G35C25T43
A44G35C22T41 A44G32C27T37 A. baumannii 59 1716 9 A44G35C25T43
A44G35C21T42 A44G32C26T38 A. baumannii 9 805 30 A44G35C25T43
A44G35C19T44 A44G32C27T37 A. baumannii 18 967 39 A45G34C25T43
A44G35C22T41 A44G32C26T38 A. baumannii 30 1322 48 A44G35C25T43
A43G36C20T43 A44G32C27T37 A. baumannii 26 1218 50 A44G35C25T43
A44G35C21T42 A44G32C26T38 A. sp. 13TU 15 875 A1 A47G33C24T43
A46G32C20T44 A44G33C27T36 A. sp. 13TU 17 895 A1 A47G33C24T43
A46G32C20T44 A44G33C27T36 A. sp. 3 12 853 B7 A46G35C24T42
A42G34C20T46 A43G33C24T40 A. johnsonii 25 1202 NEW1 A46G35C23T43
A42G35C21T44 A43G33C23T41 A. sp. 2082 87 2082 NEW2 A46G36C22T43
A42G32C20T48 A42G34C23T41
TABLE-US-00029 TABLE 17B Base Compositions Determined from A.
baumannii DNA Samples Obtained from Walter Reed Hospital and
Amplified with Triangulation Genotyping Analysis Primer Pair Nos.
1158 and 1160 and 1165 PP No: 1158 PP No: 1160 PP No: 1165 Species
Ibis# Isolate ST mutY mutY fumC A. baumannii 20 1082 1 A27G21C25T22
A32G35C29T33 A40G33C30T36 A. baumannii 13 854 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 22 1162 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 27 1230 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 31 1367 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 37 1459 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 55 1700 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 64 1777 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 73 1861 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 74 1877 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 86 1972 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 3 684 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 6 720 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 7 726 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 19 1079 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 21 1123 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 23 1188 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 33 1417 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 34 1431 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 38 1496 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 40 1523 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 42 1640 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 50 1666 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 51 1668 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 52 1695 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 65 1781 11 A27G21C25T22
A32G34C28T35 A40G33C30T36 A. baumannii 44 1649 12 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 49A 1658.1 12 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 49B 1658.2 12 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 56 1707 12 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 80 1893 12 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 5 693 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 8 749 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 10 839 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 14 865 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 16 888 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 29 1326 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 35 1440 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 41 1524 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 46 1652 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 47 1653 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 48 1657 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 57 1709 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 61 1727 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 63 1762 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 67 1806 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 75 1881 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 77 1886 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 1 649 46 A29G19C26T21
A31G35C29T34 A40G33C29T37 A. baumannii 2 653 46 A29G19C26T21
A31G35C29T34 A40G33C29T37 A. baumannii 39 1497 16 A29G19C26T21
A31G35C29T34 A40G34C29T36 A. baumannii 24 1198 15 A29G19C26T21
A31G35C29T34 A40G33C29T37 A. baumannii 28 1243 15 A29G19C26T21
A31G35C29T34 A40G33C29T37 A. baumannii 43 1648 15 A29G19C26T21
A31G35C29T34 A40G33C29T37 A. baumannii 62 1746 15 A29G19C26T21
A31G35C29T34 A40G33C29T37 A. baumannii 4 689 15 A29G19C26T21
A31G35C29T34 A40G33C29T37 A. baumannii 68 1822 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 69 1823A 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 70 1823B 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 71 1826 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 72 1860 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 81 1924 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 82 1929 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 85 1966 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 11 841 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 32 1415 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 45 1651 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 54 1697 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 58 1712 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 60 1725 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 66 1802 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 76 1883 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 78 1891 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 79 1892 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 83 1947 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 84 1964 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 53 1696 24 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 36 1458 49 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 59 1716 9 A27G21C25T22
A32G35C28T34 A39G33C30T37 A. baumannii 9 805 30 A27G21C25T22
A32G35C28T34 A39G33C30T37 A. baumannii 18 967 39 A27G21C26T21
A32G35C28T34 A39G33C30T37 A. baumannii 30 1322 48 A28G21C24T22
A32G35C29T33 A40G33C30T36 A. baumannii 26 1218 50 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. sp. 13TU 15 875 A1 A27G21C25T22
A30G36C26T37 A41G34C28T36 A. sp. 13TU 17 895 A1 A27G21C25T22
A30G36C26T37 A41G34C28T36 A. sp. 3 12 853 B7 A26G23C23T23
A30G36C27T36 A39G37C26T37 A. johnsonii 25 1202 NEW1 A25G23C24T23
A30G35C30T34 A38G37C26T38 A. sp. 2082 87 2082 NEW2 A26G22C24T23
A31G35C28T35 A42G34C27T36
TABLE-US-00030 TABLE 17C Base Compositions Determined from A.
baumannii DNA Samples Obtained from Walter Reed Hospital and
Amplified with Triangulation Genotyping Analysis Primer Pair Nos.
1167 and 1170 and 1171 PP No: 1167 PP No: 1170 PP No: 1171 Species
Ibis# Isolate ST fumC fumC ppa A. baumannii 20 1082 1 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 13 854 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 22 1162 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 27 1230 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 31 1367 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 37 1459 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 55 1700 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 64 1777 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 73 1861 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 74 1877 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 86 1972 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 3 684 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 6 720 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 7 726 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 19 1079 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 21 1123 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 23 1188 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 33 1417 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 34 1431 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 38 1496 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 40 1523 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 42 1640 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 50 1666 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 51 1668 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 52 1695 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 65 1781 11 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 44 1649 12 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 49A 1658.1 12 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 49B 1658.2 12 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 56 1707 12 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 80 1893 12 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 5 693 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 8 749 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 10 839 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 14 865 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 16 888 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 29 1326 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 35 1440 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 41 1524 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 46 1652 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 47 1653 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 48 1657 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 57 1709 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 61 1727 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 63 1762 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 67 1806 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 75 1881 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 77 1886 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 1 649 46 A41G35C32T39
A37G28C20T51 A35G37C32T45 A. baumannii 2 653 46 A41G35C32T39
A37G28C20T51 A35G37C32T45 A. baumannii 39 1497 16 A41G35C32T39
A37G28C20T51 A35G37C30T47 A. baumannii 24 1198 15 A41G35C32T39
A37G28C20T51 A35G37C30T47 A. baumannii 28 1243 15 A41G35C32T39
A37G28C20T51 A35G37C30T47 A. baumannii 43 1648 15 A41G35C32T39
A37G28C20T51 A35G37C30T47 A. baumannii 62 1746 15 A41G35C32T39
A37G28C20T51 A35G37C30T47 A. baumannii 4 689 15 A41G35C32T39
A37G28C20T51 A35G37C30T47 A. baumannii 68 1822 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 69 1823A 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 70 1823B 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 71 1826 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 72 1860 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 81 1924 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 82 1929 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 85 1966 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 11 841 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 32 1415 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 45 1651 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 54 1697 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 58 1712 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 60 1725 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 66 1802 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 76 1883 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 78 1891 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 79 1892 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 83 1947 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 84 1964 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 53 1696 24 A40G35C34T38
A39G26C22T49 A35G37C33T44 A. baumannii 36 1458 49 A40G35C34T38
A39G26C22T49 A35G37C30T47 A. baumannii 59 1716 9 A40G35C32T40
A38G27C20T51 A36G35C31T47 A. baumannii 9 805 30 A40G35C32T40
A38G27C21T50 A35G36C29T49 A. baumannii 18 967 39 A40G35C33T39
A38G27C20T51 A35G37C30T47 A. baumannii 30 1322 48 A40G35C35T37
A38G27C21T50 A35G37C30T47 A. baumannii 26 1218 50 A40G35C34T38
A38G27C21T50 A35G37C33T44 A. sp. 13TU 15 875 A1 A41G39C31T36
A37G26C24T49 A34G38C31T46 A. sp. 13TU 17 895 A1 A41G39C31T36
A37G26C24T49 A34G38C31T46 A. sp. 3 12 853 B7 A43G37C30T37
A36G27C24T49 A34G37C31T47 A. johnsonii 25 1202 NEW1 A42G38C31T36
A40G27C19T50 A35G37C32T45 A. sp. 2082 87 2082 NEW2 A43G37C32T35
A37G26C21T52 A35G38C31T45
TABLE-US-00031 TABLE 18A Base Compositions Determined from A.
baumannii DNA Samples Obtained from Northwestern Medical Center and
Amplified with Speciating Primer Pair No. 2922 and Triangulation
Genotyping Analysis Primer Pair Nos. 1151 and 1156 PP No: 2922 PP
No: 1151 PP No: 1156 Species Ibis# Isolate ST efp trpE adk A.
baumannii 54 536 3 A44G35C24T44 A44G35C22T41 A44G32C26T38 A.
baumannii 87 665 3 A44G35C24T44 A44G35C22T41 A44G32C26T38 A.
baumannii 8 80 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 9 91 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 10 92 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 11 131 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 12 137 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 21 218 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 26 242 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 94 678 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 1 9 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 2 13 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 3 19 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 4 24 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 5 36 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 6 39 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 13 139 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 15 165 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 16 170 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 17 186 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 20 202 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 22 221 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 24 234 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 25 239 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 33 370 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 34 389 10 A45G34C25T43 A44G35C21T42 A44G32C26T38 A.
baumannii 19 201 14 A44G35C25T43 A44G35C22T41 A44G32C27T37 A.
baumannii 27 257 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 29 301 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 31 354 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 36 422 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 37 424 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 38 434 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 39 473 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 40 482 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 44 512 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 45 516 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 47 522 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 48 526 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 50 528 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 52 531 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 53 533 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 56 542 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 59 550 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 62 556 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 64 557 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 70 588 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 73 603 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 74 605 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 75 606 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 77 611 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 79 622 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 83 643 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 85 653 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 89 669 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 93 674 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 23 228 51 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 32 369 52 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 35 393 52 A44G35C25T43 A43G36C20T43 A44G32C26T38 A.
baumannii 30 339 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 41 485 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 42 493 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 43 502 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 46 520 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 49 527 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 51 529 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 65 562 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 68 579 53 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 57 546 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 58 548 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 60 552 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 61 555 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 63 557 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 66 570 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 67 578 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 69 584 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 71 593 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 72 602 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 76 609 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 78 621 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 80 625 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 81 628 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 82 632 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 84 649 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 86 655 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 88 668 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 90 671 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 91 672 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 92 673 54 A44G35C25T43 A44G35C20T43 A44G32C26T38 A.
baumannii 18 196 55 A44G35C25T43 A44G35C20T43 A44G32C27T37 A.
baumannii 55 537 27 A44G35C25T43 A44G35C19T44 A44G32C27T37 A.
baumannii 28 263 27 A44G35C25T43 A44G35C19T44 A44G32C27T37 A. sp. 3
14 164 B7 A46G35C24T42 A42G34C20T46 A43G33C24T40 mixture 7 71 ?
mixture ND ND
TABLE-US-00032 TABLE 18B Base Compositions Determined from A.
baumannii DNA Samples Obtained from Northwestern Medical Center and
Amplified with Triangulation Genotyping Analysis Primer Pair Nos.
1158, 1160 and 1165 PP No: 1158 PP No: 1160 PP No: 1165 Species
Ibis# Isolate ST mutY mutY fumC A. baumannii 54 536 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 87 665 3 A27G20C27T21
A32G35C28T34 A40G33C30T36 A. baumannii 8 80 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 9 91 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 10 92 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 11 131 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 12 137 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 21 218 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 26 242 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 94 678 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 1 9 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 2 13 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 3 19 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 4 24 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 5 36 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 6 39 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 13 139 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 15 165 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 16 170 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 17 186 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 20 202 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 22 221 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 24 234 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 25 239 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 33 370 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 34 389 10 A27G21C26T21
A32G35C28T34 A40G33C30T36 A. baumannii 19 201 14 A27G21C25T22
A31G36C28T34 A40G33C29T37 A. baumannii 27 257 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 29 301 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 31 354 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 36 422 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 37 424 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 38 434 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 39 473 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 40 482 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 44 512 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 45 516 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 47 522 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 48 526 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 50 528 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 52 531 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 53 533 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 56 542 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 59 550 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 62 556 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 64 557 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 70 588 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 73 603 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 74 605 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 75 606 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 77 611 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 79 622 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 83 643 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 85 653 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 89 669 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 93 674 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 23 228 51 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 32 369 52 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 35 393 52 A27G21C25T22
A32G35C28T34 A40G33C29T37 A. baumannii 30 339 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 41 485 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 42 493 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 43 502 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 46 520 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 49 527 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 51 529 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 65 562 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 68 579 53 A28G20C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 57 546 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 58 548 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 60 552 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 61 555 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 63 557 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 66 570 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 67 578 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 69 584 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 71 593 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 72 602 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 76 609 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 78 621 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 80 625 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 81 628 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 82 632 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 84 649 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 86 655 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 88 668 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 90 671 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 91 672 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 92 673 54 A27G21C26T21
A32G34C29T34 A40G33C30T36 A. baumannii 18 196 55 A27G21C25T22
A31G36C27T35 A40G33C29T37 A. baumannii 55 537 27 A27G21C25T22
A32G35C28T34 A40G33C30T36 A. baumannii 28 263 27 A27G21C25T22
A32G35C28T34 A40G33C30T36 A. sp. 3 14 164 B7 A26G23C23T23
A30G36C27T36 A39G37C26T37 mixture 7 71 ? ND ND ND
TABLE-US-00033 TABLE 18C Base Compositions Determined from A.
baumannii DNA Samples Obtained from Northwestern Medical Center and
Amplified with Triangulation Genotyping Analysis Primer Pair Nos.
1167, 1170 and 1171 PP No: 1167 PP No: 1170 PP No: 1171 Species
Ibis# Isolate ST fumC fumC ppa A. baumannii 54 536 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 87 665 3 A41G34C35T37
A38G27C20T51 A35G37C31T46 A. baumannii 8 80 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 9 91 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 10 92 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 11 131 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 12 137 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 21 218 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 26 242 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 94 678 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 1 9 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 2 13 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 3 19 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 4 24 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 5 36 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 6 39 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 13 139 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 15 165 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 16 170 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 17 186 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 20 202 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 22 221 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 24 234 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 25 239 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 33 370 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 34 389 10 A41G34C34T38
A38G27C21T50 A35G37C33T44 A. baumannii 19 201 14 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 27 257 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 29 301 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 31 354 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 36 422 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 37 424 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 38 434 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 39 473 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 40 482 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 44 512 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 45 516 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 47 522 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 48 526 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 50 528 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 52 531 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 53 533 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 56 542 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 59 550 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 62 556 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 64 557 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 70 588 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 73 603 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 74 605 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 75 606 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 77 611 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 79 622 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 83 643 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 85 653 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 89 669 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 93 674 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 23 228 51 A40G35C34T38
A38G27C21T50 A35G37C30T47 A. baumannii 32 369 52 A40G35C34T38
A38G27C21T50 A35G37C31T46 A. baumannii 35 393 52 A40G35C34T38
A38G27C21T50 A35G37C31T46 A. baumannii 30 339 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 41 485 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 42 493 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 43 502 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 46 520 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 49 527 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 51 529 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 65 562 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 68 579 53 A40G35C35T37
A38G27C21T50 A35G37C31T46 A. baumannii 57 546 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 58 548 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 60 552 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 61 555 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 63 557 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 66 570 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 67 578 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 69 584 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 71 593 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 72 602 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 76 609 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 78 621 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 80 625 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 81 628 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 82 632 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 84 649 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 86 655 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 88 668 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 90 671 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 91 672 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 92 673 54 A40G35C34T38
A39G26C22T49 A35G37C31T46 A. baumannii 18 196 55 A42G34C33T38
A38G27C20T51 A35G37C31T46 A. baumannii 55 537 27 A40G35C33T39
A38G27C20T51 A35G37C33T44 A. baumannii 28 263 27 A40G35C33T39
A38G27C20T51 A35G37C33T44 A. sp. 3 14 164 B7 A43G37C30T37
A36G27C24T49 A34G37C31T47 mixture 7 71 -- ND ND ND
[0428] Base composition analysis of the samples obtained from
Walter Reed hospital indicated that a majority of the strain types
identified were the same strain types already characterized by the
OIF study of Example 12. This is not surprising since at least some
patients from which clinical samples were obtained in OIF were
transferred to the Walter Reed Hospital (WRAIR). Examples of these
common strain types include: ST10, ST11, ST12, ST14, ST15, ST16 and
ST46. A strong correlation was noted between these strain types and
the presence of mutations in the gyrA and parC which confer
quinolone drug resistance.
[0429] In contrast, the results of base composition analysis of
samples obtained from Northwestern Medical Center indicate the
presence of 4 major strain types: ST10, ST51, ST53 and ST54. All of
these strain types have the gyrA quinolone resistance mutation and
most also have the parC quinolone resistance mutation, with the
exception of ST35. This observation is consistent with the current
understanding that the gyrA mutation generally appears before the
parC mutation and suggests that the acquisition of these drug
resistance mutations is rather recent and that resistant isolates
are taking over the wild-type isolates. Another interesting
observation was that a single isolate of ST3 (isolate 841) displays
a triangulation genotyping analysis pattern similar to other
isolates of ST3, but the codon analysis amplification product base
compositions indicate that this isolate has not yet undergone the
quinolone resistance mutations in gyrA and parC.
[0430] The six isolates that represent species other than
Acinetobacter baumannii in the samples obtained from the Walter
Reed Hospital were each found to not carry the drug resistance
mutations.
[0431] The results described above involved analysis of 183 samples
using the methods and compositions of the present invention.
Results were provided to collaborators at the Walter Reed hospital
and Northwestern Medical center within a week of obtaining samples.
This example highlights the rapid throughput characteristics of the
analysis platform and the resolving power of triangulation
genotyping analysis and codon analysis for identification of and
determination of drug resistance in bacteria.
Example 14
Identification of Drug Resistance Genes and Virulence Factors in
Staphylococcus aureus
[0432] An eight primer pair panel was designed for identification
of drug resistance genes and virulence factors of Staphylococcus
aureus and is shown in Table 19. The primer sequences are found in
Table 2 and are cross-referenced by the primer pair numbers, primer
pair names or SEQ ID NOs listed in Table 19.
TABLE-US-00034 TABLE 19 Primer Pairs for Identification of Drug
Resistance Genes and Virulence Factors in Staphylococcus aureus
Forward Reverse Primer Primer Primer Pair (SEQ ID (SEQ ID Target
No. Forward Primer Name NO:) Reverse Primer Name NO:) Gene 879
MECA_Y14051_4507_4530_F 288 MECA_Y14051_4555_4581_R 1269 mecA 2056
MECI-R_NC003923-41798- 698 MECI-R_NC003923-41798- 1420 MecI-R
41609_33_60_F 41609_86_113_R 2081 ERMA_NC002952-55890- 217
ERMA_NC002952-55890- 1167 ermA 56621_366_395_F 56621_438_465_R 2086
ERMC_NC005908-2004- 399 ERMC_NC005908-2004- 1041 ermC 2738_85_116_F
2738_173_206_R 2095 PVLUK_NC003923-1529595- 456
PVLUK_NC003923-1529595- 1261 Pv-luk 1531285_688_713_F
1531285_775_804_R 2249 TUFB_NC002758-615038- 430
TUFB_NC002758-615038- 1321 tufB 616222_696_725_F 616222_793_820_R
2256 NUC_NC002758-894288- 174 NUC_NC002758-894288- 853 Nuc
894974_316_345_F 894974_396_421_R 2313 MUPR_X75439_2486_2516_F 172
MUPR_X75439_2548_2574_R 1360 mupR
[0433] Primer pair numbers 2256 and 2249 are confirmation primers
designed with the aim of high level identification of
Staphylococcus aureus. The nuc gene is a Staphylococcus
aureus-specific marker gene. The tufB gene is a universal
housekeeping gene but the bioagent identifying amplicon defined by
primer pair number 2249 provides a unique base composition (A43 G28
C19 T35) which distinguishes Staphylococcus aureus from other
members of the genus Staphylococcus.
[0434] High level methicillin resistance in a given strain of
Staphylococcus aureus is indicated by bioagent identifying
amplicons defined by primer pair numbers 879 and 2056. Analyses
have indicated that primer pair number 879 is not expected to prime
S. sciuri homolog or Enterococcus faecalis/faciem
ampicillin-resistant PBP5 homologs.
[0435] Macrolide and erythromycin resistance in a given strain of
Staphylococcus aureus is indicated by bioagent identifying
amplicons defined by primer pair numbers 2081 and 2086.
[0436] Resistance to mupriocin in a given strain of Staphylococcus
aureus is indicated by bioagent identifying amplicons defined by
primer pair number 2313.
[0437] Virulence in a given strain of Staphylococcus aureus is
indicated by bioagent identifying amplicons defined by primer pair
number 2095. This primer pair can simultaneously and identify the
pvl (lukS-PV) gene and the lukD gene which encodes a homologous
enterotoxin. A bioagent identifying amplicon of the lukD gene has a
six nucleobase length difference relative to the lukS-PV gene.
[0438] A total of 32 blinded samples of different strains of
Staphylococcus aureus were provided by the Center for Disease
Control (CDC). Each sample was analyzed by PCR amplification with
the eight primer pair panel, followed by purification and
measurement of molecular masses of the amplification products by
mass spectrometry. Base compositions for the amplification products
were calculated. The base compositions provide the information
summarized above for each primer pair. The results are shown in
Tables 20A and B. One result noted upon un-blinding of the samples
is that each of the PVL+ identifications agreed with PVL+
identified in the same samples by standard PCR assays. These
results indicate that the panel of eight primer pairs is useful for
identification of drug resistance and virulence sub-species
characteristics for Staphylococcus aureus. It is expected that a
kit comprising one or more of the members of this panel will be a
useful embodiment of the present invention.
TABLE-US-00035 TABLE 20A Drug Resistance and Virulence Identified
in Blinded Samples of Various Strains of Staphylococcus aureus with
Primer Pair Nos. 2081, 2086, 2095 and 2256 Primer Primer Sample
Pair No. Primer Pair No. Primer Pair No. Pair No. Index No. 2081
(ermA) 2086 (ermC) 2095 (pv-luk) 2256 (nuc) CDC0010 - - PVL-/lukD+
+ CDC0015 - - PVL+/lukD+ + CDC0019 - + PVL-/lukD+ + CDC0026 + -
PVL-/lukD+ + CDC0030 + - PVL-/lukD+ + CDC004 - - PVL+/lukD+ +
CDC0014 - + PVL+/lukD+ + CDC008 - - PVL-/lukD+ + CDC001 + -
PVL-/lukD+ + CDC0022 + - PVL-/lukD+ + CDC006 + - PVL-/lukD+ +
CDC007 - - PVL-/lukD+ + CDCVRSA1 + - PVL-/lukD+ + CDCVRSA2 + +
PVL-/lukD+ + CDC0011 + - PVL-/lukD+ + CDC0012 - - PVL+/lukD- +
CDC0021 + - PVL-/lukD+ + CDC0023 + - PVL-/lukD+ + CDC0025 + -
PVL-/lukD+ + CDC005 - - PVL-/lukD+ + CDC0018 + - PVL+/lukD- +
CDC002 - - PVL-/lukD+ + CDC0028 + - PVL-/lukD+ + CDC003 - -
PVL-/lukD+ + CDC0013 - - PVL+/lukD+ + CDC0016 - - PVL-/lukD+ +
CDC0027 + - PVL-/lukD+ + CDC0029 - - PVL+/lukD+ + CDC0020 - +
PVL-/lukD+ + CDC0024 - - PVL-/lukD+ + CDC0031 - - PVL-/lukD+ +
TABLE-US-00036 TABLE 20B Drug Resistance and Virulence Identified
in Blinded Samples of Various Strains of Staphylococcus aureus with
Primer Pair Nos. 2249, 879, 2056, and 2313 Primer Primer Primer
Pair No. Pair No. Pair Sample Primer Pair No. 2249 879 2056 No.
2313 Index No. (tufB) (mecA) (mecI-R) (mupR) CDC0010 Staphylococcus
aureus + + - CDC0015 Staphylococcus aureus - - - CDC0019
Staphylococcus aureus + + - CDC0026 Staphylococcus aureus + + -
CDC0030 Staphylococcus aureus + + - CDC004 Staphylococcus aureus +
+ - CDC0014 Staphylococcus aureus + + - CDC008 Staphylococcus
aureus + + - CDC001 Staphylococcus aureus + + - CDC0022
Staphylococcus aureus + + - CDC006 Staphylococcus aureus + + +
CDC007 Staphylococcus aureus + + - CDCVRSA1 Staphylococcus aureus +
+ - CDCVRSA2 Staphylococcus aureus + + - CDC0011 Staphylococcus
aureus - - - CDC0012 Staphylococcus aureus + + - CDC0021
Staphylococcus aureus + + - CDC0023 Staphylococcus aureus + + -
CDC0025 Staphylococcus aureus + + - CDC005 Staphylococcus aureus +
+ - CDC0018 Staphylococcus aureus + + - CDC002 Staphylococcus
aureus + + - CDC0028 Staphylococcus aureus + + - CDC003
Staphylococcus aureus + + - CDC0013 Staphylococcus aureus + + -
CDC0016 Staphylococcus aureus + + - CDC0027 Staphylococcus aureus +
+ - CDC0029 Staphylococcus aureus + + - CDC0020 Staphylococcus
aureus - - - CDC0024 Staphylococcus aureus + + - CDC0031
Staphylococcus scleiferi - - -
Example 15
Selection and Use of Triangulation Genotyping Analysis Primer Pairs
for Staphylococcus aureus
[0439] To combine the power of high-throughput mass spectrometric
analysis of bioagent identifying amplicons with the sub-species
characteristic resolving power provided by triangulation genotyping
analysis, a panel of eight triangulation genotyping analysis primer
pairs was selected. The primer pairs are designed to produce
bioagent identifying amplicons within six different housekeeping
genes which are listed in Table 21. The primer sequences are found
in Table 2 and are cross-referenced by the primer pair numbers,
primer pair names or SEQ ID NOs listed in Table 21.
TABLE-US-00037 TABLE 21 Primer Pairs for Triangulation Genotyping
Analysis of Staphylococcus aureus Forward Reverse Primer Primer
Primer Pair (SEQ ID (SEQ ID Target No. Forward Primer Name NO:)
Reverse Primer Name NO:) Gene 2146 ARCC_NC003923-2725050- 437
ARCC_NC003923-2725050- 1137 arcC 2724595_131_161_F
2724595_214_245_R 2149 AROE_NC003923-1674726- 530
AROE_NC003923-1674726- 891 aroE 1674277_30_62_F 1674277_155_181_R
2150 AROE_NC003923-1674726- 474 AROE_NC003923-1674726- 869 aroE
1674277_204_232_F 1674277_308_335_R 2156 GMK_NC003923-1190906- 268
GMK_NC003923-1190906- 1284 gmk 1191334_301_329_F 1191334_403_432_R
2157 PTA_NC003923-628885- 418 PTA_NC003923-628885- 1301 pta
629355_237_263_F 629355_314_345_R 2161 TPI_NC003923-830671- 318
TPI_NC003923-830671- 1300 tpi 831072_1_34_F 831072_97_129_R 2163
YQI_NC003923-378916- 440 YQI_NC003923-378916- 1076 yqi
379431_142_167_F 379431_259_284_R 2166 YQI_NC003923-378916- 219
YQI_NC003923-378916- 1013 yqi 379431_275_300_F 379431_364_396_R
[0440] The same samples analyzed for drug resistance and virulence
in Example 14 were subjected to triangulation genotyping analysis.
The primer pairs of Table 21 were used to produce amplification
products by PCR, which were subsequently purified and measured by
mass spectrometry. Base compositions were calculated from the
molecular masses and are shown in Tables 22A and 22B.
TABLE-US-00038 TABLE 22A Triangulation Genotyping Analysis of
Blinded Samples of Various Strains of Staphylococcus aureus with
Primer Pair Nos. 2146, 2149, 2150 and 2156 Sample Primer Pair No.
Primer Pair No. Primer Pair No. Primer Pair No. Index No. Strain
2146 (arcC) 2149(aroE) 2150 (aroE) 2156 (gmk) CDC0010 COL A44 G24
C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32 CDC0015 COL
A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0019 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30
C20 T32 CDC0026 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43
A50 G30 C20 T32 CDC0030 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36
C13 T43 A50 G30 C20 T32 CDC004 COL A44 G24 C18 T29 A59 G24 C18 T51
A40 G36 C13 T43 A50 G30 C20 T32 CDC0014 COL A44 G24 C18 T29 A59 G24
C18 T51 A40 G36 C13 T43 A50 G30 C20 T32 CDC008 ???? A44 G24 C18 T29
A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32 CDC001 Mu50 A45 G23
C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21 T31 CDC0022
Mu50 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21
T31 CDC006 Mu50 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51
G29 C21 T31 CDC0011 MRSA252 A45 G24 C18 T28 A58 G24 C19 T51 A41 G36
C12 T43 A51 G29 C21 T31 CDC0012 MRSA252 A45 G24 C18 T28 A58 G24 C19
T51 A41 G36 C12 T43 A51 G29 C21 T31 CDC0021 MRSA252 A45 G24 C18 T28
A58 G24 C19 T51 A41 G36 C12 T43 A51 G29 C21 T31 CDC0023 ST:110 A45
G24 C18 T28 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32 CDC0025
ST:110 A45 G24 C18 T28 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20
T32 CDC005 ST:338 A44 G24 C18 T29 A59 G23 C19 T51 A40 G36 C14 T42
A51 G29 C21 T31 CDC0018 ST:338 A44 G24 C18 T29 A59 G23 C19 T51 A40
G36 C14 T42 A51 G29 C21 T31 CDC002 ST:108 A46 G23 C20 T26 A58 G24
C19 T51 A42 G36 C12 T42 A51 G29 C20 T32 CDC0028 ST:108 A46 G23 C20
T26 A58 G24 C19 T51 A42 G36 C12 T42 A51 G29 C20 T32 CDC003 ST:107
A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21 T31
CDC0013 ST:12 ND A59 G24 C18 T51 A40 G36 C13 T43 A51 G29 C21 T31
CDC0016 ST:120 A45 G23 C18 T29 A58 G24 C19 T51 A40 G37 C13 T42 A51
G29 C21 T31 CDC0027 ST:105 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36
C13 T43 A51 G29 C21 T31 CDC0029 MSSA476 A45 G23 C20 T27 A58 G24 C19
T51 A40 G36 C13 T43 A50 G30 C20 T32 CDC0020 ST:15 A44 G23 C21 T27
A59 G23 C18 T52 A40 G36 C13 T43 A50 G30 C20 T32 CDC0024 ST:137 A45
G23 C20 T27 A57 G25 C19 T51 A40 G36 C13 T43 A51 G29 C22 T30 CDC0031
*** No product No product No product No product
TABLE-US-00039 TABLE 22B Triangulation Genotyping Analysis of
Blinded Samples of Various Strains of Staphylococcus aureus with
Primer Pair Nos. 2146, 2149, 2150 and 2156 Sample Primer Pair No.
Primer Pair No. Primer Pair No. Primer Pair No. Index No. Strain
2157 (pta) 2161 (tpi) 2163 (yqi) 2166 (yqi) CDC0010 COL A32 G25 C23
T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37 CDC0015 COL A32
G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37 CDC0019
COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0026 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30
C18 T37 CDC0030 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43
A37 G30 C18 T37 CDC004 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37
C22 T43 A37 G30 C18 T37 CDC0014 COL A32 G25 C23 T29 A51 G28 C22 T28
A41 G37 C22 T43 A37 G30 C18 T37 CDC008 unknown A32 G25 C23 T29 A51
G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37 CDC001 Mu50 A33 G25 C22
T29 A50 G28 C22 T29 A42 G36 C22 T43 A36 G31 C19 T36 CDC0022 Mu50
A33 G25 C22 T29 A50 G28 C22 T29 A42 G36 C22 T43 A36 G31 C19 T36
CDC006 Mu50 A33 G25 C22 T29 A50 G28 C22 T29 A42 G36 C22 T43 A36 G31
C19 T36 CDC0011 MRSA252 A32 G25 C23 T29 A50 G28 C22 T29 A42 G36 C22
T43 A37 G30 C18 T37 CDC0012 MRSA252 A32 G25 C23 T29 A50 G28 C22 T29
A42 G36 C22 T43 A37 G30 C18 T37 CDC0021 MRSA252 A32 G25 C23 T29 A50
G28 C22 T29 A42 G36 C22 T43 A37 G30 C18 T37 CDC0023 ST:110 A32 G25
C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37 CDC0025
ST:110 A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18
T37 CDC005 ST:338 A32 G25 C24 T28 A51 G27 C21 T30 A42 G36 C22 T43
A37 G30 C18 T37 CDC0018 ST:338 A32 G25 C24 T28 A51 G27 C21 T30 A42
G36 C22 T43 A37 G30 C18 T37 CDC002 ST:108 A33 G25 C23 T28 A50 G28
C22 T29 A42 G36 C22 T43 A37 G30 C18 T37 CDC0028 ST:108 A33 G25 C23
T28 A50 G28 C22 T29 A42 G36 C22 T43 A37 G30 C18 T37 CDC003 ST:107
A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0013 ST:12 A32 G25 C23 T29 A51 G28 C22 T28 A42 G36 C22 T43 A37
G30 C18 T37 CDC0016 ST:120 A32 G25 C24 T28 A50 G28 C21 T30 A42 G36
C22 T43 A37 G30 C18 T37 CDC0027 ST:105 A33 G25 C22 T29 A50 G28 C22
T29 A43 G36 C21 T43 A36 G31 C19 T36 CDC0029 MSSA476 A33 G25 C22 T29
A50 G28 C22 T29 A42 G36 C22 T43 A36 G31 C19 T36 CDC0020 ST:15 A33
G25 C22 T29 A50 G28 C21 T30 A42 G36 C22 T43 A36 G31 C18 T37 CDC0024
ST:137 A33 G25 C22 T29 A51 G28 C22 T28 A42 G36 C22 T43 A37 G30 C18
T37 CDC0031 *** A34 G25 C25 T25 A51 G27 C24 T27 No product No
product Note: *** The sample CDC0031 was identified as
Staphylococcus scleiferi as indicated in Example 14. Thus, the
triangulation genotyping primers designed for Staphylococcus aureus
would generally not be expected to prime and produce amplification
products of this organism. Tables 22A and 22B indicate that
amplification products are obtained for this organism only with
primer pair numbers 2157 and 2161.
[0441] A total of thirteen different genotypes of Staphylococcus
aureus were identified according to the unique combinations of base
compositions across the eight different bioagent identifying
amplicons obtained with the eight primer pairs. These results
indicate that this eight primer pair panel is useful for analysis
of unknown or newly emerging strains of Staphylococcus aureus. It
is expected that a kit comprising one or more of the members of
this panel will be a useful embodiment of the present
invention.
Example 16
Selection and Use of Triangulation Genotyping Analysis Primer Pairs
for Members of the Bacterial Genus Vibrio
[0442] To combine the power of high-throughput mass spectrometric
analysis of bioagent identifying amplicons with the sub-species
characteristic resolving power provided by triangulation genotyping
analysis, a panel of eight triangulation genotyping analysis primer
pairs was selected. The primer pairs are designed to produce
bioagent identifying amplicons within seven different housekeeping
genes which are listed in Table 23. The primer sequences are found
in Table 2 and are cross-referenced by the primer pair numbers,
primer pair names or SEQ ID NOs listed in Table 23.
TABLE-US-00040 TABLE 23 Primer Pairs for Triangulation Genotyping
Analysis of Members of the Bacterial Genus Vibrio Forward Reverse
Primer Primer Primer Pair (SEQ ID (SEQ ID Target No. Forward Primer
Name NO:) Reverse Primer Name NO:) Gene 1098 RNASEP_VBC_331_349_F
325 RNASEP_VBC_388_414_R 1163 RNAse P 2000 CTXB_NC002505_46_70_F
278 CTXB_NC002505_132_162_R 1039 ctxB 2001 FUR_NC002505_87_113_F
465 FUR_NC002505_205_228_R 1037 fur 2011 GYRB_NC002505_1161_1190_F
148 GYRB_NC002505_1255_1284_R 1172 gyrB 2012 OMPU_NC002505_85_110_F
190 OMPU_NC002505_154_180_R 1254 ompU 2014 OMPU_NC002505_431_455_F
266 OMPU_NC002505_544_567_R 1094 ompU 2323 CTXA_NC002505-1568114-
508 CTXA_NC002505-1568114- 1297 ctxA 1567341_122_149_F
1567341_186_214_R 2927 GAPA_NC002505_694_721_F 259
GAPA_NC_002505_29_58_R 1060 gapA
[0443] A group of 50 bacterial isolates containing multiple strains
of both environmental and clinical isolates of Vibrio cholerae, 9
other Vibrio species, and 3 species of Photobacteria were tested
using this panel of primer pairs. Base compositions of
amplification products obtained with these 8 primer pairs were used
to distinguish amongst various species tested, including
sub-species differentiation within Vibrio cholerae isolates. For
instance, the non-O1/non-O139 isolates were clearly resolved from
the O1 and the O139 isolates, as were several of the environmental
isolates of Vibrio cholerae from the clinical isolates.
[0444] It is expected that a kit comprising one or more of the
members of this panel will be a useful embodiment of the present
invention.
Example 17
Selection and Use of Triangulation Genotyping Analysis Primer Pairs
for Members of the Bacterial Genus Pseudomonas
[0445] To combine the power of high-throughput mass spectrometric
analysis of bioagent identifying amplicons with the sub-species
characteristic resolving power provided by triangulation genotyping
analysis, a panel of twelve triangulation genotyping analysis
primer pairs was selected. The primer pairs are designed to produce
bioagent identifying amplicons within seven different housekeeping
genes which are listed in Table 24. The primer sequences are found
in Table 2 and are cross-referenced by the primer pair numbers,
primer pair names or SEQ ID NOs listed in Table 24.
TABLE-US-00041 TABLE 24 Primer Pairs for Triangulation Genotyping
Analysis of Members of the Bacterial Genus Pseudomonas Forward
Reverse Primer Primer Primer Pair (SEQ ID (SEQ ID Target No.
Forward Primer Name NO:) Reverse Primer Name NO:) Gene 2949
ACS_NC002516-970624- 376 ACS_NC002516-970624- 1265 acsA
971013_299_316_F 971013_364_383_R 2950 ARO_NC002516-26883- 267
ARO_NC002516-26883- 1341 aroE 27380_4_26_F 27380_111_128_R 2951
ARO_NC002516-26883- 705 ARO_NC002516-26883- 1056 aroE
27380_356_377_F 27380_459_484_R 2954 GUA_NC002516-4226546- 710
GUA_NC002516-4226546- 1259 guaA 4226174_155_178_F 4226174_265_287_R
2956 GUA_NC002516-4226546- 374 GUA_NC002516-4226546- 1111 guaA
4226174_242_263_F 4226174_355_371_R 2957 MUT_NC002516-5551158- 545
MUT_NC002516-5551158- 978 mutL 5550717_5_26_F 5550717_99_116_R 2959
NUO_NC002516-2984589- 249 NUO_NC002516-2984589- 1095 nuoD
2984954_8_26_F 2984954_97_117_R 2960 NUO_NC002516-2984589- 195
NUO_NC002516-2984589- 1376 nuoD 2984954_218_239_F 2984954_301_326_R
2961 PPS_NC002516-1915014- 311 PPS_NC002516-1915014- 1014 pps
1915383_44_63_F 1915383_140_165_R 2962 PPS_NC002516-1915014- 365
PPS_NC002516-1915014- 1052 pps 1915383_240_258_F 1915383_341_360_R
2963 TRP_NC002516-671831- 527 TRP_NC002516-671831- 1071 trpE
672273_24_42_F 672273_131_150_R 2964 TRP_NC002516-671831- 490
TRP_NC002516-671831- 1182 trpE 672273_261_282_F
672273_362_383_R
[0446] It is expected that a kit comprising one or more of the
members of this panel will be a useful embodiment of the present
invention.
[0447] The present invention includes any combination of the
various species and subgeneric groupings falling within the generic
disclosure. This invention therefore includes the generic
description of the invention with a proviso or negative limitation
removing any subject matter from the genus, regardless of whether
or not the excised material is specifically recited herein.
[0448] While in accordance with the patent statutes, description of
the various embodiments and examples have been provided, the scope
of the invention is not to be limited thereto or thereby.
Modifications and alterations of the present invention will be
apparent to those skilled in the art without departing from the
scope and spirit of the present invention.
[0449] Therefore, it will be appreciated that the scope of this
invention is to be defined by the appended claims, rather than by
the specific examples which have been presented by way of
example.
[0450] Each reference (including, but not limited to, journal
articles, U.S, and non-U.S. patents, patent application
publications, international patent application publications, gene
bank gi or accession numbers, internet web sites, and the like)
cited in the present application is incorporated herein by
reference in its entirety.
Sequence CWU 1
1
1464124DNAArtificial SequencePrimer 1aaactagata acagtagaca tcac
24229DNAArtificial SequencePrimer 2aaccttaatt ggaaagaaac ccaagaagt
29317DNAArtificial SequencePrimer 3aacgcacaat cagaagc
17425DNAArtificial SequencePrimer 4aactaccgtc cgcagttcta cttcc
25525DNAArtificial SequencePrimer 5aactaccgtc ctcagttcta cttcc
25618DNAArtificial SequencePrimer 6aagacgacct gcacgggc
18718DNAArtificial SequencePrimer 7aagcggtgga gcatgtgg
18826DNAArtificial SequencePrimer 8aaggaaggcg tgatcaccgt tgaaga
26923DNAArtificial SequencePrimer 9aaggtactcc ggggataaca ggc
231022DNAArtificial SequencePrimer 10aagtcggaat cgctagtaat cg
221119DNAArtificial SequencePrimer 11aatctgctat ttggtcagg
191222DNAArtificial SequencePrimer 12acaacgaagt acaatacaag ac
221321DNAArtificial SequencePrimer 13acaatacaag acaaaagaag g
211419DNAArtificial SequencePrimer 14accacgccgt aaacgatga
191524DNAArtificial SequencePrimer 15accatgacag aaggcatttt gaca
241622DNAArtificial SequencePrimer 16acccagtgct gctgaaccgt gc
221719DNAArtificial SequencePrimer 17accgagcaag gagaccagc
191819DNAArtificial SequencePrimer 18acctgcccag tgctggaag
191917DNAArtificial SequencePrimer 19acgcgaagaa ccttacc
172020DNAArtificial SequencePrimer 20actcgttttt aatcagcccg
202120DNAArtificial SequencePrimer 21agaacaccga tggcgaaggc
202223DNAArtificial SequencePrimer 22agaatcaagt tcccaggggt tac
232320DNAArtificial SequencePrimer 23agagtttgat catggctcag
202428DNAArtificial SequencePrimer 24agcaggtggt gaaatcggcc acatgatt
282518DNAArtificial SequencePrimer 25agcgtaaagg tgaacctt
182626DNAArtificial SequencePrimer 26agcttttgca tattatatcg agccac
262728DNAArtificial SequencePrimer 27aggacagagt gagtactttg accgaggt
282822DNAArtificial SequencePrimer 28agtctcaaga gtgaacacgt aa
222932DNAArtificial SequencePrimer 29agttataaac acggctttcc
tatggcttat cc 323021DNAArtificial SequencePrimer 30atactcctga
ctgaccgata g 213120DNAArtificial SequencePrimer 31atatcgacgg
cggtgtttgg 203225DNAArtificial SequencePrimer 32atcaatttgg
tggccaagaa cctgg 253329DNAArtificial SequencePrimer 33atgattacaa
ttcaagaagg tcgtcacgc 293423DNAArtificial SequencePrimer
34atggacaagg ttggcaagga agg 233520DNAArtificial SequencePrimer
35atggccatgg cagaagctca 203625DNAArtificial SequencePrimer
36atgtcgattg caatccgtac ttgtg 253719DNAArtificial SequencePrimer
37atgttgggtt aagtcccgc 193825DNAArtificial SequencePrimer
38atgttgggtt aagtcccgca acgag 253928DNAArtificial SequencePrimer
39caaaacttat taggtaagcg tgttgact 284027DNAArtificial SequencePrimer
40caaaggtaag caaggacgtt tccgtca 274127DNAArtificial SequencePrimer
41caaaggtaag caaggtcgtt tccgtca 274217DNAArtificial SequencePrimer
42caacgagcgc aaccctt 174317DNAArtificial SequencePrimer
43caacggatgc tggcaag 174431DNAArtificial SequencePrimer
44caagaagaaa aagagcttct aaaaagaata c 314523DNAArtificial
SequencePrimer 45caagcaaacg cacaatcaga agc 234619DNAArtificial
SequencePrimer 46caagtcatca tggccctta 194726DNAArtificial
SequencePrimer 47caataccgca acagcggtgg cttggg 264819DNAArtificial
SequencePrimer 48cactggaact gagacacgg 194920DNAArtificial
SequencePrimer 49cagaatcaag ttcccagggg 205024DNAArtificial
SequencePrimer 50cagagaccgt tttatcctat cagc 245120DNAArtificial
SequencePrimer 51cagcgtttcg gcgaaatgga 205229DNAArtificial
SequencePrimer 52caggagtcgt tcaactcgat ctacatgat
295324DNAArtificial SequencePrimer 53caggtttagt accagaacat gcag
245423DNAArtificial SequencePrimer 54catccacacg gtggtggtga agg
235523DNAArtificial SequencePrimer 55ccacacgccg ttcttcaaca act
235628DNAArtificial SequencePrimer 56ccacagttct acttccgtac tactgacg
285719DNAArtificial SequencePrimer 57ccagcagccg cggtaatac
195819DNAArtificial SequencePrimer 58ccgtaacttc gggagaagg
195920DNAArtificial SequencePrimer 59ccgtggtatt ggagttattg
206029DNAArtificial SequencePrimer 60cctatattaa tcgtttacag
aaactggct 296119DNAArtificial SequencePrimer 61cctgataagg gtgaggtcg
196230DNAArtificial SequencePrimer 62ccttacttcg aactatgaat
cttttggaag 306314DNAArtificial SequencePrimer 63cgaagaacct tacc
146427DNAArtificial SequencePrimer 64cgaagtacaa tacaagacaa aagaagg
276518DNAArtificial SequencePrimer 65cgacgcgctg cgcttcac
186622DNAArtificial SequencePrimer 66cgagagggaa acaacccaga cc
226730DNAArtificial SequencePrimer 67cgagtatagc taaaaaaata
gtttatgaca 306823DNAArtificial SequencePrimer 68cgcaaaaaaa
tccagctatt agc 236920DNAArtificial SequencePrimer 69cgccgacttc
gacggtgacc 207020DNAArtificial SequencePrimer 70cggaattact
gggcgtaaag 207121DNAArtificial SequencePrimer 71cggattggag
tctgcaactc g 217222DNAArtificial SequencePrimer 72cggcgtactt
caacgacagc ca 227324DNAArtificial SequencePrimer 73cgtaactata
acggtcctaa ggta 247426DNAArtificial SequencePrimer 74cgtcagggta
aattccgtga agttaa 267526DNAArtificial SequencePrimer 75cgtcgggtga
ttaaccgtaa caaccg 267626DNAArtificial SequencePrimer 76cgtcgtgtaa
ttaaccgtaa caaccg 267720DNAArtificial SequencePrimer 77cgtggcggcg
tggttatcga 207825DNAArtificial SequencePrimer 78cgtgttgact
attcggggcg ttcag 257918DNAArtificial SequencePrimer 79ctagtacgag
aggaccgg 188018DNAArtificial SequencePrimer 80ctgacacctg cccggtgc
188124DNAArtificial SequencePrimer 81ctggcaggta tgcgtggtct gatg
248223DNAArtificial SequencePrimer 82ctggctaaaa ctttggcaac ggt
238324DNAArtificial SequencePrimer 83ctgtccctag tacgagagga ccgg
248422DNAArtificial SequencePrimer 84ctgttcttag tacgagagga cc
228524DNAArtificial SequencePrimer 85cttctgcaac aagctgtgga acgc
248624DNAArtificial SequencePrimer 86cttgctggta tgcgtggtct gatg
248729DNAArtificial SequencePrimer 87cttggaggta agtctcattt
tggtgggca 298819DNAArtificial SequencePrimer 88cttgtacaca ccgcccgtc
198930DNAArtificial SequencePrimer 89cttgtacttg tggctcacac
ggctgtttgg 309021DNAArtificial SequencePrimer 90cttttgcata
ttatatcgag c 219120DNAArtificial SequencePrimer 91gaatagcaat
taatccaaat 209218DNAArtificial SequencePrimer 92gaaagagttc ggattggg
189321DNAArtificial SequencePrimer 93gaaggatata cggttgatgt c
219420DNAArtificial SequencePrimer 94gaatagcaat taatccaaat
209520DNAArtificial SequencePrimer 95gacacggtcc agactcctac
209618DNAArtificial SequencePrimer 96gacagttcgg tccctatc
189718DNAArtificial SequencePrimer 97gaccacctcg gcaaccgt
189830DNAArtificial SequencePrimer 98gacctacagt aagaggttct
gtaatgaacc 309916DNAArtificial SequencePrimer 99gacgcctgcc cggtgc
1610020DNAArtificial SequencePrimer 100gacttaccaa cccgatgcaa
2010120DNAArtificial SequencePrimer 101gagagcaagc ggacctcata
2010227DNAArtificial SequencePrimer 102gagagtttga tcctggctca
gaacgaa 2710319DNAArtificial SequencePrimer 103gaggaaagtc catgctcac
1910419DNAArtificial SequencePrimer 104gaggaaagtc catgctcgc
1910517DNAArtificial SequencePrimer 105gaggaaagtc cgggctc
1710622DNAArtificial SequencePrimer 106gataccctgg tagtccacac cg
2210720DNAArtificial SequencePrimer 107gatctggagg aataccggtg
2010829DNAArtificial SequencePrimer 108gatgactttt tagctaatgg
tcaggcagc 2910930DNAArtificial SequencePrimer 109gattattgtt
atcctgttat gccatttgag 3011018DNAArtificial SequencePrimer
110gcacaacctg cggctgcg 1811127DNAArtificial SequencePrimer
111gcactatgca cacgtagatt gtcctgg 2711221DNAArtificial
SequencePrimer 112gccttgtaca cacctcccgt c 2111320DNAArtificial
SequencePrimer 113gcgaagaacc ttaccaggtc 2011420DNAArtificial
SequencePrimer 114gctacacacg tgctacaatg 2011530DNAArtificial
SequencePrimer 115gctggtgaaa ataacccaga tgtcgtcttc
3011625DNAArtificial SequencePrimer 116gcttcaggaa tcaatgatgg agcag
2511719DNAArtificial SequencePrimer 117ggacggagaa ggctatgtt
1911822DNAArtificial SequencePrimer 118ggattagaga ccctggtagt cc
2211926DNAArtificial SequencePrimer 119ggattagata ccctggtagt ccacgc
2612025DNAArtificial SequencePrimer 120ggctcagcca tttagttacc gctat
2512121DNAArtificial SequencePrimer 121gggaactgaa acatctaagt a
2112222DNAArtificial SequencePrimer 122gggagcaaac aggattagat ac
2212329DNAArtificial SequencePrimer 123gggcaacagc agcggattgc
gattgcgcg 2912423DNAArtificial SequencePrimer 124gggcagcgtt
tcggcgaaat gga 2312526DNAArtificial SequencePrimer 125ggggagtgaa
agagatcctg aaaccg 2612630DNAArtificial SequencePrimer 126ggggattcag
ccatcaaagc agctattgac 3012727DNAArtificial SequencePrimer
127ggggattgat atcaccgata agaagaa 2712824DNAArtificial
SequencePrimer 128ggtgaaagaa gttgcctcta aagc 2412915DNAArtificial
SequencePrimer 129ggtggatgcc ttggc 1513020DNAArtificial
SequencePrimer 130ggtgttaaat agcctggcag 2013120DNAArtificial
SequencePrimer 131ggtttagtac cagaacatgc 2013223DNAArtificial
SequencePrimer 132gtcaaagtgg cacgtttact ggc 2313322DNAArtificial
SequencePrimer 133gtcgtgaaaa cgagctggaa ga 2213430DNAArtificial
SequencePrimer 134gtgagatgtt gggttaagtc ccgtaacgag
3013523DNAArtificial SequencePrimer 135gtgcatgcgg atacagagca gag
2313626DNAArtificial SequencePrimer 136gtggcatgcc taatacatgc aagtcg
2613718DNAArtificial SequencePrimer 137gtgtagcggt gaaatgcg
1813821DNAArtificial SequencePrimer 138gttatcctgt tatgccattt g
2113928DNAArtificial SequencePrimer 139gttatttagc actcgttttt
aatcagcc 2814022DNAArtificial SequencePrimer 140gttgtgaggt
taagcgacta ag 2214122DNAArtificial SequencePrimer 141gttgtgaggt
taagcgacta ag 2214224DNAArtificial SequencePrimer 142tctagtaata
ataggaccct cagc 2414315DNAArtificial SequencePrimer 143tatggctcta
ctcaa 1514429DNAArtificial SequencePrimer 144taaaacaaac tacggtaaca
ttgatcgca 2914533DNAArtificial SequencePrimer 145taaaactttt
gccgtaatga tgggtgaaga tat 3314631DNAArtificial SequencePrimer
146taaacacggc tttcctatgg cttatccaaa t 3114728DNAArtificial
SequencePrimer 147taaaccccat cgggagcaag accgaata
2814830DNAArtificial SequencePrimer 148taaagcccgt gaaatgactc
gtcgtaaagg 3014928DNAArtificial SequencePrimer 149taaagttggt
tttattggtt ggcgcgga 2815025DNAArtificial SequencePrimer
150taaatctgcc cgtgtcgttg gtgac 2515129DNAArtificial SequencePrimer
151taacaactcg ccttatgaaa cgggatata 2915220DNAArtificial
SequencePrimer 152taacacatgc aagtcgaacg 2015329DNAArtificial
SequencePrimer 153taaccattca agaactagat cttcaggca
2915430DNAArtificial SequencePrimer 154taaccttaat tggaaagaaa
cccaagaagt 3015525DNAArtificial SequencePrimer 155taacggttat
catggcccag atggg 2515627DNAArtificial SequencePrimer 156taactctgat
gtttttgatg ggaaggt 2715727DNAArtificial SequencePrimer
157taactgcatg gaacccttct ttactag 2715827DNAArtificial
SequencePrimer 158taagaagccg gaaaccatca actaccg
2715922DNAArtificial SequencePrimer 159taagagcgca ccggtaagtt gg
2216028DNAArtificial SequencePrimer 160taagcatgct gtggcttatc
gtgaaatg 2816123DNAArtificial SequencePrimer 161taagctgcca
gcggaatgct ttc 2316229DNAArtificial SequencePrimer 162taaggatagt
gcaacagaga tataccgcc 2916330DNAArtificial SequencePrimer
163taaggtatga caccggataa atcatataaa 3016433DNAArtificial
SequencePrimer 164taaggtttat tgtctttgtg gagatgggga ttt
3316531DNAArtificial SequencePrimer 165taatcaagca ttggaagatg
aaatgcatac c 3116629DNAArtificial SequencePrimer 166taatcggtaa
atatcacccg catggtgac 2916729DNAArtificial SequencePrimer
167taatcggtaa gtatcaccct catggtgat 2916824DNAArtificial
SequencePrimer
168taatcgtgga atacgggttt gcta 2416930DNAArtificial SequencePrimer
169taatgaaccc taatgaccat ccacacggtg 3017027DNAArtificial
SequencePrimer 170taatgatgaa ttaggtgcgg gttcttt
2717129DNAArtificial SequencePrimer 171taatgggtaa atatcaccct
catggtgac 2917231DNAArtificial SequencePrimer 172taattgggct
ctttctcgct taaacacctt a 3117325DNAArtificial SequencePrimer
173tacaaagcaa gacactggct cacta 2517430DNAArtificial SequencePrimer
174tacaaaggtc aaccaatgac attcagacta 3017534DNAArtificial
SequencePrimer 175tacaacatat tattaaagag acgggtttga atcc
3417620DNAArtificial SequencePrimer 176tacaagcact cccagctgca
2017729DNAArtificial SequencePrimer 177tacaatgctt gtttatgctg
gtaaagcag 2917825DNAArtificial SequencePrimer 178tacacaacaa
tggcggtaaa gatgg 2517915DNAArtificial SequencePrimer 179tacagagttt
gcgac 1518021DNAArtificial SequencePrimer 180tacaggccgt gttgaacgtg
g 2118121DNAArtificial SequencePrimer 181tacatgctag ccgcgtctta c
2118227DNAArtificial SequencePrimer 182taccactatt aatgtcgctg
gtgcttc 2718325DNAArtificial SequencePrimer 183taccatgaca
gaaggcattt tgaca 2518419DNAArtificial SequencePrimer 184taccccaaac
cgacacagg 1918523DNAArtificial SequencePrimer 185taccccaggg
aaagtgccac aga 2318625DNAArtificial SequencePrimer 186taccggcgca
aaaagtcgag attgg 2518721DNAArtificial SequencePrimer 187tacctatatg
cgccagaccg c 2118826DNAArtificial SequencePrimer 188tacgatttca
cttccgcagc cagatt 2618927DNAArtificial SequencePrimer 189tacgcgtctt
gaagcgtttc gttatga 2719026DNAArtificial SequencePrimer
190tacgctgacg gaatcaacca aagcgg 2619121DNAArtificial SequencePrimer
191tacggtgaat acgttcccgg g 2119215DNAArtificial SequencePrimer
192tacagagttt gcgac 1519323DNAArtificial SequencePrimer
193tactacttca agccgaactt ccg 2319428DNAArtificial SequencePrimer
194tactagcggt aagcttaaac aagattgc 2819522DNAArtificial
SequencePrimer 195tactctcggt ggagaagctc gc 2219622DNAArtificial
SequencePrimer 196tactggaaca aagtctgcga cc 2219727DNAArtificial
SequencePrimer 197tacttactac ttcaagccga acttccg
2719828DNAArtificial SequencePrimer 198tacttacttg agaatccaca
agctgcaa 2819928DNAArtificial SequencePrimer 199tacttggtaa
ataccaccca catggtga 2820032DNAArtificial SequencePrimer
200tactttttta aaactaggga tgcgtttgaa gc 3220127DNAArtificial
SequencePrimer 201tagaaatcaa ggtgatagtg gcaatga
2720221DNAArtificial SequencePrimer 202tagaacaccg atggcgaagg c
2120322DNAArtificial SequencePrimer 203tagaacgtcg cgagacagtt cg
2220421DNAArtificial SequencePrimer 204tagactgccc aggacacgct g
2120529DNAArtificial SequencePrimer 205tagataattg ggctctttct
cgcttaaac 2920622DNAArtificial SequencePrimer 206tagataccct
ggtagtccac gc 2220728DNAArtificial SequencePrimer 207tagatgaaaa
aggcgaagtg gctaatgg 2820828DNAArtificial SequencePrimer
208tagatgaaaa gggcgaagtg gctaatgg 2820930DNAArtificial
SequencePrimer 209tagcaacaaa tatatctgaa gcagcgtact
3021029DNAArtificial SequencePrimer 210tagcaggtgg tgaaatcggc
cacatgatt 2921126DNAArtificial SequencePrimer 211tagcatcaga
actgttgttc cgctag 2621224DNAArtificial SequencePrimer 212tagcccagca
caatttgtga ttca 2421334DNAArtificial SequencePrimer 213tagcctttaa
cgaaaatgta aaaatgcgtt ttga 3421427DNAArtificial SequencePrimer
214tagcgaatgt ggctttactt cacaatt 2721519DNAArtificial
SequencePrimer 215tagcgtaaag gtgaacctt 1921620DNAArtificial
SequencePrimer 216tagctaatgg tcaggcagcc 2021730DNAArtificial
SequencePrimer 217tagctatctt atcgttgaga agggatttgc
3021822DNAArtificial SequencePrimer 218tagctggcgc gaaattaggt gt
2221926DNAArtificial SequencePrimer 219tagctggcgg tatggagaat atgtct
2622027DNAArtificial SequencePrimer 220tagcttttgc atattatatc
gagccac 2722129DNAArtificial SequencePrimer 221taggaattac
ggctgataaa gcgtataaa 2922235DNAArtificial SequencePrimer
222taggcgaaga tatacaaaga gtattagaag ctaga 3522325DNAArtificial
SequencePrimer 223taggcgtgaa agcaagctac cgttt 2522425DNAArtificial
SequencePrimer 224taggtgctgg ttacgcagat caaga 2522530DNAArtificial
SequencePrimer 225taggtttacg tcagtatggc gtgattatgg
3022623DNAArtificial SequencePrimer 226tagtaccgaa gctggtcata cga
2322717DNAArtificial SequencePrimer 227tagtacgaga ggaccgg
1722818DNAArtificial SequencePrimer 228tagtcccgca acgagcgc
1822927DNAArtificial SequencePrimer 229tagtgataga actgtaggca
caatcgt 2723022DNAArtificial SequencePrimer 230tagttgctca
aacagctggg ct 2223129DNAArtificial SequencePrimer 231tataagtggg
taaaccgtga atatcgtgt 2923224DNAArtificial SequencePrimer
232tatacttcaa cgcctgctgc tttc 2423322DNAArtificial SequencePrimer
233tatcgctcag gcgaactcca ac 2223423DNAArtificial SequencePrimer
234tatgaccaaa ctcatcagac gag 2323530DNAArtificial SequencePrimer
235tatgattaca attcaagaag gtcgtcacgc 3023627DNAArtificial
SequencePrimer 236tatgcagtgg aacgatggtt tccaaga
2723724DNAArtificial SequencePrimer 237tatgctgacc gaccagtggt acgt
2423821DNAArtificial SequencePrimer 238tatggccatg gcagaagctc a
2123915DNAArtificial SequencePrimer 239tatggctcta ctcaa
1524031DNAArtificial SequencePrimer 240tatgtccaag aagcatagca
aaaaaagcaa t 3124127DNAArtificial SequencePrimer 241tattcaaggt
ggtcctttga tgcatgt 2724222DNAArtificial SequencePrimer
242tattggacaa cggtcgtcgc gg 2224330DNAArtificial SequencePrimer
243tattgtttca aatgtacaag gtgaagtgcg 3024430DNAArtificial
SequencePrimer 244tatttcacat gtaattttga tattcgcact
3024532DNAArtificial SequencePrimer 245tcaaaaagcc ctaggtaaag
agattccata tc 3224629DNAArtificial SequencePrimer 246tcaaactggg
caatcggaac tggtaaatc 2924726DNAArtificial SequencePrimer
247tcaaatgtac aaggtgaagt gcgtga 2624829DNAArtificial SequencePrimer
248tcaacaacct cttggaggta aagctcagt 2924919DNAArtificial
SequencePrimer 249tcaacctcgg cccgaacca 1925025DNAArtificial
SequencePrimer 250tcaacctgac tgcgtgaatg gttgt 2525127DNAArtificial
SequencePrimer 251tcaacgaagg taaaaaccat ctcaacg
2725227DNAArtificial SequencePrimer 252tcaacggtaa cttctatgtt
acttctg 2725326DNAArtificial SequencePrimer 253tcaactcgaa
ttttcaacag gtacca 2625417DNAArtificial SequencePrimer 254tcaagaagaa
aaagagc 1725524DNAArtificial SequencePrimer 255tcaagcaaac
gcacaatcag aagc 2425627DNAArtificial SequencePrimer 256tcaagcagaa
gctttggaag aagaagg 2725727DNAArtificial SequencePrimer
257tcaagccgta cgtattatta ggtgctg 2725827DNAArtificial
SequencePrimer 258tcaataccgc aacagcggtg gcttggg
2725928DNAArtificial SequencePrimer 259tcaatgaacg accaacaagt
gattgatg 2826028DNAArtificial SequencePrimer 260tcaatgaacg
atcaacaagt gattgatg 2826124DNAArtificial SequencePrimer
261tcacatatcg tgagcaatga actg 2426230DNAArtificial SequencePrimer
262tcaccaggtt caactcaaaa aatattaaca 3026325DNAArtificial
SequencePrimer 263tcaccagttt gccacgtatc ttcaa 2526428DNAArtificial
SequencePrimer 264tcaccctcat ggtgactcat ctatttat
2826528DNAArtificial SequencePrimer 265tcaccctcat ggtgattcag
ctgtttat 2826625DNAArtificial SequencePrimer 266tcaccgatat
catggcttac cacgg 2526723DNAArtificial SequencePrimer 267tcaccgtgcc
gttcaaggaa gag 2326829DNAArtificial SequencePrimer 268tcacctccaa
gtttagatca cttgagaga 2926926DNAArtificial SequencePrimer
269tcacgataag aaaaccggtc aagagg 2627027DNAArtificial SequencePrimer
270tcactcttac atataaggaa ggcgctc 2727125DNAArtificial
SequencePrimer 271tcagaccatg ctcgcagaga aactt 2527225DNAArtificial
SequencePrimer 272tcagagaccg ttttatccta tcagc 2527326DNAArtificial
SequencePrimer 273tcagcaaatg catcacaaac agataa 2627425DNAArtificial
SequencePrimer 274tcagcatatg cacatggaac acctc 2527526DNAArtificial
SequencePrimer 275tcagcatatg cacatggaac acctca 2627622DNAArtificial
SequencePrimer 276tcagccatca aagcagctat tg 2227721DNAArtificial
SequencePrimer 277tcagcgcgta cagtgggtga t 2127825DNAArtificial
SequencePrimer 278tcagcgtatg cacatggaac tcctc 2527923DNAArtificial
SequencePrimer 279tcagctacat cgactatgcg atg 2328030DNAArtificial
SequencePrimer 280tcagctagac cttttaggta aagctaagct
3028129DNAArtificial SequencePrimer 281tcagctattt ttccaggtat
ccaaggtgg 2928223DNAArtificial SequencePrimer 282tcagctgtcg
cagttcatgg acc 2328325DNAArtificial SequencePrimer 283tcaggaaaag
ggcattttac ccttg 2528430DNAArtificial SequencePrimer 284tcaggagtcg
ttcaactcga tctacatgat 3028531DNAArtificial SequencePrimer
285tcaggagtcg ttcaactcga tctacatgat g 3128630DNAArtificial
SequencePrimer 286tcaggatgga aataaccacc aattcactac
3028723DNAArtificial SequencePrimer 287tcaggcattg cggttgggat ggc
2328824DNAArtificial SequencePrimer 288tcaggtactg ctatccaccc tcaa
2428922DNAArtificial SequencePrimer 289tcaggtggct tacacggcgt ag
2229026DNAArtificial SequencePrimer 290tcagtatgta tccaccgtag ccagtc
2629123DNAArtificial SequencePrimer 291tcagttccgt tatcgccatt gca
2329224DNAArtificial SequencePrimer 292tcagttccgt tatcgccatt gcat
2429325DNAArtificial SequencePrimer 293tcagttccgt tatcgccatt gcatt
2529424DNAArtificial SequencePrimer 294tcagttcggc ggtcagcgct tcgg
2429534DNAArtificial SequencePrimer 295tcagttttaa tgtctcgtat
gatcgaatca aaag 3429624DNAArtificial SequencePrimer 296tcatccacac
ggtggtggtg aagg 2429728DNAArtificial SequencePrimer 297tcatcctaag
ccaagtgtag actctgta 2829831DNAArtificial SequencePrimer
298tcatgataat atctttgaaa tcggctcagg a 3129933DNAArtificial
SequencePrimer 299tcatgttgag cttaaaccta tagaagtaaa agc
3330027DNAArtificial SequencePrimer 300tcattatcat gcgccaatga
gtgcaga 2730128DNAArtificial SequencePrimer 301tcattcaaga
actagatctt caggcaag 2830226DNAArtificial SequencePrimer
302tccaaaaaaa tcagcgcgta cagtgg 2630329DNAArtificial SequencePrimer
303tccaaaccag gtgtatcaag aacatcagg 2930429DNAArtificial
SequencePrimer 304tccaaataag tggcgttaca aatactgaa
2930532DNAArtificial SequencePrimer 305tccaacgaag tacaatacaa
gacaaaagaa gg 3230632DNAArtificial SequencePrimer 306tccaaggtac
actaaactta cttgagctaa tg 3230724DNAArtificial SequencePrimer
307tccaatgcca caaactcgtg aaca 2430824DNAArtificial SequencePrimer
308tccacacgcc gttcttcaac aact 2430921DNAArtificial SequencePrimer
309tccacacggt ggtggtgaag g 2131026DNAArtificial SequencePrimer
310tccaccaaga gcaagatcaa ataggc 2631120DNAArtificial SequencePrimer
311tccacggtca tggagcgcta 2031230DNAArtificial SequencePrimer
312tccacttatc gcaaatggaa aattaagcaa 3031333DNAArtificial
SequencePrimer 313tccagatgga caaattttct tagaaactga ttt
3331426DNAArtificial SequencePrimer 314tccagcacga attgctgcta tgaaag
2631533DNAArtificial SequencePrimer 315tccaggacaa atgtatgaaa
aatgtccaag aag 3331625DNAArtificial SequencePrimer 316tccattgttc
gtatggctca agact 2531731DNAArtificial SequencePrimer 317tcccaattaa
ttctgccatt tttccaggta t 3131834DNAArtificial SequencePrimer
318tcccacgaaa cagatgaaga aattaacaaa aaag 3431930DNAArtificial
SequencePrimer 319tcccagctag accttttagg taaagctaag
3032026DNAArtificial SequencePrimer 320tcccaggtga cgatgtacct gtaatc
2632126DNAArtificial SequencePrimer 321tccccaggac accctgaaat ttcaac
2632234DNAArtificial SequencePrimer 322tcccccacgc tttaattgtt
tatgatgatt tgag 3432331DNAArtificial SequencePrimer 323tcccggactt
aatatcaatg aaaattgtgg a 3132428DNAArtificial SequencePrimer
324tcccggagct tttatgacta aagcagat 2832519DNAArtificial
SequencePrimer 325tccgcggagt tgactgggt 1932620DNAArtificial
SequencePrimer 326tccgctgaat ctgtcgccgc 2032723DNAArtificial
SequencePrimer 327tccggctcac gttattatgg tac 2332827DNAArtificial
SequencePrimer 328tccgtacgta ttattaggtg ctggtca
2732930DNAArtificial SequencePrimer 329tccgttatcg ccattgcatt
atttggaact 3033033DNAArtificial SequencePrimer 330tccgttctta
caaatagcaa tagaacttga agc 3333136DNAArtificial SequencePrimer
331tccgttgatt attgttatcc tgttatgcca tttgag 3633234DNAArtificial
SequencePrimer 332tcctaatgga cttaatatca atgaaaattg tgga
3433322DNAArtificial SequencePrimer 333tcctagagga atggctgcca cg
2233430DNAArtificial SequencePrimer 334tcctatatta atcgtttaca
gaaactggct 3033531DNAArtificial SequencePrimer 335tcctcaatga
acgatcaaca agtgattgat g
3133631DNAArtificial SequencePrimer 336tcctcaatga atgatcaaca
agtgattgat g 3133731DNAArtificial SequencePrimer 337tcctcgatga
acgatcaaca agtgattgat g 3133831DNAArtificial SequencePrimer
338tcctcgatga atgatcaaca agtgattgat g 3133931DNAArtificial
SequencePrimer 339tcctcgatga acgatcaaca agtgattgat g
3134031DNAArtificial SequencePrimer 340tcctcgatga acgatcaaca
agtgattgat g 3134120DNAArtificial SequencePrimer 341tcctgaaaaa
tggagcacgg 2034223DNAArtificial SequencePrimer 342tcctgaagca
agtgcattta cga 2334328DNAArtificial SequencePrimer 343tcctgaccga
cccattattc cctttatc 2834433DNAArtificial SequencePrimer
344tcctgatgct caaagtgctt ttttagatcc ttt 3334534DNAArtificial
SequencePrimer 345tcctgttatc cctgaagtag ttaatcaagt ttgt
3434635DNAArtificial SequencePrimer 346tcctgttatc cctgaagtag
ttaatcaagt ttgtt 3534736DNAArtificial SequencePrimer 347tcctgttatt
cctgaagtag ttaatcaagt ttgtta 3634831DNAArtificial SequencePrimer
348tccttacttc gaactatgaa tcttttggaa g 3134929DNAArtificial
SequencePrimer 349tccttatagg gatggctatc agtaatgtt
2935022DNAArtificial SequencePrimer 350tccttgaccg cctttccgat ac
2235133DNAArtificial SequencePrimer 351tccttgcttt agttttaagt
gcatgtaatt caa 3335232DNAArtificial SequencePrimer 352tcctttgata
tattatgcga tggaaggttg gt 3235330DNAArtificial SequencePrimer
353tcctttgatg catgtaattg ctgcaaaagc 3035431DNAArtificial
SequencePrimer 354tcgaaagctt ttgcatatta tatcgagcca c
3135528DNAArtificial SequencePrimer 355tcgaagtaca atacaagaca
aaagaagg 2835628DNAArtificial SequencePrimer 356tcgacaacac
cattatctat ggtgtgaa 2835723DNAArtificial SequencePrimer
357tcgacctttg gcaggaacta gac 2335817DNAArtificial SequencePrimer
358tcgagcaggc gctgccg 1735931DNAArtificial SequencePrimer
359tcgagtatag ctaaaaaaat agtttatgac a 3136026DNAArtificial
SequencePrimer 360tcgatctggt ttcatgctgt ttcagt 2636128DNAArtificial
SequencePrimer 361tcgatgaacg accaacaagt gattgatg
2836224DNAArtificial SequencePrimer 362tcgattaggc agcaacgaaa gccg
2436324DNAArtificial SequencePrimer 363tcgcaaaaaa atccagctat tagc
2436426DNAArtificial SequencePrimer 364tcgccaatca aaactaaggg aatggc
2636519DNAArtificial SequencePrimer 365tcgccatcgt caccaaccg
1936616DNAArtificial SequencePrimer 366tcgcccgcga ggacgt
1636721DNAArtificial SequencePrimer 367tcgccgactt cgacggtgac c
2136822DNAArtificial SequencePrimer 368tcgccggcaa tgccattgga ta
2236923DNAArtificial SequencePrimer 369tcgccgtgga aaaatcctac gct
2337031DNAArtificial SequencePrimer 370tcgcgttgca acaaaacttt
ctaaagtatg t 3137124DNAArtificial SequencePrimer 371tcgctacagg
ccctttagga caag 2437227DNAArtificial SequencePrimer 372tcgctatctt
atcgttgaga agggatt 2737324DNAArtificial SequencePrimer
373tcggaatctg atgttgcagt tgtt 2437422DNAArtificial SequencePrimer
374tcggccgcac cttcatcgaa gt 2237528DNAArtificial SequencePrimer
375tcggcgaaat ccgtattcct gaaaatga 2837618DNAArtificial
SequencePrimer 376tcggcgcctg cctgatga 1837723DNAArtificial
SequencePrimer 377tcgggtgatg atgcgcgtga agg 2337831DNAArtificial
SequencePrimer 378tcggtttagt aaaagaacgt attgctcaac c
3137928DNAArtificial SequencePrimer 379tcgtacgtat tattaggtgc
tggtcact 2838021DNAArtificial SequencePrimer 380tcgtatggct
caatggtgga g 2138130DNAArtificial SequencePrimer 381tcgtcttttt
gattctttcc ctgataatgc 3038232DNAArtificial SequencePrimer
382tcgtcttttt gattctttcc ctgataatgc tc 3238325DNAArtificial
SequencePrimer 383tcgtgattat ggatggcaac gtgaa 2538424DNAArtificial
SequencePrimer 384tcgtgcccgc aatttgcata aagc 2438521DNAArtificial
SequencePrimer 385tcgtggcggc gtggttatcg a 2138627DNAArtificial
SequencePrimer 386tcgtgttgaa cgtggtcaaa tcaaagt
2738723DNAArtificial SequencePrimer 387tcgttcctgg aacacgatga cgc
2338827DNAArtificial SequencePrimer 388tcgtttggtg gtggtagatg
aaaaagg 2738911DNAArtificial SequencePrimer 389tccaccctca a
1139025DNAArtificial SequencePrimer 390tctaaaacac caggtcaccc agaag
2539124DNAArtificial SequencePrimer 391tctaaatggt cgtgcagttg cgtg
2439230DNAArtificial SequencePrimer 392tctactgatt ttggtaatct
tgcagcacag 3039324DNAArtificial SequencePrimer 393tctagtaata
ataggaccct cagc 2439431DNAArtificial SequencePrimer 394tctcaaggtg
atattggtgt aggtaactta a 3139524DNAArtificial SequencePrimer
395tctcattacg ttgcatcgga aaca 2439630DNAArtificial SequencePrimer
396tctcgatgaa cgaccaacaa gtgattgatg 3039728DNAArtificial
SequencePrimer 397tctcgtggtg cacaagtaac ggatatta
2839832DNAArtificial SequencePrimer 398tctgaaatga atagtgatag
aactgtaggc ac 3239932DNAArtificial SequencePrimer 399tctgaacatg
ataatatctt tgaaatcggc tc 3240030DNAArtificial SequencePrimer
400tctgaatgtc tatatggagg tacaacacta 3040119DNAArtificial
SequencePrimer 401tctgacacct gcccggtgc 1940220DNAArtificial
SequencePrimer 402tctgcccgtg tcgttggtga 2040324DNAArtificial
SequencePrimer 403tctggaggca caccaaataa aaca 2440421DNAArtificial
SequencePrimer 404tctggataac ggtcgtcgcg g 2140525DNAArtificial
SequencePrimer 405tctggcaggt atgcgtggtc tgatg 2540624DNAArtificial
SequencePrimer 406tctggctaaa actttggcaa cggt 2440729DNAArtificial
SequencePrimer 407tctggtccaa caaaaggaac gattacagg
2940825DNAArtificial SequencePrimer 408tctgtcccta gtacgagagg accgg
2540923DNAArtificial SequencePrimer 409tctgttctta gtacgagagg acc
2341026DNAArtificial SequencePrimer 410tcttatgcca agaggacaga gtgagt
2641129DNAArtificial SequencePrimer 411tcttatgcca agaggacaga
gtgagtact 2941231DNAArtificial SequencePrimer 412tcttattcca
acttcaaacc gaactatgac g 3141329DNAArtificial SequencePrimer
413tcttctcatc ctatggctat tatgcttgc 2941433DNAArtificial
SequencePrimer 414tcttgatact tgtaatgtgg gcgataaata tgt
3341532DNAArtificial SequencePrimer 415tcttgcagca gtttatttga
tgaacctaaa gt 3241628DNAArtificial SequencePrimer 416tcttgctctt
tcgtgagttc agtaaatg 2841731DNAArtificial SequencePrimer
417tcttgtactt gtggctcaca cggctgtttg g 3141827DNAArtificial
SequencePrimer 418tcttgtttat gctggtaaag cagatgg
2741928DNAArtificial SequencePrimer 419tctttatggt ggagatgact
gaaaccga 2842028DNAArtificial SequencePrimer 420tctttcttga
atgctggtgt acgtatcg 2842125DNAArtificial SequencePrimer
421tctttgaaat cggctcagga aaagg 2542226DNAArtificial SequencePrimer
422tctttgccat tgaagatgac ttaagc 2642329DNAArtificial SequencePrimer
423tcttttacaa aaggggaaaa agttgactt 2942434DNAArtificial
SequencePrimer 424tgaaaaatgt ccaagaagca tagcaaaaaa agca
3442530DNAArtificial SequencePrimer 425tgaaaagggt gaagtagcaa
atggagatag 3042632DNAArtificial SequencePrimer 426tgaaaagtat
ggatttgaac aactcgtgaa ta 3242727DNAArtificial SequencePrimer
427tgaaatctca ttacgttgca tcggaaa 2742830DNAArtificial
SequencePrimer 428tgaaattgct acaggccctt taggacaagg
3042925DNAArtificial SequencePrimer 429tgaacgctgg tggcatgctt aacac
2543030DNAArtificial SequencePrimer 430tgaacgtggt caaatcaaag
ttggtgaaga 3043131DNAArtificial SequencePrimer 431tgaacgtggt
caaatcaaag ttggtgaaga a 3143227DNAArtificial SequencePrimer
432tgaagcttgt tctttagcag gacttca 2743328DNAArtificial
SequencePrimer 433tgaaggtgga cgtcacactc cattcttc
2843426DNAArtificial SequencePrimer 434tgaagtagaa atgactgaac gtccga
2643528DNAArtificial SequencePrimer 435tgaagtagaa ggtgcaaagc
aagttaga 2843634DNAArtificial SequencePrimer 436tgaagtgcgt
gatgatatcg atgcacttga tgta 3443731DNAArtificial SequencePrimer
437tgaatagtga tagaactgta ggcacaatcg t 3143831DNAArtificial
SequencePrimer 438tgaatgctta tttacctgca ctcccacaac t
3143931DNAArtificial SequencePrimer 439tgaattagtt caatcatttg
ttgaacgacg t 3144026DNAArtificial SequencePrimer 440tgaattgctg
ctatgaaagg tggctt 2644127DNAArtificial SequencePrimer 441tgacagcgaa
gaaggttaga cttgtcc 2744226DNAArtificial SequencePrimer
442tgacatccgg ctcacgttat tatggt 2644327DNAArtificial SequencePrimer
443tgacatccgg ctcacgttat tatggta 2744428DNAArtificial
SequencePrimer 444tgacatccgg ctcacgttat tatggtac
2844529DNAArtificial SequencePrimer 445tgacatgata ataaccgatt
gaccgaaga 2944622DNAArtificial SequencePrimer 446tgacatgctt
gtccgttcag gc 2244731DNAArtificial SequencePrimer 447tgacatggac
tccccctata taactcttga g 3144823DNAArtificial SequencePrimer
448tgaccaggtg atggccatgt tcg 2344931DNAArtificial SequencePrimer
449tgacctacag taagaggttc tgtaatgaac c 3145023DNAArtificial
SequencePrimer 450tgacgatctt cgcggtgact agt 2345126DNAArtificial
SequencePrimer 451tgacggccta tacggtgttg gtttct 2645224DNAArtificial
SequencePrimer 452tgacgtcatc ggtaagtacc accc 2445327DNAArtificial
SequencePrimer 453tgagatggat ttaaacctgt tcaccgc
2745430DNAArtificial SequencePrimer 454tgagattgct gaacatttaa
tgctgattga 3045532DNAArtificial SequencePrimer 455tgagcaatgg
ggctttgaaa gaatttttaa at 3245626DNAArtificial SequencePrimer
456tgagctgcat caactgtatt ggatag 2645728DNAArtificial SequencePrimer
457tgagctttta gttgactttt tcaacagc 2845820DNAArtificial
SequencePrimer 458tgaggaccgt gtcgcgctca 2045935DNAArtificial
SequencePrimer 459tgagggtttt atgcttaaag ttggttttat tggtt
3546030DNAArtificial SequencePrimer 460tgaggtggtg gataactcaa
ttgatgaagc 3046129DNAArtificial SequencePrimer 461tgagtaacat
ccatatttct gccatacgt 2946222DNAArtificial SequencePrimer
462tgagtaagtt ccacccgcac gg 2246330DNAArtificial SequencePrimer
463tgagtcactt gaagttgata caaatcctct 3046428DNAArtificial
SequencePrimer 464tgagtgatga aggccttagg gttgtaaa
2846527DNAArtificial SequencePrimer 465tgagtgccaa catatcagtg
ctgaaga 2746630DNAArtificial SequencePrimer 466tgagtttaac
agttcaccat atgaaacagg 3046725DNAArtificial SequencePrimer
467tgatacttca acgcctgctg ctttc 2546825DNAArtificial SequencePrimer
468tgatcactgg tgctgctcag atgga 2546930DNAArtificial SequencePrimer
469tgatcatccg tggtataacg atttattagt 3047029DNAArtificial
SequencePrimer 470tgatcgttga gaagggattt gcgaaaaga
2947129DNAArtificial SequencePrimer 471tgatctcaga atctaataat
tgggacgaa 2947230DNAArtificial SequencePrimer 472tgatcttaaa
aatttccgcc aacttcattc 3047330DNAArtificial SequencePrimer
473tgatgacttt ttagctaatg gtcaggcagc 3047429DNAArtificial
SequencePrimer 474tgatggcaag tggatagggt ataatacag
2947524DNAArtificial SequencePrimer 475tgattaccat gagtggcaag caag
2447631DNAArtificial SequencePrimer 476tgattattgt tatcctgtta
tgccatttga g 3147719DNAArtificial SequencePrimer 477tgattccggt
gcccgtggt 1947819DNAArtificial SequencePrimer 478tgattctggt
gcccgtggt 1947934DNAArtificial SequencePrimer 479tgattttgct
aaatttagag aaattgcgga tgaa 3448024DNAArtificial SequencePrimer
480tgcaaaatct gcaacgagct ttgg 2448123DNAArtificial SequencePrimer
481tgcaaaggag gtactcagac cat 2348225DNAArtificial SequencePrimer
482tgcaagcaaa cgcacaatca gaagc 2548320DNAArtificial SequencePrimer
483tgcaagcgcg accacatacg 2048423DNAArtificial SequencePrimer
484tgcaagcttc tggtgctagc att 2348524DNAArtificial SequencePrimer
485tgcaagtggt acttcaacat gggg 2448630DNAArtificial SequencePrimer
486tgcaagttaa gaaagctgtt gcaggtttat 3048733DNAArtificial
SequencePrimer 487tgcaattgct ttagttttaa gtgcatgtaa ttc
3348831DNAArtificial SequencePrimer 488tgcacaatca gaagctaaga
aagcgcaagc t 3148924DNAArtificial SequencePrimer 489tgcacacgcc
gttcttcaac aact 2449022DNAArtificial SequencePrimer 490tgcacatcgt
gtccaacgtc ac 2249132DNAArtificial SequencePrimer 491tgcaccggct
attaagaatt actttgccaa ct 3249223DNAArtificial SequencePrimer
492tgcacgatgc ggaatggttc aca 2349328DNAArtificial SequencePrimer
493tgcacgccga ctatgttaag aacatgat 2849430DNAArtificial
SequencePrimer 494tgcacttatc gcaaatggaa aattaagcaa
3049521DNAArtificial SequencePrimer 495tgcagggaac agctttaggc a
2149622DNAArtificial SequencePrimer 496tgcatacaaa cagtcggagc ct
2249723DNAArtificial SequencePrimer 497tgcataccgg taagttggca aca
2349827DNAArtificial SequencePrimer 498tgcatattat atcgagccac
agcatcg 2749933DNAArtificial SequencePrimer 499tgcattattt
ggaactattg caactgctaa tgc 3350028DNAArtificial SequencePrimer
500tgccaagagg acagagtgag tactttga 2850131DNAArtificial
SequencePrimer 501tgccggacaa ttacgattca tcgagtatta a
3150233DNAArtificial SequencePrimer 502tgccgtaatg ataggtgaag
atatacaaag agt
3350323DNAArtificial SequencePrimer 503tgccgtgttg aacgtggtca aat
2350433DNAArtificial SequencePrimer 504tgcctagaag atcttaaaaa
tttccgccaa ctt 3350533DNAArtificial SequencePrimer 505tgcctatctt
tttgctgata tagcacatat tgc 3350627DNAArtificial SequencePrimer
506tgcctcgaag ctgaatataa ccaagtt 2750722DNAArtificial
SequencePrimer 507tgcctgtagg gaatcctgct ga 2250825DNAArtificial
SequencePrimer 508tgcctgttct tagtacgaga ggacc 2550923DNAArtificial
SequencePrimer 509tgcgcagctc ttggtatcga gtt 2351020DNAArtificial
SequencePrimer 510tgcgcggaag atgtaacggg 2051130DNAArtificial
SequencePrimer 511tgcggatcgt ttggtggttg tagatgaaaa
3051220DNAArtificial SequencePrimer 512tgcgggtagg gagcttgagc
2051331DNAArtificial SequencePrimer 513tgcgtacaat acgctttatg
aaattttaac a 3151427DNAArtificial SequencePrimer 514tgcgtataaa
aaacacagat ggcagca 2751521DNAArtificial SequencePrimer
515tgcgtttacc gcaatgcgtg c 2151629DNAArtificial SequencePrimer
516tgctacggta ggatctcctt atcctattg 2951730DNAArtificial
SequencePrimer 517tgctagtcaa tctatcattc cggttgatac
3051827DNAArtificial SequencePrimer 518tgctagttat ggtacagagt
ttgcgac 2751926DNAArtificial SequencePrimer 519tgctatggtg
ttaccttccc tatgca 2652027DNAArtificial SequencePrimer 520tgctcaaccc
gatcctaaat tagacga 2752127DNAArtificial SequencePrimer
521tgctcaatct aaacctaaag tcgaaga 2752233DNAArtificial
SequencePrimer 522tgctcgagtg attgactttg ctaaatttag aga
3352324DNAArtificial SequencePrimer 523tgctcgtaag ggtctggcgg atac
2452429DNAArtificial SequencePrimer 524tgctcgtggt gcacaagtaa
cggatatta 2952526DNAArtificial SequencePrimer 525tgctgaggcc
tggaccgatt atttac 2652627DNAArtificial SequencePrimer 526tgctggtaac
agagccttat aggcgca 2752719DNAArtificial SequencePrimer
527tgctggtacg ggtcgagga 1952831DNAArtificial SequencePrimer
528tgctggtgaa aataacccag atgtcgtctt c 3152932DNAArtificial
SequencePrimer 529tgctgtagct tatcgcgaaa tgtctttgat tt
3253028DNAArtificial SequencePrimer 530tgcttattta cctgcactcc
cacaactg 2853126DNAArtificial SequencePrimer 531tgcttcagga
atcaatgatg gagcag 2653227DNAArtificial SequencePrimer 532tgcttcggat
ccagcagcac ttcaata 2753319DNAArtificial SequencePrimer
533tgcttctggt gctagcatt 1953432DNAArtificial SequencePrimer
534tgctttccta tggcttatcc aaatttagat cg 3253529DNAArtificial
SequencePrimer 535tgcttttgat ggtgatgcag atcgtttgg
2953624DNAArtificial SequencePrimer 536tggaaagcca tgcgtctgac atct
2453723DNAArtificial SequencePrimer 537tggaaaggtg ttgcagctac tca
2353831DNAArtificial SequencePrimer 538tggaaatggc agctagaata
gtagctaaaa t 3153930DNAArtificial SequencePrimer 539tggaacaaaa
tagtctctcg gattttgact 3054033DNAArtificial SequencePrimer
540tggaacagga attaattctc atcctgatta tcc 3354130DNAArtificial
SequencePrimer 541tggaacgtta tcaggtgccc caaaaattcg
3054223DNAArtificial SequencePrimer 542tggaactatt gcaactgcta atg
2354330DNAArtificial SequencePrimer 543tggaacttga agctctcgct
cttaaagatg 3054419DNAArtificial SequencePrimer 544tggaagatct
gggtcaggc 1954522DNAArtificial SequencePrimer 545tggaagtcat
caagcgcctg gc 2254630DNAArtificial SequencePrimer 546tggaataaca
aaacatgaag gaaaccactt 3054732DNAArtificial SequencePrimer
547tggaatgatg ataaagattt cgcagatagc ta 3254829DNAArtificial
SequencePrimer 548tggacaatag acaatcactt ggatttaca
2954928DNAArtificial SequencePrimer 549tggacacata tcgtgagcaa
tgaactga 2855023DNAArtificial SequencePrimer 550tggacggcat
cacgattctc tac 2355119DNAArtificial SequencePrimer 551tggactcctc
ggtggtcgc 1955219DNAArtificial SequencePrimer 552tggagcacgg
cttctgatc 1955330DNAArtificial SequencePrimer 553tggagcttga
agctatcgct cttaaagatg 3055422DNAArtificial SequencePrimer
554tggaggtgtc actccacacg aa 2255525DNAArtificial SequencePrimer
555tggaggttgt tgtatgtatg gtggt 2555626DNAArtificial SequencePrimer
556tggatattca ccgaacacta gggttg 2655727DNAArtificial SequencePrimer
557tggatggcat ggtgaaatgg atatgtc 2755825DNAArtificial
SequencePrimer 558tggatgggga ttagcggtta caatg 2555926DNAArtificial
SequencePrimer 559tggatgttaa gggtgatttt cccgaa 2656023DNAArtificial
SequencePrimer 560tggattagag accctggtag tcc 2356119DNAArtificial
SequencePrimer 561tggcacggcc atctccgtg 1956234DNAArtificial
SequencePrimer 562tggcactctt gcctttaata ttagtaaact atca
3456331DNAArtificial SequencePrimer 563tggcagctag aatagtagct
aaaatcccta c 3156428DNAArtificial SequencePrimer 564tggcagtttt
acaaggtgct gtttcatc 2856531DNAArtificial SequencePrimer
565tggcatttct tatgaagctt gttctttagc a 3156624DNAArtificial
SequencePrimer 566tggccagcgc ttcggtgaaa tgga 2456721DNAArtificial
SequencePrimer 567tggcccgaaa gaagctgagc g 2156832DNAArtificial
SequencePrimer 568tggcctaatg ggcttaatat caatgaaaat tg
3256922DNAArtificial SequencePrimer 569tggcgaacct ggtgaacgaa gc
2257026DNAArtificial SequencePrimer 570tggcgagtgg atagggtata atacag
2657127DNAArtificial SequencePrimer 571tggcgtagta gagctattta
cagacac 2757226DNAArtificial SequencePrimer 572tggcaagtgg
atagggtata atacag 2657325DNAArtificial SequencePrimer 573tggctccttg
gtatgactct gcttc 2557425DNAArtificial SequencePrimer 574tggctgacat
cctacatgac tgtga 2557531DNAArtificial SequencePrimer 575tggcttatcc
aaatttagat cgtggtttta c 3157630DNAArtificial SequencePrimer
576tgggacttga agctatcgct cttaaagatg 3057730DNAArtificial
SequencePrimer 577tgggatgaaa aagcgttctt ttatccatga
3057834DNAArtificial SequencePrimer 578tgggattatt gttatcctgt
tatgccattt gaga 3457932DNAArtificial SequencePrimer 579tgggatttta
aaaaacattg gtaacatcgc ag 3258030DNAArtificial SequencePrimer
580tgggcaacag cagcggattg cgattgcgcg 3058124DNAArtificial
SequencePrimer 581tgggcagcgt ttcggcgaaa tgga 2458233DNAArtificial
SequencePrimer 582tgggcctaat gggcttaata tcaatgaaaa ttg
3358328DNAArtificial SequencePrimer 583tgggcgatgc tgcgaaatgg
ttaaaaga 2858427DNAArtificial SequencePrimer 584tgggcgtgag
caatgaactg attatac 2758518DNAArtificial SequencePrimer
585tgggcgtgga acgtccac 1858624DNAArtificial SequencePrimer
586tgggctcttt ctcgcttaaa cacc 2458725DNAArtificial SequencePrimer
587tgggctcttt ctcgcttaaa cacct 2558831DNAArtificial SequencePrimer
588tggggattca gccatcaaag cagctattga c 3158928DNAArtificial
SequencePrimer 589tggggattga tatcaccgat aagaagaa
2859033DNAArtificial SequencePrimer 590tggggcttta aatattccaa
ttgaagattt tca 3359133DNAArtificial SequencePrimer 591tggggctttg
ctttatagtt ttttacattt aag 3359228DNAArtificial SequencePrimer
592tgggtgatgc tgctaaatgg ttaaaaga 2859335DNAArtificial
SequencePrimer 593tgggtcgtgg ttttacagaa aatttcttat atatg
3559428DNAArtificial SequencePrimer 594tgggtgacat tcatcaattt
catcgttc 2859532DNAArtificial SequencePrimer 595tgggtttaca
catatcgtga gcaatgaact ga 3259625DNAArtificial SequencePrimer
596tggtaaatac cacccacatg gtgac 2559724DNAArtificial SequencePrimer
597tggtaacaga gccttatagg cgca 2459828DNAArtificial SequencePrimer
598tggtaacaga gccttatagg cgcatatg 2859930DNAArtificial
SequencePrimer 599tggtaagagc gcaccggtaa gttggtaaca
3060018DNAArtificial SequencePrimer 600tggtacagag tttgcgac
1860126DNAArtificial SequencePrimer 601tggtacatgt gccttcattg atgctg
2660218DNAArtificial SequencePrimer 602tggtacagag tttgcgac
1860324DNAArtificial SequencePrimer 603tggtactcac ttagcgggtt tccg
2460424DNAArtificial SequencePrimer 604tggtatgata tgatgcctgc acca
2460521DNAArtificial SequencePrimer 605tggtatgcgt ggtctgatgg c
2160631DNAArtificial SequencePrimer 606tggtattcta ttttgctgat
aatgacctcg c 3160725DNAArtificial SequencePrimer 607tggtcaaatc
aaagttggtg aagaa 2560829DNAArtificial SequencePrimer 608tggtcttatg
ccaagaggac agagtgagt 2960924DNAArtificial SequencePrimer
609tggtgactcg gcatgttatg aagc 2461030DNAArtificial SequencePrimer
610tggtgacttc ataatggatg aagttgaagt 3061127DNAArtificial
SequencePrimer 611tggtgcgagt gcttatgctc gtattat
2761213DNAArtificial SequencePrimer 612tggtgctagc att
1361324DNAArtificial SequencePrimer 613tggtgctttc tggcgcttaa acga
2461427DNAArtificial SequencePrimer 614tggtggacat ttaacacatg
gtgcaaa 2761526DNAArtificial SequencePrimer 615tggtggtgaa
atagatagga ctgctt 2661613DNAArtificial SequencePrimer 616tggtgctagc
att 1361726DNAArtificial SequencePrimer 617tggttatcgc tcaggcgaac
tccaac 2661833DNAArtificial SequencePrimer 618tggttatgta ccaaatactt
tgtctgaaga tgg 3361931DNAArtificial SequencePrimer 619tggtttagat
aattccttag gatctatgcg t 3162031DNAArtificial SequencePrimer
620tgtcctactg tttgtggttc tgtaatgaac c 3162124DNAArtificial
SequencePrimer 621tgtaactatc acccgcacgg tgat 2462230DNAArtificial
SequencePrimer 622tgtaagctct acaacccaca aaaccttacg
3062330DNAArtificial SequencePrimer 623tgtaatgaac cctaatgacc
atccacacgg 3062431DNAArtificial SequencePrimer 624tgtacccgct
gaattaacga atttatacga c 3162524DNAArtificial SequencePrimer
625tgtactcggt aagtatcacc cgca 2462621DNAArtificial SequencePrimer
626tgtactgcta tccaccctca a 2162724DNAArtificial SequencePrimer
627tgtagccgct aagcactacc atcc 2462830DNAArtificial SequencePrimer
628tgtagcttat cgcgaaatgt ctttgatttt 3062933DNAArtificial
SequencePrimer 629tgtatggtgg tgtaacgtta catgataata atc
3363027DNAArtificial SequencePrimer 630tgtattaggg gcatacagtc
ctcatcc 2763124DNAArtificial SequencePrimer 631tgtcaaagtg
gcacgtttac tggc 2463224DNAArtificial SequencePrimer 632tgtcatgggt
aaatatcacc ctca 2463328DNAArtificial SequencePrimer 633tgtccaagaa
gcatagcaaa aaaagcaa 2863423DNAArtificial SequencePrimer
634tgtcgatgca acgcgaagaa cct 2363525DNAArtificial SequencePrimer
635tgtcggtaca cgatattctt cacga 2563627DNAArtificial SequencePrimer
636tgtgaataaa tcacgattga ttgagca 2763726DNAArtificial
SequencePrimer 637tgtggagtaa cactgcatga aaacaa 2663827DNAArtificial
SequencePrimer 638tgtggtcaaa tcaaagttgg tgaagaa
2763925DNAArtificial SequencePrimer 639tgttcaagag ctagatcttc aggca
2564026DNAArtificial SequencePrimer 640tgttcaagag ctagatcttc aggcaa
2664128DNAArtificial SequencePrimer 641tgttcgctgt ttcacaaaca
acattcca 2864232DNAArtificial SequencePrimer 642tgttctttag
caggacttca caaacttgat aa 3264329DNAArtificial SequencePrimer
643tgttgaacgt ggtcaaatca aagttggtg 2964431DNAArtificial
SequencePrimer 644tgttgggagt attccttacc atttaagcac a
3164523DNAArtificial SequencePrimer 645tgttggtgct ttctggcgct taa
2364638DNAArtificial SequencePrimer 646tccttgttgt cctactgttt
gtggttctgt aatgaacc 3864729DNAArtificial SequencePrimer
647ttaaagttgg ttttattggt tggcgcgga 2964830DNAArtificial
SequencePrimer 648ttaacatgaa ggaaaccact ttgataatgg
3064926DNAArtificial SequencePrimer 649ttaacggtta tcatggccca gatggg
2665022DNAArtificial SequencePrimer 650ttaagtcccg caacgagcgc aa
2265122DNAArtificial SequencePrimer 651ttaagtcccg caacgatcgc aa
2265228DNAArtificial SequencePrimer 652ttaatttgcc aaaaatgcaa
ccaggtag 2865327DNAArtificial SequencePrimer 653ttacacatat
cgtgagcaat gaactga 2765431DNAArtificial SequencePrimer
654ttacaggaag tttaggtggt aatctaaaag g 3165530DNAArtificial
SequencePrimer 655ttactccatt attgcttggt tacactttcc
3065635DNAArtificial SequencePrimer 656ttataactta ctgcaatcta
ttcagttgct tggtg 3565726DNAArtificial SequencePrimer 657ttataccgga
aacttcccga aaggag 2665832DNAArtificial SequencePrimer 658ttatcagcta
gaccttttag gtaaagctaa gc 3265923DNAArtificial SequencePrimer
659ttatcgctca ggcgaactcc aac 2366028DNAArtificial SequencePrimer
660ttatcgtttg tggagctagt gcttatgc 2866130DNAArtificial
SequencePrimer 661ttatgaagcg tgttctttag caggacttca
3066225DNAArtificial SequencePrimer 662ttatggatgg caacgtgaaa cgcgt
2566321DNAArtificial SequencePrimer 663ttattgttat cctgttatgc c
2166425DNAArtificial SequencePrimer 664ttatttacct gcactcccac aactg
2566533DNAArtificial SequencePrimer 665ttcaaaaact ccaggccatc
ctgaaatttc aac 3366628DNAArtificial SequencePrimer 666ttcaacaggt
accaatgatt tgatctca 2866728DNAArtificial SequencePrimer
667ttcccaccga tatcatggct taccacgg 2866825DNAArtificial
SequencePrimer 668ttccgtaagt cggctaaaac agtcg 2566924DNAArtificial
SequencePrimer 669ttcctccttt tgaaagcgac ggtt 2467017DNAArtificial
SequencePrimer
670ttcctcggcc gcctggc 1767129DNAArtificial SequencePrimer
671ttcctgaccg acccattatt ccctttatc 2967222DNAArtificial
SequencePrimer 672ttcgatgcaa cgcgaagaac ct 2267327DNAArtificial
SequencePrimer 673ttcgccaatc aaaactaagg gaatggc
2767420DNAArtificial SequencePrimer 674ttcggcggtc agcgcttcgg
2067526DNAArtificial SequencePrimer 675ttctaaaaca ccaggtcacc cagaag
2667627DNAArtificial SequencePrimer 676ttctatctcg ttggtttatt
cggagtt 2767730DNAArtificial SequencePrimer 677ttctgaatgt
ctatatggag gtacaacact 3067821DNAArtificial SequencePrimer
678ttgactgccc aggtcacgct g 2167922DNAArtificial SequencePrimer
679ttgactgcgg cacaacacgg at 2268033DNAArtificial SequencePrimer
680ttgagaagac atccggctca cgttattatg gta 3368131DNAArtificial
SequencePrimer 681ttgagggtat gcaccgtctt tttgattctt t
3168224DNAArtificial SequencePrimer 682ttgcaactgc tgatttagct caga
2468322DNAArtificial SequencePrimer 683ttgcacaagc aaggcgctat tt
2268428DNAArtificial SequencePrimer 684ttgccaatga tattcgttgg
ttagcaag 2868531DNAArtificial SequencePrimer 685ttgcccgcgg
tgcggaagta accgatatta c 3168623DNAArtificial SequencePrimer
686ttgcgaatag aacgatggct cgt 2368730DNAArtificial SequencePrimer
687ttgctcgtgg tgcacaagta acggatatta 3068831DNAArtificial
SequencePrimer 688ttgctcgtgg tgcacaagta acggatatta c
3168931DNAArtificial SequencePrimer 689ttgctcgtgg tgcacaagta
acggatatta c 3169029DNAArtificial SequencePrimer 690ttgcttaaag
ttggttttat tggttggcg 2969132DNAArtificial SequencePrimer
691ttggtccttt ttatacgaaa gaagaagttg aa 3269225DNAArtificial
SequencePrimer 692ttgtaaatgc cggtgcttca gatcc 2569322DNAArtificial
SequencePrimer 693ttgtacacac cgcccgtcat ac 2269431DNAArtificial
SequencePrimer 694ttgtagcaca gcaaggcaaa tttcctgaaa c
3169530DNAArtificial SequencePrimer 695ttgtatgtat ggtggtgtaa
cgttacatga 3069627DNAArtificial SequencePrimer 696ttgtatgtat
ggtggtgtaa ctgagca 2769723DNAArtificial SequencePrimer
697tttaagtccc gcaacgagcg caa 2369828DNAArtificial SequencePrimer
698tttacacata tcgtgagcaa tgaactga 2869930DNAArtificial
SequencePrimer 699tttacactac ttttattcat tgccctaacg
3070019DNAArtificial SequencePrimer 700tttacagctt tatgcaccg
1970129DNAArtificial SequencePrimer 701tttcacacag cgtgtttata
gttctacca 2970230DNAArtificial SequencePrimer 702tttcacatgt
aattttgata ttcgcactga 3070328DNAArtificial SequencePrimer
703tttcatctta tcgaggaccc gaaatcga 2870425DNAArtificial
SequencePrimer 704tttcctcctt ttgaaagcga cggtt 2570522DNAArtificial
SequencePrimer 705tttcgaaggg cctttcgacc tg 2270623DNAArtificial
SequencePrimer 706tttcgatgca acgcgaagaa cct 2370727DNAArtificial
SequencePrimer 707tttgatttta cgccgtcctc caggtcg
2770832DNAArtificial SequencePrimer 708tttgcggatg aagtaggtgc
ctatcttttt gc 3270932DNAArtificial SequencePrimer 709ttttatgctt
aaagttggtt ttattggttg gc 3271024DNAArtificial SequencePrimer
710ttttgaaggt gatccgtgcc aacg 2471129DNAArtificial SequencePrimer
711aaactatttt tttagctata ctcgaacac 2971219DNAArtificial
SequencePrimer 712aacatagcct tctccgtcc 1971321DNAArtificial
SequencePrimer 713aacttcgcct tcggtcatgt t 2171417DNAArtificial
SequencePrimer 714aaggaggtga tccagcc 1771529DNAArtificial
SequencePrimer 715aatcgacgac catcttggaa agatttctc
2971621DNAArtificial SequencePrimer 716acaaaaggca cgccatcacc c
2171721DNAArtificial SequencePrimer 717acaaaaggta cgccgtcacc c
2171818DNAArtificial SequencePrimer 718acaacacgag ctgacgac
1871918DNAArtificial SequencePrimer 719acaacacgag ctgacgac
1872018DNAArtificial SequencePrimer 720acaacacgag ctgacgac
1872118DNAArtificial SequencePrimer 721acaacacgag ctgacgac
1872218DNAArtificial SequencePrimer 722acaacacgag ctgacgac
1872318DNAArtificial SequencePrimer 723acaacacgag ctgacgac
1872418DNAArtificial SequencePrimer 724acaacacgag ctgacgac
1872518DNAArtificial SequencePrimer 725acaacacgag ctgacgac
1872620DNAArtificial SequencePrimer 726acaaccatgc accacctgtc
2072712DNAArtificial SequencePrimer 727acacgagctg ac
1272828DNAArtificial SequencePrimer 728accactttta ataaggtttg
tagctaac 2872927DNAArtificial SequencePrimer 729acctgcaata
tctaatgcac tcttacg 2773024DNAArtificial SequencePrimer
730acctgcatcc ctaaacgtac ttgc 2473122DNAArtificial SequencePrimer
731accttgttac gacttcaccc ca 2273220DNAArtificial SequencePrimer
732acgaactgga tgtcgccgtt 2073318DNAArtificial SequencePrimer
733acgacacgag ctgacgac 1873418DNAArtificial SequencePrimer
734acgacacgag ctgacgac 1873520DNAArtificial SequencePrimer
735acgagctgac gacagccatg 2073619DNAArtificial SequencePrimer
736acgccatcag gccacgcat 1973721DNAArtificial SequencePrimer
737acgcgggcat gcagagatgc c 2173818DNAArtificial SequencePrimer
738acggcacgag gtagtcgc 1873920DNAArtificial SequencePrimer
739acggttacct tgttacgact 2074020DNAArtificial SequencePrimer
740acgtccttca tcgcctctga 2074127DNAArtificial SequencePrimer
741acgtttttcg ttttgaacga taatgct 2774217DNAArtificial
SequencePrimer 742actgctgcct cccgtag 1774320DNAArtificial
SequencePrimer 743acttagatgc tttcagcggt 2074420DNAArtificial
SequencePrimer 744agacctcctg cgtgcaaagc 2074531DNAArtificial
SequencePrimer 745agataaagaa tcacgaatat caatttgtag c
3174622DNAArtificial SequencePrimer 746agccgacatc gaggtgccaa ac
2274728DNAArtificial SequencePrimer 747agctgctaga tgagcttctg
ccatggcc 2874823DNAArtificial SequencePrimer 748aggatagatt
tatttcttgt tcg 2374920DNAArtificial SequencePrimer 749agtccatccc
ggtcctctcg 2075022DNAArtificial SequencePrimer 750ataagccatg
ttctgttcca tc 2275118DNAArtificial SequencePrimer 751ataagccggg
ttctgtcg 1875226DNAArtificial SequencePrimer 752atatgattat
cattgaactg cggccg 2675319DNAArtificial SequencePrimer 753atcccctgct
tctgctgcc 1975430DNAArtificial SequencePrimer 754attcaagagc
catttctttt ggtaaaccac 3075522DNAArtificial SequencePrimer
755attgcccaga aatcaaatca tc 2275633DNAArtificial SequencePrimer
756attgcttctt acttgcttag cataaatttt cca 3375721DNAArtificial
SequencePrimer 757attgtagcac gtgtgtagcc c 2175824DNAArtificial
SequencePrimer 758caagcggttt gcctcaaata gtca 2475922DNAArtificial
SequencePrimer 759caatctgctg acggatctga gc 2276015DNAArtificial
SequencePrimer 760caccgggcag gcgtc 1576120DNAArtificial
SequencePrimer 761cacggctacc ttgttacgac 2076220DNAArtificial
SequencePrimer 762cagataaaga atcgctccag 2076325DNAArtificial
SequencePrimer 763catgacagcc aagacctcac ccacc 2576418DNAArtificial
SequencePrimer 764catgatggtc acaaccgg 1876520DNAArtificial
SequencePrimer 765ccaaacaccg ccgtcgatat 2076626DNAArtificial
SequencePrimer 766ccaacctttt ccacaacaga atcagc 2676727DNAArtificial
SequencePrimer 767ccaagtgctg gtttacccca tggagta
2776823DNAArtificial SequencePrimer 768ccacttttaa taaggtttgt agc
2376927DNAArtificial SequencePrimer 769ccagcagtta ctgtcccctc
atctttg 2777028DNAArtificial SequencePrimer 770ccataaggtc
accgtcacca ttcaaagc 2877118DNAArtificial SequencePrimer
771ccatgcagca cctgtctc 1877229DNAArtificial SequencePrimer
772cccatttttt cacgcatgct gaaaatatc 2977321DNAArtificial
SequencePrimer 773cccccgtcaa ttcctttgag t 2177424DNAArtificial
SequencePrimer 774ccctgtagta gaagaggtaa ccac 2477521DNAArtificial
SequencePrimer 775ccgacaagga atttcgctac c 2177623DNAArtificial
SequencePrimer 776ccgcggtcga attgcatgcc ttc 2377717DNAArtificial
SequencePrimer 777ccggtcctct cgtacta 1777818DNAArtificial
SequencePrimer 778ccgtgctcca tttttcag 1877925DNAArtificial
SequencePrimer 779cctacccaac gttcaccaag ggcag 2578017DNAArtificial
SequencePrimer 780cctcctgcgt gcaaagc 1778120DNAArtificial
SequencePrimer 781cctgtagtag aagaggtaac 2078218DNAArtificial
SequencePrimer 782ccttctcccg aagttacg 1878320DNAArtificial
SequencePrimer 783ccttgttacg acttcacccc 2078424DNAArtificial
SequencePrimer 784cgaacggcca gagtagtcaa cacg 2478524DNAArtificial
SequencePrimer 785cgaacggcct gagtagtcaa cacg 2478624DNAArtificial
SequencePrimer 786cgacttgacg gttaacattt cctg 2478721DNAArtificial
SequencePrimer 787cgagttgcag actgcgatcc g 2178821DNAArtificial
SequencePrimer 788cgagttgcag actgcgatcc g 2178925DNAArtificial
SequencePrimer 789cgcaccatgc gtagagatga agtac 2579025DNAArtificial
SequencePrimer 790cgcaccgtgg gttgagatga agtac 2579118DNAArtificial
SequencePrimer 791cgcatttcac cgctacac 1879220DNAArtificial
SequencePrimer 792cgcggtcggc tcgttgatga 2079321DNAArtificial
SequencePrimer 793cggctgctgg cacgaagtta g 2179415DNAArtificial
SequencePrimer 794cggcttcaag acccc 1579524DNAArtificial
SequencePrimer 795cggtacgaac tggatgtcgc cgtt 2479615DNAArtificial
SequencePrimer 796cgtactcccc aggcg 1579730DNAArtificial
SequencePrimer 797cgtataagct gcaccataag cttgtaatgc
3079821DNAArtificial SequencePrimer 798cgtggactac cagggtatct a
2179921DNAArtificial SequencePrimer 799ctatcggtca gtcaggagta t
2180022DNAArtificial SequencePrimer 800cttctacatt tttagccatc ac
2280120DNAArtificial SequencePrimer 801ctttacgccc agtaattccg
2080225DNAArtificial SequencePrimer 802ctttcgcttt ctcgaactca accat
2580317DNAArtificial SequencePrimer 803gaatatcaat ttgtagc
1780427DNAArtificial SequencePrimer 804gaccccaacc tggccttttg
tcgttga 2780519DNAArtificial SequencePrimer 805gaccgttata gttacggcc
1980619DNAArtificial SequencePrimer 806gacgggcggt gtgtacaag
1980719DNAArtificial SequencePrimer 807gacgggcggt gtgtacaag
1980819DNAArtificial SequencePrimer 808gacgggcggt gtgtacaag
1980921DNAArtificial SequencePrimer 809gacgtcatcc ccaccttcct c
2181022DNAArtificial SequencePrimer 810gacgtcatcc ccaccttcct cc
2281119DNAArtificial SequencePrimer 811gagcatcagc gtgcgtgct
1981225DNAArtificial SequencePrimer 812gagctgcgcc aacgaataaa tcgtc
2581329DNAArtificial SequencePrimer 813gattggcgat aaagtgatat
tttctaaaa 2981426DNAArtificial SequencePrimer 814gcccaccaga
aagactagca ggataa 2681521DNAArtificial SequencePrimer 815gccgtccatc
tgagcagcac c 2181621DNAArtificial SequencePrimer 816gccgtccatt
tgagcagcac c 2181719DNAArtificial SequencePrimer 817gccttgcgac
cgtactccc 1981818DNAArtificial SequencePrimer 818gcgaccgtac
tccccagg 1881919DNAArtificial SequencePrimer 819gcgctccacg
tcttcacgc 1982019DNAArtificial SequencePrimer 820gcgtgacagg
caggtattc 1982128DNAArtificial SequencePrimer 821gcgtgacgac
cttcttgaat tgtaatca 2882224DNAArtificial SequencePrimer
822gcgttccaca gcttgttgca gaag 2482318DNAArtificial SequencePrimer
823gctgctggca cggagtta 1882426DNAArtificial SequencePrimer
824gctgctttga tggctgaatc cccttc 2682521DNAArtificial SequencePrimer
825gctggattcg cctttgctac g 2182620DNAArtificial SequencePrimer
826gcttacacac ccggcctatc 2082723DNAArtificial SequencePrimer
827ggaatttacc agcgatagac acc 2382830DNAArtificial SequencePrimer
828ggataattgg tcgtaacaag ggatagtgag 3082925DNAArtificial
SequencePrimer 829ggcatcacca tttccttgtc cttcg 2583018DNAArtificial
SequencePrimer 830ggccgtactc cccaggcg 1883120DNAArtificial
SequencePrimer 831ggcgcttgta cttaccgcac 2083225DNAArtificial
SequencePrimer 832gggtctacac ctgcacttgc ataac 2583316DNAArtificial
SequencePrimer 833gggtttcccc attcgg 1683420DNAArtificial
SequencePrimer 834ggtaaccctt gtctttgaat 2083519DNAArtificial
SequencePrimer 835ggtaaggttc ttcgcgttg 1983628DNAArtificial
SequencePrimer 836ggtataacgc atcgcagcaa aagattta
2883728DNAArtificial SequencePrimer 837gtaacccttg tctttgaatt
gtatttgc
2883822DNAArtificial SequencePrimer 838gtaagccatg ttttgttcca tc
2283922DNAArtificial SequencePrimer 839gtatctaatc ctgtttgctc cc
2284027DNAArtificial SequencePrimer 840gtccgacttg acggtcaaca
tttcctg 2784118DNAArtificial SequencePrimer 841gtgcgccctt tctaactt
1884222DNAArtificial SequencePrimer 842gtgctggttt accccatgga gt
2284321DNAArtificial SequencePrimer 843gttcaaatgc ctggataccc a
2184424DNAArtificial SequencePrimer 844gttgtcacca ggcattacca tttc
2484524DNAArtificial SequencePrimer 845gttgtcgcca ggcataacca tttc
2484624DNAArtificial SequencePrimer 846gtttcatgct tagatgcttt cagc
2484725DNAArtificial SequencePrimer 847gtttttcgtt gcgtacgatg atgtc
2584827DNAArtificial SequencePrimer 848taaacgtccg ataccaatgg
ttcgctc 2784930DNAArtificial SequencePrimer 849taaactattt
ttttagctat actcgaacac 3085028DNAArtificial SequencePrimer
850taaagacacc gctgggttta aatgtgca 2885127DNAArtificial
SequencePrimer 851taaagagacg tttggtagtt catttgc
2785233DNAArtificial SequencePrimer 852taaaggatag cggtaactaa
atggctgagc cat 3385326DNAArtificial SequencePrimer 853taaatgcact
tgcttcaggg ccatat 2685431DNAArtificial SequencePrimer 854taaattccgc
aaagactttg gcattaggtg t 3185529DNAArtificial SequencePrimer
855taacaaatcc cgtctgagtt cctcttgca 2985628DNAArtificial
SequencePrimer 856taacaacgtt accttcgcga tccactaa
2885723DNAArtificial SequencePrimer 857taaccatttc gcgtaagatt caa
2385829DNAArtificial SequencePrimer 858taaccacccc aagatttatc
tttttgcca 2985923DNAArtificial SequencePrimer 859taaccatttc
gcgtaagatt caa 2386039DNAArtificial SequencePrimer 860taacccttgt
ctttgaattg tatttgcaat taatcctgg 3986129DNAArtificial SequencePrimer
861taaccgtttc caaaggtact gtattttgt 2986234DNAArtificial
SequencePrimer 862taaccgtttc caaaggtact gtattttgtt tacc
3486326DNAArtificial SequencePrimer 863taactcctct tccttcaaca ggtgga
2686429DNAArtificial SequencePrimer 864taactgaccc aaagctgaaa
gctttactg 2986533DNAArtificial SequencePrimer 865taagacaagg
ttttgtggat tttttagctt gtt 3386626DNAArtificial SequencePrimer
866taagagtgat gcgggctggt tcaaca 2686725DNAArtificial SequencePrimer
867taagcaatac ctttacttgc accac 2586827DNAArtificial SequencePrimer
868taagcaatac ctttacttgc accacct 2786928DNAArtificial
SequencePrimer 869taagcaatac ctttacttgc accacctg
2887031DNAArtificial SequencePrimer 870taagcaccat ataagtctac
ttttttccct t 3187127DNAArtificial SequencePrimer 871taagccagca
agagctgtat agttcca 2787226DNAArtificial SequencePrimer
872taagctcccg tatcttgagt cgcctc 2687323DNAArtificial SequencePrimer
873taagttacct tgcccgtcaa cca 2387427DNAArtificial SequencePrimer
874taagttcctt cgctagtatg ttggctt 2787530DNAArtificial
SequencePrimer 875taatcgacga ccatcttgga aagatttctc
3087623DNAArtificial SequencePrimer 876taatctggct gcggaagtga aat
2387725DNAArtificial SequencePrimer 877taatctggct gcggaagtga aatcg
2587831DNAArtificial SequencePrimer 878taatgccggg tagtgcaatc
cattcttcta g 3187924DNAArtificial SequencePrimer 879taatgcgata
ctggcctgca agtc 2488033DNAArtificial SequencePrimer 880tacaaccttc
ggataatcag gatgagaatt aat 3388127DNAArtificial SequencePrimer
881tacaacgtga taaacacgac cagaagc 2788235DNAArtificial
SequencePrimer 882tacaactggt tcaaaaacat taagctgtaa ttgtc
3588332DNAArtificial SequencePrimer 883tacagcttta aagccagcaa
aatgaattac ag 3288422DNAArtificial SequencePrimer 884tacaggagca
gcaggcttca ag 2288526DNAArtificial SequencePrimer 885tacatcgttt
cgcccaagat caatca 2688633DNAArtificial SequencePrimer 886tacatctcct
tcgatagaaa tttcattgct atc 3388725DNAArtificial SequencePrimer
887taccaaagcg tgcacgatag ttgag 2588827DNAArtificial SequencePrimer
888taccatctac ccaaacatta gcaccaa 2788922DNAArtificial
SequencePrimer 889taccccagtt cccctgacct tc 2289027DNAArtificial
SequencePrimer 890taccggaagc accagcgaca ttaatag
2789127DNAArtificial SequencePrimer 891tacctgcatt aatcgcttgt
tcatcaa 2789222DNAArtificial SequencePrimer 892taccttaccg
ccaaagctgt ct 2289324DNAArtificial SequencePrimer 893taccttagga
ccgttatagt tacg 2489424DNAArtificial SequencePrimer 894taccttttcc
acaacagaat cagc 2489521DNAArtificial SequencePrimer 895tacgagctga
cgacagccat g 2189623DNAArtificial SequencePrimer 896tacgagctga
cgacagccat gca 2389722DNAArtificial SequencePrimer 897tacgcattac
tcacccgtcc gc 2289820DNAArtificial SequencePrimer 898tacgccatca
ggccacgcat 2089927DNAArtificial SequencePrimer 899tacgctaagc
cacgtccata tttatca 2790035DNAArtificial SequencePrimer
900tacgtatgta aattccgcaa agactttggc attag 3590130DNAArtificial
SequencePrimer 901tacgtcgcct ttaacttggt tatattcagc
3090231DNAArtificial SequencePrimer 902tacgttctac gatttcttca
tcaggtacat c 3190324DNAArtificial SequencePrimer 903tacgtttgta
tcttctgcag aacc 2490429DNAArtificial SequencePrimer 904tacacctggt
ttcgttttga tgatttgta 2990524DNAArtificial SequencePrimer
905tactagacga cgggtcaggt aacc 2490632DNAArtificial SequencePrimer
906tacttcagct tcgtccaata aaaaatcaca at 3290731DNAArtificial
SequencePrimer 907tactttaagg ggctatcttt accatgaacc t
3190827DNAArtificial SequencePrimer 908tagagagtag ccatcttcac
cgttgtc 2790923DNAArtificial SequencePrimer 909tagcaccaat
caccctttcc tgt 2391028DNAArtificial SequencePrimer 910tagcagcaaa
agttatcaca cctgcagt 2891125DNAArtificial SequencePrimer
911tagcagctag ctcgtaacca gtgta 2591231DNAArtificial SequencePrimer
912tagccatacg taccattgct tcataaatag a 3191322DNAArtificial
SequencePrimer 913tagcccagct gtttgagcaa ct 2291420DNAArtificial
SequencePrimer 914tagccgcggt cgaattgcat 2091525DNAArtificial
SequencePrimer 915tagccttggc aacatcagca aaact 2591624DNAArtificial
SequencePrimer 916tagccttttc tccggcgtag atct 2491734DNAArtificial
SequencePrimer 917tagcgatttc tactcctaga gttgaaattt cagg
3491829DNAArtificial SequencePrimer 918tagctgctag atgagcttct
gccatggcc 2991923DNAArtificial SequencePrimer 919taggatgaaa
gcattccgct ggc 2392028DNAArtificial SequencePrimer 920taggatgagc
attatcaggg aaagaatc 2892123DNAArtificial SequencePrimer
921taggattttt ccacggcggc atc 2392231DNAArtificial SequencePrimer
922taggcataac catttcagta ccttctggta a 3192328DNAArtificial
SequencePrimer 923tagtatcacc acgtacaccc ggatcagt
2892428DNAArtificial SequencePrimer 924tagtatcacc acgtacaccc
ggatcagt 2892532DNAArtificial SequencePrimer 925tagtcctttc
tgaattttac catcaaaggt ac 3292632DNAArtificial SequencePrimer
926tagtcttttg gaacaccgtc tttaattaaa gt 3292730DNAArtificial
SequencePrimer 927tagtgttgta cctccatata gacattcaga
3092829DNAArtificial SequencePrimer 928tagttgaagt tgcactatat
actgttgga 2992923DNAArtificial SequencePrimer 929tataacgcac
atcgtcaggg tga 2393026DNAArtificial SequencePrimer 930tatagcacca
tccatctgag cggcac 2693129DNAArtificial SequencePrimer 931tatatgaaca
ataccagttc cttctgagt 2993227DNAArtificial SequencePrimer
932tatatgatta tcattgaact gcggccg 2793328DNAArtificial
SequencePrimer 933tatccattga accaaagtta ccttggcc
2893420DNAArtificial SequencePrimer 934tatcccctgc ttctgctgcc
2093528DNAArtificial SequencePrimer 935tatcgacaga tccaaagtta
ccatgccc 2893627DNAArtificial SequencePrimer 936tatggtctat
ttcaatggca gttacga 2793724DNAArtificial SequencePrimer
937tatgtgctca cgagtttgcg gcat 2493828DNAArtificial SequencePrimer
938tatgtgtagt tgagcttact acatgagc 2893925DNAArtificial
SequencePrimer 939tattcttcgt tactcatgcc ataca 2594023DNAArtificial
SequencePrimer 940tattgcccag aaatcaaatc atc 2394130DNAArtificial
SequencePrimer 941tattgcggat caccatgatg atattcttgc
3094231DNAArtificial SequencePrimer 942tattgctttt tttgctatgc
ttcttggaca t 3194324DNAArtificial SequencePrimer 943tattggaaat
accggcagca tctc 2494430DNAArtificial SequencePrimer 944tatttgggtt
tcattccact cagattctgg 3094532DNAArtificial SequencePrimer
945tcaaaaacaa agaattcatt ttctggtcca aa 3294634DNAArtificial
SequencePrimer 946tcaaaacgca tttttacatc ttcgttaaag gcta
3494729DNAArtificial SequencePrimer 947tcaaaacttg ctctagacca
tttaactcc 2994830DNAArtificial SequencePrimer 948tcaaaatctt
ttgattcgat catacgagac 3094927DNAArtificial SequencePrimer
949tcaaacgatc cgcatcacca tcaaaag 2795030DNAArtificial
SequencePrimer 950tcaaagaacc agcacctaat tcatcattta
3095130DNAArtificial SequencePrimer 951tcaaagaacc cgcacctaat
tcatcattta 3095226DNAArtificial SequencePrimer 952tcaacaacac
ctccttattc ccactc 2695329DNAArtificial SequencePrimer 953tcaacaatca
gatagatgtc agacgcatg 2995428DNAArtificial SequencePrimer
954tcaacaccag cgttacctaa agtacctt 2895535DNAArtificial
SequencePrimer 955tcaactggtt caaaaacatt aagttgtaat tgtcc
3595628DNAArtificial SequencePrimer 956tcaacttctg ccattaaaag
taatgcca 2895724DNAArtificial SequencePrimer 957tcaagcgatc
tacccgcatt acaa 2495830DNAArtificial SequencePrimer 958tcaagcgcca
tctctttcgg taatccacat 3095930DNAArtificial SequencePrimer
959tcaagcgcca tttcttttgg taaaccacat 3096031DNAArtificial
SequencePrimer 960tcaagctata tgctacaact ggttcaaaaa c
3196130DNAArtificial SequencePrimer 961tcaagctcta caccataaaa
aaagctctca 3096228DNAArtificial SequencePrimer 962tcaaggttct
caccgtttac cttaggag 2896332DNAArtificial SequencePrimer
963tcaagtgctt ttacttctat aggtttaagc tc 3296430DNAArtificial
SequencePrimer 964tcaatacaga gtctacactt ggcttaggat
3096525DNAArtificial SequencePrimer 965tcaatctcga ctttttgtgc cggta
2596628DNAArtificial SequencePrimer 966tcacaaggac cattataatc
aatgccaa 2896723DNAArtificial SequencePrimer 967tcacaccaag
tagtgcaagg atc 2396829DNAArtificial SequencePrimer 968tcacacctgt
aagtgagaaa aaggttgat 2996934DNAArtificial SequencePrimer
969tcacaggttc tacttcatca ataatttcca ttgc 3497034DNAArtificial
SequencePrimer 970tcaccagctt cagcgtagtc taataattta cgga
3497122DNAArtificial SequencePrimer 971tcaccatgcg cccgttcaca ta
2297237DNAArtificial SequencePrimer 972tcaccgataa ataaaatacc
taaagttaat gccattg 3797329DNAArtificial SequencePrimer
973tcacctacag ctttaaagcc agcaaaatg 2997428DNAArtificial
SequencePrimer 974tcacgatacc tgcatcatca aattggtt
2897532DNAArtificial SequencePrimer 975tcacgatcta aatttggata
agccatagga aa 3297624DNAArtificial SequencePrimer 976tcacgcgacg
agtgccatcc attg 2497722DNAArtificial SequencePrimer 977tcacgcgcat
catcaccagt ca 2297818DNAArtificial SequencePrimer 978tcacgggcca
gctcgtct 1897928DNAArtificial SequencePrimer 979tcacgtcgtc
cgacttcacg gtcagcat 2898026DNAArtificial SequencePrimer
980tcagaatcga tgccaaatgc gtcatc 2698130DNAArtificial SequencePrimer
981tcagatataa atggaacaaa tggagccact 3098232DNAArtificial
SequencePrimer 982tcagcgtagt ctaataattt acggaacatt tc
3298325DNAArtificial SequencePrimer 983tcagctgtta acggcttcaa gaccc
2598429DNAArtificial SequencePrimer 984tcaggtatga aacacgatta
gtcctttct 2998529DNAArtificial SequencePrimer 985tcagtttgca
cttcaaaaga aattgtgtt 2998629DNAArtificial SequencePrimer
986tcataactag catttgtgct ttgaatgct 2998731DNAArtificial
SequencePrimer 987tcataagggt tgcgttgcag attatcttta c
3198826DNAArtificial SequencePrimer 988tcatctggtt taggatctgg ttgact
2698925DNAArtificial SequencePrimer 989tcatctgtgg tatggcgggt aagtt
2599026DNAArtificial SequencePrimer 990tcatgacagc caagacctca cccacc
2699131DNAArtificial SequencePrimer 991tcatgataga actacctggt
tgcatttttg g 3199228DNAArtificial SequencePrimer 992tcatgtgcta
atgttactgc tggatctg 2899331DNAArtificial SequencePrimer
993tcattaggta aaatgtctgg acatgatcca a 3199428DNAArtificial
SequencePrimer 994tcatttattt cttcgctttt ctcgctac
2899520DNAArtificial SequencePrimer 995tcatttgtgc tttgaatgct
2099628DNAArtificial SequencePrimer 996tccaaacgat ctgcatcacc
atcaaaag 2899729DNAArtificial SequencePrimer 997tccaacccag
aaccacatac tttattcac 2999827DNAArtificial SequencePrimer
998tccaaccttt tccacaacag aatcagc 2799924DNAArtificial
SequencePrimer 999tccaagtgct ggtttacccc atgg 24100026DNAArtificial
SequencePrimer 1000tccaagtgct ggtttacccc atggag
26100128DNAArtificial SequencePrimer 1001tccaagtttg acttaaacgt
accatcgc 28100232DNAArtificial SequencePrimer 1002tccacactgg
attgtaattt accttgttct tt 32100326DNAArtificial SequencePrimer
1003tccaccacct caaagaccat gtggtg 26100423DNAArtificial
SequencePrimer 1004tccagcaggt tctgacggaa acg
23100528DNAArtificial SequencePrimer 1005tccagcagtt actgtcccct
catctttg 28100630DNAArtificial SequencePrimer 1006tccaggcatt
accatttcta ctccttctgg 30100729DNAArtificial SequencePrimer
1007tccataaggt caccgtcacc attcaaagc 29100835DNAArtificial
SequencePrimer 1008tccatacctt tatgcaactt tgtatcaact ggaat
35100928DNAArtificial SequencePrimer 1009tccatattgt tgcataaaac
ctgttggc 28101027DNAArtificial SequencePrimer 1010tccatccata
gaaccaaagt taccttg 27101126DNAArtificial SequencePrimer
1011tccatcgcag tcacgtttac tgttgg 26101232DNAArtificial
SequencePrimer 1012tccatcgcca gtttttgcat aatcgctaaa aa
32101333DNAArtificial SequencePrimer 1013tccatctgtt aaaccatcat
ataccatgct atc 33101426DNAArtificial SequencePrimer 1014tccatttccg
acacgtcgtt gatcac 26101527DNAArtificial SequencePrimer
1015tcccaatcta acttccacat accatct 27101629DNAArtificial
SequencePrimer 1016tcccaatctt ttgattcgat catacgaga
29101727DNAArtificial SequencePrimer 1017tcccatacct atggcgataa
ctgtcat 27101830DNAArtificial SequencePrimer 1018tcccattttt
tcacgcatgc tgaaaatatc 30101915DNAArtificial SequencePrimer
1019tccccacctt cctcc 15102025DNAArtificial SequencePrimer
1020tccccatctc cgcaaagaca ataaa 25102133DNAArtificial
SequencePrimer 1021tccccattta ataattccac ctactatcac act
33102233DNAArtificial SequencePrimer 1022tcccctcatg tttaaatgat
caggataaaa agc 33102331DNAArtificial SequencePrimer 1023tcccctttaa
agcaccatta ctcattatag t 31102433DNAArtificial SequencePrimer
1024tcccgaacaa tgagttgtat caactatttt tac 33102521DNAArtificial
SequencePrimer 1025tcccgctggc aaataaactc g 21102625DNAArtificial
SequencePrimer 1026tcccggctag agattctgta tacga
25102728DNAArtificial SequencePrimer 1027tcccgtctga gttcctcttg
catgatca 28102832DNAArtificial SequencePrimer 1028tccctaatag
tagaaataac tgcatcagta gc 32102934DNAArtificial SequencePrimer
1029tcccttattt ttctttctac taccttcgga taat 34103030DNAArtificial
SequencePrimer 1030tcccttcctt aatatgagaa ggaaaccact
30103132DNAArtificial SequencePrimer 1031tccgaaactt gttttgtagc
tttaatttga gc 32103221DNAArtificial SequencePrimer 1032tccgaagttg
ccctggccgt c 21103324DNAArtificial SequencePrimer 1033tccgagacca
gcgtaggtgt aacg 24103422DNAArtificial SequencePrimer 1034tccgataagc
cggattctgt gc 22103528DNAArtificial SequencePrimer 1035tccgcaaaga
ctttggcatt aggtgtga 28103627DNAArtificial SequencePrimer
1036tccgccaaaa actccccttt tcacagg 27103724DNAArtificial
SequencePrimer 1037tccgccttca aaatggtggc gagt 24103831DNAArtificial
SequencePrimer 1038tccggctaga gattctgtat acgaaaatat c
31103931DNAArtificial SequencePrimer 1039tccggctaga gattctgtat
acgacaatat c 31104023DNAArtificial SequencePrimer 1040tccggtaact
gggtcagctc gaa 23104134DNAArtificial SequencePrimer 1041tccgtagttt
tgcataattt atggtctatt tcaa 34104227DNAArtificial SequencePrimer
1042tccgtcatcg ctgacagaaa ctgagtt 27104328DNAArtificial
SequencePrimer 1043tccgtctatc cacaagttaa ttggtact
28104426DNAArtificial SequencePrimer 1044tcctacccaa cgttcaccaa
gggcag 26104529DNAArtificial SequencePrimer 1045tcctccttgt
gcctcaaaac gcattttta 29104630DNAArtificial SequencePrimer
1046tcctctatgc aacttagtat caacaggaat 30104724DNAArtificial
SequencePrimer 1047tcctcttggg ccacgcaaag tttt 24104827DNAArtificial
SequencePrimer 1048tcctcttttc acaggctcta cttcatc
27104930DNAArtificial SequencePrimer 1049tcctgaagat ctagttcttg
aatggttact 30105027DNAArtificial SequencePrimer 1050tcctgcaata
tctaatgcac tcttacg 27105125DNAArtificial SequencePrimer
1051tcctgcagct ctacctgctc catta 25105220DNAArtificial
SequencePrimer 1052tcctggccat cctgcaggat 20105327DNAArtificial
SequencePrimer 1053tcctgtttta tagccgccaa gagtaag
27105421DNAArtificial SequencePrimer 1054tccttcacgc gcatcatcac c
21105527DNAArtificial SequencePrimer 1055tccttctgat gcctgatgga
ccaggag 27105626DNAArtificial SequencePrimer 1056tccttggcat
acatcatgtc gtagca 26105733DNAArtificial SequencePrimer
1057tccttgtgct tcaaaacgca tttttacatt ttc 33105828DNAArtificial
SequencePrimer 1058tcctttaaaa taaccgctag tagctcct
28105930DNAArtificial SequencePrimer 1059tcctttatgc aacttagtat
caaccggaat 30106030DNAArtificial SequencePrimer 1060tcctttatgc
aacttggtat caacaggaat 30106130DNAArtificial SequencePrimer
1061tcctttatgc aacttggtat caaccggaat 30106229DNAArtificial
SequencePrimer 1062tcctttcaat gttacagaaa actctacag
29106324DNAArtificial SequencePrimer 1063tcgaaccgaa gttaccctga ccat
24106430DNAArtificial SequencePrimer 1064tcgaattcag ctaaatactt
ttcagcatct 30106526DNAArtificial SequencePrimer 1065tcgacctgga
ggacgacgta aaatca 26106625DNAArtificial SequencePrimer
1066tcgacgacca tcttggaaag atttc 25106725DNAArtificial
SequencePrimer 1067tcgagccgaa gttaccctgt ccgtc
25106827DNAArtificial SequencePrimer 1068tcgatccgca tcaccatcaa
aagcaaa 27106926DNAArtificial SequencePrimer 1069tcgatcgaac
cgaagttacc ctgacc 26107028DNAArtificial SequencePrimer
1070tcgatcgtga ctctctttat tttcagtt 28107120DNAArtificial
SequencePrimer 1071tcgatctcct tggcgtccga 20107226DNAArtificial
SequencePrimer 1072tcgcaccgtg ggttgagatg aagtac
26107318DNAArtificial SequencePrimer 1073tcgcagcgtg cgtggcac
18107426DNAArtificial SequencePrimer 1074tcgcaggctt acagaacgct
ctccta 26107523DNAArtificial SequencePrimer 1075tcgcagttca
tcagcacgaa gcg 23107626DNAArtificial SequencePrimer 1076tcgccagcta
gcacgatgtc attttc 26107731DNAArtificial SequencePrimer
1077tcgccatagc taagttgttt attgtttcca t 31107822DNAArtificial
SequencePrimer 1078tcgcctggtg caggcatcat at 22107924DNAArtificial
SequencePrimer 1079tcgcgctgta tttttcctcc gaga 24108018DNAArtificial
SequencePrimer 1080tcgctacctt aggaccgt 18108129DNAArtificial
SequencePrimer 1081tcgctcagca ataattcact ataagccga
29108229DNAArtificial SequencePrimer 1082tcgctctctc aagtgatcta
aacttggag 29108325DNAArtificial SequencePrimer 1083tcgcttgagt
gtagtcatga ttgcg 25108432DNAArtificial SequencePrimer
1084tcggaaacaa agaattcatt ttctggtcca aa 32108533DNAArtificial
SequencePrimer 1085tcggaaatat tctttcaata cctttatgca act
33108634DNAArtificial SequencePrimer 1086tcggaaatat tctttcaata
cctttatgca actt 34108734DNAArtificial SequencePrimer 1087tcggaaatat
tctttcaata cctttatgca actt 34108820DNAArtificial SequencePrimer
1088tcggactcgc tttcgctacg 20108920DNAArtificial SequencePrimer
1089tcggataagc tgccacaagg 20109019DNAArtificial SequencePrimer
1090tcggcatcac gccgtcgtc 19109120DNAArtificial SequencePrimer
1091tcggcgaaca tggccatcac 20109233DNAArtificial SequencePrimer
1092tcgggcgtag tttttagtaa ttaaatcaga agt 33109325DNAArtificial
SequencePrimer 1093tcggtacgaa ctggatgtcg ccgtt
25109424DNAArtificial SequencePrimer 1094tcggtcagca aaacggtagc ttgc
24109521DNAArtificial SequencePrimer 1095tcggtggtgg tagccgatct c
21109631DNAArtificial SequencePrimer 1096tcggtttaag ctctacatga
tcgtaaggat a 31109729DNAArtificial SequencePrimer 1097tcggtttcag
tcatctccac cataaaggt 29109826DNAArtificial SequencePrimer
1098tcgtatgacc agcttcggta ctacta 26109932DNAArtificial
SequencePrimer 1099tcgtcaacac taccattatt accatgcatc tc
32110026DNAArtificial SequencePrimer 1100tcgtccgact taacggtcag
catttc 26110129DNAArtificial SequencePrimer 1101tcgtccgact
taacggtcag catttcctg 29110231DNAArtificial SequencePrimer
1102tcgtccgact taacggtcag catttcctgc a 31110326DNAArtificial
SequencePrimer 1103tcgtcctctc gaatctccga tatacc
26110420DNAArtificial SequencePrimer 1104tcgtcgcgga cttcgaagcc
20110526DNAArtificial SequencePrimer 1105tcgtcggact taacggtcag
catttc 26110629DNAArtificial SequencePrimer 1106tcgtcggact
taacggtcag catttcctg 29110731DNAArtificial SequencePrimer
1107tcgtcggact taacggtcag catttcctgc a 31110828DNAArtificial
SequencePrimer 1108tcgtcgtatt tatagtgacc agcaccta
28110928DNAArtificial SequencePrimer 1109tcgtgcctaa caaatcccgt
ctgagttc 28111022DNAArtificial SequencePrimer 1110tcgtggacta
ccagggtatc ta 22111117DNAArtificial SequencePrimer 1111tcgtgggcct
tgccggt 17111228DNAArtificial SequencePrimer 1112tcgttaatta
atctggctgc ggaagtga 28111327DNAArtificial SequencePrimer
1113tcgttgagat ggtttttacc ttcgttg 27111425DNAArtificial
SequencePrimer 1114tcgtttaagc gccagaaagc accaa
25111521DNAArtificial SequencePrimer 1115tcgtttcacc ctgtcatgcc g
21111626DNAArtificial SequencePrimer 1116tctttcgtat aaaaaggacc
aattgg 26111735DNAArtificial SequencePrimer 1117tctacaacac
ttgattgtaa tttgccttgt tcttt 35111824DNAArtificial SequencePrimer
1118tctagcggaa caacagttct gatg 24111927DNAArtificial SequencePrimer
1119tctatagagt ccggactttc ctcgtga 27112030DNAArtificial
SequencePrimer 1120tctataggta ctgtagtttg ttttccgtct
30112127DNAArtificial SequencePrimer 1121tctcacctac agctttaaag
ccagcaa 27112231DNAArtificial SequencePrimer 1122tctcacctac
agctttaaag ccagcaaaat g 31112325DNAArtificial SequencePrimer
1123tctcatcccg atattaccgc catga 25112429DNAArtificial
SequencePrimer 1124tctcatgaaa aaggctcagg agatacaag
29112527DNAArtificial SequencePrimer 1125tctcttaccc caccctttca
cccttac 27112631DNAArtificial SequencePrimer 1126tctctttcaa
agcaccattg ctcattatag t 31112724DNAArtificial SequencePrimer
1127tctgcatttt tgcgagcctg tcta 24112828DNAArtificial SequencePrimer
1128tctgcctgag atgtcgaaaa aaacgttg 28112926DNAArtificial
SequencePrimer 1129tctggcccct ccatacatgt atttag
26113023DNAArtificial SequencePrimer 1130tctggctgcg gaagtgaaat cgt
23113123DNAArtificial SequencePrimer 1131tctgggtgac ctggtgtttt aga
23113220DNAArtificial SequencePrimer 1132tctgtttcag ttgcaaattc
20113334DNAArtificial SequencePrimer 1133tcttcacact tttagaatca
accgttttat tgtc 34113435DNAArtificial SequencePrimer 1134tcttcagcgt
agtctaataa tttacggaac atttc 35113530DNAArtificial SequencePrimer
1135tcttccaagg atagatttat ttcttgttcg 30113633DNAArtificial
SequencePrimer 1136tcttctgtaa agggtggttt attattcatc cca
33113732DNAArtificial SequencePrimer 1137tcttcttctt tcgtataaaa
aggaccaatt gg 32113828DNAArtificial SequencePrimer 1138tcttcttgaa
aaattgttgt cccgaaac 28113931DNAArtificial SequencePrimer
1139tcttctttcg tataaaaagg accaattggt t 31114018DNAArtificial
SequencePrimer 1140tcttgacagc atccgttg 18114132DNAArtificial
SequencePrimer 1141tcttgagcat tggttcttac ttgttttgca ta
32114223DNAArtificial SequencePrimer 1142tcttgagcca tacgtaccat tgc
23114332DNAArtificial SequencePrimer 1143tcttggctta ggatgaaaat
atagtggtgg ta 32114439DNAArtificial SequencePrimer 1144tctttaagtt
cttccaagga tagatttatt tcttgttcg 39114531DNAArtificial
SequencePrimer 1145tcttttcttt gcttaatttt ccatttgcga t
31114614DNAArtificial SequencePrimer 1146tgttactgct ggat
14114725DNAArtificial SequencePrimer 1147tgaacatttg cgacggtata
cccat 25114831DNAArtificial SequencePrimer 1148tgaatatgta
atgcaaacca gtctttgtca t 31114921DNAArtificial SequencePrimer
1149tgaatcttga aacaccatac g 21115026DNAArtificial SequencePrimer
1150tgaatcttga aacaccatac gtaacg 26115134DNAArtificial
SequencePrimer 1151tgaattatgc aagaagtgat caattttctc acga
34115234DNAArtificial SequencePrimer 1152tgaattcttt caaagcacca
ttgctcatta tagt 34115330DNAArtificial SequencePrimer 1153tgacaggaca
caatctgcat gaagtctgag 30115425DNAArtificial SequencePrimer
1154tgacccaaag ctgaaagctt tactg 25115528DNAArtificial
SequencePrimer 1155tgaccccaac ctggcctttt gtcgttga
28115620DNAArtificial SequencePrimer 1156tgaccgttat agttacggcc
20115722DNAArtificial SequencePrimer 1157tgacggcatc gataccaccg tc
22115820DNAArtificial SequencePrimer 1158tgacgtcatc cccaccttcc
20115922DNAArtificial SequencePrimer 1159tgacgtcatc cccaccttcc tc
22116020DNAArtificial SequencePrimer 1160tgacgtcatg cccaccttcc
20116120DNAArtificial SequencePrimer 1161tgacgtcatg gccaccttcc
20116232DNAArtificial SequencePrimer 1162tgacttaaac gtaccatcgc
ttcatataca ga 32116327DNAArtificial SequencePrimer 1163tgactttcct
cccccttatc agtctcc 27116431DNAArtificial SequencePrimer
1164tgagatgtcg aaaaaaacgt tggcaaaata c 31116531DNAArtificial
SequencePrimer 1165tgagatgttg atgatttacc agttccgatt g
31116620DNAArtificial SequencePrimer 1166tgagcatcag cgtgcgtgct
20116728DNAArtificial SequencePrimer 1167tgagcatttt tatatccatc
tccaccat 28116832DNAArtificial SequencePrimer 1168tgagccatac
gaacaatggt ttcataaaca gc 32116932DNAArtificial SequencePrimer
1169tgagccatga gtaccatggc ttcataacat gc 32117026DNAArtificial
SequencePrimer 1170tgagcgtgtg gaaaaggact tggatg
26117129DNAArtificial SequencePrimer 1171tgagctggtg ctatatgaac
aataccagt 29117230DNAArtificial SequencePrimer
1172tgagtcaccc tccacaatgt atagttcaga 30117325DNAArtificial
SequencePrimer 1173tgagtcgggt tcactttacc tggca
25117427DNAArtificial SequencePrimer 1174tgagtctaca cttggcttag
gatgaaa 27117532DNAArtificial SequencePrimer 1175tgagttaaaa
tgcgattgat ttcagtttcc aa 32117632DNAArtificial SequencePrimer
1176tgagtttgaa ccatttcaga gcgaatatct ac 32117728DNAArtificial
SequencePrimer 1177tgagtttgca cttcaaaaga aattgtgt
28117829DNAArtificial SequencePrimer 1178tgataaaaag cactaagcga
tgaaacagc 29117927DNAArtificial SequencePrimer 1179tgataatgaa
gggaaacctt tttcacg 27118032DNAArtificial SequencePrimer
1180tgatattgaa ctggtgtacc ataatagttg cc 32118130DNAArtificial
SequencePrimer 1181tgatcctgaa tgtttatatc tttaacgcct
30118222DNAArtificial SequencePrimer 1182tgatctccat ggcgcggatc tt
22118319DNAArtificial SequencePrimer 1183tgatgcgggc tggttcaac
19118424DNAArtificial SequencePrimer 1184tgatgcgggc tggttcaaca agag
24118530DNAArtificial SequencePrimer 1185tgatggtcta tttcaatggc
agttacgaaa 30118619DNAArtificial SequencePrimer 1186tgattatcag
cggaagtag 19118728DNAArtificial SequencePrimer 1187tgattcaaat
gcagaaccat caaactcg 28118831DNAArtificial SequencePrimer
1188tgattcgatc atacgagaca ttaaaactga g 31118930DNAArtificial
SequencePrimer 1189tgattggcga taaagtgata ttttctaaaa
30119022DNAArtificial SequencePrimer 1190tgattgtttt gcagctgatt gt
22119122DNAArtificial SequencePrimer 1191tgattgtttt gcagctgatt gt
22119230DNAArtificial SequencePrimer 1192tgcaaaagta acggttacat
ctgctccaat 30119333DNAArtificial SequencePrimer 1193tgcaacaatt
aatgctccga caattaaagg att 33119424DNAArtificial SequencePrimer
1194tgcaactcat ctggtttagg atct 24119532DNAArtificial SequencePrimer
1195tgcaactgaa tagattgcag taagttataa gc 32119623DNAArtificial
SequencePrimer 1196tgcaagagca accctagtgt tcg 23119729DNAArtificial
SequencePrimer 1197tgcaagggaa acctagaatt acaaaccct
29119829DNAArtificial SequencePrimer 1198tgcaatgtgt gctatgtcag
caaaaagat 29119918DNAArtificial SequencePrimer 1199tgcacctgcg
gtcgagcg 18120024DNAArtificial SequencePrimer 1200tgcacgcaaa
cgctttactt cagc 24120126DNAArtificial SequencePrimer 1201tgcacgtctg
tttcagttgc aaattc 26120213DNAArtificial SequencePrimer
1202tgcagctgat tgt 13120326DNAArtificial SequencePrimer
1203tgcataggga aggtaacacc atagtt 26120425DNAArtificial
SequencePrimer 1204tgcatcacca tttccttgtc cttcg
25120535DNAArtificial SequencePrimer 1205tgcatgaagc ataaaaactg
tatcaagtgc tttta 35120636DNAArtificial SequencePrimer
1206tgcatgctta ctcaaatcat cataaacaat taaagc 36120729DNAArtificial
SequencePrimer 1207tgcattgtac cgaagtagtt cacattgtt
29120825DNAArtificial SequencePrimer 1208tgccaagtgc tggtttaccc
catgg 25120926DNAArtificial SequencePrimer 1209tgccactttg
acaactcctg ttgctg 26121021DNAArtificial SequencePrimer
1210tgccagcgac agaccatcgt a 21121124DNAArtificial SequencePrimer
1211tgccagctta gtcatacgga cttc 24121227DNAArtificial SequencePrimer
1212tgccagtttc cacatttcac gttcgtg 27121330DNAArtificial
SequencePrimer 1213tgccatacgt accatcgttt cataaacagc
30121424DNAArtificial SequencePrimer 1214tgccatagca aagcctacag catt
24121528DNAArtificial SequencePrimer 1215tgccatccat aatcacgcca
tactgacg 28121630DNAArtificial SequencePrimer 1216tgccatttcc
atgtactctt ctctaacatt 30121727DNAArtificial SequencePrimer
1217tgcccaccag aaagactagc aggataa 27121820DNAArtificial
SequencePrimer 1218tgcccaggta caacctgcat 20121927DNAArtificial
SequencePrimer 1219tgccccattg ctcatgatag tagctac
27122030DNAArtificial SequencePrimer 1220tgccctttct aaaagtcttg
agtgaagata 30122125DNAArtificial SequencePrimer 1221tgcccttttg
taaaagcagg gctat 25122223DNAArtificial SequencePrimer
1222tgccgataag ccggattctg tgc 23122328DNAArtificial SequencePrimer
1223tgccgtaaca tagaagttac cgttgatt 28122433DNAArtificial
SequencePrimer 1224tgccgtaact aacataagag aattatgcaa gaa
33122533DNAArtificial SequencePrimer 1225tgccgtatac gaaaatatct
tatcatttag cgt 33122625DNAArtificial SequencePrimer 1226tgcctaacaa
atcccgtctg agttc 25122720DNAArtificial SequencePrimer
1227tgcctcgcgc aacctacccg 20122820DNAArtificial SequencePrimer
1228tgcctcgtgc aacccacccg 20122922DNAArtificial SequencePrimer
1229tgcgaggaac ttcacgtcct gc 22123030DNAArtificial SequencePrimer
1230tgcgatggta ggtatcttag caatcattct 30123124DNAArtificial
SequencePrimer 1231tgcgcgagct tttatttggg tttc 24123229DNAArtificial
SequencePrimer 1232tgcgctaatt cttcaacttc ttctttcgt
29123332DNAArtificial SequencePrimer 1233tgcgctatca acgattttga
caatatatgt ga 32123423DNAArtificial SequencePrimer 1234tgcggcagca
ctatcaccat cca 23123521DNAArtificial SequencePrimer 1235tgcgggctgg
ttcaacaaga g 21123623DNAArtificial SequencePrimer 1236tgcgggtgat
acttaccgag tac 23123722DNAArtificial SequencePrimer 1237tgcggtctgg
cgcatatagg ta 22123830DNAArtificial SequencePrimer 1238tgcgtagtct
aataatttac ggaacatttc 30123929DNAArtificial SequencePrimer
1239tgcgtgacga ccttcttgaa ttgtaatca 29124023DNAArtificial
SequencePrimer 1240tgcgtggact accagggtat cta 23124113DNAArtificial
SequencePrimer 1241tgcagctgat tgt 13124230DNAArtificial
SequencePrimer 1242tgctaaagtc ttgagccata cgaacaatgg
30124324DNAArtificial SequencePrimer 1243tgctagacct ttacgtgcac cgtg
24124423DNAArtificial SequencePrimer 1244tgctaggcca tcaggccacg cat
23124534DNAArtificial SequencePrimer 1245tgctatatgc tacaactggt
tcaaaaacat taag 34124629DNAArtificial SequencePrimer 1246tgctcacctg
ctacaacaag tccagcaat 29124729DNAArtificial SequencePrimer
1247tgctcttacc tcaccgttcc acccttacc 29124829DNAArtificial
SequencePrimer 1248tgctgctttc gcatggttaa ttgcttcaa
29124927DNAArtificial SequencePrimer 1249tgctgctttg atggctgaat
ccccttc 27125022DNAArtificial SequencePrimer 1250tgctggattc
gcctttgcta cg 22125121DNAArtificial SequencePrimer 1251tgctgtaggg
aaatcagggc c 21125218DNAArtificial SequencePrimer 1252tgcttagatg
ctttcagc 18125334DNAArtificial SequencePrimer 1253tgcttcaaaa
cgcattttta cattttcgtt aaag 34125427DNAArtificial SequencePrimer
1254tgcttcagca cggccaccaa cttctag 27125531DNAArtificial
SequencePrimer 1255tgcttcagcg tagtctaata atttacggaa c
31125620DNAArtificial SequencePrimer 1256tgcttctctt ccgggtcggc
20125732DNAArtificial SequencePrimer 1257tgcttgctca aatcatcata
aacaattaaa gc 32125831DNAArtificial SequencePrimer 1258tgcttgctct
ttcaagcagt cttgaatgaa g 31125923DNAArtificial SequencePrimer
1259tgcttggtgg cttcttcgtc gaa 23126032DNAArtificial SequencePrimer
1260tgctttgtaa tctagttcct gaatagtaac ca 32126130DNAArtificial
SequencePrimer 1261tggaaaactc atgaaattaa agtgaaagga
30126229DNAArtificial SequencePrimer 1262tggaaaccgg ctaagtgagt
accaccatc 29126330DNAArtificial SequencePrimer 1263tggaacaccg
tctttaatta aagtatctcc 30126424DNAArtificial SequencePrimer
1264tggaatttac cagcgataga cacc 24126520DNAArtificial SequencePrimer
1265tggaccacgc cgaagaacgg 20126630DNAArtificial SequencePrimer
1266tggacgatat tcacggttta cccacttata 30126731DNAArtificial
SequencePrimer 1267tggactaata acaatgagct cattgtactg a
31126831DNAArtificial SequencePrimer 1268tggataattg gtcgtaacaa
gggatagtga g 31126927DNAArtificial SequencePrimer 1269tggatagacg
tcatatgaag gtgtgct 27127027DNAArtificial SequencePrimer
1270tggatcactg cttacgaact cagcttc 27127126DNAArtificial
SequencePrimer 1271tggatgtgct cacgagtctg tggcat
26127223DNAArtificial SequencePrimer 1272tggcaacagc tcaacacctt tgg
23127326DNAArtificial SequencePrimer 1273tggcaccgtg ggttgagatg
aagtac 26127419DNAArtificial SequencePrimer 1274tggcacgagc
ctgacctgt 19127534DNAArtificial SequencePrimer 1275tggcagcaat
agtttgacgt acaaatgcac acat 34127626DNAArtificial SequencePrimer
1276tggcatcacc atttccttgt ccttcg 26127729DNAArtificial
SequencePrimer 1277tggccacttt tatcagcaac cttacagtc
29127819DNAArtificial SequencePrimer 1278tggccgtact ccccaggcg
19127920DNAArtificial SequencePrimer 1279tggcgatgca ctggcttgag
20128024DNAArtificial SequencePrimer 1280tggctcataa gacgcgcttg taga
24128122DNAArtificial SequencePrimer 1281tggctgcgga agtgaaatcg ta
22128219DNAArtificial SequencePrimer 1282tggctgcttc taagccaac
19128326DNAArtificial SequencePrimer 1283tggcttgaga atttaggatc
cggcac 26128430DNAArtificial SequencePrimer 1284tgggacgtaa
tcgtataaat tcatcatttc 30128536DNAArtificial SequencePrimer
1285tgggataaca ttggttggaa tataagcaga aacatc 36128630DNAArtificial
SequencePrimer 1286tgggatggag gtgtagaagg tgttatcatc
30128730DNAArtificial SequencePrimer 1287tgggatggag gtgtagaagg
tgttatcatc 30128832DNAArtificial SequencePrimer 1288tgggcaccat
ttatccacaa attgattggt at 32128931DNAArtificial SequencePrimer
1289tggggacttc cttaccactt ttagtatcta a 31129033DNAArtificial
SequencePrimer 1290tggggatatg gaggtgtaga aggtgttatc atc
33129127DNAArtificial SequencePrimer 1291tggggtaaga cgcggctagc
atgtatt 27129225DNAArtificial SequencePrimer 1292tgggtacgaa
ctggatgtcg ccgtt 25129327DNAArtificial SequencePrimer
1293tgggtaggtt tttatctgtg acgcctt 27129426DNAArtificial
SequencePrimer 1294tgggtctaca cctgcacttg cataac
26129524DNAArtificial SequencePrimer 1295tgggtgctgg tttaccccat ggag
24129629DNAArtificial SequencePrimer 1296tgggttgcgt tgcagattat
ctttaccaa 29129725DNAArtificial SequencePrimer 1297tgggtttcgc
gcttagatgc tttca 25129818DNAArtificial SequencePrimer
1298tggtaaccct tgtctttg 18129931DNAArtificial SequencePrimer
1299tggtaaccct tgtctttgaa ttgtatttgc a 31130033DNAArtificial
SequencePrimer 1300tggtacaaca tcgttagctt taccactttc acg
33130132DNAArtificial SequencePrimer 1301tggtacacct ggtttcgttt
tgatgatttg ta 32130230DNAArtificial SequencePrimer 1302tggtacttca
acttcatcca ttatgaagtc 30130331DNAArtificial SequencePrimer
1303tggtatattc gttaattaat ctggctgcgg a 31130421DNAArtificial
SequencePrimer 1304tggtctgagt acctcctttg c 21130531DNAArtificial
SequencePrimer 1305tggtgggtat cttagcaatc attctaatag c
31130632DNAArtificial SequencePrimer 1306tggtgttcta gtatagattg
aggtagtggt ga 32130724DNAArtificial SequencePrimer 1307tggttagaag
tcgtaacgtg gacc 24130825DNAArtificial SequencePrimer 1308tggttcaaca
agagttgccg ttgca 25130931DNAArtificial SequencePrimer
1309tggttcttac ttgctttgca taaactttcc a 31131031DNAArtificial
SequencePrimer 1310tggttgtagt tcctgtagtt gttgcattaa c
31131130DNAArtificial SequencePrimer 1311tggtttgtca gaatcacgtt
ctggagttgg 30131228DNAArtificial SequencePrimer 1312tgtaaaagca
gggctataat aaggactc 28131329DNAArtificial SequencePrimer
1313tgtaaattcc gcaaagactt tggcattag 29131429DNAArtificial
SequencePrimer 1314tgtaaccctt gtctttgaat tgtatttgc
29131531DNAArtificial SequencePrimer 1315tgtaattaac cgaaggttct
gtagaagtat g 31131628DNAArtificial SequencePrimer 1316tgtacaagga
ccattataat caatgcca 28131731DNAArtificial SequencePrimer
1317tgtacaataa ggagtcacct tatgtccctt a 31131830DNAArtificial
SequencePrimer 1318tgtacaccat ttatccacaa attgattggt
30131929DNAArtificial SequencePrimer 1319tgtaggcaag tgcataagaa
attgataca 29132027DNAArtificial SequencePrimer 1320tgtcaatatg
aaggtgctct gtggata 27132128DNAArtificial SequencePrimer
1321tgtcaccagc ttcagcgtag tctaataa 28132219DNAArtificial
SequencePrimer 1322tgtcactccc gacacgcca 19132329DNAArtificial
SequencePrimer 1323tgtcagctaa gctaataacg tttgtagag
29132426DNAArtificial SequencePrimer 1324tgtcatcaag caccccaaaa
tgaact 26132528DNAArtificial SequencePrimer 1325tgtccgactt
gacggtcaac atttcctg 28132628DNAArtificial SequencePrimer
1326tgtccgactt gacggtcagc atttcctg 28132728DNAArtificial
SequencePrimer 1327tgtccgactt gacggttagc atttcctg
28132821DNAArtificial SequencePrimer 1328tgtcgcagca tctgttcctg c
21132929DNAArtificial SequencePrimer 1329tgtctattgt cgattgttac
ctgtacagt 29133027DNAArtificial SequencePrimer 1330tgtgaacatt
tgcgacggta tacccat 27133129DNAArtificial SequencePrimer
1331tgtgaagaac tttcaaatct gtgaatcca 29133224DNAArtificial
SequencePrimer 1332tgtgatatgg aggtgtagaa ggtg 24133327DNAArtificial
SequencePrimer 1333tgtgatatgg aggtgtagaa ggtgtta
27133424DNAArtificial SequencePrimer 1334tgtgcaggca tcatgtcata ccaa
24133531DNAArtificial SequencePrimer 1335tgtgctgctt tcgcatggtt
aattgcttca a 31133622DNAArtificial SequencePrimer 1336tgtgctggtt
taccccatgg ag 22133723DNAArtificial SequencePrimer 1337tgtgctggtt
taccccatgg agt 23133815DNAArtificial SequencePrimer 1338tgtgctttga
atgct 15133928DNAArtificial SequencePrimer 1339tgtgcttttt
ttgctgccat agcaaagc
28134026DNAArtificial SequencePrimer 1340tgtggccgat ttcaccacct
gctcct 26134118DNAArtificial SequencePrimer 1341tgtgttgtcg ccgcgcag
18134220DNAArtificial SequencePrimer 1342tgttaacggc ttcaagaccc
20134328DNAArtificial SequencePrimer 1343tgttaagtgt gttgcggctg
tctttatt 28134436DNAArtificial SequencePrimer 1344tgttaatggt
aacccttgtc tttgaattgt atttgc 36134522DNAArtificial SequencePrimer
1345tgttactcac ccgtctgcca ct 22134614DNAArtificial SequencePrimer
1346tgttactgct ggat 14134734DNAArtificial SequencePrimer
1347tgttcatgtt taaatgatca ggataaaaag cact 34134830DNAArtificial
SequencePrimer 1348tgttccaata gcagttccgc ccaaattgat
30134930DNAArtificial SequencePrimer 1349tgttctggat tgattgcaca
atcaccaaag 30135030DNAArtificial SequencePrimer 1350tgttcttgat
acacctggtt tcgttttgat 30135130DNAArtificial SequencePrimer
1351tgttgaagct gtacttgacc tgattttacg 30135219DNAArtificial
SequencePrimer 1352tgttgaccat gcttcttag 19135328DNAArtificial
SequencePrimer 1353tgttgtgccg cagtcaaata tctaaata
28135425DNAArtificial SequencePrimer 1354tgtttgtgat gcatttgctg
agcta 25135533DNAArtificial SequencePrimer 1355tgttttatgt
gtagttgagc ttactacatg agc 33135629DNAArtificial SequencePrimer
1356tgttttgtat ccaagtgctg gtttacccc 29135711DNAArtificial
SequencePrimer 1357tactcatgcc a 11135811DNAArtificial
SequencePrimer 1358tattcttcgt t 11135917DNAArtificial
SequencePrimer 1359ttacttctaa cccactc 17136027DNAArtificial
SequencePrimer 1360ttaatctggc tgcggaagtg aaatcgt
27136128DNAArtificial SequencePrimer 1361ttaccatctt caaatacccg
aacagtaa 28136226DNAArtificial SequencePrimer 1362ttaccgagca
ggttctgacg gaaacg 26136320DNAArtificial SequencePrimer
1363ttacgccatc aggccacgca 20136417DNAArtificial SequencePrimer
1364ttactcaccc gtccgcc 17136520DNAArtificial SequencePrimer
1365ttactcaccc gtccgccgct 20136634DNAArtificial SequencePrimer
1366ttacttcctt accactttta gtatctaaag cata 34136717DNAArtificial
SequencePrimer 1367ttacttctaa cccactc 17136821DNAArtificial
SequencePrimer 1368ttagaagtcg taacgtggac c 21136922DNAArtificial
SequencePrimer 1369ttagatgctt tcagcactta tc 22137026DNAArtificial
SequencePrimer 1370ttcaaaacct tgctctcgcc aaacaa
26137124DNAArtificial SequencePrimer 1371ttcaaaagtt gctcgagacc attg
24137223DNAArtificial SequencePrimer 1372ttcaaaatgc ggaggcgtat gtg
23137322DNAArtificial SequencePrimer 1373ttcaacaaga gttgccgttg ca
22137428DNAArtificial SequencePrimer 1374ttcaacactc tcacctacag
ctttaaag 28137524DNAArtificial SequencePrimer 1375ttcaagtgct
tgctcaccat tgtc 24137626DNAArtificial SequencePrimer 1376ttcaggtaca
gcaggtggtt caggat 26137723DNAArtificial SequencePrimer
1377ttcaggtcca tcgggttcat gcc 23137829DNAArtificial SequencePrimer
1378ttcataagca atacctttac ttgcaccac 29137930DNAArtificial
SequencePrimer 1379ttcattttct ggtccaaagt aagcagtatc
30138025DNAArtificial SequencePrimer 1380ttccaagtgc tggtttaccc
catgg 25138133DNAArtificial SequencePrimer 1381ttccaccttg
gatacctgga aaaatagctg aat 33138236DNAArtificial SequencePrimer
1382ttccatttca actaattcta ataattcttc atcgtc 36138328DNAArtificial
SequencePrimer 1383ttcccctgac cttcgattaa aggatagc
28138427DNAArtificial SequencePrimer 1384ttcgcgcatc caggagaagt
acatgtt 27138515DNAArtificial SequencePrimer 1385ttcgctcgcc gctac
15138618DNAArtificial SequencePrimer 1386ttcgctctcg gcctggcc
18138722DNAArtificial SequencePrimer 1387ttcggtataa cgcatcgcag ca
22138826DNAArtificial SequencePrimer 1388ttcgtgctgg attttgtcct
tgtcct 26138921DNAArtificial SequencePrimer 1389ttcgtgctta
gatgctttca g 21139024DNAArtificial SequencePrimer 1390ttctgagcta
aatcagcagt tgca 24139123DNAArtificial SequencePrimer 1391ttctgcgaat
caatcgcacg ctg 23139224DNAArtificial SequencePrimer 1392ttctgcttga
ggaatagtgc gtgg 24139324DNAArtificial SequencePrimer 1393ttctgggtga
cctggtgttt taga 24139431DNAArtificial SequencePrimer 1394ttcttccaag
gatagattta tttcttgttc g 31139524DNAArtificial SequencePrimer
1395ttcttgaacg cgaggtttcg attg 24139622DNAArtificial SequencePrimer
1396ttgacatcgt ccctcttcac ag 22139726DNAArtificial SequencePrimer
1397ttgacatttg catgcttcaa agcctg 26139823DNAArtificial
SequencePrimer 1398ttgacgtcat ccccaccttc ctc 23139924DNAArtificial
SequencePrimer 1399ttgacgttgc atgttcgagc ccat 24140030DNAArtificial
SequencePrimer 1400ttgcaatcga catatccatt tcaccatgcc
30140127DNAArtificial SequencePrimer 1401ttgcacgtct gtttcagttg
caaattc 27140227DNAArtificial SequencePrimer 1402ttgcacgtct
gtttcagttg caaattc 27140320DNAArtificial SequencePrimer
1403ttgcatcggg ttggtaagtc 20140427DNAArtificial SequencePrimer
1404ttgccacttt gacaactcct gttgctg 27140525DNAArtificial
SequencePrimer 1405ttgccatagc aaagcctaca gcatt
25140630DNAArtificial SequencePrimer 1406ttgccattca tggtatttaa
gtgtagcaga 30140721DNAArtificial SequencePrimer 1407ttgcgccata
cgtaccatcg t 21140825DNAArtificial SequencePrimer 1408ttgcgttgca
gattatcttt accaa 25140925DNAArtificial SequencePrimer
1409ttgctgccat agcaaagcct acagc 25141030DNAArtificial
SequencePrimer 1410ttgctgcttt cgcatggtta atcgcttcaa
30141130DNAArtificial SequencePrimer 1411ttgctgcttt cgcatggtta
attgcttcaa 30141227DNAArtificial SequencePrimer 1412ttggacctgt
aatcagctga atactgg 27141322DNAArtificial SequencePrimer
1413ttggccatca gaccacgcat ac 22141422DNAArtificial SequencePrimer
1414ttggccatca ggccacgcat ac 22141528DNAArtificial SequencePrimer
1415ttggcgacgg tatacccata gctttata 28141617DNAArtificial
SequencePrimer 1416ttggtgcgct tggcgta 17141732DNAArtificial
SequencePrimer 1417ttggttctta cttgttttgc ataaactttc ca
32141835DNAArtificial SequencePrimer 1418ttgtacattt gaaacaatat
gcatgacatg tgaat 35141923DNAArtificial SequencePrimer
1419ttgtcagact catcgcgaac atc 23142028DNAArtificial SequencePrimer
1420ttgtgatatg gaggtgtaga aggtgtta 28142126DNAArtificial
SequencePrimer 1421ttgtgattgt tttgcagctg attgtg
26142227DNAArtificial SequencePrimer 1422ttgtggccga tttcaccacc
tgctcct 27142321DNAArtificial SequencePrimer 1423ttgttaacgg
cttcaagacc c 21142432DNAArtificial SequencePrimer 1424ttgtttattg
tttccatatg ctacacactt tc 32142523DNAArtificial SequencePrimer
1425tttaagcgcc agaaagcacc aac 23142625DNAArtificial SequencePrimer
1426tttacctcgc ctttccaccc ttacc 25142729DNAArtificial
SequencePrimer 1427tttagctact attctagctg ccatttcca
29142827DNAArtificial SequencePrimer 1428tttatgacca gcttcggtac
tactaaa 27142930DNAArtificial SequencePrimer 1429tttatggtct
atttcaatgg cagttacgaa 30143037DNAArtificial SequencePrimer
1430tttcaatacc tttatgcaac tttgtatcaa ctggaat 37143130DNAArtificial
SequencePrimer 1431tttcacagca tgcacgtctg tttcagttgc
30143235DNAArtificial SequencePrimer 1432tttccccgat ctaaatttgg
ataagccata ggaaa 35143327DNAArtificial SequencePrimer
1433tttccgatgc aacgtaatga gatttca 27143422DNAArtificial
SequencePrimer 1434tttcgtgctt agatgctttc ag 22143530DNAArtificial
SequencePrimer 1435tttcttgaag agtatgagct gctccgtaag
30143622DNAArtificial SequencePrimer 1436tttgcacctt accgccaaag ct
22143728DNAArtificial SequencePrimer 1437tttgctcatg atctgcatga
agcataaa 28143824DNAArtificial SequencePrimer 1438tttgctctcc
gccaaagttt ccac 24143928DNAArtificial SequencePrimer 1439tttggacctg
taatcagctg aatactgg 28144029DNAArtificial SequencePrimer
1440tttgtgaaac agcgaacatt ttcttggta 29144120DNAArtificial
SequencePrimer 1441ttttccagcc atgcagcgac 20144234DNAArtificial
SequencePrimer 1442ttttcccttt atgcaactta gtatcaactg gaat
34144329DNAArtificial SequencePrimer 1443ttttgctcat gatctgcatg
aagcataaa 2914442118DNAArtificial SequenceConcatenation of A.
baumannii genes 1444cgcgcggtaa aactaaagaa gaagatatag cattagaaaa
agatttgctg tctgatgaaa 60aagagattgc tgaacattta atgctgattg atcttgggcg
aaacgatgta gggcgtgtat 120cgaaaatagg taaagtccaa gtcacggatc
aaatggtgat cgagcgttat tcacatgtca 180tgcatattgt ttcaaatgta
caaggtgaag tgcgtgatga tatcgatgca cttgatgtat 240ttaaagccac
ctttccagca ggaacgttat caggtgcccc aaaaattcgt gcaatggaaa
300ttattgatga agtagaacct gtgaaaaggg gagtttttgg cggggctgtt
ggttatttgg 360gatggcatgg tgaaatggat atgtcgattg caatccgtac
ttgtgttatc cgtgataaaa 420aggtgtatgt acaggctggt gcagggnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480nnnnnnggaa tctggcggtt
tagtttcaga tgaactcatt atcggtttag taaaagaacg 540tattgctcaa
cctgactgcg tgaatggttg tattttcgac ggcttcccac gcactattcc
600tcaagcagaa gctttggaaa aagaagggat cagcattgat catgtaattg
aaattgatgt 660acctgatgaa gaaatcgtaa aacgtctttc tggtcgtcgt
cagcatcctg cttctggtcg 720tgtttatcac gttgtataca atccacctaa
agtggaaggt aaagatgatg tcacaggnnn 780nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnncgt tcaaccgtgt aaaattacgt 840aaccttaaaa
ctggtaaagt tttagaaaaa acttttaaat ctggtgatac tttagaagct
900gctgacatcg tagaagtaga aatgaactac ctatacaacg atggcgaaat
gtggcacttc 960atggacccag aaagcttcga acaaattgca gctgacaaaa
ctgcaatggg tgatgctgct 1020aaatggttaa aagacgactc aaatgaaaca
tgtacaatca tgttattcaa cggcgttcct 1080ttaaacgtaa atgcacctaa
cttcgttgta ttgaaagttg ttgaaactga tccgggcgta 1140cgtggtgata
cttctggtgg tnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
1200ntcgtgcccg yaatttgcat aaagctgccg gccttgtagc acagcaaggc
aaatttcctg 1260aaactctaga agaatggatt gcactacccg gcattggtcg
ctcgaccgca ggtgcactca 1320tgtctttagg tttacgtcag tatggcgtga
ttatggatgg caacgtgaaa cgcgttttag 1380cccgtttctt tgccattgaa
gatgacttaa gcaaaccaca gcacgaacgt gaaatgtgga 1440aactggctga
agagctttgt cccacccaac gcaatcatga ctacactcaa gcgannnnnn
1500nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnttaaaa acactagcgg
taagcttaaa 1560caagattgcc aatgatattc gttggttagc aagtggtcca
cgttgcggct tcggcgaaat 1620ccgtattcct gaaaatgaac ctggttcaag
tatcatgcca ggtaaagtga acccgactca 1680aagtgaagcc atgaccatgg
ttgttgctca agtacttggc aacgatacca ctattaatgt 1740cgctggtgct
tctggtaact tcgagctcaa tgtatttatg ccagtgattg cttataactt
1800actgcaatct attcagttgc ttggtgatgc atgtaatagt tttaatgatc
actgtgcagt 1860agggatcgag ccaaatcgtg agaaaattga tcatttcttg
cataattctc ttatgttagt 1920tacggcannn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnccc ggttatgtac 1980caaatacttt gtctgaagat
ggtgacccat tagacgtact tgttgtaact ccacatcctg 2040ttgctgccgg
ttctgtaatt cgttgccgcc cagtgggcaa attaaacatg gaagacgacg
2100gtggtatcga tgccnnnn 21181445102DNAArtificial
SequenceCalibration Polynucleotide 1445tttaagtccc gcaacgagcg
caacccttga tcttagttgt ttagttgggc actctaaggt 60gactgccggt gacaaaccgg
aggaaggtgg ggatgacgtc aa 102144694DNAArtificial SequenceCalibration
Polynucleotide 1446tagaacaccg atggcgaagg cgactttctg gtctgtaact
gacactgaga aagcgtgggg 60agcaaacagg attagatacc ctggtagtcc acga
941447108DNAArtificial SequenceCalibration Polynucleotide
1447tggattagag accctggtag tccacgccgt aaacgatgag tgctaagtgt
tagaggcctt 60tagtgctgaa gttaacgcat taagcactcc gcctggggag tacggcca
1081448108DNAArtificial SequenceCalibration Polynucleotide
1448tttcgatgca acgcgaagaa ccttaccagg tcttgacatc ctctgacaac
cctagcttct 60ccttcgggag cagagtgaca ggtggtgcat ggctgtcgtc agctcgta
108144995DNAArtificial SequenceCalibration Polynucleotide
1449tctgacacct gcccggtgct ggaaggttaa ggagaggggt tagcgtaact
ctgaactgaa 60gccccagtaa acggcggccg taactataac ggtca
951450117DNAArtificial SequenceCalibration Polynucleotide
1450tctgttctta gtacgagagg accgggatgg acgcaccggt accagttgtt
ctgccaaggg 60catagctggg tagctatgtg cggaagggat aagtgctgaa agcatctaag
cacgaaa 1171451100DNAArtificial SequenceCalibration Polynucleotide
1451tgattattgt tatcctgtta tgccatttga gatttttgag tggtattgga
gttattgttc 60caggattaat tgcaaataca attcaaagac aagggttaca
1001452112DNAArtificial SequenceCalibration Polynucleotide
1452tcgaagtaca atacaagaca aaagaaggta aaattactgt tttaggggaa
aaattcaaga 60aatatagaag tgatggctaa aaatgtagaa ggggtcttga agccgttaac
aa 1121453100DNAArtificial SequenceCalibration Polynucleotide
1453ttgctcgtgg tgcacaagta acggatatta caatcattgt tgttgcagct
gatgacggcg 60taataaacag ttgaagcaat taaccatgcg aaagcagcaa
1001454114DNAArtificial SequenceCalibration Polynucleotide
1454tagcttttgc atattatatc gagccacagc atcgtgatgt tttacagctt
tatgcaccgg 60aagcttttaa tggataaatt taacgaacaa gaaataaatc tatccttgga
agaa 1141455116DNAArtificial SequenceCalibration Polynucleotide
1455tgacctacag taagaggttc tgtaatgaac cctaatgacc atccacacgg
tggtggtgaa 60ggtagatctc ctatcggaaa gtccacgtac tccatggggt aaaccagcac
ttggaa 116145670DNAArtificial SequenceCalibration Polynucleotide
1456tccacacggt ggtggtgaag gtagatctcc tatcggaaag tccacgtact
ccatggggta 60aaccagcaca 70145782DNAArtificial SequenceCalibration
Polynucleotide 1457ttatcgctca ggcgaactcc aacctggatg atgaaggccg
ctttttagaa ggtgacttgt 60cgtagcaaag gcgaatccag ca
82145887DNAArtificial SequenceCalibration Polynucleotide
1458tgggcagcgt ttcggcgaaa tggaagtggc tcgaagcgta tggcgcttcg
tacgtgctgc 60aggaaatgtt gaccgtcaag tcggaca 87145997DNAArtificial
SequenceCalibration Polynucleotide 1459tcaggagtcg ttcaactcga
tctacatgat ggccgaccgc ccggggttcg gcggtgcaga 60ttcgtcagct ggccggcatg
cgtggcctga tggcgta 971460117DNAArtificial SequenceCalibration
Polynucleotide 1460tctggcaggt atgcgtggtc tgatggccaa tccatctggt
cgtatcatcg aacttccaat 60caagtttccg tgaaggttta acagtacttg agtacttcat
ctcaacccac ggtgcga 117146198DNAArtificial SequenceCalibration
Polynucleotide 1461tcaagcaaac gcacaatcag aagctaagaa agcgcaagct
tctggaaagc acaaatgcta 60gttatggtac agaatttgca actgaaacag acgtgcaa
98146299DNAArtificial SequenceCalibration Polynucleotide
1462tccacacgcc gttcttcaac aactaccgtg ttctacttcc gtacgacgga
cgtgacgggc 60tcgatcgagc tgccgaagga caaggaaatg gtgatgcca
991463111DNAArtificial SequenceCalibration Sequence 1463tcgtggcggc
gtggttatcg aacccatgct gaccgatcaa tggtacgtgc acaccgcccc 60ccaaagtcgc
gattgaagcc gtagagaacg gcgacatcca gttcgtaccg a
11114642100DNAArtificial
SequenceCombination Calibration Polynucleotide 1464gaagtagaga
tatggaggaa caccagtggc gaaggcgact ttctggtctg taactgacac 60tgagaaagcg
tggggagcaa acaggattag ataccctggt agtccacgcc gtaaacgatg
120agtgctaagt gttagaggcc tttagtgctg aagttaacgc attaagcact
ccgcctgggg 180agtacggccg caaggctgaa actcaaagga attgacgggg
cacaagcggt ggagcatgtg 240gtttaattcg aagcaacgcg aagaacctta
ccaggtcttg acatcctctg acaaccctag 300cttctccttc gggagcagag
tgacaggtgg tgcatggttg tcgtcagctc gtgtcgtgag 360atgttgggtt
aagtcccgca acgagcgcaa cccttgatct tagttgttta gttgggcact
420ctaaggtgac tgccggtgac aaaccggagg aaggtgggga tgacgtcaaa
tcatcatgcc 480ccagtaccgt gagggaaagg tgaaaagcac cccggaaggg
gagtgaaaga gatcctgaaa 540ccgtgtgcca tagtcagagc ccgttaacgg
gtgatggcgt gccttttgta gaatgaaccg 600gcgagttata agatccgtag
tcaaaaggga aacagcccag accgccagct aaggtcccaa 660agtgtgtatt
gaaaaggatg tggagttgct tagacaacta ggatgttggc ttagaagcag
720ccaccattta aagagtatag ggggtgacac ctgcccggtg ctggaaggtt
aaggagaggg 780gttagcgtaa ctctgaactg aagccccagt aaacggcggc
cgtaactata acggtcctaa 840ggtagcgaaa gaaatttgag aggagctgtc
cttagtacga gaggaccggg atggacgcac 900cggtaccagt tgttctgcca
agggcatagc tgggtagcta tgtgcggaag ggataagtgc 960tgaaagcatc
taagcatgaa gcccccctca agatgagagc agtaaaacaa gcaaacgcac
1020aatcagaagc taagaaagcg caagcttctg gaaagcacaa atgctagtta
tggtacagaa 1080tttgcaactg aaacagacgt gcatgctgtg aaatttgcga
aagcttttgc atattatatc 1140gagccacagc atcgtgatgt tttacagctt
tatgcaccgg aagcttttaa tggataaatt 1200taacgaacaa gaaataaatc
tatccttgga agaacttaaa gatcaacgga tgctggcaag 1260atatgaaaaa
taagataaaa cagcactatc aacactggag cgattcttta tctgaagaag
1320gaagagcgat gaaaacaacg aagtacaata caagacaaaa gaaggtaaaa
ttactgtttt 1380aggggaaaaa ttcaagaaat atagaagtga tggctaaaaa
tgtagaaggg gtcttgaagc 1440cgttaacagc tgttatggcg accgtggcgg
cgtggttatc gaacccatgc tgaccgatca 1500atggtacgtg cacaccgccc
cccaaagtcg cgattgaagc cgtagagaac ggcgagatcc 1560agttcgtccc
taaacagtac ggcaacttcg ttatcgctca ggcgaactcc aacctggatg
1620atgaaggccg ctttttagaa ggtgacttgt cgtagcaaag gcgaatcaag
cctgtttagc 1680cacaactatg cgtgctcgtg gtgcacaagt aacggatatt
acaatcattg ttgttgcagc 1740tgatgacggc gtaataaaca gttgaagcga
ttaaccatgc gaaagcagca ggagtaccaa 1800ctttactcag cttgctggta
tgcgtggtct gatggccaat ccatctggtc gtatcatcga 1860acttccaatc
aagtttccgt gaaggtttaa cagtacttga gtacttcatc tctacgcatg
1920gtgcgcgtaa aggtcatggg agtaagacct acagtaagag gttctgtaat
gaaccctaat 1980gaccatccac acggtggtgg tgaaggtaga tctcctatcg
gaaagtccac gtactccatg 2040gggtaaacca gcacttggat acaaaacaag
cgcagttcgg cggccagcgc ttcggtgaaa 2100
* * * * *